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In 2015, 52 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (1.13 cases per 100,000 
total population). This is a 14.8% decrease on the number 
reported in the previous year. In 2004 the incidence rate was 
0.89 cases/100,000. No imported cases were reported in 
2015.
The main change in 2015, when compared to 2014, is the 
decrease in the number of non-typeable/non-capsular 
strains from 38 to 24 (Figure 1). 
Non-typeable/non-capsular cases accounted for the majority 
of the invasive H. influenzae cases notified in 2015 (46.2%, 
n=24/52). The remaining cases were due to H. influenzae ‘not 
type b’ (9.6%; n=5), type f (3.8%; n=2), and isolates that were 
not typed (40.4%; n=21), of which 10 (19.2%) were diagnosed 
by PCR testing only. The median age of cases was 25 years 
(range two days to 93 years). The incidence rates were 
highest in infants <1 year (15.2/100,000) and those aged 1 to 
4 years (2.8/100,000) (Table 1).
Cases occurring in children <10 years of age (n=22) and in 
elderly adults (65 years of age and older (n=18)) accounted 
for 76.9% of all invasive H. influenzae notifications in 2015 
(Table 1). One notable trend since 2004 is the increase in the 
overall proportion of cases 65+ years of age from 26.3% to 
34.6% in 2015 compared to the decline over the same period 
in those aged between 5 and 64 years from 47.4% to 26.9%. 
In 2015, the highest frequency of cases occurs in the 0-4 year 
age group (38.5%; n=20), after which it falls sharply before 
increasing again among those aged 65+ years (34.6%; n=18) 
(Table 1), consistent with what has been observed since 2004 
(Figure 2).
In 2015, the number of male cases (n=26) was identical to 
that of females giving a male to female ratio of 1:1. The M:F 
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2015: 52
Number of cases, 2014: 61
Number of cases, 2013: 41
Crude incidence rate, 2015: 1.1/100,0000
Summary
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Figure 1. Number of invasive H. influenzae cases and proportion of cases attributable to type b and non-typeable strains with 95% confidence 
intervals, Ireland, 2004-2015
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ratio has been observed to vary considerably in recent years 
with a 0.5:1 ratio recorded in 2014 and 2.7:1 in 2013 (Figure 3).
Between 2005 and 2011, the fewest quarterly number of cases 
has consistently been in the third quarter, but since 2012 that 
pattern no longer applies (Figure 3). 
Incidence of disease in 2015 was highest in the HSE E 
area (1.6/100,000) with the lowest in the HSE M area 
(0.35/100,000) (Table 2). No HSE area had an incidence rate 
that was significantly different from the national rate (Figure 4).
A breakdown by clinical diagnosis for all cases by age group 
between 2004 and 2015 is presented in Table 3. In 2015, 
23.1% (n=12/52) of cases did not have a clinical diagnosis 
recorded. 
Two deaths were reported among the 52 cases in 2015, one 
aged 1-2 years and one aged 70-74 years. Their cause of 
death was not reported. One had a confirmed non-typeable 
infection with bacteraemia and the other, a possible case, had 
epiglottitis.
 
In 2015, there were no cases of H. influenzae type b (Hib) 
reported, the result of a long term trend: in 2014, only one 
case of Hib occurred, with two cases in 2013 and 18 cases 
notified in both 2004 and 2005. Between Q3-2007 and 
Q4-2015, an eight and a half year period, only one true Hib 
vaccine failure was reported, highlighting the continuing 
positive impact that the Hib booster catch up campaign has 
had in Ireland. 
Since September 2008, the Hib booster dose has been 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the three 
doses given during infancy (at 2, 4 and 6 months of age). 
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Figure 2. Number of H. influenzae cases by agegroup and type*, Ireland, 2004-2015
* Typed includes b, e, f, not-b
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Table 1. Number and incidence rates of invasive H. influenzae cases by serotype and age group, Ireland, 2015
Age 
Group type b type e type f not type b
non-typeable/
non-capsular
not 
typed 
(all)
not typed, 
PCR only 
diagnosis
not 
typed Total ASIR 
<1 0 0 0 3 2 6 5 1 11 15.19
1-4 0 0 0 0 1 8 3 5 9 2.81
5-9 0 0 0 0 0 2 1 1 2 0.66
10-14 0 0 0 0 0 0 0 0 0 0.00
15-19 0 0 0 1 0 0 0 0 1 0.34
20-24 0 0 0 0 2 1 0 1 3 0.40
25-34 0 0 1 0 2 1 0 1 4 0.58
35-44 0 0 0 0 2 0 0 0 2 0.35
45-54 0 0 0 0 1 1 1 0 2 0.43
55-64 0 0 0 0 0 0 0 0 0 0.00
65+ 0 0 1 1 14 2 0 2 18 0.39
Total 0 0 2 5 24 21 10 11 52 1.13
CIR 0.00 0.00 0.04 0.11 0.52 0.46 0.22 0.24 1.13 -
CIR, crude incidence rate per 100,000 total population; ASIR, age specific incidence rate per 100,000 population
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Figure 3. Number of H. influenzae cases by year/quarter and gender, Ireland, 2004-2015
Table 2. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, Ireland, 2004-2015
HSE 
Area 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
E 1.07 1.00 0.87 0.80 0.53 0.74 0.56 1.11 1.11 0.62 0.99 1.60
M 1.19 1.19 0.40 1.19 0.79 1.06 0.35 1.06 0.35 1.42 1.77 0.35
MW 0.83 0.28 0.83 0.55 0.83 2.11 0.53 0.53 1.05 0.79 2.11 1.05
NE 0.25 1.27 0.25 0.00 0.00 0.23 0.45 1.59 0.91 1.36 1.59 0.91
NW 0.42 0.00 2.11 0.42 0.00 0.39 0.39 0.77 0.77 1.16 0.39 0.77
SE 1.08 0.43 0.87 1.08 0.65 1.00 1.00 0.80 1.21 1.00 2.41 1.21
S 1.13 0.32 1.29 0.32 0.64 1.20 1.05 0.30 0.60 0.90 1.20 0.75
W 0.48 1.45 0.72 1.45 0.48 1.12 0.22 1.35 0.45 0.90 0.90 0.90
Ireland 0.90 0.80 0.90 0.73 0.52 0.94 0.61 0.96 0.89 0.89 1.33 1.13
Table 3. Number of invasive H. influenzae cases by clinical diagnosis, Ireland, 2004-2015
Clinical diagnosis 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 % 2015
Septicaemia 8 14 13 6 3 9 9 11 11 14 15 14 26.9%
Pneumonia 5 0 3 6 3 8 5 12 12 4 12 8 15.4%
Meningitis 3 9 3 2 2 2 1 3 2 2 7 3 5.8%
Bacteraemia 
(without focus) 1 0 1 1 2 0 0 3 5 6 9 8 15.4%
Other 1 2 1 0 0 0 0 3 4 7 7 3 5.8%
Epiglottitis 1 3 3 1 1 0 2 0 0 3 1 1 1.9%
Cellulitis 1 1 2 1 1 0 0 1 0 0 0 1 1.9%
Meningitis & 
septicaemia 1 0 1 0 1 1 1 1 1 0 0 2 3.8%
Osteomyelitis 1 0 0 0 0 0 0 0 0 0 0 0 0.0%
Septic arthritis 0 1 0 0 1 0 0 0 0 0 0 0 0.0%
Not specified 16 4 11 14 8 23 10 10 6 5 10 12 23.1%
Total 38 34 38 31 22 43 28 44 41 41 61 52 100 %
% Not specified 42.1% 11.8% 28.9% 45.2% 36.4% 53.5% 35.7% 22.7% 14.6% 12.2% 16.4% 23.1% -
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence intervals for  
H. influenzae notifications by HSE area, Ireland, 2015
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Furthermore, vaccination is routinely recommended for 
those at increased risk of Hib disease due to underlying 
medical conditions or treatments.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 30th August, 2016. These figures 
may differ from those published previously due to on-going 
updating of notification data on CIDR.
There were two measles cases (0.04/100,000) in 2015. This 
is the lowest annual number reported since 1948 (figures 1 
and 2). 
Both measles cases were classified as confirmed. The first 
case was imported, with probable country of infection 
reported as Indonesia. Measles virus from this case was 
genotyped by the NVRL and was genotype D8. The second 
case was epidemiologically linked to it with probable 
country of infection recorded as Ireland. The cases were in 
the age groups 10-14 years and 15-19 years. One case was 
unvaccinated while the second case had one dose of MMR. 
Both cases were hospitalised. One of the cases was reported 
as having pneumonia.
The figures presented above are based on data extracted 
from the Computerised Infectious Disease Reporting (CIDR) 
system on 16th August 2016. These figures may differ slightly 
from those published previously due to ongoing updating of 
notification data on CIDR. 
1.2 Measles 
Summary
Number of cases, 2015: 2
Number of confirmed cases, 2015: 2
Crude incidence rate, 2015: 0.04/100,000
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MR campaign 1995 
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Figure 1. Annual number of measles cases in Ireland 1948-2015, the year of introduction of the measles vaccine and the measles mumps rubella 
(MMR) vaccine and vaccination campaigns years
A measles and rubella (MR) campaign for primary school age children was conducted in 1995
*A MMR vaccination campaign started in April 2009 for students in fourth, fifth and sixth year of second level schools
*A MMR catch-up campaign was conducted during the 2012/2013 and 2013/2014 academic years for children/students attending primary 
schools, second level schools and special schools and home-schooled students who had not completed (or were not sure they had) their two 
dose MMR vaccination schedule.
MMR1-first dose of MMR
MMR2-second dose of MMR
1948-June 2000 data collated by DoHC
July 2000-2015 data collated by HPSC
WHO require information on discarded measles cases ie 
measles cases investigated and who were found not to meet 
the case definition. The HSE Areas reported the number 
of discarded CIDR cases to HPSC. For 2015, 69 cases were 
discarded from CIDR as following investigation they were 
not considered to be measles cases. Discarded cases are not 
available in CIDR for reporting and are therefore not included 
in the analysis above.
The NVRL is the WHO accredited National Measles Rubella 
laboratory for Ireland. Laboratories that perform measles or 
rubella investigations in their own laboratories are requested 
to send all positive samples for measles or rubella to the 
NVRL for confirmatory testing. In addition, a selection of 
negative specimens should also be referred. Genotyping is 
undertaken on a selection of specimens. 
 
 
-15-HPSC Annual Epidemiological Report 2015 1. Vaccine Preventable Diseases
Figure 2. Number of measles cases by year, 2004-2015 
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Between 1999 and 2012, a marked downward trend in 
invasive meningococcal disease (IMD) incidence was 
observed: in 1999 there were 536 cases (14.8/100,000) 
and in 2012 there were 66 cases (1.4/100,000), a decline of 
almost 88%. In 2015, however, 75 cases (1.6/100,000) of 
IMD were notified, seven fewer reported than in the previous 
year (n=82). 
Typically, most cases in 2015 were diagnosed by blood/CSF 
culture testing, blood/CSF PCR testing or by detection of 
Gram negative diplococci in skin lesions/culture or in CSF 
specimens. Isolation of the organism from non-sterile sites 
(such as the eye, nose or throat) in clinically compatible 
cases is considered a possible case. 
Of the 75 cases notified in 2015, 67 (89.3%) were case 
classified as confirmed and eight (10.7%) as possible. 
Confirmation of diagnosis by laboratory testing of cases has 
improved with time. In 2015, 89.3% (n=67/75) of cases were 
confirmed by laboratory testing in comparison to 83.0% 
(n=445/536) in 1999.
In 2015, 31 of the 67 confirmed cases (46.3%) were confirmed 
by PCR testing alone and another 12 confirmed cases (17.9%) 
were diagnosed by culture of sterile specimens alone. Of the 
remaining 24 (35.8%) confirmed cases, all were diagnosed 
by both culture and PCR testing of sterile specimens. 
Additional laboratory testing was done on the 67 confirmed 
cases: four had positive CSF microscopy test results and one 
had a positive skin lesion culture. 
Of the eight possible cases reported in 2015, one had a 
positive laboratory test result based on an eye culture in 
which serogroup 29E was identified.
In 2015, male cases (n=42) exceeded female cases (n=33), 
resulting in a male to female ratio of 1.3:1.0, following a 
consistent pattern observed since 2005. IMD cases in 2015 
ranged in age from one month to 92 years (median age of 3 
years). 
Overall incidence in Ireland was 1.6/100,000 population in 
2015. The incidence of IMD was highest in infants and young 
children. Age specific incidence rate (ASIR) was highest 
among infants <1 year of age (18.0/100,000; n=13), followed 
by children in the 1 to 4 years (5.3/100,000; n=15), and 15 to 
19 year age groups (4.9/100,000; n=14) (Table 1, Figure 1). 
Figure 2 presents the number of IMD cases by gender and 
age group between 1999 and 2015 and shows the decline 
in numbers across all of the age groups, with the steepest 
declines observed in the <1, 5-9 and 10-24 year age groups 
following the introduction of the meningococcal C conjugate 
(MCC) vaccine in late 2000.
At regional level, incidence was highest in the HSE MW area 
1.3 Meningococcal disease 
Summary
Number of cases, 2015: 75
Number of cases, 2014: 82
Number of cases, 2013: 81
Crude incidence rate, 2015: 1.6/100,000
Table 1. Number of cases, deaths, age-group specific incidence rates per 100,000 population (calculated using Census 2011 denominator data) 
and case fatality ratios of IMD, Ireland, 2015
Age Group No. Cases ASIR No. Deaths %CFR
<1 13 18.0 0 0.0%
1-4 15 5.3 1 6.7%
5-9 8 2.5 0 0.0%
10-14 4 1.3 0 0.0%
15-19 14 4.9 1 7.1%
20-24 2 0.7 0 0.0%
25+ 19 0.6 1 5.3%
All ages 75 1.6 3 4.0%
ASIR, age specific incidence rate per 100,000 population; %CFR, case fatality ratio
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(2.4/100,000) and lowest in the HSE E area (1.1/100,000) 
(Table 2). No area had an incidence rate that was 
significantly different from the national rate (Figure 3). There 
were no imported cases identified in 2015.
Apart from the years 2003, 2013 and 2014, IMD cases have 
tended to occur most frequently in the first quarter of each 
calendar year (Figure 4). 
Neisseria meningitidis serogroup B was the pathogen most 
commonly associated with IMD in 2015 and accounted for 
43 of the 75 (57.3%) notifications. However, this is a marked 
decline on what was previously reported between 2003 
and 2014 when serogroup B accounted for more than 80% 
(n=1,703/2,031) of all IMD notifications (Figure 5). 
In February 2015, a cluster of cases was reported in HSE 
S in Cork involving two siblings, aged 4 and 5 years with a 
serogroup B infection. Both cases recovered. 
Figure 1. Age-specific rates per 100,000 population for invasive meningococcal disease (IMD), 
Ireland, 1999-2015
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TTable 2. Age specific incidence rates per 100,000 population (calculated using Census 2011 denominator data) of IMD by HSE area and age 
group, Ireland, 2015
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
HSE E 11.5 1.0 0.9 1.0 5.2 0.0 0.7 1.1
HSE M 20.7 5.2 0.0 4.9 11.3 0.0 0.6 2.1
HSE MW 17.5 17.5 11.4 0.0 0.0 4.1 0.0 2.4
HSE NE 39.0 3.2 0.0 0.0 14.7 0.0 0.0 1.8
HSE NW 0.0 6.3 5.3 0.0 18.0 0.0 0.6 2.3
HSE SE 26.2 6.5 2.8 5.7 0.0 0.0 0.6 1.8
HSE S 19.9 5.0 2.2 0.0 0.0 2.4 1.4 1.8
HSE W 15.1 11.5 3.2 0.0 0.0 0.0 0.7 1.6
Ireland 18.0 5.3 2.5 1.3 4.9 0.7 0.6 1.6
Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year for meningococcal B and C disease, Ireland, 1999-2015
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1 135 5 3.7
2000 258 13 5.0 139 11 7.9
2001 245 8 3.3 35 3 8.6
2002 199 8 4.0 14 0 0.0
2003 206 11 5.3 5 1 20.0
2004 163 7 4.3 5 1 20.0
2005 169 5 3.0 5 0 0.0
2006 168 5 3.0 4 0 0.0
2007 158 6 3.8 2 0 0.0
2008 149 6 4.0 4 1 25.0
2009 119 6 5.0 5 0 0.0
2010 93 4 4.3 4 0 0.0
2011 84 2 2.4 2 0 0.0
2012 58 1 1.7 0 0 0.0
2013 68 4 5.9 1 0 0.0
2014 69 3 4.3 6 1 16.7
2015 43 2 4.7 11 0 0.0
%CFR, case fatality ratio
There were three IMD related notified deaths in 2015 (case 
fatality ratio of 4.0%) (age range 16 months to 92 years) 
(Table 1). The death in a 16 month old was reported to be due 
to a serogroup B infection, but the cause of death was not 
reported in the other two: one had a serogroup B infection 
and the other had a non-groupable infection. This compares 
to an annual average of 4.9 deaths between 2005 and 2014. 
In 2015, the %CFR was highest amongst cases 15-19 years 
of age (7.1%) as a result of one death among 14 cases. The 
next highest %CFR was 6.7% (n=1/15) among cases aged 1-4 
years.
IMD due to serogroup C (MenC) has remained at relatively 
low levels between 2003 and 2014 with an average of 3.4 
cases occurring annually. However, in 2015, the highest 
number of MenC cases (n=11) since 2002 was observed, aged 
between 4 months and 73 years (Table 3). Three of these six 
cases that were unvaccinated (aged between 4 months and 
73 years) had no risk factors reported; there were four vaccine 
failures (aged 3 to 16 years) and the vaccination status of the 
remaining case was incomplete (aged 15-19 years).
Since 2003, 14 true vaccine failures have been recorded. 
Prior to the introduction of the MCC vaccine, serogroup C 
incidence rate in 1999 was 3.7/100,000 population; in 2015 
it was 0.24/100,000.
The recent increase in MenC cases, which began in 2014, 
may be attributable to waning population herd immunity. 
Recent studies undertaken in the United Kingdom have 
reported waning immunity to serogroup C disease following 
infant vaccination in early childhood. Furthermore, 
protection given by vaccination at 12 months also wanes 
by the teenage years, but vaccination later in childhood 
provides higher levels of antibody that persist for longer.1-4 
Evidence shows that MCC vaccination significantly reduces 
nasopharyngeal carriage of the serogroup C meningococcus, 
providing indirect protection through herd immunity.5-6 The 
continuing increase in MenC cases in Ireland in 2015 may 
reflect a decline in this herd immunity. 
The routine meningococcal C conjugate (MCC) vaccination 
programme in Ireland has recently changed in response 
Figure 2. Number of IMD cases by gender and age group in Ireland, 1999-2015 (excludes one case with 
unknown gender details in 2009)
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Figure 3. Crude incidence rates per 100,000 population with 95% confidence intervals for IMD 
notifications by HSE area, Ireland, 2015
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Figure 4. Number of IMD cases by quarter and serogroup, Ireland, 1999-2015
to the recent increase in MenC cases and the emerging 
evidence of waning immunity. Instead of three doses of the 
MCC vaccine being administered to children at 4, 6 and 
13 months of age, from July 2015 a single dose is given at 
4 months, 13 months and at 12-13 years (if not previously 
vaccinated at >10 years of age) (http://www.hse.ie/eng/
health/immunisation/hcpinfo/guidelines/chapter13.pdf). 
The National Immunisation Advisory Committee (NIAC) 
also recommended a booster dose of the MCC vaccine for 
those considered at increased risk of MenC disease, and 
since 2011, the MCC vaccine booster has been recommended 
for close contacts of cases if their last dose was more than 
one year before. In August 2014, NIAC recommended an 
adolescent booster at 12-13 years to be offered in the first 
year of secondary level school. The adolescent booster MenC 
programme commenced in January 2015. 
Despite the marked reduction in the overall incidence in 
the past decade, IMD is still an important public health 
concern due to its associated severity, high mortality rate 
and serious adverse sequelae. Complete IMD prevention 
and control requires effective vaccination. Effective vaccines 
are now available against serogroups A, B, C, W135 and 
Y forms of the disease. In 2012, Bexsero®, a recombinant 
multicomponent vaccine (4CMenB) against serogroup B 
disease was approved by the European Medicines Agency. 
In March 2014, the United Kingdom’s Joint Committee on 
Vaccination and Immunisation (JCVI) recommended the 
vaccination of infants against serogroup B.7 In Ireland, 
the primary childhood immunisation (PCI) schedule were 
updated in July 2016 so that all babies born on or after 
1st October 2016 will be offered the MenB vaccine at 2, 4 
and 12 months of age (https://www.hse.ie/eng/health/
immunisation/infomaterials/newsletter/newsletter23.pdf). 
The MenB vaccine cannot be given at same time as MenC 
vaccine, which is given at 6 and 13 months of age.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 26th August, 2016. These figures 
may differ from those published previously due to on-going 
updating of notification data on CIDR.
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Figure 5. Number of IMD notifications in Ireland by serogroup and proportion of cases attributable to serogroup 
B with 95% confidence intervals, Ireland, 1999-2015
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There was a large increase in mumps in 2015 with 2,014 
(43.9/100,000) mumps cases notified. This is 2.7 fold higher 
than 2014 when 742 cases were notified and nine fold higher 
than 2013 when 223 cases were notified (figure 1). Large 
mumps outbreaks previously occurred during the years 
2004/2005 and 2008/2009 (figure 1). Two-thirds (n=1,354) 
of the cases in 2015 were notified between January and June 
(figure 2). 
In 2015, the largest number of cases was notified in the HSE 
S while the highest crude incidence rate was in the HSE NW 
(table 1).
Of the 2,014 mumps cases notified 50% (n=998) were 
classified as confirmed, 19% (n=381) as probable and 32% 
(n=635) were classified as possible.
The mean age of cases was 23 years and the median age 
of cases was 20 years with cases ranging in age from two 
months to 90 years. The highest age specific incidence rates 
were in those 15-19 years and 20-24 years (figure 3). Fifty 
eight per cent (n=1,173) of cases were male and 42% (n=838) 
were female while gender was not reported for three cases.
Mumps vaccine in Ireland is available as part of the 
combined measles mumps rubella (MMR) vaccine. In 
Ireland, vaccination with the first dose of MMR is routinely 
recommended at twelve months of age and the second 
dose at four to five years of age. A MMR catch up campaign 
started during the academic year 2012/2013 and continued 
during the academic year 2013/2014. During the MMR catch 
up campaign the HSE offered a dose of MMR vaccine to 
1.4 Mumps 
Summary
Number of cases, 2015: 2,014
Number of cases, 2014: 742
Crude incidence rate, 2015: 43.9/100,000
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Figure 1. Number of mumps cases by year 
A MMR catch-up campaign was conducted during the 2012/2013 and 2013/2014 academic years for children/students attending primary schools, second level 
schools and special schools and home-schooled students who had not completed (or were not sure they had) their two dose MMR vaccination schedule
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2015 data collated by HPSC
children/students attending primary schools, second level 
schools and special schools and home-schooled students 
who had not completed (or were not sure they had) their two 
dose MMR vaccination schedule. Additionally, MMR vaccine 
continued to be recommended for students in college or 
universities if not previously vaccinated. 
Of the 2,014 mumps cases, 10% (n=203) were unvaccinated, 
12% (n=239) had one dose of MMR, 33% (n=667) were 
reported to have received two doses of MMR, one per cent 
(n=20) were reported to have three doses of MMR while for 
44% (n=885) of cases the number of doses of MMR were 
not reported. The vaccination date was reported for 76% 
(n=182/239) of cases reported to have received one dose 
of MMR. Both vaccination dates were reported for 50% 
(n=336/667) of cases vaccinated with two doses of MMR. 
Forty per cent (n=268/667) of the cases reported to have 
received two doses of MMR were classified as confirmed; 
41% (n=110/268) of these cases had both MMR vaccination 
dates reported. All three vaccination dates were available for 
45% (n=9/20) of the cases given three doses of MMR. Of the 
20 cases reported to have received three MMR doses eight 
were classified as confirmed cases; one of these eight cases 
had all three vaccination dates reported.
The country of birth was recorded as Ireland for 480 cases, 
was recorded as being a country other than Ireland for 94 
cases and was unknown or not specified for the remainder.
Seventy two cases were hospitalised, representing four per 
cent (n=72/2,014) of all cases and six per cent (n=72/1,156) 
of cases where hospitalisation data was known. The number 
of days hospitalised was reported for 36 of the hospitalised 
cases; the median number of days hospitalised was four days 
(range one to 11 days). 
The most commonly reported complications of mumps 
included orchitis (13%, n=68/520), meningitis (1.6%, 
n=14/865), pancreatitis (1.2%, n=10/855), deafness (0.8%, 
n=7/858), mastitis (0.2%, n=2/859), headache (n=4) and 
abdominal pain (n=3). For some cases a number of clinical 
complications were reported. 
The setting where the case most likely acquired mumps 
was reported for 40% (n=815/2,014) of cases. The identified 
settings were: university/college (14%, n=279), social 
setting (12%, n=249), secondary school (8%, n=154), family/
household (3%, n=63), primary school (2%, n=39), work (1%, 
n=23), other healthcare facility (0.2%, n=4), international 
travel (0.1%, n=3) and day-care/pre-school (0.05%, n=1).
The probable countries of infection were recorded as Ireland 
(n=767), Spain (n=2), Brazil (n=1), France (n=1), Italy (n=1), 
Poland (n=1), United Kingdom (n=1), United States Minor 
Outlying Islands (n=1) and was unknown or not specified for 
the remainder.
Thirty nine localised outbreaks of mumps were notified 
during 2015 with a total of 370 associated cases of illness. 
The outbreak locations included 15 school outbreaks (with 
200 ill), nine private houses (with 32 ill), seven university/
college outbreaks (with 90 ill), three community outbreaks 
(with 30 ill), two childcare facility outbreaks (with five 
ill), one extended family outbreak (with four ill) and two 
workplace outbreaks (with nine ill). 
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 7th September 2016. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR.
Figure 3. The age specific incidence rates (per 100,000 population) 
of mumps cases in 2015 by case classification
Figure 2. Number of mumps cases in 2015 by month and HSE Area
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Table 1. Number of mumps cases and the crude incidence rate per 
100,000 population (CIR) by HSE Area in 2015
HSE Area Number CIR
HSE E 379 23.4
HSE M 57 20.2
HSE MW 165 43.5
HSE NE 85 19.3
HSE NW 267 103.4
HSE SE 230 46.2
HSE S 438 65.9
HSE W 393 88.2
Total 2014 43.9
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Other Forms of Bacterial Meningitis* 
Apart from Neisseria meningitidis, which is the most common 
cause of bacterial meningitis in Ireland, other pathogens 
cause this disease, including those caused by non-notifiable 
organisms. For information on invasive meningococcal 
disease (Neisseria meningitidis), see that chapter within 
this report. Information on bacterial meningitis caused 
by specified notifiable diseases is summarised below and 
further pathogen-specific data are available in the relevant 
chapter. The figures presented in this chapter are based on 
data extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 30th August, 2016. These figures 
may differ from those published previously due to on-going 
updating of notification data on CIDR. 
Bacterial meningitis caused by diseases not otherwise specified 
(NOS):
In total, 32 cases of meningitis under this disease category 
were notified in 2015, two of whom died. Of these two 
deaths, one had a Staphylococcus aureus infection, which 
was reported as the cause of death and the other had an 
Escherichia coli infection. Half of the 32 (50%) cases were 
case classified as confirmed, nine as probable (28.1%) and 
seven as possible (21.9%) (Table 1). The causative pathogens 
were identified in 53.1% (n=17/32) of cases (Table 2).
Prior to 1st January 2012, all cases of Group B streptococcus, 
also known as S. agalactiae, were notifiable under the 
‘Bacterial Meningitis (NOS)’ disease category. In 2012, this 
changed when Streptococcus agalactiae in children <90 days 
of age was notifiable in its own right, including those which 
were meningitis-related. This has meant that the overall 
number of bacterial meningitis (NOS) cases has, as a result, 
declined between 2012 and 2015 compared to previous 
years. In other words, without this change there would have 
been 25 extra cases reported under the bacterial meningitis 
(NOS) category between 2012 and 2015. Furthermore, there 
is evidence of an additional 43 possible meningitis-related 
cases of this disease in this same age group during this same 
four year period where S. agalactiae was either isolated from 
or detected in CSF specimens from patients that were not 
clinically categorised as having ‘meningitis’ and had in fact 
no clinical diagnosis reported on CIDR. These 43 cases have 
been excluded from Table 3, which is a summary breakdown 
of all bacterial meningitis cases by their causative 
pathogen (both specified and not specified types except for 
meningococcal disease) between 2010 and 2015.
Among the bacterial meningitis (NOS) cases notified in 2015 
were 15 caused by Escherichia coli (age range two weeks to 
82 years; none of which had serotype details reported) and 
one each caused by Pasteurella multocida (0-2 months) and 
Staphylococcus aureus (70-74 years). There were 15 other 
cases whose causative organism was not identified. 
Bacterial meningitis caused by specified notifiable diseases:
Haemophilus influenzae
Five cases of meningitis due to H. influenzae were notified in 
2015, three of which were attributable to strains that were 
not type b, one to a non-typeable/non-capsulated strain and 
one that was PCR diagnosed positive, not typed. The age 
range was one month to 86 years. No deaths were reported 
among these cases. See Table 3 and the chapter on invasive 
H. influenzae disease for further details.
Listeria species
Five cases of listeriosis meningitis were notified in 2015 
(age range 16 months to 76 years), all of whom were male 
and one of which, an adult, died from the infection. Of the 
three serotypes identified, two were type 4b and one was 
type 1/2a. Of the five cases, two had an underlying medical 
condition reported, one of whom died. See Table 3 and the 
chapter on listeriosis disease for further details.
Mycobacterium species
During 2015 two tuberculosis meningitis cases, aged 40-
79 years, were notified and both had risk factors reported 
(provisional at the time of writing). See Table 3 and the 
chapter on tuberculosis for further details.
1.5  Other Forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Number of cases, 2015: 32
Number of cases, 2014: 23
Number of cases, 2013: 21
Crude incidence rate, 2015: 0.69/100,000
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Table 1. Number and percentage of bacterial meningitis (NOS) cases reported by case classification, Ireland, 2010-2015
Case Classification 2010 2011 2012 2013 2014 2015 2010-2015
Confirmed 21 18 12 6 13 16 86
Probable 7 4 5 5 8 9 38
Possible 14 13 12 10 2 7 58
Total 42 35 29 21 23 32 182
% Confirmed 50.0% 51.4% 41.4% 28.6% 56.5% 50.0% 47.3%
Note: Meningitis related-Streptococcus agalactiae < 90 days of age excluded from 2012, 2013, 2014 and 2015 figures
Table 2. Number and percentage of bacterial meningitis (NOS) cases reported with and without an identified causative organism, Ireland, 
2010-2015
Causative Organism 2010 2011 2012 2013 2014 2015 2010-2015
Known 21 20 11 6 13 17 88
Unknown/Not specified 21 15 18 15 10 15 94
Total 42 35 29 21 23 32 182
% Known 50.0% 57.1% 37.9% 28.6% 56.5% 53.1% 48.4%
Note: Meningitis related-Streptococcus agalactiae < 90 days of age excluded from 2012, 2013, 2014 and 2015 figures
Table 3. Annual notifications of bacterial meningitis (specified and NOS) except invasive meningococcal disease, Ireland, 2010-2015
Notified under Causative organism 2010 2011 2012 2013 2014 2015 2010-2015
Haemophilus influenzae disease 
(invasive) Haemophilus influenzae 2 4 3 2 7 5 23
Leptospirosis Leptospira spp. 0 1 1 0 0 0 2
Listerosis Listeria spp. 3 2 2 2 1 5 15
Streptococcus pneumoniae infection 
(invasive) Streptococcus pneumoniae 16 23 37 33 39 29 177
Streptococcus Group A infection 
(invasive) (iGAS) Streptococcus pyogenes 2 0 1 3 0 4 10
Streptococcus Group B infection 
(invasive) (Group B Strep) < 90 days 
of age
Streptococcus agalactiae† NA NA 11 5 5 4 25
Tuberculosis* Mycobacterium spp.* 9 2 4 3 1 2 21
Total Bacterial Meningitis, 
specified 32 32 59 48 53 49 273
Bacterial Meningitis, not otherwise 
specified
Enterococcus faecium 0 0 1 0 0 0 1
Enterococcus species 0 0 0 0 1 0 1
Escherichia coli 2 1 7 4 8 15 37
Group C Streptococcus 0 0 1 0 0 0 1
Klebsiella oxytoca 0 1 0 0 0 0 1
Klebsiella pneumoniae 0 0 0 0 1 0 1
Micrococcus luteus 0 0 0 0 1 0 1
Mycoplasma pneumoniae 1 0 0 0 0 0 1
Pasteurella multocida 0 0 0 0 0 1 1
Staphylococcus aureus 6 2 1 0 0 1 10
Staphylococcus aureus & 
Staphylococcus capitis
0 0 1 0 0 0 1
Staphylococcus capitis 1 0 0 0 0 0 1
Streptococcus agalactiae** 11 16 0 1 1 0 29
Streptococcus salivarius 0 0 0 1 0 0 1
Streptococcus suis 0 0 0 0 1 0 1
Unknown 1 1 2 2 1 2 9
Not specified 20 14 16 13 9 13 85
Total Bacterial Meningitis, not 
otherwise specified
42 35 29 21 23 32 182
Total Bacterial Meningitis, 
specified and not otherwise 
specified
74 67 88 69 76 81 455
*Tuberculosis meningitis figure for 2015 is provisional       
†Streptococcus agalactiae < 90 days of age in 2012 to 2015-these figures do not include 43 meningitis-related cases where the causative organism was 
isolated from or detected in CSF specimens from patients that were not clinically categorised as having ‘meningitis’ 
**Streptococcus agalactiae for all ages only in 2010 to 2011 and for cases > 90 days of age only in 2012 to 2015
NA not applicable
Streptococcus Group A infection (invasive) (iGAS) 
Four cases of iGAS were notified during 2015, compared to 
none in the previous year (Table 3). The age range was 12 
months to 39 years. Three of the cases were male and one 
female. Three of the four cases had risk factors identified, but 
no deaths were reported.
Streptococcus Group B infection (invasive) (Group B Strep) <90 
days of age
Four cases of Group B Strep under 90 days of age were 
notified to CIDR during 2015, compared to five in 2014 (Table 
3). Three of the four cases in 2015 were female and one was 
male. No deaths were reported.
Streptococcus pneumoniae
In 2015, 29 cases of pneumococcal meningitis were 
notified, compared to 39 in the previous year (Table 3). The 
median age was 54 years (range one month to 77 years). 
No pneumococcal meningitis-related deaths were reported 
during 2015. Of the 29 cases in 2015, data on vaccination 
status were available for 22 (75.9%) of the 29 cases; four 
cases were aged >65 years. Table 4 presents the vaccination 
status, serotype and additional risk factor for each case. 
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Table 4. Details of the 29 pneumococcal meningitis cases reported, Ireland, 2015
Case No. Age Group (years)
Vaccination 
Status
No. of PCV13 
/ Prevenar 13 
Doses
No. of PPV23 / 
Pneumovax 23 
Doses
Serotype of 
Infection
Serotype Covered 
by Vaccine Type
Additional Risk 
Factors (excluding 
age 65+ years)
1
<1
Y 2 NA 12A Not covered N
2 N 0 0 NA N
3 I 2 0 15B PPV23 N
4
5-9
N 0 0 23A Not covered N
5 Y 2 0 NA N
6
10-14
Y 0 1 33F PPV23 Y
7 N 0 0 NA N
8 20-24 U 0 NA NA Y
9 30-34 N 0 0 9N PPV23 Y
10 35-39 U 0 NA 8 PPV23 N
11 40-44 U 0 NA 34 Not covered NA
12 45-49 N 0 0 NA N
13
50-54
N 0 0 19A PCV13, PPV23 Y
14 U 0 NA NA Y
15 N 0 0 NA Y
16
55-59
N 0 0 24F Not covered N
17 N 0 0 NA Y
18 U 0 U 7F PCV13, PPV23 N
19 Y NA U NA Y
20 N 0 0 NA Y
21 U 0 NA NA NA
22
60-64
U 0 U 23A Not covered Y
23 N 0 0 8 PPV23 Y
24 N 0 0 NA Y
25 N 0 0 24F Not covered Y
26
65+
N 0 0 22F PPV23 N
27 N 0 0 22F PPV23 Y
28 Y 0 1 9N PPV23 Y
29 N 0 0 18C PCV13, PPV23 Y
NA=not applicable or not available; Vaccinated: Y=Yes, N=No, U=Unknown, I=Incompletely vaccinated
Following an increase in pertussis in 2012 with 458 
notifications (10.0/100,000), pertussis declined to 73 cases 
(1.6/100,000) in 2014 but increased slightly in 2015 with 117 
cases (2.5/100,000) notified (figures 1 and 2).
Of the 117 cases in 2015, 64% (n=75) were classified as 
confirmed, 7% (n=8) were classified as probable and 29% 
(n=34) were classified as possible.
The largest number of cases was notified in the HSE E while 
the highest crude incidence rate was in the HSE W (table 1).
Fifty-seven percent of cases (n=67) were female and 43% 
(n=50) were male.
The largest number of cases and the highest age-specific 
incidence rate were in children aged less than one year 
followed by those in the age group 1-4 years (figures 3 and 
4). Twenty nine percent (n=34/117) of all cases were aged 
less than six months of age. Six percent (n=7/117) of all cases 
were aged less than two months of age.
Maternal antibodies from women immunised before 
pregnancy wane quickly and the concentration of pertussis 
antibodies is unlikely to be high enough to provide passive 
1.6 Pertussis
Summary
Number of cases, 2015: 117
Number of cases, 2014: 73
Crude incidence rate, 2015: 2.5/100,000
-26-HPSC Annual Epidemiological Report 2015 1. Vaccine Preventable Diseases
Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2015
1948-June 2000 data collated by DoHC
July 2000-2015 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2015
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protection to their infants prior to primary vaccination. 
Since August 2012, the National Immunisation Advisory 
Committee (NIAC) has recommended that pregnant women 
should be offered tetanus and low dose diphtheria and 
acellular pertussis (Tdap) vaccine during 27 -36 weeks 
gestation in each pregnancy, to protect themselves and their 
infant. Tdap can be given at any time in pregnancy before 27 
or after 36 weeks gestation although it may be less effective 
in providing passive protection to the infant.
In 2015, data on maternal antenatal vaccination status 
was provided for 27 children aged less than one year (69%, 
n=27/39). The mothers of 24 of these infant pertussis cases 
(62%, n=24/39) were unvaccinated during the antenatal 
period. Gestational age at birth was reported for seven 
of these 24 cases and ranged from 32 to 40 weeks with a 
median gestational age at birth of 39 weeks and a mean of 
38 weeks. Three of the mothers of the infant pertussis cases 
(8%, n=3/39) reported vaccination during the antenatal 
period; one was vaccinated at 28 weeks gestation, one at 35 
weeks gestation while this data was unreported for the third 
case.
In Ireland, it is recommended that children be vaccinated 
with an acellular pertussis containing vaccine at two, four 
and six months of age and a booster dose at four to five 
years of age. In 2008, NIAC recommended a booster with 
low dose acellular pertussis vaccine for children aged 11-14 
years. The adolescent pertussis booster was introduced into 
the school programme, in 19 LHOs, in 2011 and to all schools 
in 2012. In August 2012, an additional pertussis booster was 
recommended for health care workers and pregnant women; 
please see the HSE National Immunisation Office website at 
http://www.immunisation.ie for additional information on 
pertussis vaccination recommendations.
In 2015, the number of doses of pertussis vaccine the cases 
received was reported for 66% (n=77/117) of cases. Twenty 
seven percent of cases (n=32/117) were unvaccinated; these 
cases ranged in age from one month to 73 years, with 59% 
(n=19/32) of these cases aged less than six months. Twenty 
two percent of the unvaccinated cases (n=7/32) were less 
than two months of age and were therefore not eligible for 
pertussis vaccine in the Irish schedule.
Nine percent (n=10/117) of cases were reported to have one 
dose of pertussis vaccine, all were less than eight months 
of age. Two percent (n=2/117) had two doses of pertussis 
vaccine, these cases were five months of age. Twenty one 
percent (n=24/117) had three doses of pertussis vaccine, 
these cases ranged in age from 9 months to 12 years. Eight 
percent (n=9/117) had four doses of pertussis vaccine, 
these cases ranged in age from six to 34 years. Of the cases 
reported to have four doses of pertussis vaccine one third 
were classified as confirmed (n=3/9) and 56% (n=5/9) had 
all four vaccine dates recorded. 
Country of birth was reported as Ireland for 42 cases, 
Philippines for one, United Kingdom for one, and was 
unknown or not specified for the remainder (n=73).
Where data were provided, reported symptoms included 
cough (100%, n=86/86), paroxysmal cough (97%, n=87/90), 
any inspiratory whoop (74%, n=56/76), post-tussive 
vomiting (62%, n=49/79), choking episodes in infant 
(50%, n=13/26), apnoea (34%, n=25/74) and cyanosis 
(33%, n=22/66). Where data were provided, reported 
complications included pneumonia (3%, n=2/70), seizures 
(3%, n=2/71) and conjunctival haemorrhages (2%, n=1/66).
Thirty three cases were hospitalised, representing 28% 
(n=33/117) of all cases and 38% (n=33/87) of cases where 
hospitalisation data was known. Seventy nine percent 
(n=26/33) of those hospitalised were aged less than one 
year and 18% (n=6/33) were less than two months of age.
One of the cases was recorded as having long-term sequelae 
following infection.
Table 1. Number of pertussis cases notified and the crude incidence 
rate per 100,000 population (CIR) by HSE Area in 2015
HSE Area Number CIR
HSE E 48 3.0
HSE M 7 2.5
HSE MW 1 0.3
HSE NE 14 3.2
HSE NW 4 1.5
HSE SE 14 2.8
HSE S 14 2.1
HSE W 15 3.4
Total 117 2.5
Figure 3. Number of notified pertussis cases in 2015 by age group and 
case classification.
‘Mo’ in graph indicates months ie 0-5 months and 6-11 months, the 
remaining age groups are in years
Figure 4. The age specific incidence rate (per 100,000 population) of 
notified pertussis cases in 2015 by case classification
Age group (months/years)
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Of the 117 cases, the likely setting of exposure to pertussis 
included home (23%, n=27), school (3%, n=3), other family 
setting (2%, n=2), crèche/childcare (1%, n=1), work (1%, n=1), 
and was unreported or not specified for the remainder (71%, 
n=83).
The likely source of exposure included sibling (8%, n=9), 
other relative (5%, n=6), mother (3%, n=4), father (2%, n=2), 
and was unknown or not specified for the remainder (82%, 
n=96).
Antibiotic usage was reported for 92% (n=81/88) of cases 
where this data was provided and for 69% of all cases 
(n=81/117). A second antibiotic was known to be given for 
28% (n=23/81) of cases given a first antibiotic and known 
not to be given for 36% (n=29/81) of cases given a first 
antibiotic while this information was not provided for the 
remainder (36%, n=29/81).
Six localised pertussis outbreaks were notified during 2015, 
with 14 associated cases of illness. All outbreaks were 
associated with private houses.
The figures presented in this summary are based on data 
extracted from the CIDR system on 22nd August 2016. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR.
In 2015, two cases (0.04/100,000) of rubella were notified in 
Ireland compared to three cases notified in 2014. Of the two 
cases in 2015 one was in the age group 3-4 years and one 
was in the age group 20-29 years.
Both cases were classified as possible cases.
One of the possible cases met the criteria for possible rubella 
case classification; unfortunately no samples were obtained. 
A second case, also classified as possible, was serum IgM 
negative for rubella, however, no onset date or rash onset 
dates were reported and therefore it is not known when the 
specimen was taken in relation to symptom onset. Both 
cases had one dose of MMR vaccine. Neither of the cases 
had an epidemiological link to any known cases so these 
cases are unlikely to be rubella. 
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 19th August 2016. These figures 
may differ slightly from those published previously due to 
ongoing updating of data on CIDR.
WHO require information on discarded rubella cases ie 
rubella cases investigated and who were found not to meet 
the case definition. The HSE Areas reported the number 
of discarded CIDR cases to HPSC. For 2015, 21 cases were 
discarded from CIDR as following investigation they were 
not considered to be rubella cases. Discarded cases are not 
available in CIDR for reporting and are therefore not included 
in the analysis above.
The Regional Verification Commission for Measles and 
Rubella Elimination (RVC) was established in the WHO 
European Region in 2011 to evaluate the documentation 
submitted by Member States with a view to verifying the 
elimination of measles and rubella at the regional level. The 
WHO Regional Office serves as the secretariat to the RVC.1
The RVC comprises public health experts, including 
epidemiologists, clinicians and virologists. It includes a 
chairperson, a vice-chairperson and a maximum of eight 
additional members, all of whom are independent of the 
managerial and operational aspects of elimination activities. 
The RVC works in close collaboration with the WHO Regional 
Office for Europe, and reports to the WHO Regional Director 
for Europe. Its main task is to provide periodic updates 
to, and coordinate technical and policy issues with, the 
European Technical Advisory Group of Experts.1
The RVC has recommended establishment of national 
verification committees (NVC) in all Member States and 
suggested a standard format for annual status reports from 
countries. These reports include information on measles 
and rubella epidemiology, virologic surveillance supported 
by molecular epidemiology, the analysis of vaccinated 
population cohorts and the quality of surveillance, and 
the sustainability of the country’s National Immunisation 
Programme.1
The review and evaluation of annual national reports will 
continue for at least three years after the RVC confirms that, 
according to established criteria, endemic measles and 
rubella transmission have been interrupted in all Member 
States of the Region. Only then can Regional elimination be 
declared.1 
Based on the data provided by the Irish National Verification 
Committee in 2014 to the WHO RVC the RVC concluded that 
endemic transmission of rubella remained interrupted in 
Ireland in 2014. In view of the reported data for the period 
2012-2014, the RVC declared rubella eliminated in Ireland.2
References
1.  WHO. Regional Verification Commission for Measles and Rubella 
Elimination (RVC). Available at http://www.euro.who.int/en/health-
topics/communicable-diseases/measles-and-rubella/activities/
regional-verification-commission-for-measles-and-rubella-elimination-
rvc. 
2.  WHO. 4th Meeting of the European Regional Verification Commission for 
Measles and Rubella Elimination (RVC). Available at http://www.euro.
who.int/__data/assets/pdf_file/0011/304958/4th-RVC-meeting-report.
pdf?ua=1. 
1.7 Rubella
Summary
Number of cases, 2015: 2
Number of confirmed cases, 2015: 0
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Streptococcus pneumoniae (invasive)
Background
Invasive Streptococcus pneumoniae infection is a notifiable 
disease in Ireland; clinicians and laboratories are legally 
obliged to notify this infection. For the purposes of this report 
the term invasive pneumococcal disease (IPD) will be used 
to describe these infections. IPD includes meningitis and 
bloodstream infection (BSI) with and without pneumonia.
A number of different initiatives are in place in Ireland 
for the surveillance of IPD. Data on IPD notifications are 
collated in the Computerised Infectious Disease Reporting 
(CIDR) system. Enhanced surveillance of IPD notifications 
is undertaken by Departments of Public Health. A separate 
surveillance strand (EARS-Net project) involving the 
microbiology laboratories and HPSC is used to monitor 
in detail the antimicrobial resistance profiles of invasive 
S. pneumoniae isolates from blood and/or CSF. EARS-
Net laboratories can also collect additional information, 
including risk factors, admission and outcome for each S. 
pneumoniae isolate reported and these data are collated by 
HPSC through the Enhanced Surveillance of Bloodstream 
Infection (ESBSI) system. To improve data quality regular 
processes for cross-checking CIDR data with other data 
sources was established in 2012; CIDR data are linked to the 
typing and ESBSI databases and additional information on 
either of these systems but missing or incomplete in CIDR is 
collated on an annual basis.
Since April 2007, the Irish Pneumococcal Reference 
Laboratory has provided a typing service to Irish laboratories 
for all invasive S. pneumoniae isolates. This is a collaborative 
project involving the Royal College of Surgeons in Ireland/
Beaumont Hospital, the Children’s University Hospital, 
Temple Street and HPSC. In addition, since August 2012 
HPSC has participated in a European Centre for Disease 
Prevention and Control (ECDC) project called SpIDnet and 
since 2015 HPSC has joined the ECDC project I-MOVE plus. 
Both projects aim to strengthen or set up long term active 
population-based IPD surveillance in order to estimate the 
impact of the pneumococcal conjugate vaccines in children 
less than five years of age, in those aged 5-64 years of age 
and in adults aged 65 and over in Europe.
In September 2008, the 7-valent pneumococcal conjugate 
vaccine (PCV7) was introduced into the Irish infant 
immunisation schedule at 2, 6 and 12 months of age. A 
catch-up campaign was also implemented at that time, 
targeting children <2 years of age. In December 2010, PCV13 
replaced PCV7 in the infant schedule. Uptake of three doses 
of PCV by 24 months of age for 2015 was 93%.
Notification data for IPD was extracted from CIDR on 30th 
May 2016. These figures may differ slightly from those 
previously published due to ongoing updating of notification 
data on CIDR. For the 2012- 2014 notifications, the 2012 
HPSC case definition for IPD was used. In brief, isolation or 
detection of S. pneumoniae from a normally sterile site was 
classified as confirmed; detection of S. pneumoniae antigen 
from urine was classified as a possible case. Since 2012, 
the previously used probable case definition is no longer 
applicable and any case in which S. pneumonia antigen was 
detected from urine (previously defined as a probable case) 
was classified as possible, and antigen detection from a 
sterile site was categorised as confirmed. Since July 2015, 
the case definition of S. pneumoniae was amended and 
only those cases of IPD meeting the laboratory criteria for 
laboratory confirmed are now notifiable and urinary antigen 
detection (possible cases) are no longer notifiable.
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of confirmed cases in 2015: 368
Number of confirmed cases in 2014: 350
Number of deaths in 2015: 37
Number of deaths in 2014: 37
Crude incidence rate of confirmed cases in 2015: 
8.0/100,000
Figure 1. Number of confirmed invasive pneumococcal disease 
(IPD) notifications by typing status and the incidence rate (IR) of 
confirmed IPD with 95% confidence intervals, 2008-2015
Data source: CIDR
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Results
All IPD notifications
In 2015, 549 cases of IPD (12.0/100,000) were notified 
in Ireland, a decrease compared with 2014 (681 cases; 
14.8/100000). This decrease is related to a decrease in the 
number of possible cases notified in 2015 in comparison to 
2014 due to definition changes.
In 2015, 67% (n=368) of notifications were classified as 
confirmed and 33% (n=181) as possible. The majority of 
possible cases (83%) were notified by HSE E, HSE SE and 
HSE MW (n=47/181; n=59/181 and n=44/181, respectively). 
Confirmed IPD notifications
Focusing specifically on the confirmed IPD notifications, 
368 cases were notified in 2015 (8.0/100,000; 95% CI 7.2 - 
8.8/100,000), a slight increase in the number of cases was 
observed compared with 2014 (7.6/100,000; 95% CI 6.8 
- 8.4/100,000; 350 cases) (Figure 1). In 2015, the incidence 
of confirmed IPD decreased by 20% compared with 2008 
(9.5/100,000; 95% CI 8.6 – 10.5/100,000; 404 cases; 
p<0.05) (Figure 1).
In 2015, 77% of the confirmed IPD notifications had an 
isolate submitted for serotyping, less than the proportion 
of cases in 2014 (81%) and in 2013 (80%), but similar to 
the proportions reported in 2008 and 2009 when 79% 
of notifications had an isolate typed. In 2012, 86% of all 
isolates were typed (Figure 1). In 2015, 37% of notifications 
(13/35) relating to children <5 years of age did not have an 
isolate submitted for serotyping. For two of the 13 cases IPD 
was confirmed by PCR only and no isolate was available. For 
the remaining eleven isolates from a sterile site, no sample 
was available for typing.
Incidence rates by HSE area ranged from 5.8 per 100,000 
in HSE W to 8.8 per 100,000 in HSE E, with the highest 
incidence in the HSE MW, HSE S and HSE-SE (Figure 2). 
However, the incidence rates in each of the eight HSE areas 
were not statistically different from the national one.
In 2015, a clinical diagnosis was reported for 229 of the 368 
confirmed cases (62%), which included BSI with pneumonia 
(n=163), meningitis (n=29), and other BSI for the remainder 
(n=37). This reflects an improvement in completeness of data 
provided in comparison to 2014, when clinical diagnosis was 
reported for 168 of the 350 confirmed cases (48%), 14% less 
than in 2015. 
More cases occurred in males (n=194, 53%) than in females. 
Cases ranged in age from 1 month to 99 years, with an 
average age of 57.3 years (median age 65.5 years). Those 
aged 65 years and older accounted for half of the cases 
(51%, n=189). The age specific incidence rate (ASIR) was 
highest in those 85 years of age and older (77.0/100,000; 
n=45), followed by those in the 75-84 years age group 
(40.7/100,000; n=70) and the 65-74 year age group 
(24.3/100,000; n=74) (Figure 3). In children <2 years of 
age the ASIR was 13.1 cases per 100,000 population (n=19). 
A statistically significant decline (60%) in IPD incidence 
was seen in this age group when compared with 2008 
(42/100,000; n=52; p<0.0001), highlighting the positive 
impact of the introduction of PCV7 in September 2008 to the 
infant schedule followed by PCV13 in December 2010 (Figure 
3). 
The medical risk factor field was completed for 178 (48%) 
confirmed cases; 37 cases (16%) did not have an identified 
risk factor; for the remaining 131 cases this information was 
either unknown or not specified. Based on the 178 cases for 
whom this information was reported, 144 (81%) of them had 
an underlying medical risk factor, with some patients having 
multiple risk factors. The main medical risk factors reported 
included immunosuppressive condition or therapies (n=58; 
40.3%), chronic lung disease (n=59; 41%), chronic heart 
disease (n=64; 44.4%), chronic liver disease (n=15; 10.4%) 
and renal diseases (n=21; 14.6%). It should also be noted that 
being aged 65 years and older was also a recognised IPD risk 
factor; 189 (51%) cases in 2015 were in this age group. Apart 
from their age, 103 (54%) cases in this age group also had a 
reported medical risk factor.
IPD death notifications
Outcome was reported in 56% (n=309) of the IPD 
notifications in 2015 versus 39% in 2014. Therefore, these 
figures may not accurately estimate the burden of IPD in 
terms of mortality. Based on the data available in 2015, 41 
deaths in individuals with IPD were reported; for seven cases 
the cause of death was reported as directly due to IPD, not 
due to IPD in four cases and for the remaining 30, the cause 
of death was not specified or was unknown. Forty deaths 
occurred in adults, ranging in age from 50-99 years and 
one in an infant three months of age. Forty deaths were in 
confirmed cases. 
The apparent increase in IPD death notifications in 2012-
2015 (41 cases in 2015 and also in 2014, 24 cases in 2013 and 
Figure 2. Crude incidence rate of confirmed invasive pneumococcal 
disease notifications by HSE area, 2015
Data source: CIDR
Figure 3. Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2015
Data source: CIDR
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37 cases in 2012 versus 11 cases in 2011) is most likely related 
to the additional information that was available by linking 
CIDR data to the Enhanced Surveillance of Blood Stream 
Infections (ESBSI) database. Using BSI data it was possible 
to identify missing information on outcome in CIDR and then 
the CIDR database was updated by HSE areas. 
Impact of pneumococcal conjugate vaccines (PCV)
Data from the National Pneumococcal Typing Laboratory 
were used to assess the impact of introducing PCV on the 
distribution of S. pneumoniae serotypes associated with 
IPD and on the burden of IPD in Ireland. In 2015, of the 
368 confirmed IPD notifications reported in CIDR, 283 had 
isolates sent for typing (77%). Two percent of IPD infections 
were due to serotypes covered by PCV7 (4, 6B, 9V, 14, 18C, 
19F and 23F), 26% were associated with the six additional 
serotypes included in PCV13 (1, 3, 5, 6A, 7F and 19A) and the 
remaining 72% of infections were due to non-vaccine types 
(NVTs). 
Since introducing PCV7 to the Irish childhood immunisation 
schedule towards the end of 2008, there has been a 20% 
reduction in the overall burden of IPD disease. Reductions 
in the incidence of IPD due to PCV7 serotypes have been 
seen in all age groups (Figure 4a). Overall, the incidence of 
IPD due to PCV7 serotypes has significantly declined in 2015 
compared with 2008 (99% decline, p<0.001). The greatest 
impact has been seen in children <5 years of age where 
the incidence due to PCV7 serotypes has declined by 100% 
(p<0.001) (Figure 4a). In 2015 the incidence of disease due 
to the additional six serotypes covered by the PCV13 declined 
by 60% in children <2 years of age compared with 2008 
(Figure 4b). The decline was also observed in the other age 
groups with these additional six serotypes compared with 
2008; however, this decline was not significant (Figure 4b). 
An increase in incidence due to NVTs was also seen in 2015 
compared with 2008. In those aged 65 years and older, an 
increase in incidence was observed in 2015 compared with 
2014. There has been little change in the incidence of NVTs 
among other age groups (Figure 4c). 
The predominant serotypes in circulation in 2015, were 8 
(NVT), 19A, 7F and 3 (all included in PCV13) and followed by 
serotypes and 12F and 22F (both NVT). In children <5 years 
of age, the predominant serotypes were 19A (included in 
PCV13), 12F, 15A, 23B, 12A and 15B/C (all NVTs); all these 
serotypes accounted for 91% of the isolates serotyped in this 
age group (Figure 5).
For ongoing updates, see “Slides – Impact of PCV in 
Ireland” at http://www.hpsc.ie/A-Z/VaccinePreventable/
PneumococcalDisease/PostersPresentations/
PCV vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, two PCV vaccine failures were reported 
in 2015, both due to serotype 19A (PCV 13). Since 2008, a 
total of 11 vaccine failures have been reported in addition to 
the two reported in 2015, two in 2014 (19A), three in 2013 
(19A), two in 2012 (19F and 19A) and two in 2010 (19F and 
14). 
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2015, the proportion of penicillin non-susceptible invasive 
S. pneumoniae (PNSP) was 17.5%, (0.3% and 17.2% with 
high and intermediate level resistance, respectively) while 
PCV7
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Figure 4. Age specific incidence rate by age group of confirmed 
invasive pneumococcal disease cases due to (a) PCV7 serotypes, (b) 
the additional six serotypes covered by PCV13 and (c) non-vaccine 
types, 2008-2015. 
Data source: Irish Pneumococcal Reference Laboratory
Figure 4a Figure 4b
Figure 4c
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15.2% of isolates were resistant to erythromycin (Data 
source: HPSC/EARS-Net Ireland). This compares to 17.1% 
and 13.8% in 2014, respectively. In 2015, the proportion of 
PNSP increased slightly compared to 2014, but the overall 
trend for the past 3 years has been downward. In 2015, the 
proportion of S. pneumoniae
with resistance to erythromycin increased compared to 
2014, but the overall trend for the past four years has been 
downward.
The predominant PNSP serotypes in 2015 were 8, 19A and 
12F whereas in 2008 serotypes 9V and 14 were the predomi-
nant serotypes associated with PNSP. For details on the 
antimicrobial resistance patterns of S. pneumoniae, please 
see the link on EARS-Net Report, Quarters 1-4 2015:   
http://www.hpsc.ie/A-Z/MicrobiologyAntimicrobialResi
stance/EuropeanAntimicrobialResistanceSurveillanceSyste
mEARSS/EARSSSurveillanceReports/2015Reports/
Discussion
Although there was slight increase in the incidence of 
confirmed cases of IPD in Ireland in 2015 compared with 
2014, since vaccine introduction in 2008, PCV7 has had 
a significant impact in reducing the overall burden of the 
disease in the total population. There has been a decline 
in IPD in all age groups due to serotypes covered by PCV7, 
indicating the indirect/herd immunity effect the vaccine 
confers on the population. The greatest impact has been 
in children <5 years of age where disease incidence due to 
PCV7 serotypes has fallen by over 100%. The impact due to 
the additional six serotypes covered by PCV13 vaccine was 
observed in children <2 years of age, amongst whom the 
reduction in the incidence of disease was 60%.
However, despite reductions in the IPD burden during 
childhood, the incidence of disease due to non-PCV7 
serotypes has increased in other age groups. There has been 
a shift in the prevalent serotypes associated with invasive 
disease. Serotypes 8, 19A and 7F were the predominant 
serotypes identified in 2015. 
Ireland (HPSC) is participating in ECDC funded projects, 
SpIDnet (since 2012) and I-Move plus (since 2015). 
Participation in these projects allows the strengthening of 
the IPD surveillance system in Ireland. As part of SpIDnet 
project since January 2013 enhanced surveillance was 
extended to all children and adolescents aged <15 years 
of age and since December 2014 enhanced surveillance 
was undertaken in one of the HSE regions on all adult IPD 
cases particularly focusing on data collection for clinical 
presentation, risk factor, outcome and vaccination history. 
This approach has improved data quality, completeness 
and timeliness. All HSE regions are striving to improve the 
quality of enhanced data collection for all cases (paediatric 
and adults). 
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in Ireland, 
it is crucial that samples from sterile sites are obtained 
for culture and sensitivity. Isolates obtained by culture 
are required for serotyping and antibiotic susceptibility. 
Furthermore it is crucial that laboratories continue to 
send all invasive S. pneumoniae isolates for typing to the 
National Pneumococcal Typing Laboratory. Although 77% 
of confirmed notifications had an isolate submitted for 
serotyping in 2015, 23% (n=85) did not, including 13 cases 
in children <5 years of age. In two of these 13 cases, an 
isolate was not available for typing and confirmation was 
by PCR only. Serotype information is unavailable for 37% of 
confirmed notifications in this age group and the absence of 
this data is of concern.
Continued good quality IPD surveillance including 
the monitoring of invasive S. pneumoniae serotypes is 
crucial in identifying any epidemiological changes in 
the disease, in assessing the impact of PCV13 on public 
health and in guiding further vaccination strategies, as 
newer expanded valency vaccines become available and 
changes to recommendations of PCV are made e.g. age 
related. For example, due to the incomplete data we do 
not know the impact of IPD on mortality and this is a key 
metric in assessing the true impact of this disease and the 
effectiveness of interventions, including new vaccines.
Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age group (years) in 
Ireland, 2015
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: Irish Pneumococcal Reference Laboratory
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Tetanus
Tetanus is a rare disease in Ireland since the introduction of 
tetanus vaccines in the 1930s. However, cases still occur.  
One case of non-fatal tetanus was notified in 2015. The 
case was in the age group 35-44 years and was classified 
as confirmed. It was not known if the case had ever received 
any tetanus vaccinations. The case developed paralysis with 
muscle spasms days after injecting heroin (“skin popping”). 
The case was on a ventilator for 12 days.
Summary of case data since 1981:
Sixteen cases of tetanus were reported since tetanus became 
notifiable in November 1981. The number of tetanus cases 
notified by age group is shown in figure 1. Two deaths were 
reported, both cases were aged >60 years.
Of the 16 tetanus cases, nine (56%) were male, five (31%) 
were female while gender was unreported for two (13%).
The following wound injuries (n=11) were reported among the 
16 notified cases: wound injuries from a road traffic accident 
(n=1), wound from a fall outdoors (n=1), wound associated 
with a dog bite (n=1), wound from a kitchen knife (n=1), 
gardening associated leg wound (n=1), leg scratches in an 
avid gardener (n=1), hand wound associated with a clean 
piece of wood (n=1), a farming associated hand wound (n=1), 
a foot wound from a thorn (n=1), hand injuries from a can 
and a rusty nail (n=1) and, as mentioned above, in the case 
reported in 2015 the case developed paralysis with muscle 
spasms days after injecting heroin (n=1). An additional case 
was reported having a discharging wound on a toe one week 
prior to onset of tetanus symptoms developing, however, the 
cause of the wound was not reported.
Vaccination data were reported for six of the 16 cases. Two 
cases, in the age groups 10-14 years and 20-24 years, were 
unvaccinated. One case, in the age group 15-19 years, was 
reported to have received three doses of tetanus vaccine as a 
child and a booster at four years and again at five-six years of 
age. One case was reported to have received a single tetanus 
vaccine around 40 years prior to infection. One case was 
reported as having received one dose of a tetanus vaccine 
20 years earlier but it was not known if the case had received 
any previous doses (ie primary tetanus vaccines as an infant). 
One case (age group 15-19 years) was reported as having 
received one dose of a tetanus vaccine as an infant and a 
dose when they were two years of age.
Vaccine efficacy after a complete series of vaccines (five 
doses) is almost 100%. However, immunity wanes and 
after 10 years may be insufficient to provide protection. The 
1.9 Tetanus
Summary
Number of cases, 2015: 1
Number of cases, 2014: 1
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Figure 1. Tetanus cases notified (n=16) from November 1981 to 2015 by age group
childhood immunisation schedule in Ireland recommends 
children receive a dose of tetanus toxoid containing vaccine 
at two, four and six months of age and booster doses at 
four-five years of age and 11-14 years of age. For vaccinated 
persons who have received five doses of tetanus toxoid, 
booster doses may be considered every 10 years. This is 
based on concern regarding the decline of antibody levels 
with age and potential failure of single booster doses to 
produce protective levels in older individuals. For more 
complete and detailed information on recommended 
tetanus immunisations please see the HSE National 
Immunisation Office website at www.immunisation.ie.  
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 27th May 2016. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR. 
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2.1  Influenza and Other Seasonal Respiratory 
Viruses
2015/2016 influenza season summary: 
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Peak influenza-like illness rate: 80.6/100,000 population
Total confirmed influenza cases hospitalised:1856
Total confirmed influenza cases admitted to ICU: 161
Total notified influenza cases that died: 84
Total number of acute respiratory infection and influenza 
outbreaks: 63
 
HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College of 
General Practitioners (ICGP) and the Departments of Public 
Health on the influenza sentinel surveillance project since 
2000. During the 2015/2016 influenza season, 61 general 
practices (located in all HSE-Areas) were recruited to report 
electronically, on a weekly basis, the number of patients who 
consulted with influenza-like illness (ILI). Sentinel GPs were 
requested to send a combined nose and throat swab to the 
NVRL on one ILI patient per week. The NVRL also tested 
respiratory non-sentinel specimens, referred mainly from 
hospitals. 
Other surveillance systems set up to monitor ILI/influenza 
activity include: 
•   Surveillance of all calls to GP out-of-hours (OOHs) centres, 
monitored for self-reported influenza. These data were 
provided by HSE-NE.  
•   Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System (CIDR) 
in Ireland. 
•   Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years.   
•   Intensive Care Society of Ireland (ICSI) and the Critical 
Care Programme (CCP) enhanced surveillance of all 
critical care patients with confirmed influenza 
•   Surveillance of all reported influenza deaths. 
•   All-cause mortality monitoring associated with the 
European mortality monitoring group (EuroMOMO)
•   A network of sentinel hospitals reporting admissions data.
•   Outbreak surveillance – Acute respiratory infections and 
influenza
•   Influenza vaccine effectiveness study (I-MOVE)
This report summarises influenza and other seasonal 
respiratory virus activity in Ireland during the 2015/2016 
influenza season. The 2015/2016 season commenced on 
28th September 2015 (week 40 2015) and ended on 22nd May 
2016 (week 20 2016). The data presented in this summary 
were based on all data reported to HPSC by the 28th 
November 2016. 
Sentinel GP Clinical Data
Influenza activity reported from the sentinel GP network 
in Ireland was at moderate levels during the 2015/2016 
influenza season, with ILI consultation rates peaking at 80.6 
per 100,000 population during week 4 2016 (late January), 
the highest peak rate since the 2010/2011 season. ILI rates 
first increased above baseline levels (17.9 per 100,000) 
during week 1 2016 and remained there for 10 consecutive 
weeks, which is the average length of time above baseline 
in Ireland. ILI rates were above medium intensity levels for 
five consecutive weeks (figure 1). The highest age specific 
ILI rates were reported in the 5-14 year age group (peaking 
at 131.6/100,000), followed by the 0-4 year age group 
(112.9/100,000), the 15-64 year age group (81.7/100,000) 
and those aged 65 years and older (69.1/100,000). It is 
notable that the age specific rates in the 0-4, 5-14 and 
15-64 year age groups were the highest reported in these 
age groups since the 2010/2011 season. Age specific rates 
in those aged 65 years and older were the highest reported 
since the 2008/2009 season and were only higher during 
the 2003/04 season. 
Virological Data from National Virus Reference Laboratory 
(NVRL) – Influenza 
Sentinel GP data: The NVRL tested 1158 sentinel specimens 
for influenza virus during the 2015/2016 season. Five 
hundred and seventy-three (49.5%) sentinel specimens were 
positive for influenza: 329 influenza A (313 A(H1)pdm09, 
6 A(H3) and 10 A not subtyped) and 244 influenza B. Fifty 
seven percent of all confirmed influenza sentinel cases were 
positive for influenza A and 43% for influenza B. Of subtyped 
influenza A specimens, 98% were positive for influenza A(H1)
pdm09. Overall, 89% (968/1088 with known vaccination 
status) of ILI patients tested for influenza were not 
vaccinated with the 2015/2016 seasonal influenza vaccine. 
Sixty-four percent of those aged 65 years and older were not 
vaccinated and 76% of those aged less than 65 years with a 
known risk factor for influenza were not vaccinated.  Fifteen 
ILI patients were reported as having commenced antiviral 
treatment. 
Non-sentinel data: The NVRL tested 11,362 non-sentinel 
respiratory specimens during the 2015/2016 season, 1694 
(14.9%) of which were positive for influenza: 1130 influenza 
A (1023 A(H1)pdm09, 42 A(H3), and 65 A (not subtyped)) 
and 564 influenza B. Sixty-seven percent of all confirmed 
influenza non-sentinel cases were positive for influenza A 
and 33% were positive for influenza B. Of subtyped influenza 
A specimens, 96% were positive for influenza A(H1)pdm09. 
Influenza A(H1)pdm09 was the predominant influenza virus 
circulating during the 2015/2016 season, co-circulating with 
influenza B throughout the season. Influenza A accounted 
for 64% of all influenza positive specimens and influenza B 
for 36%. Of the 1384 influenza A sentinel and non-sentinel 
specimens that were subtyped, influenza A(H1)pdm09 
accounted for 96.5% and influenza A(H3) for 3.5%. In total 
1336 positive influenza A(H1)pdm09 cases were detected by 
the NVRL during the 2015/2016 season, this is the highest 
number of A(H1)pdm09 viruses detected since the 2010/2011 
season. 
Influenza virus characterisation: 
For the 2015/2016 influenza season, genetic and antigenic 
characterisation of influenza viruses circulating in Ireland 
was carried out by the NVRL on 122 positive samples: 83 
A(H1)pdm09, 9 A(H3), and 30 B. All influenza A(H1N1)
pdm09 viruses genetically characterised belonged to the 
genetic group A/South Africa/3626/2013 (subgroup 6B). 
All influenza A(H1)pdm09 viruses successfully isolated 
and antigenically characterised by the NVRL during the 
2015/2016 season were similar to the 2015/2016 A(H1)
pdm09 vaccine strain A/California/07/2009. Nine influenza 
A(H3) viruses were genetically characterised, all belonged 
to the genetic group A/Hong Kong/4801/2014 (3C.2a), 
which is a genetic group of viruses that was antigenically 
similar to the 2015/2016 influenza A(H3) vaccine strain. 
One of 30 influenza B viruses genetically characterised 
during the 2015/16 season belonged to the genetic group 
B/Phuket/3073/2013 (Yamagata lineage clade 3); this 
virus was also successfully isolated and antigenically 
characterised as being similar to the 2015/16 trivalent 
influenza vaccine strain B/Phuket/3073/2013. The majority 
(29 of 30; 96.7%) of influenza B viruses genetically 
characterised belonged to the genetic group B/Victoria/2/87 
(clade 1A). The vast majority of influenza B viruses 
successfully isolated and antigenically characterised by the 
NVRL during the 2015/2016 season were similar to the B/
Brisbane/60/2008-like virus. The B/Brisbane/60/2008-like 
virus (a B/Victoria virus) was not present in the 2015/2016 
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Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold, medium and high intensity ILI thresholds1 and 
number of positive influenza A and B specimens tested by the NVRL, by influenza week and season. 
Source: Clinical ILI data from ICGP and virological data from the NVRL.
1 For further information on the Moving Epidemic Method (MEM) to calculate ILI thresholds: http://www.ncbi.nlm.nih.gov/pubmed/22897919
trivalent influenza vaccine used in Ireland and throughout 
most of Europe. 
Virological Data from NVRL - Other seasonal respiratory 
viruses 
During the 2015/2016 season, of 11,362 non-sentinel 
specimens tested by the NVRL, 951 (8.4%) positive 
detections of respiratory syncytial virus (RSV) were reported, 
peaking (at 33.8% positivity) during week 50 2015. A total of 
199 (1.8%) positive detections of human metapneumovirus 
(hMPV) were reported, peaking during mid-December 2015. 
One hundred and fifty-eight (1.4%) positive detections of 
adenovirus were reported, peaking in mid-February 2016. 
Sixty-five (0.6%) parainfluenza virus type 1 (PIV-1), 29 
(0.3%) PIV-2, 59 (0.5%) PIV-3 and 19 (0.04%) PIV-4 positive 
detections were reported during the 2015/2016 season. 
Positive detections of RSV, adenovirus and parainfluenza 
virus type 1 reached the highest numbers ever reported by 
the NVRL for any season. 
Of the 1158 sentinel specimens tested during the 2015/2016 
season, 27 (2.3%) were positive for RSV, 16 (1.4%) for hMPV, 
13 (1.1%) for adenovirus, six (0.5%) PIV-1, one (0.2%) PIV-2, 
and two (0.2%) PIV-4. There were no positive detections of 
PIV-3 from sentinel sources during the 2015/2016 season. 
Outbreaks, GP OOHs & sentinel hospital data
Thirty-six confirmed influenza general outbreaks were 
reported to HPSC during the 2015/2016 influenza season 
(table 1), a significant decrease compared to 90 reported 
during the 2014/2015 season. The majority of influenza 
outbreaks reported during the 2015/16 season were 
associated with influenza A(H1)pdm09. Thirty outbreaks 
were associated with influenza A (27 A(H1)pdm09 and 3 
A - not subtyped) and five with influenza B. No influenza 
type/subtype was reported for one outbreak.  Twenty-
one confirmed influenza outbreaks were reported from 
community hospitals/residential care facilities, 13 from 
acute hospital settings and two from schools. In total 
four deaths were recorded as associated with these 36 
outbreaks. It is probable that the actual number of deaths 
linked with these outbreaks exceeds this number. A further 
27 acute respiratory infection (ARI) general outbreaks 
were reported during the 2015/2016 influenza season, 
eight were associated with RSV, two with hMPV, two with 
parainfluenza type 1, one with rhinovirus and 14 associated 
with unidentified pathogens. For all ARI and influenza 
outbreaks, vaccination status was reported for patients 
from 14 healthcare facilities/residential institutions, with 
over 92% (466/507) of patients vaccinated prior to these 
outbreaks. Vaccination status was reported for staff from 
only six healthcare facilities/residential care facilities, with 
only 7% (17/244) of staff reported as vaccinated prior to 
these outbreaks. Use of antivirals for treatment in healthcare 
settings was reported from 11 ARI/influenza outbreaks (of 
17 outbreaks that reported data) and use of antivirals for 
chemoprophylaxis was reported from seven ARI/influenza 
outbreaks (of 14 outbreaks that reported data).
The percentage of influenza-related calls to GP out-of-hours 
services in Ireland, peaked during week 5 2016 (the first week 
in February) at 5.1%, one week later than the peak in sentinel 
GP ILI consultation rates. The peak in influenza-related calls 
was the highest peak since the 2012/13 season. During the 
peak of activity, each service received on average, one call 
per hour relating to influenza.
  
Hospital respiratory admissions reported from a network 
of sentinel hospitals during the 2015/2016 season, peaked 
at 531 during week 51 2015, this is the highest peak level 
in recent years. The peak coincided with high levels of RSV 
activity and increasing influenza activity. Total emergency 
admissions reported from sentinel hospitals peaked during 
weeks 3-6 2016, coinciding with peak influenza activity. Total 
emergency admissions peaked at 3003 during week 3 2016. 
Influenza and RSV notifications
A total of 4252 influenza notifications were reported on 
Ireland’s Computerised Infectious Disease Reporting System 
(CIDR) during the 2015/2016 influenza season; the highest 
number of influenza notifications reported ever with the 
exception of the 2009 pandemic. Of the 4252 notifications, 
4245 were confirmed cases, two were probable cases and 
five were possible cases. Of the 4245 confirmed influenza 
cases, 2072 (48.8%) were positive for influenza A(H1)pdm09, 
30 (0.7%) for influenza A (H3), 559 (13.2%) influenza A (not 
subtyped) and 1584 (37.3%) influenza B. A total of 2078 RSV 
notifications were reported to HPSC during the 2015/2016 
season; the highest number of notifications reported since 
RSV was made notifiable in 2012. 
Confirmed influenza cases hospitalised 
During the 2015/16 season, 1856 confirmed influenza cases 
(40.5/100,000 population) were reported as hospitalised; 
44% of all confirmed influenza notified cases. The highest 
age specific rate in hospitalised cases for the 2015/2016 
season was in those aged less than one year of age (150.5 
per 100,000 population) which was the highest rate ever 
-39-HPSC Annual Epidemiological Report 2015 2. Respiratory and Direct Contact Diseases
Table 1: Number of influenza outbreaks by HSE-Area for the 2015/2016 influenza season (n=36). 
HSE-Area No. of outbreaks Total number ill Total number lab 
confirmed
Total number 
hospitalised
Total number dead
HSE-E 13 97 50 22 0
HSE-M 1 3 3 3 0
HSE-MW 4 41 19 14 1
HSE-NE 2 18 6 6 1
HSE-NW 4 64 19 12 2
HSE-SE 3 33 5 3 0
HSE-S 6 166 14 11 0
HSE-W 3 44 7 12 0
Total 36 466 123 83 4
reported in this age group, followed by those aged 1-4 years 
(130.7 per 100,000) (table 2). Of the 1856 hospitalised 
cases, 1223 (65.9%) were confirmed influenza A cases and 
633 (34.1%) were influenza B cases. Of the 954 subtyped 
influenza A cases, over 99% were influenza A(H1)pdm09 
and less than 1% were influenza A(H3).  Further data on 
confirmed influenza hospitalised cases are detailed in tables 
1-4. 
Enhanced surveillance hospital data on 0-14 year age group 
A total of 1445 confirmed influenza cases aged between 
0 and 14 years were notified on CIDR for the 2015/2016 
influenza season, 754 (52.2%) of these cases were 
hospitalised. Sixty percent (n=452) of hospitalised cases 
were positive for influenza A [346 A(H1)pdm09, 2 A(H3) 
and 104 A (not subtyped)] and 40% (n=302) were positive 
for influenza B. The median age of cases was 3 years. 
Over 63% of cases were aged between 0 and 4 years, 
with 15% of cases aged less than one year. The most 
frequently reported symptoms included: fever (59.2%), 
cough (48.5%) and fatigue (36.0%). Complications were 
reported for 476 (63%) cases; of these cases more than one 
complication was reported for 26.7% of cases. The most 
frequently reported complications included secondary 
bacterial pneumonia, primary influenza viral pneumonia 
and other respiratory complications. The median length 
of stay in hospital was 2 days (ranging from 1 - 56 days). 
Approximately, 29% of hospitalised cases in this age group 
were reported as belonging to a risk group for influenza, 
with chronic respiratory disease (including asthma), chronic 
neurological disease, congenital/chronic heart disease, 
immunosuppression, conditions that can compromise 
respiratory function and other medical conditions being 
the most frequently reported. Trisomy 21 was reported as a 
risk group for 12 cases. Five cases were reported as being 
premature. Of the 130 cases with reported underlying 
medical conditions and known vaccination status, 91% were 
not vaccinated. Approximately, 47% of cases (216/459) 
commenced antiviral treatment. Thirty-six cases were 
reported as being admitted to critical care units and seven 
children died (for further details, see below). 
Confirmed influenza cases admitted to ICU 
Of the 1856 hospitalised confirmed influenza cases 
reported during the 2015/16 influenza season, 161 (9%) 
were admitted to critical care (125 adults and 36 paediatric 
cases). Of the 161 critical care cases, 109 (68%) were 
infected with influenza A(H1)pdm09, 1 (0.6%) with influenza 
A(H3), 22 (14%) influenza A (not subtyped) and 29 (18%) 
with influenza B. Age specific rates for patients admitted 
to critical care units were highest in those aged less than 
one year (18.0 per 100,000 population), followed by those 
aged 65 years and older (7.7 per 100,000 population) (table 
2). The overall median age of all cases was 51 years. The 
median age in years for paediatric cases was 3, and 58 for 
adult cases. One hundred and one (101/117, 86%) adults and 
25 (25/34, 74%) paediatric cases had pre-existing medical 
conditions. The most frequently reported underlying medical 
conditions for adults were chronic respiratory disease 
(54/101, 54%), followed by chronic heart disease (46/101, 
46%), and immunosuppression (26/101, 26%). Five adult 
cases were pregnant. Fifty-one (41%) adult cases were 
reported as current/former smokers and two (2%) adult 
cases were reported to have alcohol related disease. The 
most frequently reported underlying medical conditions 
for paediatric cases were neurological/neuromuscular 
conditions (15/25, 60%) and cardiovascular conditions 
(8/25; 32%). Ninety percent (112/125) of adults were 
ventilated during their stay in critical care units. Ventilation 
status was only reported for 13 paediatric cases; 11 (85%) of 
which were ventilated. The median length of stay in critical 
care for adult cases was 9 days (ranging from 1 - 139 days) 
and for paediatric cases 5 days (ranging from 1 - 35 days). 
Of the adult cases with known risk factors for influenza, 77% 
were not vaccinated. Of the 20 paediatric cases with known 
risk factors for influenza and known vaccination status, 
95% were not vaccinated. Ninety-five percent of adult and 
paediatric cases were reported to have received antiviral 
therapy. Forty-two adult (42/125, 33.6%) and five paediatric 
(5/36 (13.9%) confirmed influenza cases admitted to critical 
care units during the 2015/2016 season died. 
Mortality data 
During the 2015/2016 influenza season, of the 4252 
influenza cases notified, 84 (2%) cases were reported 
as having died. The case classification of influenza was 
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Table 2: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2015/2016 influenza season. Age 
specific rates are based on the 2011 CSO census.
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 109 150.5 13 18.0
1-4 371 130.7 14 4.9
5-14 274 44.0 7 1.1
15-24 86 14.8 2 0.3
25-34 184 24.4 6 0.8
35-44 164 21.7 22 3.2
45-54 119 20.5 22 3.8
55-64 152 32.8 34 7.3
≥65 397 74.2 41 7.7
Total 1856 40.5 161 3.5
confirmed for 83 of these cases and possible for one case. Of 
the 83 cases with known virology, 55 were associated with 
influenza A(H1)pdm09, 13 with influenza A (not subtyped) 
and 15 with influenza B. No influenza A(H3) associated 
deaths were reported. Influenza was reported as a cause of 
death (either on the death certificate or by the physician) 
for 56 cases. The median age of cases who died during the 
2015/2016 influenza season was 65 years, ranging from 
0-97 years. There was no significant cumulative excess all-
cause mortality reported during the 2015/2016 season for 
the age groups monitored: 0-4, 5-14, 15-64 and 65 years 
and older. 
Summary tables of confirmed influenza hospitalised and 
critical care cases and influenza-associated deaths for all 
ages are detailed in tables 3, 4 and 5.
Overview of the 2015/2016 season 
In Ireland, the 2015/2016 influenza season was more 
severe than recent seasons. Influenza A (H1)pdm09 viruses 
predominated, co-circulating with influenza B. Only sporadic 
cases of influenza A (H3) were detected throughout the 
season. The 2015/2016 season was the first season since the 
2009 pandemic and the 2010/2011 post-pandemic season 
that influenza A(H1)pdm09 viruses predominated in Ireland 
throughout the season. The impact of influenza during the 
2015/2016 season affected all age groups, in particular 
younger age groups, with high hospitalisation and critical 
care admission rates and an increase in the number of 
notified influenza deaths reported. The number of confirmed 
influenza hospitalised cases (n=1856) reported during the 
2015/2016 season, was the highest ever reported (data are 
available since 2009). Similarly, the number of critical care 
admissions was at the highest levels ever reported. There 
was a significant increase in the overall hospitalisation rate 
for those aged less than one year compared to previous 
seasons, reaching the highest rate (151/100,000 population) 
ever reported for this age group. Unlike the 2014/2015 
season, when influenza A(H3) predominated, excess all-
cause mortality was not reported in Ireland among people 
aged 65 years and older during the 2015/2016 season. 
Some countries in Europe reported excess mortality in the 
15-64 year age group during the 2015/2016 season; this was 
not observed in Ireland.1
Sentinel GP ILI consultation rates in Ireland were above 
baseline levels for 10 consecutive weeks during the 
2015/2016 season, which is the average length of time ILI 
rates remain above baseline in Ireland. ILI rates were at 
their highest levels since the 2010/2011 season. The NVRL 
reported the highest number of influenza A(H1)pdm09 
viruses detected since the 2010/2011 season. RSV activity 
was high during the 2015/2016 season. Positive detections 
of adenovirus and parainfluenza virus type 1 reported by the 
NVRL, were at higher levels than are usually observed. 
The number of acute respiratory infection and influenza 
outbreaks reported during the 2015/2016 season was lower 
than the previous season. The majority of these outbreaks 
were caused by influenza A(H1)pdm09 and mainly affected 
the elderly in residential care facilities. Reported influenza 
vaccination status of patients/clients in these outbreaks was 
high, whilst vaccination status of staff was low, highlighting 
the need to improve influenza vaccine uptake among health-
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Table 3: Summary table of confirmed influenza cases hospitalised for all ages by influenza season: 2009-2016. Rates are based on the 2011 
CSO census.
Hospitalised  
2009 pdm period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16
Predominant flu type AH1pdm09 AH1pdm09; B AH3 B; AH3 & AH1pdm09 AH3; AH1pdm09 AH3; B AH1pdm09; B
Total cases 1059 968 147 469 693 1009 1856
Crude rate /100,000 23.1 21.1 3.2 10.2 15.1 22.0 40.5
Median age (years) 17 29 27 32 51 59 30
Females 50% 55% 56% 57% 57% 53% 53%
Total deaths - all 
causes 25 42 6 22 34 47 75
Case fatality rate 2% 4% 4% 5% 5% 5% 4%
Table 4: Summary table of confirmed influenza cases admitted to critical care units for all ages by influenza season: 2009-2016. Rates are 
based on the 2011 CSO census.
Admitted to ICU
Pandemic period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16
Predominant flu type AH1pdm09 AH1pdm09; B AH3 B; AH3 & AH1pdm09 AH3; AH1pdm09 AH3; B AH1pdm09; B
Total cases 100 121 15 39 83 69 161
Crude rate /100,000  2.2 2.6 0.3 0.8 1.8 1.5 3.5
Median age (years) 34 49 60 39 50 63 51
Females 50% 53% 80% 49% 41% 41% 42%
Cases with risk factor 82% 74% 93% 90% 85% 86% 83%
% Vaccinated NA 17% - - 32% 47% 18%
ICU: Hospital ratio 9% 13% 10% 8% 12% 7% 9%
ICU Median LOS - Adult 12 14 5 9 9 9 9
ICU Median LOS - Paediatric 8 7 3 5 8 3 5
Total deaths - all causes 18 35 5 11 27 23 47
Case fatality rate 18% 29% 33% 28% 33% 33% 29%
care workers in order to reduce influenza-related morbidity 
and mortality. Further information on seasonal influenza 
vaccine uptake in hospitals and long term care facilities is 
available in the Immunisation Uptake chapter of the HPSC 
Annual Epidemiological Report, 2015. Only two influenza 
outbreaks in schools were reported during the 2015/2016 
season. With levels of transmission of influenza amongst 
children high in community and hospital settings throughout 
the 2015/2016 season, it is likely that influenza outbreaks in 
schools were under-reported. 
All influenza A(H1)pdm09 and A(H3) viruses characterised 
in Ireland during the 2015/2016 season belonged to 
genetic groups that were antigenically similar to the strains 
recommended for inclusion in the 2015/2016 trivalent 
influenza vaccines. The majority of influenza B viruses 
characterised during the 2015/2016 season in Ireland 
belonged to the B/Victoria lineage; these viruses were not 
present in the 2015/2016 trivalent vaccine used in Ireland 
and throughout most of Europe. Influenza A(H1N1)pdm09 
viruses have evolved since 2009, with newly emerging 
subclades 6B.1 and 6B.2, reported worldwide during the 
2015/2016 season. Despite this genetic evolution, most 
A(H1)pdm09 viruses remained antigenically closely related 
to the 2015/2016 A(H1N1)pdm09 vaccine virus. WHO has 
however recommended that trivalent vaccines for use in 
the 2017 southern hemisphere influenza season contain the 
influenza A(H1)pdm09 subclade 6B.1 virus.1, 2, 3
The Irish overall adjusted vaccine effectiveness (VE) 
estimates in preventing influenza confirmed infection in 
primary care for all influenza, influenza A(H1)pdm09 and 
influenza B and for all influenza in targeted patients were 
moderate for the 2015/2016 season. Despite the fact that 
B/Victoria viruses (not present in the trivalent influenza 
vaccine) were circulating in Ireland during the season, 
moderate protection against medically-attended laboratory 
confirmed influenza B presenting to general practice was 
observed, possibly due to cross protective immunity. The 
adjusted influenza VE estimate against A(H1N1)pdm09 (for 
all ages) was lower than for influenza B. Reasons for lower 
influenza A(H1N1)pdm09 vaccine estimates as of yet remain 
unclear and may possibly be due to the newly emerged 
influenza A(H1N1)pdm09 subclade 6B.1, although this 
subclade is not purported to have any changed antigenic 
properties.1, 2, 3
For the 2016/2017 influenza season in the northern 
hemisphere, WHO have recommended trivalent 
influenza vaccines contain the following strains: an 
A/California/7/2009 (H1N1)pdm09-like virus; an A/
Hong Kong/4801/2014 (H3N2)-like virus; and a B/
Brisbane/60/2008-like virus.3 This represents a change 
in the influenza A(H3) and influenza B components 
compared with the composition of the Northern Hemisphere 
2015/2016 influenza vaccine. 
In Ireland, for the 2016/2017 season, existing surveillance 
systems are being further strengthened. HPSC are currently 
evaluating severe influenza surveillance systems, with a 
view to improving the efficiency of these systems and overall 
reporting of severe influenza cases for future seasons. 
A severe influenza surveillance working group has been 
established to review these evaluations and implement the 
required changes to improve severe influenza surveillance 
in Ireland. It is important to note the improvements in 
surveillance, reporting and testing when interpreting 
influenza surveillance data since the 2009 pandemic.
In light of the significant increase in notified influenza cases 
during the 2015/16 season, HPSC are currently conducting 
an influenza survey of all microbiology laboratories in 
Ireland. HPSC are also focusing on improving influenza 
vaccine uptake and antiviral data on severe influenza cases, 
outbreaks, health care workers and those in risk groups 
for influenza. HPSC, ICGP and the NVRL are continuing 
to work on the European influenza vaccine effectiveness 
study (I-MOVE project). Data from all of these surveillance 
projects will assist in guiding the management and control 
of influenza and of any future epidemics or pandemics.   
www.hpsc.ie
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Table 5: Summary table of notified influenza cases that died from all causes and were reported on Ireland’s Computerised Infectious Disease 
Reporting System (CIDR) by influenza season: 2009-2016. Rates are based on the 2011 CSO census.
Influenza notifications - Deaths from all causes
Pandemic period 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16
Total deaths 32 43 12 38 58 66 84
Crude rate /100,000 0.7 0.9 0.3 0.8 1.3 1.4 1.6
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In 2015, there were 12 cases of Legionnaires’ disease notified 
in Ireland, a rate of 2.6 per million population which is an 
increase from the rate of 1.7 per million observed in 2014. 
Three deaths due to Legionnaires’ disease were reported 
among the 12 cases, giving a case fatality rate of 25%.
Eight cases were reported from HSE East, one from HSE Mid-
West, one from HSE North West and two from HSE South.
Males and females were equally affected by Legionnaires’ 
disease with half of all cases occurring in males and half 
in females. This was the second consecutive year since 
the reporting of cases to the national infectious disease 
surveillance system, CIDR that the majority of cases did not 
occur in males. The median age for all cases was 66 years 
with a range from 36 to 83 years.
Eleven cases were classified as confirmed and one case as 
probable. The organism involved in the 11 confirmed cases, 
which was detected by urinary antigen test, was Legionella 
pneumophila serogroup 1. The diagnosis in one of the 11 cases 
also included the use of the laboratory method nucleic acid 
amplification (PCR). Further sequence analysis of the clinical 
isolate determined it to be sequence type 42. As none of the 
cases had the specimen cultured, monoclonal subtyping was 
not available. Nucleic acid amplification was the diagnostic 
method used for the probable case. 
Six cases were travel-associated. Countries of travel included 
Dominican Republic (1), Ireland (2), South Africa (1), United 
Arab Emirates (1) and United States (1). Two cases were 
linked to travel related clusters. The remaining six cases were 
assumed to be community acquired.
No seasonality was evident in the cases in 2015, as described 
in Figure 1.
2.2 Legionellosis
Summary
Number of cases in 2015: 12
Crude incidence rate: 2.6 per million
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Table 1. Number of Legionnaires’ disease cases per million population in Ireland, 2008-2015
Age group (years) 2008 2009 2010 2011 2012 2013 2014 2015
<30 0 0 1 0 0 0 0 0
30-39 0 0 0 0 1 1 1 1
40-49 2 0 2 0 1 3 1 1
50-59 3 2 1 1 1 4 2 3
60-69 4 3 3 4 6 1 3 1
70+ 2 2 4 2 6 5 1 6
Total 11 7 11 7 15 14 8 12
CIR 2.6 1.5 2.4 1.5 3.3 3.1 1.7 2.6
For details of denominator data used, please see Explanatory Notes section at the end of the HPSC annual epidemiological report
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Figure 1. Number of Legionnaires’ disease cases by month of 
notification in Ireland, 2015
Figures for the year 2015 presented in this report were extracted from 
the computerised infectious disease reporting (CIDR) system on the 4th 
May, 2016.
Notifications
In 2015, 107 cases of invasive group A streptococcal (iGAS) 
disease were notified, which was the lowest figure in four 
years. This corresponds with a rate of 2.33 iGAS cases per 
100,000 population [95% confidence interval (CI): 1.91-2.82], 
lower than that seen in 2014 (3.57 [95% CI: 3.13 – 4.26]). This 
decrease is statistically significant. 
Case classification
The majority were classified as confirmed cases (n=105; 
98%): patients with group A streptococcus (GAS; 
Streptococcus pyogenes) isolated from a sterile site. Two 
were classified as probable iGAS cases: patients with 
streptococcal toxic shock syndrome (STSS) or necrotising 
fasciitis and GAS isolated from a non-sterile site (e.g. throat, 
sputum, leg wound). 
Patient demographics
Of the 107 cases, 60 (56%) were male. The mean age was 
43 years (range = 5 months – 99 years) and iGAS was more 
common in young children and older adults (Figure 1). 
Geographic spread and seasonal variation
Table 1 displays the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2011 to 2015. While 
HSE East accounted for the highest number of reported 
cases in 2015 (n=40), HSE West had the highest CIR (3.82 
per 100,000 population). In two HSE areas, Midlands and 
Northwest, both the numbers of cases and CIRs increased, 
while in the other six HSE areas, decreases were reported.
The peak month in 2015 was July (15 cases), followed by 
April, June and December (12 cases each). Contrary to 
previous years, there were more cases reported in the second 
half (July – December: 61 cases) than the first half of the 
year (January – June: 46 cases) (Figure 2). Figure 3 displays 
cumulative monthly iGAS cases from 2011 to 2015 inclusive. 
An increase in notifications which occurred from April 
2012 was sustained throughout 2013 and into 2014, with a 
stabilisation in the latter months of 2014. The opposite can 
be said of 2015, where the number of cases was much lower 
than normal in the earlier months, increasing towards the 
end of the year. Data presented are based on the date the 
case was notified to Public Health, not on the date the case 
was first detected. 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Total number of cases, 2015 = 107
Crude incidence rate, 2015 = 2.3 per 100,000 population
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Figure 1. Age and sex specific rates of iGAS disease in 2015
Isolate details
Of 105 confirmed cases, GAS was isolated from a sterile site 
in 79, with source site not reported for 26. Of reported sterile 
sites, GAS was isolated primarily from blood cultures (n=57; 
72%), deep tissue (n=9; 11%), joints (n=5; 6%), abscesses 
(n=4; 5%), pleural fluid (n=1; 1%), bone (n=1; 1%), drain fluid 
(n=1; 1%) and cerebrospinal fluid (CSF) (n=1; 1%). For two 
cases, GAS was isolated from another sterile site in addition 
to blood: tissue (n=1) and joint (n=1). 
Of the two probable cases, GAS was isolated from non-
sterile sites (superficial wound swabs). There were no 
possible cases of iGAS notified.  
Typing data, based on sequencing of the emm genes that 
encode the M protein (the major virulence factor), were 
available on 92 isolates submitted from 27 laboratories: 
emm-types 1 (n=27; 29%), 12 (n=14; 15%), 28 (n=12; 13%), 89 
(n=8; 9%), 3 and 4 (n=4; 4% each) comprised 74% of all the 
isolates typed. Fifteen other emm-types (each represented by 
≤3 isolates) were also detected. Of the 10 patients with STSS 
for whom emm-typing was undertaken, four GAS isolates 
belonged to emm1 (40%) and three to emm12 (30%). 
Enhanced surveillance data
 Enhanced data were provided for 96 (90%) of 107 iGAS 
cases. The source laboratory could be ascertained for 
all cases. As in previous years, there was wide variation 
in completeness of enhanced data reporting. Table 2 
summarises characteristics of iGAS cases in Ireland from 
2011 to 2015.
Clinical details
Clinical presentation data were provided for 89 cases (83%). 
As in previous years, bacteraemia (n=64 cases, including 
cases where bacteraemia was not specifically stated but 
GAS was isolated from blood) and cellulitis (n=34) were 
the commonest presentations, followed by septic arthritis 
(n=13), pneumonia (n=12), STSS (n=11; two of which were 
implied based on the information provided on the clinical 
presentation), puerperal sepsis (n=6), necrotising fasciitis 
(n=5), meningitis (n=4), peritonitis (n=3), myositis (n=2) and 
erysipelas (n=1). Note that an iGAS case could have more 
than one clinical manifestation of infection.
Risk factors
Risk factor data were provided for 77 iGAS cases (72%). Risk 
factors included: presence of skin or wound lesions (n=32), 
diabetes mellitus (n=7), malignancy (n=6), steroid use (n=6), 
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Figure 2. Monthly distribution of iGAS cases, 2013-2015
HSE Area 2011 2012 2013 2014 2015
 n   CIR    n   CIR    n   CIR    n   CIR    n CIR
HSE E 29 1.79 51 3.15 67 4.14 65 4.01 40 2.47
HSE M 5 1.77 7 2.48 7 2.48 4 1.42 7 2.48
HSE MW 6 1.58 8 2.11 16 4.22 13 3.43 6 1.58
HSE NE 1 0.23 11 2.50 14 3.18 12 2.72 10 2.27
HSE NW 2 0.77 5 1.94 6 2.32 3 1.16 7 2.71
HSE SE 7 1.41 16 3.22 21 4.22 18 3.62 9 1.81
HSE S 12 1.81 14 2.11 18 2.71 27 4.06 11 1.66
HSE W 5 1.12 10 2.25 19 4.27 22 4.94 17 3.82
IRELAND 67 1.46 122 2.66 168 3.66 164 3.57 107 2.33
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area (2011-2015)
CIRs calculated using the 2011 census
recent childbirth (n=5), varicella infection (n=3), alcoholism 
(n=3), injecting drug use (IDU) (n=3) and non-steroidal anti-
inflammatory drug (NSAID) use (n=1). Note that an iGAS 
case could have more than one risk factor. No risk factors 
were identified for 24 cases. 
Clinical management/severity
Surgical intervention was required for 26 patients (age 
range = 2 months – 85 years). This included four patients 
with STSS and three patients with necrotising fasciitis.
Among patients requiring surgical intervention, risk factor 
data were provided for 20 cases. Risk factors included: skin 
and wound lesions (n=12), age ≥65 years (n=3), malignancy 
(n=1), IDU (n=1) and NSAID use (n=1). Note that an iGAS case 
requiring surgery could have more than one risk factor. No 
risk factors were identified for six patients.
Twenty-five patients (aged 12 months – 84 years) required 
intensive care unit (ICU) admission. This included nine 
patients with STSS and three patients with necrotising 
fasciitis.
Among patients admitted to an ICU, risk factor data were 
provided for 22. Risk factors included: age ≥65 years (n=9), 
skin and wound lesions (n=9), diabetes mellitus (n=3), 
alcoholism (n=2), IDU (n=1) and varicella infection (n=1). 
Note that an iGAS case requiring ICU admission could have 
more than one risk factor. No risk factors were identified for 
seven patients. Length of ICU stay was provided for 12 cases. 
The median length of ICU stay was three days (range = 1 – 
18). 
Other epidemiological information
Seven cases of iGAS were reported as hospital-acquired in 
2015. 
There was one iGAS outbreak reported in 2015. This was 
a family outbreak in HSE-E, with three people reported 
ill. However, just one of the three cases was a confirmed 
invasive infection. There were also two outbreaks of scarlet 
fever reported in 2015; one in a crèche with four reported ill 
and the other in a school with two reported ill.
Outcome
Outcome at seven days following GAS detection was 
reported for 73 cases: 
•    66 were still alive 
•    Six patients had died, where GAS was the main or 
contributory cause of death
The seven-day case fatality rate (CFR) for iGAS disease was 
9.5%.
Of 11 STSS cases, outcome at seven days was reported for 
seven. Of those, there was one death due to GAS (CFR = 
14%).  
Of 26 cases requiring surgical intervention, outcome at 
seven days was reported for 19. Of those, there were no 
deaths due to GAS. 
Of 25 cases admitted to ICU, outcome at seven days was 
reported for 17. Of those, there was one death due to GAS 
(CFR = 6%). 
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 79 GAS 
isolates (63 from blood and 16 from other specimens) by 
23 laboratories via the European Antimicrobial Resistance 
Surveillance Network (EARS-Net). All isolates tested were 
susceptible to penicillin (n=75) and vancomycin (n=56).  
Resistance to erythromycin was reported in five (7%) of 70 
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Figure 3. Cumulative monthly numbers of iGAS cases, 2011-2015 
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Table 2. Characteristics of iGAS cases in Ireland, 2011-2015
2011 2012 2013 2014 2015
Notifications
Total iGAS cases notified 67 122 168 164 107
iGAS incidence rate per 100,000 population 1.46 2.66 3.66 3.57 2.30
Cases for which Enhanced data provided** (%) 60 (90%) 106 (87%) 156 (93%) 150 (91%) 96 (90%)
Patient Demographics
Male (%) 28 (42%) 59 (48%) 95 (57%) 94 (57%) 60 (56%)
M:F ratio 0.72:1 0.94:1 1.30:1 1.34:1 1.19:1
Mean age 43 44 41 44 43
Median age 39 42 40 44 42
Age range 0-97 0-92 0-93 0-99 0-99
Paediatric cases (aged <18 years) (%) 15 (22%) 28 (23%) 45 (27%) 47 (29%) 26 (24%)
Older cases (aged 65+ years) (%) 22 (33%) 42 (34%) 50 (30%) 56 (34%) 34 (31%)
Clinical Presentation†
Data on Clinical Presentation (%) 58 (87%) 103 (84%) 142 (85%) 132 (80%) 89 (83%)
Streptococcal Toxic Shock-like Syndrome (STSS) without 
NF (%) 4 (7%) 22 (21%) 28 (20%) 18 (14%) 11(12%)
Necrotising fasciitis (NF) without STSS (%) 1 (2%) 2 (2%) 6 (4%) 4 (3%) 5 (6%)
STSS and NF (%) 2 (3%) 4 (4%) 4 (3%) 3 (2%) 0 (0%)
Bacteraemia with focal presentations (%) 30 (52%) 42 (41%) 45 (32%) 43 (33%) 34 (38%)
Bacteraemia with no focal presentations (%) 15 (26%) 21 (20%) 36 (25%) 34 (26%) 22 (25%)
Other focal presentations with no bacteraemia (%) 6 (10%) 11 (11%) 23 (16%) 30 (23%) 17 (19%)
Bacteraemia (%) 52 (90%) 80 (78%) 107 (75%) 95 (72%) 64 (72%)
Other focal presentations:
Cellulitis (%) 24 (41%) 41 (40%) 45 (32%) 58 (44%) 34 (38%)
STSS (%) 6 (10%) 26 (25%) 32 (23%) 21 (16%) 11 (12%)
Pneumonia (%) 8 (14%) 17 (17%) 24 (17%) 14 (11%) 12 (13%)
Septic arthritis (%) 2 (3%) 7 (7%) 10 (7%) 11 (8%) 13 (15%)
Necrotising fasciitis (%) 3 (5%) 6 (6%) 10 (7%) 7 (5%) 5 (6%)
Myositis (%) 0 (0%) 4 (4%) 3 (2%) 6 (5%) 2 (2%)
Puerperal sepsis (%) 5 (9%) 6 (6%) 6 (4%) 4 (3%) 6 (7%)
Erysipelas (%) 0 (0%) 3 (3%) 3 (2%) 2 (2%) 1 (1%)
Peritonitis (%) 3 (5%) 1 (1%) 4 (3%) 1 (1%) 3 (3%)
Meninigtis (%) 1 (2%) 3 (3%) 3 (2%) 0 (0%) 4 (4%)
Risk Factors†
Data on Risk Factors (%) 49 (73%) 96 (79%) 138 (82%) 126 (77%) 77 (72%)
Skin lesions/wounds (%) 20 (41%) 34 (35%) 56 (41%) 50 (40%) 32 (42%)
Diabetes (%) 7 (14%) 5 (5%) 16 (12%) 11 (9%) 7 (9%)
Malignancy (%) 6 (12%) 10 (10%) 23 (17%) 10 (8%) 6 (8%)
Varicella (%) 2 (4%) 9 (9%) 5 (4%) 7 (6%) 3 (4%)
Steroid use (%) 1 (2%) 8 (8%) 11 (8%) 6 (5%) 6 (8%)
Alcoholism (%) 1 (2%) 5 (5%) 6 (4%) 5 (4%) 3 (4%)
Injecting drug user (%) 3 (6%) 6 (6%) 5 (4%) 5 (4%) 3 (4%)
Childbirth (%) 5 (10%) 6 (6%) 6 (4%) 4 (3%) 5 (6%)
Non-steroid anti-inflammatory drug use (%) 1 (2%) 2 (2%) 4 (3%) 2 (2%) 1 (1%)
No identified risk factor (%) 12 (24%) 24 (25%) 47 (34%) 47 (37%) 24 (31%)
Outcome at 7 days
Data on outcome at 7 days (%) 43 (64%) 65 (53%) 108 (64%) 102 (62%) 73 (68%)
RIP/GAS main cause or contributory (%) 5 (12%) 8 (12%) 16 (15%) 10 (10%) 6 (8%)
STSS cases: Data on outcome at 7 days (%) 5 (83%) 17 (65%) 26 (81%) 17 (81%) 7 (64%)
STSS cases: RIP/GAS main cause or contributory (%) 1 (20%) 6 (35%) 10 (38%) 6 (35%) 1 (14%)
Severity
Data on Admission to ITU (%) 57 (85%) 99 (81%) 153 (91%) 144 (88%) 92 (86%)
Admitted to ITU (%) 11 (19%) 40 (40%) 44 (29%) 36 (25%) 25 (27%)
Data on Surgical Intervention (%) 45 (67%) 86 (70%) 136 (81%) 127 (77%) 86 (80%)
Surgical Intervention Required (%) 8 (18%) 26 (30%) 39 (29%) 41 (32%) 26 (30%)
Typing
iGAS isolates that were typed (%) 109 (89%) 140 (83%) 130 (79%) 92 (86%)
Emm-1 (%) 53 (49%) 41 (29%) 21 (16%) 27 (29%)
Emm-3 (%) 4 (4%) 33 (24%) 47 (36%) 4 (4%)
Emm-12 (%) 11 (10%) 4 (3%) 6 (5%) 14 (15%)
Emm-28 (%) 8 (7%) 8 (6%) 12 (9%) 12 (13%)
Emm-89 (%) 4 (4%) 13 (9%) 8 (6%) 8 (9%)
Other emm-types (%) 29 (27%) 41 (29%) 36 (28%) 27 (29%)
** Degree of completion of enhanced surveillance forms varies from case to case: information may not be available on all variables/categories, thus 
calculations of percentages take into account only those cases for which data are provided
†Note: A patient may have more than one clinical presentation or risk factor
isolates, to clindamycin in four (6%) of 65 isolates and to 
tetracycline in six (12%) of 49 isolates.
CONCLUSION
In 2015, 107 cases of iGAS infection were notified in Ireland, 
a substantial decrease from that of the previous two years 
(2014; n=164, 2013; n=168). The CIR decreased from 3.57 in 
2014 to 2.3 per 100,000 in 2015 and this was statistically 
significant. 
Invasive GAS is a potentially life-threatening disease. In 
2015, the CFR was 9.5% for all iGAS infections and even 
higher for patients presenting with STSS (14%). For the first 
time since 2012, there has been a drop in the number of 
patients presenting with STSS: 2012 (n=26), 2013 (n=32), 
2014 (n=21) and 2015 (n=11).
Typing of emm genes was undertaken on a national basis 
for the first time in 2012, with the establishment of a GAS 
typing service by the Epidemiology and Molecular Biology 
Unit (EMBU) at the Children’s University Hospital, Temple 
St. In 2015, one emm type, emm1, predominated comprising 
29% of all isolates typed. This is similar to the situation in 
2012 when emm1 was also predominant comprising 49% 
of all isolates typed; while in 2013 both emm1 and emm3 
were the dominant emm types and in 2014, emm3 was the 
predominant emm type, comprising 36% of all isolates 
typed. Certain emm types, including emm1 and emm3, are 
associated with STSS and STSS in turn is strongly associated 
with increased mortality. The changes observed in the 
predominant emm types in circulation and in the clinical 
presentations over the last couple of years highlight the 
dynamic nature of iGAS infection. 
Ongoing surveillance is essential, specifically completion 
of the enhanced data questionnaire, to gain a greater 
understanding of iGAS, to enable early detection of clusters/
outbreaks, to ensure prompt implementation of infection 
prevention and control precautions and appropriate 
management of contacts. Epidemiological typing as 
provided by the EMBU is another vital element to increase 
insight into GAS infection in Ireland, as certain emm types 
are associated with greater morbidity and mortality.
Antimicrobial susceptibility data confirm that iGAS remains 
susceptible to penicillin and that penicillin should continue 
to be the treatment of choice for iGAS.  
HPSC thanks participating microbiology laboratories and 
public health departments for their ongoing contribution to 
the iGAS enhanced surveillance scheme. 
All microbiology laboratories are encouraged:
•    to return enhanced iGAS surveillance forms for every 
patient with iGAS 
•    to submit all iGAS isolates to the Epidemiology and 
Molecular Biology Unit (EMBU), Children’s University 
Hospital, Temple St for emm-typing 
•    to submit antimicrobial susceptibility data on all iGAS 
cases along with EARS-Net quarterly returns
Further information on iGAS disease in Ireland, including 
the enhanced surveillance form, factsheets for patients and 
contacts and national guidelines is available at:
http://www.hpsc.ie/A-Z/Other/GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Diseases 
Reporting (CIDR) System on 22nd July 2016. 
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Background
Invasive group B streptococcal (iGBS; Streptococcus 
agalactiae) infections in infants <90 days old or 
stillborn infants have been notifiable in Ireland via the 
Computerised Infectious Diseases Reporting (CIDR) 
system since January 2012.
In neonates two syndromes exist:
•  Early-onset disease (EOD; age at onset/diagnosis <7 
days old)
•  Late-onset disease (LOD; age at onset/diagnosis 7-89 
days old)
Both include sepsis, pneumonia and meningitis. Stillbirth 
associated with isolation/detection of Streptococcus 
agalactiae from the placenta or amniotic fluid is also 
notifiable.
Notifications
In 2015, there were 69 iGBS cases: EOD = 43; 
rate = 0.69 per 1,000 live births and LOD = 26; 
rate = 0.39 (Figure 1 and Table 1). (65,909 live 
births, CSO 2015 data obtained from http://www.
cso.ie/en/releasesandpublications/ep/p-vsys/
vitalstatisticsyearlysummary2015/) 
Three cases presented with meningitis and two cases 
were associated with stillbirth.
The figures presented in this summary are based on 
data extracted from CIDR on 28th July 2016.
2.4  Invasive Group B Streptococcal 
Infections
Summary
2015 Summary
Number of cases: 69 
•   Early-onset disease (EOD) = 43
•   Late-onset disease (LOD) = 26
EOD rate per 1,000 live births, 2015: 0.65
LOD rate per 1,000 live births, 2015: 0.3
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 Figure 1. Invasive Group B streptococcal infection by age (in days) at time of onset/diagnosis 2015: EOD 
<7 days and LOD 7 – 89 days).
Table 1. Breakdown and rates of iGBS cases, by disease syndrome: 2013 – 2015.
Year
Disease syndrome
2013 2014 2015
n (%) Rate* n (%) Rate* n (%) Rate*
EOD 42 (64%) 0.61 46 (68%) 0.68 43 (62%) 0.65
LOD 24 (36%) 0.35 22 (32%) 0.33 26 (38%) 0.39
Total 66 0.96 68 1.01 69 1.04
* Incidence rate per 
1,000 live births
Live births in the Republic of Ireland (source: www.cso.ie): 2013, 68,930; 2014, 67,462; 2015, 65,909
In 2015, 303 cases of tuberculosis (TB) were notified in 
Ireland, corresponding to a crude incidence rate (CIR) of 6.6 
per 100,000 population*, remaining stable in comparison to 
the CIR of 6.8 reported for 2014 (n=313). A summary of the 
epidemiology of TB in Ireland during 2015 is shown in table 
1 while the number of cases and crude incidence rates from 
1991 to 2015 with three-year moving averages are shown in 
figure 1. 
The highest crude incidence rate was reported by HSE-S 
(10.4/100.000) while the lowest rate was reported by HSE-
SE (3.0/100,000). 
Cases ranged in age from two to 90 years, with a median 
age of 40 years. The highest age-specific rate (ASIR) in 
2015 occurred among those aged 65 years and older (11.8) 
followed by those aged 25-34 years (10.2). The rate among 
males (8.0) was higher than that among females (5.2). Rates 
among males were higher than females for all age groups. 
The highest ASIRs among both males (14.0) and females 
(9.9) were observed in those aged 65 years and older. The 
male to female ratio (1.5:1) reported in 2015 was consistent 
with that reported in previous years. 
Geographic origin
During 2015, 42.6% (129 cases) of TB cases were born 
outside Ireland, a slight decrease from the proportion 
reported in 2014 (43.5%). The crude rate in the foreign-born 
population decreased from 17.7 per 100,000 population 
in 2014 to 16.8 per 100,000 population in 2015. The crude 
rate in the indigenous population was 4.0 per 100,000 
population in 2015, which decreased compared to 4.7 per 
100,000 population reported in 2014. There was a notable 
difference in age between those born in Ireland and those 
born outside Ireland, with a median age of 56 years and 33 
years respectively. 
Site of infection 
Pulmonary TB was reported in 197 (65.0%) cases and 100 
(33.0%) had exclusively extrapulmonary disease. Six cases did 
2.5  Tuberculosis 2015 
Summary
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  *All rates reported are calculated per 100,000 population
  †Country of birth was unknown for 22 cases
Table 1: Summary of the epidemiology of TB in Ireland, 2015
Parameter Number % of total cases CIR / 100,000 population
Total number of cases 303 6.6
Cases in indigenous population† 152 50.2 4.0
Cases in foreign-born persons† 129 42.6 16.8
Culture positive cases 198 65.3 4.3
Pulmonary cases 197 65.0 4.3
Smear positive pulmonary cases 81 26.7 1.8
MDR-TB cases 1 0.3 0.02
XDR-TB cases 0 0.0 0.0
Mono-resistant to isoniazid 6 2.0 0.1
Deaths attributable to TB 4 1.3 0.1
TB meningitis cases 2 0.7 0.04
Number of cases in 2015: 303
Crude incidence rate in 2015: 6.6/ 100,000 population
Number of cases in 2014: 313
Treatment outcome known in 2014: 247 (78.9%)
Treatment outcome successful in 2014: 208 (66.5%)
not have the site of infection reported. Of the extrapulmonary 
cases reported in 2015, there were two cases of TB meningitis 
corresponding to a rate of 0.04 per 100,000 population (0.4 
per million population).
Microbiology
Of the 303 cases reported in 2015, 65.3% (198 cases) 
were culture confirmed. Species identification showed M. 
tuberculosis in 93.9% (186 cases), M. tuberculosis complex‡ 
in 3.0% (6 cases), M. bovis in 2.0% (4 cases). Two culture 
confirmed cases (1.0%) did not specify the species identified. 
Of the 197 cases with a pulmonary component, 138 (70.1%) 
were reported as culture confirmed, and 81 (41.1%) were 
reported as smear positive. 
Drug sensitivity 
Information on antibiotic sensitivity testing was available for 
190 (96.0%) of the 198 culture confirmed cases. Resistance 
was documented in 13 (6.8%) cases that reported antibiotic 
sensitivity, one (0.3% of total cases) of which was an MDR-TB 
case. Mono-resistance to isoniazid was recorded in six cases, 
to streptomycin in four and to pyrazinamide in one case. 
One further case reported resistance to both isoniazid and 
streptomycin. 
HIV status
Information on HIV status was reported for 105 (34.7%) of 
cases in 2015, a decrease compared to 39.0% with HIV status 
reported in 2014. Of the cases with HIV status reported, eight 
(7.6%) were HIV positive and 97 (92.4%) were HIV negative.
Outbreaks 
The introduction of the amendment to the Infectious Disease 
Regulations 1981 on January 1st 2004, made outbreaks, 
unusual clusters or changing patterns of illness statutorily 
notifiable by medical practitioners and clinical directors 
of laboratories to the medical officer of health. Standard 
reporting procedures for surveillance of TB outbreaks were 
formally agreed in 2007. 
During 2015, five outbreaks of TB were reported to HSPC, 
with 18 reported cases of active TB, 35 persons with 
latent TB infection (LTBI) and two hospitalisations. Three 
outbreaks were reported by HSE-S and one outbreak each 
was reported by HSE-NW and -W. There was one general 
outbreak, which occurred in a workplace with five cases of 
active TB and 35 cases of LTBI. There were also four family 
outbreaks, comprising three to four cases each. Three of 
the family outbreaks occurred in private houses and one 
occurred across an extended family. The number of LTBI 
cases was not reported for any of the family outbreaks. 
 
The number of outbreaks reported during 2015 remained 
stable compared to 2014. Figure 2 shows a summary 
of reported TB outbreaks from 2004 to 2015 by year of 
outbreak, number of active TB cases and number of persons 
with LTBI. Please note that numbers of LTBI for outbreaks 
reported during 2015 are provisional and may increase as 
outbreak investigations continue.
Treatment outcome for 2014 data
In 2014, information on treatment outcome was provided 
for 78.9% (247) of cases, an increase compared to 74.7% 
in 2013. Treatment outcome was reported as completed 
for 208 (66.5%) cases, 21 (6.7%) cases died, nine cases 
transferred out (2.9%), six were still on treatment (1.9%) 
and three (1.0%) had treatment interrupted. The remaining 
66 cases were either lost to follow up or did not have 
treatment outcome reported. 
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Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2015 and 3-year moving 
averages, 1992-2014
Year 
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‡ Species of mycobacteria not specified when reported
Four (1.3% of total cases) of the 21 deaths were reported 
as attributable to TB. During 2014, the reported treatment 
success rate was 66.9% for new culture confirmed 
pulmonary TB cases and 71.0% for new smear-positive 
pulmonary TB cases. 
Further details on the epidemiology of TB cases reported in 
2015 will be available in the HPSC Report on the Epidemiology 
of TB in Ireland, 2015 (www.hpsc.ie). 
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Figure 2: TB outbreak summary by year, 2004-2015
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Chickenpox-hospitalised cases
The Health Act, 1947 entitles the Minister for Health to 
declare by regulation diseases that are infectious, covered 
by legislation and that require notification to a Medical 
Officer of Health. The infectious diseases notifiable in Ireland 
are regulated in the 1981 Infectious Diseases Regulations. 
The amendment S.I. No. 452 of 2011 to these regulations 
specified for the first time the disease chickenpox, 
hospitalised cases only, as notifiable. Chickenpox is caused 
by varicella-zoster virus. The case definition is available at 
www.hpsc.ie.
In 2015, 69 (1.5/100,000) hospitalised chickenpox cases 
were notified in Ireland compared to 61 (1.3/100,000) in 
2014. In 2015, the largest number of cases was in the HSE 
E (table 1). Of the 69 cases, 44 (64%) were classified as 
confirmed and 25 (36%) as possible. The highest age specific 
incidence rates were in those aged less than ten years (figure 
1). Of the 69 cases, 38 (55%) were male and 29 (42%) were 
female while sex was unreported for two cases (3%).
Chickenpox/varicella outbreaks
The amendment S.I. No. 707 of 2003 to the infectious 
disease regulations specified that unusual clusters or 
changing patterns of illness that may be of public health 
concern must be reported. Therefore, outbreaks of 
chickenpox must be notified regardless of hospitalisation 
status. One outbreak of possible chickenpox was notified in 
2015. This outbreak occurred in a private house with two ill; 
both cases were reported as being hospitalised.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 1st September 2016. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR.
2.6 Chickenpox-hospitalised cases
Summary
Number of cases, 2015: 69
Crude incidence rate, 2015: 1.5/100,000
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Figure 1. The age specific incidence rate (per 100,000 population) of 
notified hospitalised chickenpox cases in 2015 by case classification
Age group (years)
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Table 1. Number of notified hospitalised chickenpox cases and the 
crude incidence rate per 100,000 population (CIR) by HSE Area in 
2015
HSE Area Number CIR
HSE E 32 2.0
HSE M 7 2.5
HSE MW 2 0.5
HSE NE 7 1.6
HSE NW 3 1.2
HSE SE 8 1.6
HSE S 6 0.9
HSE W 4 0.9
Total 69 1.5
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Campylobacteriosis became a notifiable disease in Ireland 
in 2004 under the Infectious Diseases (Amendment) 
Regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were collected 
nationally as part of the EU Zoonoses Regulations (while 
some cases were included in the former category of 
“Food Poisoning (bacterial other than Salmonella)”). It 
is an acute zoonotic bacterial disease characterised by 
diarrhoea, abdominal pain, malaise, fever, nausea and 
vomiting. Symptoms generally last for only a few days. 
Campylobacteriosis is the commonest bacterial cause of 
gastroenteritis in Ireland and Europe.1
Although levels of campylobacteriosis remained elevated 
during 2015 for the fifth consecutive year, a decrease of 6.1% 
was observed in comparison with 2014. During 2015, 2,451 
notifications were reported to HPSC, corresponding to a 
crude incidence rate of 53.4/100,000 population, which is 
lower than the 2014 European crude incidence rate of 71.0 
per 100,000 population.1 
Historically, variation in campylobacteriosis crude incidence 
rates (CIRs) has been reported between HSE areas. During 
2015, the highest CIRs occurred in HSE-SE (72.6) and 
HSE-M (72.6). The lowest CIR was reported by HSE-NW 
(29.8) and -NE (36.3). 
Campylobacteriosis occurs in all age groups with the 
highest rate of notification reported in the 0-4 year age 
group. This preponderance in younger children is a well 
described characteristic of the disease and is also observed 
at European level. A comparison of the mean age-specific 
incidence rate between 2004-2014 and the age-specific rate 
in 2015 showed an increase of >40% in those aged 65 years 
and older. This is the fourth consecutive year that the CIR has 
been markedly above the mean rate in this age group. Figure 
1 compares the campylobacteriosis age specific rates (ASIR) 
for 2015 with the mean campylobacteriosis ASIR for 2004 to 
2014. 
Campylobacteriosis has a well-documented seasonal 
distribution with a peak in summer. In Ireland, notifications 
typically peak during May to July. During 2015, notifications 
3.1 Campylobacter 
Summary
Number of campylobacteriosis cases: 2,451
Campylobacteriosis crude incidence rate  (CIR):   
53.4/100,000
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Figure 1: Campylobacteriosis ASIR 2015 compared to 2004-2014 mean ASIR (CIDR)
1 Rates are calculated per 100,000 population
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2004-2014 mean CIR 2015 
peaked during May, with two smaller secondary peaks also 
observed during July and September. Figure 2 compares 
the monthly number of campylobacteriosis notifications for 
2015 to the mean monthly number of campylobacteriosis 
notifications between 2004 and 2014. 
All bar one of the cases notified in Ireland during 2015 were 
laboratory confirmed. However, as there is currently no 
national reference facility for routine typing of Campylobacter 
isolates, information on Campylobacter species is strikingly 
incomplete. In 2015, 21.1% (n=518) of isolates were speciated. 
Of the 518 speciated isolates, 89.8% (n=465) of isolates were 
C. jejuni and 10.2% (n=53) were C. coli. 
During 2015, there were six outbreaks of campylobacteriosis 
reported to HPSC as described in Table 1. 
References:
1.  European Food Safety Authority (EFSA), European Centre for Disease 
Prevention and Control (ECDC). The Community summary report 
on trends and sources of zoonoses, zoonotic agents and food-borne 
outbreaks in the European Union in 2014. The EFSA Journal (2015); 
11(4):3129 Available at:      
https://www.efsa.europa.eu/en/efsajournal/pub/4329 
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Figure 2: Campylobacteriosis notifications by month during 2015 compared to mean monthly notifications 2004-2014 
(CIDR)
Table 1: Campylobacteriosis outbreaks summary, 2015 (CIDR)
Outbreak location Mode of transmission Number outbreaks Number ill Number hospitalised Number dead
Private house
P-P - Person-to-person 2 3 0 0
Unknown 1 2
Childcare facility P-P and Animal 1 2 0
Residential institution Unknown 1 3 1 0
Workplace Animal contact 1 5 0
Total 6 15 1
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Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faeco-oral route, with both animals 
and humans serving as potential reservoirs. Human 
cryptosporidiosis became a notifiable disease in Ireland in 
2004, and the case definition in current use is published on 
the HPSC website. 
In 2015, 439 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 9.6 per 100,000 
population (95% CI 8.7-10.5). Of the notified cases 39.4% 
were hospitalised. There were no reported deaths.
Although, the incidence increased by 11% in 2015 compared 
with 2014 (8.6/100,000), this was not statistically 
significant (p=0.06) and was lower than the incidence in 
2012 and 2013 (Figure 1). In 2015 the European Centre 
for Disease Prevention and Control (ECDC) reported an 
overall notification rate of 3.1 per 100,000 population in 
the European Union. Among the countries reporting on 
cryptosporidiosis in 2015, Ireland has the highest rate 
followed by the United Kingdom (9.1/100,000) and Sweden 
(5.4/100,000).1
Consistent with previous years, the highest age-specific 
incidence rate (ASIR) was in children under 5 years of age, 
with 60 cases per 100,000 population in this age group 
(Figure 2). While there is likely to be a bias towards testing 
of diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference in risk 
between adults and children. In 2015, the distribution of 
cases by gender in children under 5 years of age was higher 
in males (M:F ratio 1.5:1). 
Compared with 2014, the incidence rate in 2015 increased in 
five of the eight HSE areas, remaining stable in the HSE-
NE and decreasing in the HSE-NW and HSE-S (Figure 3). 
As in previous years, there was a strong urban-rural divide, 
with the HSE-E having the lowest incidence rate (3.0 per 
100,000). Although incidence remains low in HSE-E in 2015, 
compared with 2014, the incidence rate doubled (Figure 
3). The HSE-W, HSE-SE and HSE-M reported the highest 
incidence rates (18.2, 17.9 and 17.4 per 100,000, respectively). 
As in previous years, the highest number of cases was 
notified in spring and peaked in April, followed by a second 
less intense peak in September (Figure 4).
Risk factors
Reviewing case-based enhanced surveillance data, 
exposure to farm animals or their faeces either by virtue of 
residence on a farm or by visiting a farm during the potential 
incubation period was common among cases; 51% of cases 
reported one or both of these exposures (Table 1). This is 
3.2 Cryptosporidiosis
Summary
Number of cases, 2015: 439
Number of cases, 2014: 394
Crude incidence rate, 2015: 9.6/100,000
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Figure 1. Annual number and crude incidence rate cryptosporidiosis, 
Ireland, 2004-2015
Figure 2. Age-specific incidence rate (ASIR) cryptosporidiosis, Ireland, 
2015
Year 
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consistent with the low incidence of cryptosporidiosis among 
residents in the largely urban HSE-E population and the 
higher incidence reported in more rural parts of the country. 
The proportion of cases reporting exposure to pets and 
swimming pools was similar to last year (Table 1). 
Of note, in 2015 there was a significant increase in the 
proportion of cryptosporidiosis infections acquired abroad 
(12.7%) compared with 3.7% in 2014 (p<0.001). The highest 
proportion of travel-related cases in 2015 occurred in late 
summer/early autumn, with Spain being the most commonly 
reported travel-destination (Figure 5). 
Table 2 shows the distribution of notified cases by home 
water supply type. Persons who are not served by public 
water supplies have an increased risk of cryptosporidiosis; 
they are over-represented among cases relative to the 
distribution of households by water supply type nationally. 
This was particularly noticeable for private well users (25% 
and 10%, respectively). 
However, it should be borne in mind that persons whose 
household drinking water is not from a public supply are 
more likely to be rural dwellers and therefore may also have 
a higher likelihood of exposure to farm animals and rural 
environments which are also likely to increase their risk. 
Outbreaks
In total 18 cryptosporidiosis outbreaks were reported in 2015 
(5 general and 13 family outbreaks) and this is identical to 
the total number reported in 2014 (Figure 6). Overall since 
2011 there has been an increase in the number of outbreaks 
notified. This is most likely due to the increased recognition 
of small family outbreaks following the introduction of 
enhanced surveillance for cryptosporidiosis cases late in 
2010.
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Figure 3.  Regional crude incidence rates (CIR) cryptosporidiosis, 
Ireland, 2012-2015. 
Figure 4.  Seasonal distribution of cryptosporidiosis cases, Ireland, 
2015 compared to the mean for 2012-2014
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Table 2. Number of cases and percentage of cases where information is available by home water supply type compared to the number and 
percentage of households by water supply type, Ireland 2015
Home water supply of notified cases Number of 
cases
% of known 
cases
No. households served by these water 
supply types in the general population 
2011 (Census 2011)
% of known 
households P value*
Group water scheme (private) 22 5.5% 45,774 2.9%
<0.001
Group water scheme (public) 36 8.9% 144,428 9.0%
Other 2 0.5% 2,080 0.1%
Private well 101 25.1% 161,532 10.1%
Public water supply 242 60.0% 1,247,185 77.9%
Unknown/not specified 36 48,409
Total 439 1,649,408 100%
*Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=52.1, P<0.001
Table 1.  Number of cases (and percentage of cases where information available) where selected risk factors were reported for cryptosporidiosis 
cases (n=439), Ireland, 2015 
Risk factor Yes No Unknown /  Not specified % of known
Travel outside of Irelanda 51 350 38 12.7
Lives/cared for on farm 111 286 42 28.0
Visited farm 109 242 88 31.1
Lives/works on or visited farmb 204 196 39 51.0
Swimming pool visit 108 276 55 28.1
Other water based activities 30 274 135 9.9
Contact with domestic pets 273 112 54 70.9
aBased on country of infection variable
bComposite of the two previous variables
Among the five general outbreaks reported, one was 
associated with a childcare setting, one with drinking water, 
one with a swimming pool and one with an agricultural 
college (Table 3 and Figure 7). The general outbreaks were 
small in size (range: 2-8 cases per outbreak) and four of the 
cases were hospitalised. 
The 13 family outbreaks notified in 2015 occurred in private 
homes; 33 cases were ill and three were hospitalised. 
The most common transmission route reported in these 
outbreaks was person-person spread (seven outbreaks, 
20 persons ill and two hospitalised), followed by animal 
contact (2 outbreaks, 4 persons ill, no one hospitalised) and 
waterborne (2 outbreaks, 4 persons ill, no one hospitalised). 
Figure 5.  Seasonal distribution of cryptosporidiosis cases based on 
country of infection, Ireland, 2015
Figure 6.  Number of cryptosporidiosis outbreaks notified by type, 
Ireland 2004-2015
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Table 3.  Number of outbreaks and number ill by transmission route and location, Ireland 2015
Outbreak location
Person-to-person Waterborne Animal contact UNK/Not specified Total
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
No. 
outbreaks No. ill
Private house 5 12 2 4 3 6 2 5 12 27
Extended family 2 8 0 0 0 0 0 0 2 8
Community 1 6 1 8 0 0 0 0 2 14
Swimming pool 0 0 1 4 0 0 0 0 1 4
College 0 0 0 0 1 2 0 0 1 2
Total 8 26 4 16 4 8 2 5 18 55
Figure 7. Number of general cryptosporidiosis outbreaks by 
transmission route and year, Ireland 2004-2015
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as foodborne, 
any outbreak where water contributed was reported as waterborne, any 
outbreak where animal contact contributed was reported as animal contact. 
Person-to-person outbreaks include only those outbreaks reported as being 
due only to person-to-person transmission. 
Year of notification
Animal contact Waterborne +/- foodborne 
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Figure 8. Number of cryptosporidiosis outbreaks by transmission 
route, Ireland 2004-2015
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as animal contact. Person-to-person outbreaks include 
only those outbreaks reported as being due only to person-to-person 
transmission.
The transmission route was unknown for the remaining two 
family outbreaks; five persons ill including one hospitalised 
case (Table 3 and Figure 8).
Summary
In 2015, the incidence of cryptosporidiosis in Ireland 
increased compared with 2014, but was still lower than 
the rates reported in 2012 and 2013. The incidence of 
cryptosporidiosis in Ireland remains high relative to 
most other EU countries. The seasonal, age and regional 
distribution in incidence reported in 2015 was also typical 
of previous years; consistently there has been a higher 
incidence in springtime, in young children and in non HSE-E 
areas. 
Person-to-person spread appears to be an important 
mode of transmission within family outbreaks, while 
both enhanced surveillance data on cases and outbreak 
surveillance data are consistent with animal contact being 
an important risk factor for cryptosporidiosis in Ireland, over 
half the cases reported contact with a farm. Unlike previous 
years, in 2015 there was an increase in the proportion of 
travel-associated cases reported with many of these cases 
occurring in late summer/early autumn. 
From the enhanced information on CIDR, exposure to water 
from non-public supplies appears to present a higher risk 
of cryptosporidiosis; persons who are not served by public 
water supplies were over-represented among the sporadic 
cases relative to the distribution of households by water 
supply type nationally. 
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Introduction
For many years, Ireland has the highest verotoxigenic 
Escherichia coli (VTEC) notification rate in Europe, with the 
exception of 2011 when Germany reported the highest rate 
due to a large VTEC O104 outbreak linked with fenugreek 
seeds.1-2  In 2015, the notification rate for confirmed VTEC 
cases in the European Union/European Economic Area 
was 1.52 per 100,000 (similar to 2014; 1.56/100,000) and 
the highest country-specific rates were in Ireland, Sweden 
and the Netherlands (12.92, 5.65 and 5.08 per 100,000 
population, respectively).3
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-8 Other important transmission 
routes identified internationally include food (often minced 
beef products or fresh produce such as lettuce and spinach), 
and contact with infected animals or contaminated 
environments.2, 9-10
Materials and Methods
Infection with verotoxigenic E. coli became a notifiable 
disease in 2012; prior to that VTEC were notifiable under the 
category Enterohaemorrhagic E. coli (EHEC) since 2004. 
Enhanced epidemiological information was supplied as in 
previous years by HSE personnel, and the VTEC National 
Reference Laboratory at the Public Health Laboratory, 
Cherry Orchard Hospital Dublin (VTEC-NRL at PHL) provided 
VTEC confirmation and typing data. Data from all sources 
are maintained in the Computerised Infectious Disease 
Reporting (CIDR) system. Outbreaks of VTEC are notifiable 
since 2004 and these data are reported to CIDR by the eight 
regional Departments of Public Health. The data presented 
in this report were extracted from CIDR on 23rd November 
2016.
Data from the Central Statistics Office (CSO) 2011 census 
were used to provide denominators for the calculation of 
national, regional and age-specific incidence rates in 2015.
Results
Incidence
In 2015, 730 cases of VTEC were notified in Ireland, equating 
to a crude incidence rate (CIR) of 15.9 per 100,000 (95% CI 
14.8-17.1). Compared with 2014 there was a 3% increase in 
the incidence of VTEC (15.4 per 100,000); p=0.54). Of the 
730 VTEC notifications in 2015, 600 (82%) were classified 
as confirmed cases (CIR 13.1 per 100,000; 95% CI 12.0-14.1), 
126 as probable cases and four as possible cases. The criteria 
under which notified cases were reported in 2015 is outlined 
in Table 1. 
As the classification of VTEC cases changed significantly 
upon the amendment of the Irish VTEC case definition 
in 2012, it is not valid to directly compare the number of 
notifications by case classification before 2012. 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2015: 730
Crude incidence rate, 2015: 15.9/100,000
Number of VTEC-associated HUS, 2015: 22
Number of VTEC cases, 2014: 707
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Table 1. Number of VTEC notifications by criteria for notification, Ireland, 2015
Notification criteria Confirmed Probable Possible Total
Laboratory confirmation by culturea 483 88 - 571
Laboratory confirmation by PCR onlyb 117 15 - 132
Serodiagnosis (valid for HUS only) - - - 0
Reported solely on the basis of epidemiological link - 23 - 23
Clinical HUS not meeting lab or epi criteria - - 4 4
Total 600 126 4 730
a Symptomatic culture confirmed cases are classified as confirmed cases, while asymptomatic culture confirmed cases are classified as probable cases
b Symptomatic PCR-confirmed cases are classified as confirmed cases, while asymptomatic PCR-confirmed cases are classified as probable cases
Of the 703 cases with laboratory evidence of infection, 241 
cases (34%) were reported as being infected with E. coli 
O26 (5.3 per 100,000; 95% CI 4.6-5.9), 150 cases (21%) 
with E. coli O157 (3.3 per 100,000; 95% CI 2.7-3.8), 308 
cases (44%) with other VTEC strains, and 4 cases had mixed 
VTEC infections and were infected with more than one VTEC 
strain. Of the 23 probable cases reported on the basis of an 
epidemiological link to a confirmed case, one was linked 
to an E. coli O157 case, one was linked to an E. coli O26 
case and 21 were linked to an outbreak due to mixed VTEC 
infection. Figure 1 illustrates the distribution of VTEC cases 
in Ireland by serogroup since 1999. The downward trend in 
VTEC infections due to E. coli O157 and the upward trend 
in E. coli O26 observed in recent years continued in 2015. 
Compared with 2014, there was a 16% decrease in O157 
infections, a 3% increase O26 infections and a 7% increase in 
other non-O157/non-O26 infections.
Severity of illness
Of the 730 notified cases in 2015, 622 (85%) were 
symptomatic and 197 (32%) of the symptomatic cases 
developed bloody diarrhoea (36% of symptomatic cases 
when limited to where the bloody diarrhoea variable is 
completed). Twenty-two individuals (3%) developed HUS, 
a decrease of 19% on 2014 (n=27) and of 29% on 2013 
(n=31). In 2015, five deaths occurred among VTEC cases, 
however only one of these five deaths was attributed to 
VTEC infection. Where hospitalisation status was reported 
(n=714), 237 (33%) of these cases were hospitalised (36% of 
symptomatic cases).
Of the 22 HUS cases, seven were infected with E. coli O26, 
four with E. coli O157, two ungroupable and one each with 
E. coli O103, O145 and O177 (Table 2). Of the remaining six 
HUS cases, two were reported as confirmed cases (verotoxin 
genes detected in stool samples but no isolate was cultured) 
and four were possible cases (i.e. clinical HUS, without 
laboratory or epidemiological criteria). Although, numbers 
are small, 27% (i.e. 3 of 8) E. coli O26 vertotoxin 2 (vt2) 
developed HUS. 
HUS cases ranged in age from 6 months to 74 years and 
73% (n=16) of the cases were in children under 10 years of 
age. Fifteen of the HUS cases were considered sporadic, 
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Figure 1. Annual number of confirmed and probable VTEC cases by 
serogroup, Ireland 1999-2015
Note: For simplicity in this figure, cases with mixed VTEC O157/other 
serogroup infections are included in the data for O157, as are probable 
cases linked to known E. coli O157 outbreaks. Non-O157 data includes cases 
with mixed non-O157 infections and probable cases linked to known O26 
outbreaks
Figure 2. Seasonal distribution of the number of VTEC notifications in 
Ireland, 2015 and the mean of 2012-2014
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Table 2. Number of VTEC notifications by serogroup, verotoxin and HUS status, Ireland, 2015
Serogroupa Verotoxin HUS non-HUS Total % with HUS
O26
vt1 0 77 77 0.0%
vt2 3 8 11 27%
vt1+vt2 4 150 154 2.6%
Not reported 0 1 1 0.0%
O157
vt1 0 0 0 0.0%
vt2 4 115 119 3.4%
vt1+vt2 0 32 32 0.0%
Not reported 0 1 1 0.0%
Other
vt1 0 117 117 0.0%
vt2 6 125 131 4.6%
vt1+vt2 1 57 58 1.6%
Not reported 0 3 3 0.0%
No organism Unknown 4 22 26 15.4%
Total 22 708 730 3.0%
aFor simplicity mixed infections were recorded as O157 if at least one strain was O157, as O26 if at least one strain was O26 but not O157, and as Other if 
only non-O157 or non-O26 strains were detected. 
four were part of family outbreaks and three were part of 
general outbreaks (including two cases linked to the same 
community outbreak).
Seasonal distribution
Figure 2 shows the seasonal distribution of notifications 
in 2015 relative to the mean monthly number of cases in 
the years 2012-2014. The typical summer peak normally 
seen in July was not observed in 2015; two distinct peaks 
were seen of almost similar magnitude, one in April and 
the other in September. However, examining the seasonal 
distribution by serogroup variations were observed; O26 
and non-O157/non-O26 (others) had a bimodal distribution 
(Figure 3). E. coli O26 peaked in July and September and 
non-O157/non-O26 (others) peaked in May and September. 
Although, the numbers of E. coli O157 notifications peaked 
in September, this peak was not as pronounced as previous 
years and was preceded with smaller peaks in May and July 
(Figure 3). 
Regional distribution
In 2015, the highest VTEC incidence rates were reported in 
the HSE-W followed by the HSE-M, HSE-MW and HSE-SE, 
where the rates were significantly higher than the national 
crude incidence rate (Table 3). The incidence of VTEC in 
HSE-E and HSE-NW were significantly lower than the 
national crude incidence rate. The highest incidence of HUS 
amongst VTEC cases was in HSE-M and HSE-MW (Table 3).
In the eight HSE areas, the incidence of E. coli O26 in 2015 
exceeded or equaled that of E. coli O157 (Figure 3). Other 
serogroups (i.e. non-O157/non-O26) accounted for the 
highest rates of VTEC infections in five of the eight HSE areas 
(Figure 3)
Age-sex distribution
As in previous years, the highest reported age-specific 
incidence rate in 2015 was in the 0-4 year age group (81.4 
per 100,000). Incidence rates were higher among females 
in all age groups 20 years of age and older but were slightly 
higher in males in those <15 years of age (Figure 5).
Laboratory typing
In 2015, the serogroup and verotoxin profiles of VTEC 
isolates/samples referred to the VTEC-NRL at PHL, Cherry 
Orchard Hospital are presented in Table 4. The most 
common serogroup reported was E. coli O26 (n=241), 
followed by E. coli O26 (n=150). Among the other serogroups 
listed by the World Health Organisation as having the 
highest association with HUS internationally, there were 41 
E. coli O145, 15 E. coli O103 cases and 6 E. coli O111. Although 
numbers are relatively small, infections due to O145 
continued to increase from 17 cases in 2013, to 31 cases in 
2014 and 41 cases in 2015. 
As usual among E. coli O157 cases in Ireland, isolates 
containing the genes for vt2 were more common (78%) than 
strains containing genes for both vt1 and vt2. Among the 
VTEC O26 strains those containing the genes for both vt1 and 
vt2 accounted for the majority (64%), followed by vt1 only 
(32%) and those containing vt2 making up the remaining 4% 
of E. coli O26 cases. In contrast, the majority (85%) of O145 
strains were vt2-postive. Furthermore, vt1-containing strains 
made up the majority of O103 strains (87%), while VTEC O111 
comprised of vt1 (50%) and vt1+vt2 (50%) containing strains 
(Table 4).
Risk factors
Under the enhanced surveillance system for VTEC, risk factor 
information is routinely collected on all notifications (Table 
5).
Exposure to farm animals or their faeces and exposure to 
private well water were relatively common among cases in 
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Figure 3: Seasonal distribution of VTEC notifications by serogroup, 
Ireland, 2015
For simplicity mixed infections were recorded as O157 if at least one strain was O157, 
as O26 if at least one strain was O26 but not O157, and as Other if only non-O157 or 
non-O26 strains were detected.
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Table 3. Number and crude incidence rates of by serogroup and HSE area, and number and crude incidence rate of VTEC-associated HUS by 
HSE area, Ireland, 2015
HSE-area Number of VTEC cases Crude incidence rate /100,000 
(95% CI)
Number HUS cases Incidence of HUS /100,000 
(95% CI)
E 84 5.2 (4.1-6.3) 3 0.2 (0.0-0.4)
M 85 30.1 (23.7-36.5) 3 1.1 (0.0-2.3)
MW 109 28.7 (23.3-34.1) 4 1.1 (0.0-2.1)
NE 67 15.2 (11.6-18.8) 1 0.2 (0.0-0.7)
NW 25 1.9 (5.9-13.5) 0 0.0 (0.0-0.0)
S 112 16.9 (13.7-20.0) 4 0.6 (0.0-1.2)
SE 112 22.5 (18.3-26.7) 3 0.6 (0.0-1.3)
W 136 30.5 (25.4-35.7) 4 0.9 (0.0-1.8)
IE 730 15.9 (14.8-17.1) 22 0.5 (0.3-0.7)
2015; 37.9% and 33% reported these exposures, respectively. 
According to CSO data, in the general population, around 
10.1% of households are served by private wells, indicating 
that, on a national basis, exposure to private wells appears 
to be more common among VTEC cases than among the 
general population.
Unlike salmonellosis, foreign travel plays only a minor role 
in VTEC infection in Ireland, with the majority of infections 
acquired indigenously (>97%). 
Where the information was available, just under a fifth of 
VTEC cases in 2015 were attending a childcare facility (CCF). 
When these analyses were restricted to notified VTEC under 
five years of age, 43.2% reported attendance at a childcare 
facility. This is similar to the proportion of children in the 
general population who use non-parental childcare (42%) as 
reported by the Central Statistics Office.11
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in our 
understanding of the transmission of VTEC infection in 
Ireland. Ninety-one VTEC outbreaks were notified in 2015, 
which included 280 of the 730 VTEC notifications. Forty-one 
outbreaks were due to E. coli O26, 18 to E. coli O157, 16 were 
mixed E. coli strain outbreaks, and 16 were caused by other 
VTEC strains. 
The majority of outbreaks (n=78, 86%) were family outbreaks, 
with 13 general outbreaks also notified. The 73 family 
outbreaks resulted in 148 persons becoming ill, an average 
of 1.95 (range 1-7) persons ill per outbreak. The 13 general 
outbreaks resulted in 84 persons becoming ill, an average of 
7 (range 1-44) persons ill per outbreak. 
Seventy-four outbreaks occurred in private homes, eight 
involved extended families, five involved childcare facilities, 
three were community outbreaks and one was in a residential 
institution. 
The suspected modes of transmission are listed in Table 6.
Person-to-person spread is consistently the most common 
mode of VTEC transmission reported in Ireland, particularly 
between young children, and was suspected to have played a 
role in 51 (56%) VTEC outbreaks in 2015 in which 114 persons 
were reported ill (Table 6 and Figure 5). Thirty-four of these 
outbreaks were reported as being solely due to person-to-
person transmission, including two outbreaks which occurred 
in CCFs. 
Waterborne transmission was reported to have contributed to 
19 outbreaks (21%) with 82 persons ill. 
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Figure 4: Crude incidence rate VTEC O157, O26 and other serogroups 
by HSE area, Ireland, 2015
For simplicity mixed infections were recorded as O157 if at least one strain was 
O157, as O26 if at least one strain was O26 but not O157, and as Other if only 
non-O157 or non-O26 strains were detected.
Table 4. Serotype and verotoxin (vt) profiles for strains associated with 
laboratory confirmed VTEC cases, as determined at the VTEC-NRL at 
PHL, Cherry Orchard Hospital, 2015 
Serogroup vt1 vt2 vt1 + vt2 Not reported Total
O26 77 11 152 1 241
O157 - 117 32 1 150
O145 1 35 5 - 41
O103 13 2 - - 15
O146 10 - 1 - 11
O5 6 - 3 - 9
O78 6 1 - - 7
O111 3 - 3 - 6
O128ab - 2 4 - 6
O177 2 4 - - 6
O182 6 - - - 6
O84 6 - - - 6
O91 1 2 2 - 5
O76 2 - 2 - 4
O8 - 3 - - 3
O108 2 - - - 2
O113 - 1 1 2
O117 2 - - - 2
O128ad - 2 - - 2
O98 2 - - - 2
O101 - 1 - - 1
O105 - 1 - - 1
O105ac - 1 - - 1
O117:H17 - 1 - - 1
O126 - 1 - - 1
O130 - 1 - - 1
O136 1 - - - 1
O136:H12 - 1 - - 1
O141 - 1 - - 1
O149 1 - - - 1
O150 - - 1 - 1
O156 - 1 - - 1
O174 1 - - - 1
O178 1 - - - 1
O185 1 - - - 1
O186 - - 1 - 1
O2 - 1 - - 1
O22 1 - - - 1
O71 - - 1 - 1
O74 - - 1 - 1
O87 1 - - - 1
OE11362-78 - 1 - - 1
OE7477-77 1 - - - 1
Ungroupable/
unidentifiable
47 33 67 3 150
Mixed - 2 2 - 4
Total 194 226 278 5 703
This is higher than the number of waterborne VTEC 
outbreaks reported in 2014 (n=9) and 2013 (n=8) but similar 
to the number reported in 2012 (n=21) (Figure 6). Of the 19 
outbreaks with links to waterborne transmission, 16 were 
family outbreaks with exposure to private wells reported in 
13 of these and three were general outbreaks. One of the 
three general outbreaks occurred in the community resulting 
in 44 people ill and was linked to a private group water 
scheme.
Similar to 2014, in 2015 animal/environmental contact was 
reported to have contributed to nine outbreaks (9.9%) with 
20 persons ill. All occurred in private houses (Figure 6).
One outbreak (family outbreak, 2 persons ill) was reported as 
foodborne and linked to unpasteurised cheese while another 
family outbreak with three persons ill was reported as food/
waterborne, where the individuals had been exposure to 
unpasteurised milk and water from a private well.
For 31% (n=28) of VTEC outbreaks in 2015, the transmission 
route was reported as unknown (Table 6 and Figure 6).
Summary
The number of VTEC notifications in Ireland continued to rise 
(but not significantly) in 2015. Within the European Union, 
Ireland continues to have the highest incidence rate for 
VTEC, reporting over seven times the European average in 
2015.3 
The upward trend observed in Ireland in recent years of 
non-O157 notifications continued in 2015 and reflects the 
more widespread use by the primary hospital laboratories, 
of diagnostic methods that detect a broader range of E. coli 
serogroups and the use of more sensitive molecular methods 
that detect verotoxin genes directly in stool samples12 
Furthermore, national guidance developed for the laboratory 
diagnosis of human VTEC in Ireland provides a co-ordinated 
approach to VTEC diagnosis in Ireland.13
Foodborne transmission was the first recognised 
transmission route for VTEC infection historically, with 
minced beef, unpasteurised dairy products, and fresh 
produce consumed raw all having been implicated in 
outbreaks across the world. Foodborne outbreaks typically 
comprise a small percentage of the total number of VTEC 
outbreaks in Ireland and 2015 was not an exception 
with foodborne outbreaks comprising 2.2 % of the VTEC 
outbreaks notified.
Transmission by person-to-person spread, however, 
remained the most common transmission route reported 
in VTEC outbreaks and was involved in 56% of outbreaks. 
As usual, person-to-person spread was most frequently 
associated with private house and childcare facility 
outbreaks. Hand-washing and exclusion of cases in risk 
groups from high risk settings remains a key prevention 
measures for VTEC.14
In 2015, after person-to person spread, contaminated 
drinking water was the second most commonly suspected 
mode of transmission. As in previous years, the majority 
of the drinking-water associated outbreaks reported were 
linked with private water supplies and one outbreak was 
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Figure 5. Age-sex distribution VTEC notifications, Ireland, 2015
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Table 5. Number of cases of VTEC (and percentage where information available) for selected risk factors, Ireland, 2015 (n=730)
Risk factor Yes (% of known) No Unknown or not reported
Food suspected 27 (5.4) 473 230
Exposure to farm animals or their faeces 245 (37.9) 402 83
Exposure to private well watera 215 (33.0) 437 78
Travel-associatedb 18 (2.7) 645 67
Attendance at a CCFc 112 (18.8) 485 133
Attendance at a CCFc (among <5 yrs) 104 (43.2) 137 49
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bInferred from CIDR core variable Country of Infection
c CCF=childcare facility
linked to contaminated water from a private group water 
scheme. Exposure to water from contaminated untreated 
or poorly treated private water supplies has historically 
been recognised as a strong risk factor for VTEC infection in 
Ireland.6-8, 15This has been particularly pronounced following 
periods of heavy rainfall. 
Animal/environmental contact was reported as the third 
most common route of transmission for VTEC outbreaks in 
2015. This has long been recognised as a risk factor for VTEC 
infection 9-10 and cases due to this transmission route are 
not unexpected in Ireland given the large cattle population, 
the high proportion of rural dwellers, and the large number 
of farming families.8 Fortunately, none of these animal 
contact outbreaks were associated with public venues such 
as open farms, and so the numbers of people affected were 
small. Advice is available on the HPSC website on how to 
minimise the risk of gastrointestinal infections following 
exposure to farm animals and environments, and for the 
safe recreational use of farmland.16
The focus for reducing the incidence of VTEC should be on 
reducing person-to-person and waterborne transmission. 
Efforts should focus initially on publicizing materials already 
developed in Ireland, including national guidance for crèche 
owners on the management of infectious-disease spread 
in CCFs 17, guidance for public health professionals on the 
management of VTEC cases and outbreaks in CCFs14  and 
a leaflet developed for well owners outlining the infectious 
disease risks associated with drinking water from private 
wells, providing advice on actions that can be taken and 
what to do in the event the well water is contaminated.18
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Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as foodborne, 
any outbreak where water contributed was reported as waterborne, any 
other outbreak where animal contact contributed was reported as animal 
contact. Person-to-person outbreaks include only those outbreaks reported 
as being due only to person-to-person transmission
Table 6. VTEC outbreaks by suspected mode of transmission, Ireland, 2015 
Transmission route Number of  outbreaks Number ill Number of associated 
CIDR eventsa
Person-to-person 34 73 83
Foodborne 1 2 2
Waterborne 8 55 57
Person-to-person and waterborne 10 24 29
Foodborne and waterborne 1 3 3
Animal contact 2 3 4
Person-to-person and animal contact 7 17 17
Unknown 28 55 85
Total 91 232 280
a These figures may differ from the number ill, as asymptomatic cases identified as a result of screening will also be reported in CIDR
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from person to 
person via the faecal-oral route and is associated with poor 
hygiene and sanitation. Common source outbreaks due to 
contaminated food or water also occur.
The incidence of hepatitis A in Ireland has been low in recent 
years and remained low in 2015, with 36 cases notified 
(0.8/100,000 population) (figure 1). Although this was an 
increase compared to 2014 (n=21, 0.5/100,000 population), 
the number of cases of hepatitis A fluctuates from year to 
year. The average number of cases notified annually over the 
past ten years was 38 (median: 39). Case classification was 
reported for all cases and thirty four (94%) were laboratory 
confirmed. The notification rate in each HSE area is shown in 
figure 2.
Fifty six percent (n=20) of cases were male and 44% (n=16) 
were female. The highest notifications rates were in children 
3.4 Hepatitis A
Summary
Number of cases, 2015: 36
Crude notification rate, 2015:  0.8/100,000 population
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Figure 1. Number of hepatitis A notifications, 1996-2015
Figure 2. Notification rate for hepatitis A by HSE area, 2015
and young adults, with 61% (n=22) of cases aged between 0 
and 24 years (figure 3). Almost half of the 2015 cases (n=17) 
were notified in April and May, but a large proportion of 
these were part of a single outbreak.
Overall, thirteen cases were linked to travel outside of 
Ireland. Nineteen cases were reported as infected in Ireland, 
but three of these were part of an outbreak where the index 
case was infected outside Ireland. Country of infection was 
not known for the remaining four cases.
Three hepatitis A outbreaks were reported in 2015. The 
largest involved 7 adults and 4 children and was an extended 
family and local community outbreak linked to a crèche in 
the HSE-E. In an outbreak in the HSE-M, involving 4 children, 
the index case had travelled to Pakistan and the remaining 
cases were infected through person-to-person contact in 
Ireland. The remaining outbreak involved two children in the 
HSE-E and was linked to travel to Sudan.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 21st September 2016. These 
figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
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Figure 3. Hepatitis A age and sex-specific notification rates/100,000 population, 2015
Rotavirus is the commonest global cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and watery 
diarrhoea. Transmission is usually person-to-person, mainly 
via the faecal-oral route. Children less than two years of 
age are most susceptible to infection, although cases are 
often seen in elderly and immunocompromised adults, 
particularly in institutional settings. By the age of six years, 
virtually all children will have had at least one episode of 
rotavirus infection. Symptoms usually last for only a few days 
but in severe cases hospitalisation may be required due to 
dehydration. 
Prior to 2004, rotavirus cases were notified under the 
“Gastroenteritis in children under two years” disease 
category. From 2004 to 2010, rotavirus was notifiable in 
all age groups under the “Acute Infectious Gastroenteritis” 
(AIG) disease category, until it became notifiable as a 
disease in its own right under the Infectious Diseases 
(Amendment) Regulations 2011 (S.I. No. 452 of 2011). Since 
March 2013, rotavirus notifications from HSE-East are based 
on laboratory testing results rather than patient episodes. 
Notifications from HSE-E may also refer to area of laboratory 
testing rather than area of patient residence.
During 2015, there were 4,158 cases of rotavirus notified in 
Ireland, corresponding to a national crude incidence rate 
(CIR) of 90.6 per 100,000 population (figure 1).* This is the 
highest number of cases reported since surveillance began in 
2004, and represents an increase of 75.9% compared to the 
mean CIR during 2004-2014 (51.5). 
Significant geographical variation was observed in regional 
rotavirus CIR. The highest regional CIRs were observed 
in HSE-M (120.0), -W (114.5) and -SE (112.7). The lowest 
regional CIR was observed in HSE-MW (65.1) and HSE-NW 
(76.3). 
3.5 Rotavirus
Summary
Number of cases:  4,158
Crude incidence rate: 90.6/100,000 population
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Figure 1: Number of rotavirus notifications and crude incidence rate per 100,000 population by year (CIDR)
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Rotavirus infection has a well-documented seasonal pattern 
in Ireland with the number of cases typically peaking during 
March to May. During 2015, rotavirus notifications peaked 
during March (n=847) and April (n=987). Figure 2 illustrates 
the seasonal variation in rotavirus cases by month of 
notification for 2015 compared to the mean monthly number 
of notifications reported during 2004 to 2014.  
During 2015, 1,962 cases (47.2%) were female and 2,192 
(52.7%) were male. Sex was not reported for the remaining 
four cases. 
Six outbreaks of rotavirus were notified during 2015 with 42 
cases of associated illness, eight of whom were hospitalised. 
Two general outbreaks occurred in child-care facilities. 
The remaining four outbreaks were family outbreaks that 
occurred in private homes. All outbreaks reported mode of 
transmission as person to person spread. 
Figure 2: Rotavirus CIR by month (CIDR)
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Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. S. Typhi 
and S. Paratyphi can cause enteric fever, a severe systemic 
life threatening condition, but these are not common in 
Ireland and are almost invariably travel-associated.
The common reservoirs for non-typhoidal Salmonella are 
the intestinal tract of domestic and wild animals (including 
birds), which may result in a variety of foodstuffs, of both 
animal and plant origin, becoming contaminated with faecal 
organisms either directly or indirectly. The organism may 
also be transmitted through direct contact with infected 
animals or humans or faecally contaminated environments. 
Infected food handlers may also act as a source of 
contamination for foodstuffs. Of particular concern is the 
number of cases of infection associated with direct contact 
with reptiles kept as companion animals. 
During 2015, 269 cases of salmonellosis were notified, 
corresponding to a crude incidence rate (CIR) of 5.9 per 
100,000 population (figure 1). The annual CIR has remained 
consistently low over the last five years (2010-2014 mean: 
6.8) compared to the previous five year (2005-2009: 9.3). 
The highest CIR in 2015 occurred in HSE-W (7.0) and the 
lowest in HSE-NW (3.9). 
The highest age-specific incidence rate among both sexes 
was in children under 5 years of age (15.2). This is likely to be 
influenced by clinicians more readily seeking clinical samples 
in that age group. The lowest age specific rate was observed 
in the 35-44 year age group (2.4).The male to female ratio 
was equal in all age groups apart from the 25-34 year age 
group (0.5:1.0) and the 45-54 year age group (1.4:1.0).
Foreign travel as a risk factor for salmonellosis in Ireland
Country of infection was reported for over 90% of 
notifications in 2015. Where country of infection was 
reported, 45.5% of cases were travel associated. The number 
of travel associated cases peaked during the period August 
to October while indigenous cases peaked during September 
to November (Figure 2). High numbers of indigenous 
3.6 Salmonella 
Summary
Number of confirmed cases: 269
Crude incidence rate: 5.9/100,000 population1
Figure 1: Salmonellosis notifications and CIR by year of notification (CIDR)
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Figure 2: Salmonellosis notifications by month of notification and travel history, 2015 (CIDR)
Figure 3: Annual number of Salmonella isolates referred to NSSLRL by serotype (NSSLRL)
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cases were also observed in April and June. Among travel 
associated cases, the most common countries of infection 
reported were: Spain (n=22), Poland (n=9) and Thailand 
(n=8). The popularity of a country as a travel destination is 
likely to be an important factor in determining the number of 
cases associated with each country. 
When serotyping data were analysed by travel history, 
almost half of all indigenous cases were infected with S. 
Typhimurium (or monophasic S. Typhimurium), with ‘Other’ 
serotypes making up a further 36.1% of cases. In contrast, 
S. Enteritidis features more prominently among travel-
associated cases (36.0%) with just 15.8% of indigenous 
cases due to S. Enteritidis (table 1).
Typhoid/Paratyphoid:
In 2015 nine cases of typhoid and one case of paratyphoid 
(Paratyphi B) were notified. Of the nine S. Typhi cases, 
two each had travelled to India and Pakistan, one each 
to Bangladesh, Nigeria and Uganda. The remaining two 
typhoid cases did not report country of infection. The 
paratyphoid case reported travel to Bolivia. 
National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) data:
The National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) based in Galway has been providing 
reference services nationally since 2000. In 2015, the 
NSSLRL analysed 272 human Salmonella isolates 
referred for further typing, including six typhoid and one 
paratyphoid. Figure 3 shows the trend in referral of isolates 
to NSSLRL by organism over time. 
The NSSLRL conducted phage typing analysis on all 94 S. 
Typhimurium and all 68 S. Enteritidis isolates. Phage type 
DT193 (n=21) comprised 22.3% of all S. Typhimurium strains. 
Other currently important S. Typhimurium phage types 
included Untypable (14.9%) and DT104 (6.4%). Phage types 
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PT21 (23.5%), PT8 (17.6%) and PT1 (16.2%) were the most 
common phage types observed among S. Enteritidis isolates. 
Of the 272 isolates analysed for antimicrobial resistance, 
137 (50.4%) were fully susceptible to all antimicrobials 
tested. The remaining 135 isolates exhibited some degree of 
antimicrobial resistance across 47 antibiograms. Thirty-seven 
isolates exhibited resistance to five or more antimicrobials 
among 25 antibiograms. The majority of isolates exhibiting 
this level of resistance were S. Typhimurium (54.1% of multi-
drug resistant isolates). Overall, the commonest resistance 
pattern seen was resistance to ampicillin, streptomycin, 
sulphadiazine and tetracycline (ASSuT, n=35, 25.9% 
of resistant isolates). The ASSuT pattern was identified 
exclusively in S. Typhimurium isolates. Resistance to nalidixic 
acid and ciprofloxacin (NaCp, n=24, 17.8% of resistant 
isolates) was the second most common AMR profile among 
all isolates, This pattern was identified mainly in S. Enteritidis 
isolates (79.2%). The NSSLRL’s Annual Report 2015 provides 
a more detailed analysis of clinical Salmonella typing results 
and a comparison with isolates from non-human sources.1 
Outbreaks
During 2015, nine outbreaks of salmonellosis were reported, 
comprising 22 cases of illness and one travel associated 
outbreak of typhoid with three associated cases of illness. 
Six family outbreaks occurred in private houses. Two general 
outbreaks occurred in community settings and one general 
outbreak occurred in a hospital. Four outbreaks were 
reported as due to person to person spread and one was 
due to animal contact while mode of transmission for the 
remaining four outbreaks was reported as unknown. 
In consequence of the increasing recognition in recent years 
of fresh produce as a cause of gastrointestinal disease 
outbreaks, the National Salmonella Outbreak Trawling 
Questionnaire was recently expanded and updated. The 
form is available at http://www.hpsc.ie/A-Z/Gastroenteric/
Salmonellosis/SurveillanceInvestigativeForms/ 
References: 
1.  National Salmonella Reference Laboratory of Ireland, Annual Report for 
2015. Available at:        
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
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Table 1: Salmonellosis notifications by serotype and travel history, 2015 (CIDR)
Salmonella serotype Travel associated Indigenous Travel history unknown
Number % Number % Number %
S. Typhimurium 21 18.9 64 48.1 6 24.0
S. Enteritidis 40 36.0 21 15.8 8 32.0
Other serotypes 50 45.0 48 36.1 11 44.0
All serotypes (n) 111 100.0 133 100.0 25 100.0
Listeriosis 
In 2015, 19 cases of listeriosis were notified, an increase 
compared to 2014 and 2013 when 15 and 8 cases were 
reported, respectively. For 2015, this equates to a crude 
incidence rate of 0.41 per 100,000 population which remains 
below the EU average of 0.48 per 100,000 for the same 
year.1
In 2015, two neonatal cases and three pregnancy-related 
cases were reported (Figure 1). The number of adult/juvenile 
cases reported in 2015 increased by 75% (n=14) compared 
with 2014 (n=8) and it was the highest since listeriosis 
became notifiable as a specified disease in 2004 (Figure 1). 
Eight of the fourteen adult/juvenile cases were male, cases 
ranged in age from 16 months to 87 years and 64% (n=9) 
of these cases were 65 years of age and older. Five adult/
juvenile cases had septicaemia, three had meningitis and 
two had both. Two patients died, one death was due to 
listeriosis and for the second death the cause of death was 
unknown but the patient had an underlying illness. 
Since 2007, the National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) in Galway provides a national 
service for the typing of Listeria strains. In 2015, isolates from 
fifteen of the 19 notified cases were referred by the primary 
laboratories for serotyping. Serotype 4b was the most 
common (n=8) followed by serotype 1/2a (n=6) (Table 1).
In Ireland, listeria remains a hazard for the elderly, persons 
with underlying illness, and other vulnerable groups such as 
pregnant women and neonates.
3.7  Less common gastroenteric 
 infections
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Figure 1: Number listeriosis notifications by case type, Ireland, 2004-2015
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Table 1: Listeriosis notifications by case type and serotype, Ireland, 2015*
Type Serotype 1/2a Serotype 1/2b Serotype 4b Not referred for 
serotyping
Total
Adult or juvenile 5 1 5 3 14
Pregnancy-related 0 0 2 1 3
Neonatal 1 0 1 0 2
Total 6 1 8 4 19
* Typing data provided by the National Salmonella, Shigella and Listeria Reference Laboratory (NSSLRL)
Giardiasis
In 2015, there were 146 cases of giardiasis notified, 
corresponding to a crude incidence rate (CIR) of 3.2 per 
100,000 population and representing a doubling of CIR. 
This increase appears to be largely due to the introduction 
of molecular methods for multi-pathogen screening of 
stool samples during 2015. In a recent laboratory survey 
conducted by HPSC, seven laboratories reported the 
introduction of such methods during 2015. This is likely to 
have led to an increased number of stool specimens tested 
for Giardia since 2015. 
Cases ranged in age from one month-90 years with a median 
age of 30 years. Between 2004 and 2014, the highest age 
specific incidence rates (ASIR) occurred in the 0-4 years age 
group (mean = 3.0/100,000). This increased from 3.6 in 2014 
to 7.0 in 2015. The 2nd highest ASIR in 2015 was observed in 
those aged 25-34 years at 4.8, an increase compared to 2.6 
in 2014 and a mean ASIR of 2.0 between 2004 and 2014. 
Other age groups that reported large increases in the ASIR 
during 2015 compared to the mean ASIR between 2004 and 
2014, were those aged 5-14 years (2015: 7.0 vs mean 3.0) and 
those aged 65 years and older (2015: 3.0 vs mean: 0.5). 
The male to female ratio was 1.5:1.0, but was higher for 
non-travel associated cases (1.9:1.0) compared to travel 
associated cases (1.2:1.0). The majority of cases were 
diagnosed in GP patients (60.0%). 
Country of infection was reported for 66.2% of cases in 2015, 
a decrease compared to 69.0% in 2014 (Figure 2). Of the 96 
cases where country of infection was reported 47 (49.0%) 
were reported as being associated with foreign travel. The 
most commonly reported countries of infection were India 
(n=13) and Spain (n=6), two cases each were reported from 
Lebanon and Pakistan and there was one case each reported 
associated with travel to 12 other countries. Forty-nine cases 
(51.0%) were reported as being acquired in Ireland, a marked 
increase compared to 32.7% in 2014. The remaining 49 cases 
(33.8%) did not report country of infection. 
Four family outbreaks of giardiasis were notified in 2015, 
all of which occurred in private houses. Three outbreaks 
reported waterborne transmission and one was considered 
to be due to person to person transmission.  
Yersiniosis 
In 2015, there were 13 cases of yersiniosis reported, a sharp 
increase compared to five cases reported in 2014 and four 
cases in 2013. This increase is mainly due to a research 
project in a regional laboratory which used a molecular 
method for multi-pathogen screening of faecal samples 
during 2014. This research resulted in an unexpectedly 
high yield of Yersinia positive specimens which prompted 
further testing during 2015. Table 2 outlines the age and 
sex distribution of cases in 2015. One was reported as 
being infected with Y. pseudotuberculosis and 12 were Y. 
enterocolitica. The reported incidence of yersiniosis in Ireland 
is low relative to the EU as a whole, and to Northern Europe 
in particular. 
Table 2: Number of yersiniosis notifications by sex and age group, 
2015
Age group Female Male Total
0-4 yrs 2 2
5-14 yrs 1 3 4
25-34 yrs 1 1 2
45-54 yrs 1 1
55-64 yrs 1 1
65+ yrs 1 2 3
Total 3 10 13
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. There was one case of Bacillus cereus foodborne 
infection notified in an infant in 2015. There were no cases or 
outbreaks of botulism, Clostridium perfringens (type A) food-
borne intoxication or staphylococcal food poisoning notified 
in 2015.
References
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Figure 2: Number of giardiasis notifications by country of infection, 2004-2015
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Summary
Number of notifications: 90
Crude incidence rate: 2.0/100,000
Ninety cases of shigellosis were notified in Ireland in 2015, 
corresponding to a crude incidence rate (CIR) of 2.0 per 
100,000. This represents an increase of 58% compared 
to 2014. Of 85 cases where hospitalisation status was 
recorded, 17 (20%) were reported as hospital in-patients. Of 
the 90 cases, 87 were laboratory confirmed. 
During 2015, there was an excess of male cases compared 
to females, with a male to female ratio of 2.1:1.0. This trend 
has been observed since 2009 with the exception of 2013 
where more females were notified (figure 1). During 2015, 
cases ranged in age from 1 month to 95 years (median 
age=34 years). The male to female ratio was highest in the 
age groups 15-24 years (3.0:1.0), 25-34 years (3.2:1.0) and 
35-44 years (3.0:1.0). Of the 26 cases that were reported as 
indigenous, 76.9% were male which compares to 53.3% of 
travel associated cases (table 1). 
3.8 Shigellosis
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Figure 1: Annual number of notifications shigellosis by sex and year (Data source: CIDR)
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Table 1: Number of notifications shigellosis by travel association, age group and sex, 2015 (Data source: CIDR)
2015
Travel associated Indigenous Travel history unk Total notifications
F M F M F M F M Total M: F ratio
0-4 yrs 2 2 2 1 1 2 5 5 10 1.0
5-14 yrs 2 3 1 3 3 6 1.0
15-24 yrs 2 3 3 2 6 8 3.0
25-34 yrs 5 4 8 1 7 6 19 25 3.2
35-44 yrs 3 6 1 4 2 4 12 16 3.0
45-54 yrs 5 2 1 3 4 6 9 15 1.5
55-64 yrs 2 3 1 1 2 5 7 2.5
65+ yrs 1 1 1 1 2 1.0
Age unk 1 1 1
Total 21 24 6 20 2 17 29 61 90 2.1
M:F ratio 1.1: 1.0 3.3: 1.0 8.5: 1.0 2.1: 1.0
Information on travel history is very valuable when reviewing 
surveillance data for possible indigenous clusters. Data 
on country of infection was available for 79% of shigellosis 
notifications this year. Forty-five cases were reported as 
being associated with foreign travel in at least 23 countries 
during 2015. Twenty-six cases were reported as being 
acquired in Ireland, while no country of infection information 
was available for 19 cases. 
S. sonnei was the most common species reported (n=45), 
followed by S. flexneri (n=27). Three S. boydii and two 
S. dysenteriae were also reported while species was not 
reported for the remaining 13 confirmed cases. When 
analysed by travel association, S. flexneri was equally 
common among indigenous cases (30.8%) as travel 
associated cases (31.1%). S. sonnei was more common 
among indigenous cases (57.7%) than travel associated 
cases (42.2%).
Three shigellosis outbreaks were notified in 2015, resulting 
in 32 cases of illness and five associated hospitalisations. 
Table 2 summarises the three outbreaks reported during 
2015. A large outbreak of shigellosis comprising 28 episodes 
of illness among 27 individuals, was reported among men 
who have sex with men (MSM). Infection with multiple 
serotypes was recorded. 
More detailed typing of Shigella isolates can provide useful 
information on the relatedness of strains which can be used 
by public health personnel to outrule/provide evidence for 
links between cases during investigations of case clusters. 
The National Salmonella, Shigella and Listeria Reference 
Laboratory (NSSLRL) provide laboratory services for 
speciation, serotyping, antimicrobial resistance profiling, 
and where appropriate, Pulsed Field Gel Electrophoresis 
(PFGE) of Shigella isolates. The species/serotype and 
antimicrobial resistance patterns of these cases are reported 
in Table 3. 
During 2015, the NSSLRL reported an increase in specimen 
referral from regional laboratories. This is likely a result 
of the increased sensitivity of direct molecular detection 
methods which were recently introduced by regional 
laboratories for faecal pathogen screening. 1 An increase 
in ciprofloxacin resistance among S. sonnei isolates has 
been identified by NSSLRL since 2010; this appears to be 
particularly evident among isolates originating in South 
Asia.1 Further details of Shigella strain characterisation 
performed at NSSLRL can be found in the NSSLRL Annual 
Report.1 
References
1. National Salmonella Reference Laboratory of Ireland, Annual Report for 
2015. Available at:       
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
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Table 2: Shigellosis outbreaks 2015 (Data source: CIDR)
HSE-area Outbreak type Location Transmission mode Number ill Serotype
HSE-E General Community Person-to-person 28 S. sonnei & S. flexneri
HSE-W General Workplace Person-to-person 2 S. sonnei
HSE-M Family Travel-related Unknown 2 S. boydii
Table 3: Species/serotypes and AMR profiles of Shigella isolates referred to 
NSSLRL in 2015 
Serotype Number by serotype AMR profile
Number by 
serotype and 
AMR profile
Shigella boydii
4
none 1
Shigella boydii T 2
Shigella boydii 2 STm 1
Shigella dysenteriae
2
ACSSuTTm 1
Shigella dysenteriae
ACSSuTTm-
NaCpCtxCef 1
Shigella flexneri
27
ACSSuTTm-
NaAzt 1
Shigella flexneri 1b ACSSuTTm 2
Shigella flexneri 1b ACSTTmNa 1
Shigella flexneri 1b ASSuTTm 1
Shigella flexneri 2 SSuTTmNaCp 1
Shigella flexneri 2a ACSSuTTm 2
Shigella flexneri 2a ACSSuTTmAzt 2
Shigella flexneri 2a
ACSSuTTm-
NaCp 1
Shigella flexneri 2a ACST 5
Shigella flexneri 2a ACSTTmNaCp 1
Shigella flexneri 2b ACSTm 1
Shigella flexneri 3a ACST 2
Shigella flexneri 3b ACST 1
Shigella flexneri 4 ACSSuTTm 1
Shigella flexneri X 
variant
ASSuTTmAzt 3
Shigella flexneri X 
variant
none 1
Shigella flexneri X 
variant
T 1
Shigella sonnei
33
ASSuTmGmCtx 1
Shigella sonnei
ASSuTTm-
NaAzt 1
Shigella sonnei
ASSuTTm-
NaCpCtx 1
Shigella sonnei
ASSuTTm-
NaGmCtx 1
Shigella sonnei SSuTm 1
Shigella sonnei SSuTTm 13
Shigella sonnei SSuTTmNa 9
Shigella sonnei SSuTTmNaCp 1
Shigella sonnei
SSuTTmNaC-
pAzt
1
Shigella sonnei STmNaCp 1
Shigella sonnei TmNaCp 3
Total 66 Total 66
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In 2015, 81 malaria cases were notified in Ireland, which 
remains stable in comparison to 80 cases reported in 2014 
(Figure 1). Among European Union (EU) member states 
reporting malaria data to the European Centre for Disease 
Prevention and Control, Ireland had the fifth highest 
incidence rate for imported malaria in 2014 (the latest year 
for which comparative data are available); only Belgium, 
Norway, Sweden and the United Kingdom had higher 
reported incidence rates.
In common with the rest of the EU, males predominated with 
a male: female ratio of 2.2:1.0. The highest numbers of cases 
were aged between 25 and 54. The number of paediatric 
cases reported was 6, a decrease compared to 10 cases 
reported during 2014 (Figure 1).
Three of the paediatric cases reported “visiting family in 
country of origin” as their reason for travel and one was an 
Irish citizen living abroad who had returned to Ireland for a 
holiday. There was no information on reason for travel for 
the remaining two paediatric cases. Four paediatric cases 
visited sub-Saharan Africa while country of infection was 
not available for the remaining two cases. Only one of the 
paediatric cases reported taking malaria prophylaxis but 
this case was not fully compliant, three paediatric cases 
reported not taking any prophylaxis for their travel, while the 
remaining two paediatric cases did not have information on 
prophylaxis reported. 
Among all age groups, the category of traveller most 
affected in Ireland continued to be African immigrants and 
their families who were exposed while returning to “visit 
family in country of origin”. This almost certainly reflects the 
greater frequency with which this group travels to malarious 
areas, but also reflects Ireland’s importance as a destination 
for those emigrating from English speaking West Africa. 
Where the reason for travel was reported in 2015, 88.5% 
cited “visiting family in country of origin”, all of whom 
travelled to Africa.
Other reasons cited for travel this year were “Business/
professional travel” (n=2) and “Irish citizen living abroad” 
(n=1). Three cases reported no recent history of travel, two of 
whom were relapses. The remaining 52 cases did not report 
country of infection. 
4.1 Malaria 
Summary
Number of cases malaria, 2015: 81
Crude incidence rate malaria 2015: 1.8/100,000
-80-HPSC Annual Epidemiological Report 2015 4 Vectorborne and Zoonotic Diseases
Figure 1: Annual number of malaria notifications by age, Ireland 2004-2015
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Nigeria remained the country most frequently visited, 
accounting for 61.5% of cases where country of infection 
was reported. The remaining cases were exposed in other 
countries within Africa. The majority of cases who reported 
travel to Nigeria were “visiting family in country of origin” 
(15/16) with known reason for travel.
Plasmodium falciparum accounted for 76.5% of infections 
in 2015, reflecting the dominance of exposure in Africa as 
the source of the majority of notifications. Ten cases of P. 
ovale, five cases of P. vivax, and one case of P. malariae were 
also reported. This is the highest number of P. ovale cases 
reported since surveillance began. The remaining three 
cases did not have Plasmodium species specified.
HPSC resources for health professionals include a poster 
which can be downloaded from the HPSC website for display 
in GP surgeries, maternity hospitals, paediatric hospitals 
and emergency departments, advising immigrant families 
travelling to Africa to consult their doctor about malaria 
before travelling. A leaflet for intending travellers, available 
in English and French, highlights the value of antimalarial 
prophylaxis and protection against mosquito bites. The 
poster and leaflet are available at http://www.hpsc.ie/A-Z/
Vectorborne/Malaria/LeafletsandPosters/.
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Figure 2: Annual number of notifications malaria by reason for travel, Ireland 2006-2015
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Sixteen cases of leptospirosis were notified in Ireland in 2015. 
This represents a decrease compared to 23 cases notified 
in 2014 (Figure 1). This equates to a crude incidence rate 
(CIR) of 0.3 per 100,000 population in 2015. The EU crude 
incidence rate was 0.2 per 100,000 in 2014, latest year for 
which data was available for. Among the countries that 
reported leptospirosis incidence in 2014, Ireland reported the 
fifth highest incidence rate after Croatia, Slovenia, Portugal 
and the Netherlands. 
The age range of cases was 29-72 (mean age =50 years, 
median age=51 years). Cases in the younger age groups 
are more likely to be associated with recreational exposure 
and history of foreign travel while older cases are mainly 
indigenous and associated with occupational exposure. 
Figure 1 illustrates the annual trend by travel history. The 
leptospirosis notification dataset is typically dominated by 
adult males, and this year was no exception with male cases 
accounting for 75% of cases (Table 1).
Five cases (31.3%) were believed to have acquired their 
illness occupationally, four of whom were either farmers 
or reported contact with farm environments while the 
remaining occupationally acquired case reported contact 
with rat’s urine. Two cases (12.5%) reported accidental 
exposure to potentially contaminated environments while 
one case (6.3%) was reported as being associated with 
recreational activities, including river water exposure in 
Columbia. No risk factors were reported for the remaining 
eight cases (50.0%). Figure 2 shows the trend in notifications 
by exposure group and year. 
Among the 13 cases for which hospital admission status was 
reported, 10 (77%) required hospitalisation. One death was 
reported but the cause of death was not leptospirosis. 
Activities that continue to be associated with leptospirosis 
risk in Ireland include recreational activities such as water 
sports, and farming. In recent years, travel to Asia and 
other tropical destinations has emerged as a risk factor for 
leptospirosis. 
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4.2 Leptospirosis           
Summary
Number of cases: 16
Crude incidence rate: 0.3/100,000 population
Figure 1: Annual number of leptospirosis notifications by year and 
travel history (Data source: CIDR)
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Figure 2: Annual number of leptospirosis notifications by exposure 
group by year (Data source: CIDR)
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Table 1: Leptospirosis notifications by age and sex, 2015
Age group 
(years)
Female Male Total
25-34 yrs 1 2 3
35-44 yrs 2 2
45-54 yrs 1 3 4
55-64 yrs 2 4 6
65+ yrs 1 1
Total 4 12 16
Toxoplasmosis
During 2015, 26 cases of toxoplasmosis were notified, 
remaining slightly lower than the annual mean of 
31 notifications in the previous five years. Among 
cases where patient type was reported, 26.3% were 
hospitalised. One congenital case was reported. 
Cases ranged in age from 0 to 67 years (median: 35 years). 
As in previous years, more cases were reported among 
females then males, (F:M ratio 1.4:1.0). This was particularly 
evident among females in the 25-34 year age group, which is 
most likely a reflection of enhanced testing during pregnancy 
(Table 1). 
Q Fever
Four cases of Q fever were reported in Ireland in 2015. All 
cases were male, with a median age of 56 years. Three were 
from HSE-W and one was from HSE-SE.
Brucellosis,Echinococcosis, 
Trichinosis and Q Fever
No cases of brucellosis, echinococcosis and trichinosis were 
notified in Ireland in 2015. 
4.3  Other Notifiable Non-IID Zoonotic 
Diseases
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Table 1: Toxoplasmosis notifications by age and sex, Ireland 2015
Age group Female Male Total Female: Male Ratio
0.-4 yrs 1 1 0.0
10-14 yrs 1 1 0.0
15-19 yrs 1 1 0.0
20-24 yrs 1 1
25-34 yrs 7 2 9 3.5
35-44 yrs 5 3 8 1.7
45-54 yrs 1 1
55-64 yrs 2 2 0.0
65+ yrs 1 1 2 1.0
Total 15 11 26 1.4
% 57.7 42.3 100.0
-84-HPSC Annual Epidemiological Report 2015 4 Vectorborne and Zoonotic Diseases
Four vectorborne diseases were added to the notifiable 
disease list in Ireland from the beginning of 2012. This 
chapter summarises the information gathered on these 
notifications in the second year of formal surveillance. The 
case definitions for these diseases are outlined on the HPSC 
website at 
http://www.hpsc.ie/NotifiableDiseases/CaseDefinitions/.
Lyme neuroborreliosis
Lyme neuroborreliosis is an infection caused by a spiral-
shaped bacterium called Borrelia burgdorferi that is 
transmitted to humans by bites from ticks, generally hard-
bodied ticks (Ixodidae). 
During 2015, 12 cases of Lyme neuroborreliosis were notified 
in Ireland, six female and six male. Six patients were 
admitted to hospital, four were GP patients and one each 
were reported as a hospital out-patient and a hospital day 
patient. One case was reported as being acquired abroad, 
two acquired the infection in Ireland and the remaining nine 
cases did not report country of infection.
Cases were reported from five of the eight HSE areas. Table 
2 displays the regional distribution of cases by age group in 
years. 
Chikungunya fever
One case of chikungunya was notified in Ireland in 2015. 
Country of infection was reported as the Cook Islands.
West Nile fever 
No cases of West Nile fever were notified in Ireland in 2015. 
Dengue Fever
During 2015, eight confirmed cases of dengue fever were 
notified. Four cases were reported as GP patients and one 
was admitted to hospital. Patient type was not reported 
for the remaining three cases. Table 2 displays the regional 
distribution of cases by age group in years.
Dengue is found commonly throughout the tropics and 
subtropics and is endemic in about 100 countries. Of the 
eight cases reported in 2015, country of infection was 
reported for five cases (62.5%). One case each reported 
country of infection as Brazil, Dominican Republic, Haiti, Sri 
Lanka and Thailand. The remaining three cases did not have 
a country of infection specified. 
4.4 Other Vectorborne Diseases
Table 1: Lyme neuroborreliosis notifications by age group (years) and HSE-area, 2015
Age group (years) HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
5-9 yrs 1 1
10-14 yrs 1 1
25-34 yrs 1 1
35-44 yrs 2 1 3
45-54 yrs 1 1
55-64 yrs 1 1 2
65+ yrs 3 3
Total 2 1 3 0 0 0 3 3 12
Table 2: Dengue fever notifications by age group (years) and HSE-area, 2015
Age group (years) HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
20-24 yrs 1 1
25-34 yrs 2 1 3
35-44 yrs 2 2
45-54 yrs 1 1 2
Total 6 0 1 1 0 0 0 0 8
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Hepatitis B is a vaccine preventable disease caused by the 
hepatitis B virus. It is transmitted through percutaneous 
or mucocutaneous contact with the blood or body fluids of 
an infected person. After acute HBV infection, the risk of 
developing chronic hepatitis B declines with increasing age.1 
Approximately 90% of infants infected at birth will develop 
chronic infection, compared to 20-50% of children infected 
between the ages of one and five years. Only 1-10% of those 
infected as older children or adults will develop chronic 
hepatitis B. An estimated 15-25% of those who develop 
chronic infection with die prematurely of either cirrhosis of 
the liver or hepatocellular carcinoma.
The prevalence of hepatitis B in the general population in 
Ireland is low (less than 1%). Most cases fall into defined risk 
groups such as people with multiple sexual partners, sexual 
or household contacts of known cases, injecting drug users 
and people who were born in countries with intermediate (2-
7%) or high ( >8%) hepatitis B endemicity.
The number of hepatitis B cases reported in Ireland increased 
by 24% in 2015, with 549 cases (12/100,000 population) 
notified compared to 442 in 2014. Hepatitis B notifications 
had been generally decreasing since their highest levels in 
2008 (n=899, 21.2/100,000 population), but recent trends 
indicate that this decline is not continuing. Annual hepatitis B 
notifications since 1997 are shown in figure 1. 
The highest notification rates were in HSE E (21.4/100,000 
population, n=346) and HSE NE (15.4/100,000 population, 
n=68) and the increase in notifications in 2015 was mostly due 
to higher numbers of cases in these two areas. Geographic 
trends for the past four years are shown in figure 2.
All cases were laboratory confirmed. Ninety six percent 
(n=528) of the 549 notifications contained information on 
acute/chronic status. Of these, 5% (n=26, 0.6/100,000 
population) of cases were acutely infected and 95% (n=502, 
10.9/100,000 population) were chronically infected. Both 
acute and chronic cases of hepatitis B are notifiable in 
Ireland.
5.1 Hepatitis B
Summary
Number of cases, 2015: 549
Crude notification rate, 2015: 12/100,000 population
Number of cases, 2014: 442
HPSC Annual Report 2008  
-86-HPSC Annual Epidemiological Report 2015 5 Blood-borne and Sexually Transmitted Infections
Acute Chronic Unknown
31 
157 158 188 
341 
452 
545 
702 
849 
787 
845 
899 
783 
639 
518 560 
423 442 
549 
0 
100 
200 
300 
400 
500 
600 
700 
800 
900 
1000 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
N
um
be
r o
f n
ot
ifi
ca
tio
ns
 
Year 
Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2015
Acute cases (recent infections)
The number of acute cases of hepatitis B notified in Ireland 
is relatively low and decreased slightly in 2015 (n=26) 
compared to 2014 (n=29) (figure 3). This is the lowest 
number of acute infections reported since acute/chronic case 
definitions were introduced in 2004. 
Eighty five percent (n=22) of acute cases notified in 2015 
were male. The age at notification ranged from 21 to 78 
years, with a median age of 41.5 years. Notification rates 
for older age groups were higher than observed in previous 
years (figures 3 & 4). 
 
Information on risk factor was available for 88% (n=23) of 
the acute cases notified in 2015. Of these, 74% (n=17) were 
likely to have been sexually acquired (eight heterosexual, six 
men who have sex with men and three of unknown sexual 
orientation). No risk factor was identified for four cases 
despite public health follow up. 
Country of birth was specified for 92% (n=24) of acute 
cases, 79% (n=19) of whom were born in Ireland. The reason 
for testing was known for 25 cases and most were tested 
because they were experiencing symptoms (n=15, 60%) or 
because they requested STI screening (n=4, 16%).
Chronic cases (long-term infections)  
There was a 22% increase in chronic hepatitis B notifications 
in 2015 (n=502) compared to 2014 (n=411) (figure 5). 
However, chronic notifications have decreased significantly 
since peak levels in 2008 (n=769). 
Of the 502 chronic cases notified in 2015, 59% (n=297) were 
male, 40% (n=203) were female and sex was not reported 
for 2 cases. Seventy eight percent (n=392) of chronic cases 
were aged between 20 and 44 years when notified and the 
median age at notification was 34 years (figures 5 & 6). 
Although primary risk factor was reported for a minority of 
chronic cases in 2015, data on country of birth or asylum 
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Figure 3. Number of acute cases of hepatitis B notified, by sex and median age, 2004-2015
Figure 2. Hepatitis B notification rates/100,000 population, by HSE area, 2012-2015
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seeker status was available for 50% (n=251). Of these, 90% 
(n=225) were either born in a hepatitis B endemic country 
(hepatitis B surface antigen prevalence >2%) or were 
asylum seekers. Most of these cases are likely to have been 
infected outside Ireland, but the actual mode of acquisition 
of infection is unknown for the majority. Where country 
of birth was available (45%, n=227), the most common 
birth countries were in Central or Eastern Europe (38%, 
n=87), Asia (33%, n=75), Sub-Saharan Africa (19%, n=44) 
and Western Europe (7%, n=16). Of those born in Western 
Europe, twelve were born in Ireland. 
The reason for testing was known for 60% (n=301) of chronic 
cases. The main reasons were: antenatal screening (20%, 
n=59), STI screening (18%, n=54), asylum seeker screening 
(16%, n=47) and re-testing of known cases (not previously 
notified) (13%, n=38). 
Immigration and hepatitis B notifications
Hepatitis B notifications are likely to be influenced by trends 
in immigration to Ireland. The large increase in the number 
of hepatitis B cases between 1997 and 2008 (figure 1) 
coincided with significant numbers of people migrating to 
Ireland from hepatitis B endemic countries. The economic 
downturn, in 2008, lead to a decline in both immigration and 
hepatitis B notifications. The subsequent economic recovery 
has resulted in increased immigration in recent years and 
this is likely to have contributed to the recent increase in 
hepatitis B notifications. Figure 7 shows trends in hepatitis B 
notifications alongside immigration trends.2
Co-infections
Co-infection with other blood-borne viruses can lead to more 
severe liver disease and an increased risk of liver cancer 
in people with hepatitis B infection. Eleven of the cases of 
hepatitis B notified in 2015 were co-infected with HIV. Three 
other cases were infected with hepatitis C.
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Figure 5. Number of chronic cases of hepatitis B notified, by sex and median age, 2004 to 2015
Figure 4. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B, 2015
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The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 5th September 2016. These 
figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
1.  Heyman DL. Control of Communicable Diseases Manual. 19th Edition. 
Washington: American Public Health Association, 2008.
2.  Central Statistics Office (2016) Immigrants (thousand) by country of origin. 
Accessed 20th September 2016. Available from:    
http://www.cso.ie/multiquicktables/quickTables.aspx?id=pea18_1
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Figure 6. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis B, 2015
Figure 7. Number of hepatitis B notifications and number of immigrants from EU16-28 & non EU/EEA countries (excluding North 
America and Australia)
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Hepatitis B notifications 
Immigration from EU16-28 & non EU/EEA countries excl North America & Australia 
Hepatitis C is a major cause of liver disease worldwide. The 
hepatitis C virus (HCV) is primarily transmitted through 
sharing contaminated equipment when injecting drugs or 
through receipt of unscreened blood or blood products (this 
is no longer a risk in Ireland).1,2 Sexual, occupational and 
vertical transmission can also occur but are less common.
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear the virus and 
develop chronic infection. Between 5 and 20% of chronically 
infected individuals develop cirrhosis of the liver after 20 
years of infection. Of those with cirrhosis, 1.5% to 2.5% will 
go on to develop hepatocellular carcinoma (liver cancer) each 
year.1 There have been major advances in the treatment of 
hepatitis C in recent years. The latest generation of direct-
acting antivirals (DAAs) can cure more than 90% of patients 
using all-oral drug regimes, which have fewer side effects 
than previous treatments.3 
The overall prevalence of chronic hepatitis C in Ireland is 
comparable to other Northern European countries, and is 
estimated to be between 0.5 and 1.2%. Most cases fall into 
defined risk groups such as people who inject drugs, people 
who received unscreened blood or blood products in the past 
and people who were born in hepatitis C endemic countries.4
There were 675 notifications of hepatitis C in 2015 
(14.7/100,000 population). This is a small decrease 
compared to 2014 (n=698, 15.2/100,000 population) (figure 
1). Notifications have declined by 56% since peak levels in 
2007 (n=1,538). However recent trends indicate that levels 
are stabilizing rather than continuing to decrease. 
Notification rates for each HSE area for the past four years are 
shown in figure 2. Sixty eight percent of notifications in 2015 
were from HSE E (n=462, 28.5/100,000 population).
More than two thirds of the cases reported in 2015 were male 
(68%, n=457), 32% (n=215) were female and sex was not 
reported for three cases. The highest notification rates were in 
young to middle aged adults, with 81% (n=546) of cases aged 
between 25 and 54 years. The median age at notification has 
gradually increased from 31 years in 2004 to a high of 38.5 
years in 2015 (figures 1&3). 
Information on most likely risk factor was available for 38% 
(n=255) of the cases reported in 2015. More than three 
quarters reported injecting drug use as their most likely mode 
of infection (76%, n=194). Seven percent (n=17) were likely 
to have been infected through contaminated blood or blood 
5.2 Hepatitis C
Summary
Number of cases, 2015: 675
Crude notification rate, 2015:  14.7/100,000 population
Number of cases in 2014: 698
  
-90-HPSC Annual Epidemiological Report 2015 5 Blood-borne and Sexually Transmitted Infections
Figure 1. Number of notifications of hepatitis C and median age at notification, by sex, 2004-2015
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products, six of whom were infected in Ireland. These Irish 
infections occurred many years in the past, but were notified 
for the first time in 2015. A further 5% (n=12) reported sexual 
exposure (six heterosexual, three men who have sex with 
men and three unknown sexual orientation) and 4% (n=11) 
reported tattooing/body piercing as their most likely risk 
factor. Other risk factors were reported for nine cases and 
no risk factor was identified for twelve cases despite Public 
Health follow up. Figure 4 shows recent risk factor trends for 
hepatitis C in Ireland. 
Data on country of birth were available for 33% of cases 
(n=222) in 2015. Where information was available, 45% 
(n=99) of cases were born in Ireland, 34% (n=76) were 
Central or Eastern European, 9% (n=19) were Asian and 5% 
(n=12) were born in other Western European countries. Just 
over a third of cases with information on country of birth 
or asylum seeker status were born in a hepatitis C endemic 
country (>2% anti-HCV prevalence) or were asylum seekers. 
As data on country of birth were not very complete, this may 
not be representative of all cases. Figure 5 shows most likely 
risk factor by region of birth for the 222 cases where country 
of birth was known.
Hepatitis C genotype data were collected retrospectively 
from NVRL and were available for 50% of notifications in 
2015. Of these, 57% (n=192) were genotype 1, 36% (n=120) 
were genotype 3, 4% (n=12) were genotype 2 and 3% (n=11) 
were genotype 4. Subtype was available for 94% (n=180) of 
genotype 1 cases, 71% of which were genotype 1a. 
Co-infections can lead to more severe liver disease and 
an increased risk of liver cancer in those with hepatitis C 
infection. Nineteen of the hepatitis C cases notified in 2015 
were known to be co-infected with HIV. Where risk factor 
data were available, nine were people who inject drugs and 
two were men who have sex with men. Four additional cases 
were coinfected with hepatitis B.
Hepatitis C notifications decreased in recent years. The 
decline was fairly dramatic in 2012, but this may have 
been partially attributable to the introduction of new 
case definitions, specifically excluding cases known to 
have resolved infection. While notifications continued to 
decline slightly in 2015, hepatitis C levels now appear to be 
stabilizing rather than further declining. Trends in hepatitis 
C notifications are difficult to interpret as infections are often 
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Figure 3. Age and sex-specific notification rates/100,000 population for hepatitis C, 2015
Figure 2. Notification rates/100,000 population for hepatitis C by HSE area, 2012-2015
2012 2013 2014 2015
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
E M MW NE NW SE S W 
N
ot
ifi
ca
ito
n 
ra
te
 p
er
 1
00
,0
00
 
HSE area 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ 
No
tif
ic
at
io
n 
ra
te
s 
pe
r 1
00
,0
00
 
Age group (years) 
Male Female 
initially asymptomatic and most cases that are diagnosed 
and notified are identified as a result of screening in key risk 
groups. Therefore notification trends are highly influenced 
by testing practices, which may vary over time and may not 
reflect incidence well.
Risk factor data were available for less than 40% of cases of 
hepatitis C in 2015. The distribution of risk factors for these 
cases may differ from cases where data were not available. 
Where information on risk factor was available, over three 
quarters of cases were people who inject drugs who were 
likely to have been infected through unsafe injecting 
practices. The incompleteness of our risk factor and country 
of birth data represents a significant gap in our knowledge of 
the current epidemiology of hepatitis C in Ireland. 
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 26th September 2016. These 
figures differ from those published previously due to ongoing 
updating of notification data on CIDR.
1.   Global Burden of Hepatitis C Working Group. Global burden of disease 
(GBD) for hepatitis C.J Clin Pharmacol. 2004 Jan;44(1):20-9.
2.   Health Protection Surveillance Centre. National Hepatitis C Database 
for infection acquired through blood and blood products, 2015 Report. 
Available from: http://www.hpsc.ie/A-Z/Hepatitis/HepatitisC/
HepatitisCDatabase/BaselineandFollow-upReports/File,15238,en.pdf
3.   World Health Organization. Guidelines for the screening, care 
and treatment of persons with chronic hepatitis C infection. 
Updated version April 2016. Available at: http://apps.who.int/iris/
bitstream/10665/205035/1/9789241549615_eng.pdf 
4.   Thornton L, Murphy N, Jones L, Connell J, Dooley S, Gavin S et al. 
Determination of the burden of hepatitis C virus infection in Ireland. 
Epidemiol Infect. 2011 Sep 19:1-8
Figure 5. Number of hepatitis C notifications by most likely risk factor and country/region of birth (where country of birth known, 33%, n=222), 2015
Figure 4. Number of hepatitis C notifications by most likely risk factor (where risk factor known, 54%, n=2956) 2010-2015
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Summary
Number of notifications: 485
Crude notification rate: 10.6 per 100,000 population
In 2015, 485 people were newly diagnosed with HIV in 
Ireland, giving a rate of 10.6 per 100,000 population. 
Between 2010 and 2014, HIV diagnosis rates in Ireland were 
stable but increased by 30% between 2014 and 2015. This 
increase was mainly confined to HSE East (where a 38% 
increase in rate was seen). A number of factors contributed 
to the increase in HSE East, including an improvement to the 
national surveillance case definition introduced in January 
2015 which resulted in improved sensitivity, timeliness 
and increased number of notifications1; an outbreak of HIV 
among people who inject drugs (PWID) (1); and an increase 
in diagnoses among migrant men who have sex with men 
(MSM). 
Among the new diagnoses in 2015, 27% were reported to 
have previously tested HIV positive abroad, compared to 17% 
1   In January 2015, there was a change to the HIV surveillance case definition 
for HSE East (Dublin;  Kildare; Wicklow). Previously, confirmatory testing by 
the NVRL was required on two separate samples prior to notification. From 
January 2015 onwards, confirmatory testing by NVRL on one sample was 
sufficient prior to notification.
in 2014, and 16% in 2013. The majority of these people (79% 
in 2015) transferred their HIV care to Ireland. 
For a summary of new HIV diagnoses in 2015, refer to Table 1.
Age and gender
In 2015, 76% of HIV diagnoses were in men with 24% among 
women (male to female ratio, 3.2:1). The median age at 
diagnosis increased from 31 years in 2014 to 34 years in 
2015. The rate of diagnosis in 2015 among men was 16 per 
100,000 population compared to 5 per 100,000
population among women.
Geographic origin
Of the diagnoses in 2015, 55% were born abroad, 30% were 
born in Ireland and 15% did not have information on country 
of birth. Of the cases in migrants, 35% (n=94) were born 
in sub-Saharan Africa and 33% (n=88) were born in Latin 
America. 
Probable route of transmission 
Information on probable route of transmission was available 
for 89% of diagnoses in 2015. Sex between men remains the 
predominant mode of HIV transmission reported in Ireland, 
accounting for 51% (n=247) of diagnoses in 2015. From 
2005 to 2015, the number of new diagnoses among MSM 
increased fourfold (from 60 to 247). There was a notable 
5.3 HIV
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Figure 1: Trends in HIV diagnoses by route of transmission, 2003 to 2015
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increase in diagnoses among migrant MSM, from 85 in 2014 
to 141 in 2015. 
Heterosexual transmission was the second most commonly 
reported mode of transmission accounting for 27% (n=130) of 
HIV diagnoses. Since 2010, the number of diagnoses among 
heterosexuals has remained stable, ranging from 125 to 133 
diagnoses per year. The majority of heterosexuals (58%) 
diagnosed in 2015 were born in countries with generalised 
HIV epidemics2. 
Ten percent (n=49) of diagnoses in 2015 were attributed to 
injecting drug use, an increase of 81% compared to 2014 
(n=27). This increase was due to an outbreak of recently 
acquired HIV infection among PWID in Dublin in 2014/2015. 
Of the new diagnoses, 55% were Irish-born, and 53% were 
co-infected with hepatitis C. Three quarters of new diagnoses 
(n=37) were in men.  
There were five cases reported where the route of 
transmission was identified as mother to child transmission 
(MTCT). None of these cases were born in Ireland and there 
were no reported MTC transmissions in Ireland in 2015 
(Personal communication: Michelle Goode, Rainbow Clinic).
Figure 1 shows the trends in new HIV diagnoses by probable 
route of transmission from 2003 to 2015.
2   A generalised HIV epidemic is where greater than 1% of the general 
population is HIV positive.
Late diagnosis
Information on stage of diagnosis (CD4 count at diagnosis 
or AIDS defining illness at diagnosis) was available for 74% 
of cases in 2015. From the available information, 45% of 
people newly diagnosed in 2015 were late presenters (with 
CD4 <350 cells/µl or an AIDS defining illness at diagnosis) 
including 23% who had advanced HIV infection (with CD4 
<200 cells/µl or an AIDS defining illness at diagnosis). 
Considering the high proportion of people diagnosed with 
HIV in Ireland who have previously been diagnosed HIV 
positive abroad, it is important to separate out these groups 
when looking at late presentation. The proportion of people 
who presented late was much lower (31%) among those who 
had a previous HIV diagnosis abroad compared to those 
who were not reported to have a previous diagnosis abroad 
(52%). 
Discussion
MSM accounted for just over half of diagnoses in 2015. This 
is also the predominant mode of transmission in EU/EEA 
countries (42% in 2014) (2). In light of the significant increase 
in new HIV diagnoses and other STIs among MSM, a national 
outbreak response group was established in early 2016 to 
address this evolving situation. This group is developing 
responses to the situation including: increasing promotion 
of safer sex messages and promoting regular HIV and STI 
testing through the man2man.ie programme; increasing 
testing capacity for MSM in Dublin via a new clinic, being 
piloted at the Gay Mens Health Service; and employing 
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Table 1: Characteristics of HIV diagnoses, 2015
Number of HIV diagnoses 485
Rate of diagnoses (per 100,000 population)1 10.6
Gender Males (%) 76.1
Females (%) 23.9
Male to female ratio 3.2
Age Median age of adult cases (years) 34
Age range of adult cases (years) 18-72
Young people aged 15-24 years (%) 8.0
Aged 50 and older (%) 9.3
Route of Transmission MSM (%) 50.9
Heterosexual (%) 26.8
Injecting Drug Use (%) 10.1
Mother to Child transmission (%) 1.0
Unknown (%) 11.1
Region of Birth Born in Ireland (%) 29.9
Born abroad (%) 55.1
Unknown (%) 15.1
Previous history of testing Previously tested positive abroad (%) 26.6
Transfer of care (of those previously diagnosed positive abroad) 79.1
1  Based on 2011 census
outreach workers on a pilot basis to deliver peer support 
and interventions among the MSM community, in particular 
among Latin American MSM. 
Diagnoses of PWID increased in 2015 due to the HIV 
outbreak among homeless PWID in Dublin (1). This outbreak 
was associated with the injection of snow blow, a new 
psychoactive substance, the re-use of needles and syringes, 
and having a sexual partner who was also injecting drugs (3). 
Prevention and control efforts were targeted to this group 
and the outbreak was declared over in February 2016. As a 
result of the outbreak, there was increased testing among 
PWID and improved surveillance in this group. However, 
there is a need for ongoing sustained health promotion and 
harm reduction activities among this very vulnerable group.
In 2015, there was a significant increase in the number of 
cases notified who had a previous HIV positive diagnosis 
abroad (27%). Seventy nine percent of these people 
transferred their HIV care to Ireland. The change in case 
definition in January 2015 may account for some of this 
increase as data on these people may not have been 
captured prior to 2015. 
Overall, the proportion of individuals who were diagnosed 
at a late stage of infection was high. This proportion varied 
by risk group and was highest among heterosexual males 
and those from sub-Saharan Africa (after those with a 
previous diagnosis abroad had been removed from analysis). 
Continued and sustained emphasis on the benefits of early 
testing, and ready access to HIV testing are needed to 
address this issue. 
The detailed 2015 annual report and slide set are available at 
http://www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/
SurveillanceReports/   
Note: Data for this chapter were extracted from CIDR in 
August, 2016 and were correct at the time of publication.
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Background
Eighteen (of nineteen) maternity hospitals and units 
provided antenatal HIV screening data for 2015 (no 
antenatal screening data was available from Letterkenny 
General Hospital). Nine of the eighteen hospitals (50%) were 
able to provide data on public patients only. Booking data 
was retrieved from a variety of sources including maternity IT 
systems (7 hospitals), maternity unit manual data collection 
(5 hospitals), patient administrations systems (6 hospitals), 
and laboratory IT systems (5 hospitals).
More information on the system, a copy of the data collection 
form and the full 2015 report can be found at 
www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/AntenatalHIVTesting
Results
There were 65,909 live births in 2015, with antenatal 
screening data available for 63,217 women. Eighty four 
women tested HIV positive in 2015 at their antenatal screen, 
giving a HIV prevalence rate of 0.13%, slightly lower than 
the rate in 2014 (0.15%). Nine of the 84 women were newly 
diagnosed HIV positive (prevalence of 0.01%) while the 
remaining 75 women were known to be HIV positive. Table 
1 describes the data collected from maternity hospitals 
between 2008 and 2015. The prevalence of HIV infection 
among pregnant women varied among HSE areas, ranging 
from 0.02% in HSE West to 0.18% in HSE Dublin Northeast. 
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1   Uptake of HIV antenatal test is calculated as the number of women tested 
divided by the number of women booked, multiplied by 100
2   Prevalence of HIV infection is calculated as the number of women testing 
positive divided by the number of women tested, multiplied by 100
5.4  Voluntary antenatal HIV testing in 
Ireland: 2015 
Key Points
National reported uptake rate: 100.0%*
Number HIV positive cases: 84
Prevalence: 0.13%
Number new HIV positive cases: 9
Prevalence of new HIV positive cases: 0.01%
*  Returns not available for approximately 4% of antenatal women 
in 2015
Table 1: Results of the antenatal screening programme, 2008 to 2015
2008 2009 2010 2011 2012 2013 2014 2015
Number of hospitals participating 18/20 19/20 19/20 20/20 18/20 16/20 17/19 18/19
Number of live births (from CSO) 75,173 75,554 75,174 74,650 72225 68,954 67,462 65,909
Number of women booked 66,558 68,378 70,024 68,111 64,803 57,638 63,538 63,217
Number offered test 66,558 68,026 69,615 67,849 64,803 57,638 63,538 63,217
Number tested 66,210 67,694 69,292 67,135 64,781 57,618 63,532 63,214
Uptake of HIV antenatal test (%)1 99.5 99.0 99.0 98.6 99.9 99.9 100.0 100.0
Number HIV positive 123 140 118 109 105 83 93 84
Prevalence of HIV (%)2 0.19 0.21 0.17 0.16 0.16 0.14 0.15 0.13
Number newly diagnosed HIV positive 34 32 21 17 22 14 11 9
Prevalence of new diagnoses of HIV (%) 0.05 0.05 0.03 0.03 0.03 0.02 0.02 0.01
Summary
During 2015, a total of 12,590 cases of sexually transmitted 
infections (STIs) were reported. The most frequently reported 
STIs were Chlamydia trachomatis infection (n=6,797), ano-
genital warts (n=1,843), gonorrhoea (n=1,302) and herpes 
simplex (n=1,274) (table 1). Compared to 2014, the largest 
increase was in cases of early infectious syphilis which 
increased by 31% in 2015 (to 268). 
The burden of STIs is greatest among those aged 15-24 
years, and among men who have sex with men (MSM). The 
15-24 years age group accounted for over 38% of chlamydia, 
gonorrhoea and herpes simplex (genital) cases. MSM 
accounted for 55% of gonorrhoea and 87% of syphilis cases, 
where mode of transmission was known. 
In response to increases in STIs among MSM in 2015, 
a national multidisciplinary group was established to 
analyse the epidemiological data, and to propose effective 
communications and interventions to curb the increases.  
Chlamydia trachomatis infection
Chlamydia trachomatis infection was the most frequently 
reported STI with 6,797 notifications in 2015. The crude 
incidence rate (CIR) increased to 148.1 per 100,000 
population, from 145.8/100,000 in 2014. Chlamydia 
infections were steady in the years from 2011 to 2013, with 
rates between 139.6/100,000 and 136.4/100,000 (figure 
1). More than three-quarters (n=5,084) of chlamydia 
cases were among those under 30 years, with the largest 
proportion aged 20-24 years (40%). There were 16 cases of 
Chlamydia trachomatis infection in young infants (aged 2 
months or younger) of which three-quarters were reported as 
conjunctivitis. 
Gonorrhoea
In 2015, a total of 1,302 cases of gonorrhoea were reported 
in Ireland, giving a notification rate of 28.4 per 100,000 
population. The overall trend has increased by 200% 
between 2009 and 2015. In 2015, the notification rate 
amongst women remained the same as 2014 (9.7/100,000), 
whereas the rate in males decreased slightly from 
47.2/100,000 in 2014 to 46.7/100,000 in 2015. The vast 
majority of gonorrhoea cases were among men (n=1,081, 
83%). Almost a third of cases (28%, n=364) were among 
people aged between 20 and 24 years old. Mode of 
transmission was available for 56% of cases (n=727) in 2015. 
Where data were known, mode of transmission was reported 
as MSM for 55% of cases (n=401) and heterosexual for 45% 
of cases (n=324; 107 males and 217 females). While genital 
infections were the most frequently reported site of infection 
among cases (males 36%, females 62%), pharyngeal 
infection was reported among 26% of males and 10% of 
females. 
Ano-genital warts
During 2015, 1,843 cases of ano-genital warts were reported 
in Ireland giving a crude incidence rate (CIR) of 40.2 per 
5.5  Sexually Transmitted Infections  
 (STIs), 2015
Summary
Total number of STIs in 2015: 12,590
Most frequently reported STI in 2015: Chlamydia 
trachomatis infection (n=6,797)
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STI Number CIR Median Age (range)
Chlamydia trachomatis infection 6,797 148.1 25 years (14-72 years)*
Ano-genital warts (AGW) 1,843 40.2 NA
Gonorrhoea 1,302 28.4 27 years (14-75 years)*
Herpes simplex (genital) 1,274 27.8 30 years (4-81 years)
Non-specific urethritis (NSU) 1,028 22.4 NA
Syphilis (early infectious) 268 5.8 33 years (20-65 years)
Trichomoniasis 58 1.3 35 years (20-59 years)
Lymphogranuloma venereum (LGV) 20 0.4 31 years (21-62 years)
Total 12,590 -
*Excludes those <14 years; NA: case-based data were not collected
Table 1: Number, crude incidence rate (CIR) per 100,000 population & median age of STIs, 2015
100,000 population, a decrease from 2014 (46.8/100,000) 
(figure 1). There were more notifications among men (56%) 
than women (36%). Gender was not provided for 7% of 
cases, and age group was not provided for 33% of cases. The 
highest age-specific incidence rate was among those aged 
20-24 years (128.2/100,000). The numbers reported here 
are likely to be an underestimate of the true incidence as 
data were not reported from every STI clinic. Further details 
on the completeness of reporting are available in the report 
Ano-genital warts in Ireland, 2015, available on the HPSC 
website, www.hpsc.ie.
Herpes simplex (genital)
There were 1,274 cases of herpes simplex (genital) notified 
in Ireland during 2015 corresponding to a CIR of 27.8 
per 100,000 population, a small increase from 2014 
(26.9/100,000) (figure 1). Most cases were reported as 
Herpes simplex virus (HSV) type 1 (56%), with 34% reported 
as HSV type 2. Subtype was not reported for 10% of cases. 
Almost three-quarters of cases (n=927) were in women, and 
86% of cases in women (n=794) were in those aged under 40 
years. 
Trichomoniasis
During 2015 there were 58 cases of trichomoniasis notified 
in Ireland corresponding to a CIR of 1.3 per 100,000 
population, the lowest rate since 2006. All reported cases 
were among women, with over one third (n=20) of cases 
aged between 20 and 29 years. The highest gender- and 
age-specific rates were among women aged 20-24 years 
(6.6/100,000) and 25-29 years (5.3/100,000). 
Lymphoganuloma venereum (LGV)
There were 20 cases of LGV reported in 2015 giving a CIR 
of 0.4 per 100,000 population (compared with 35 cases 
in 2014, five cases in 2013 and four in 2012). The majority 
of cases were reported in HSE East (n=16), with one case 
reported in each of HSE Midlands, HSE Midwest, HSE 
Northeast and HSE Southeast. All but one case were in 
MSM. The majority of LGV cases were HIV positive (n=14). 
Seventeen cases had a diagnosis of another STI in 2016. 
Almost two-thirds (60%) of these cases (n=12) were linked 
to an outbreak among MSM in the Greater Dublin area. A 
multidisciplinary outbreak control team (OCT) was convened 
in October, 2014 to instigate control measures1. 
Non-specific urethritis
At total of 1,028 cases of non-specific urethritis were 
reported in 2015 compared with 897 cases in 2014. 
More detailed annual reports on STIs are available on 
the HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIAnnualReports/. 
Weekly reports on STIs and HIV are available on the 
HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIWeeklyReports/.
Data on syphilis, HIV and hepatitis B are presented 
elsewhere in this report.
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Figure 1 Trend in Crude incidence rate (CIR) per 100,000 population of selected STIs, 1995-2015
Year 
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All laboratories were asked to notify new cases of syphilis, 
with one of: positive serology (T. pallidum EIA and 
TPPA) AND either RPR OR T. pallidum EIA IgM positive; 
demonstration of treponemes in lesions, exudates or 
tissues from clinically appropriate sites by dark ground 
microscopy; or demonstration of treponemes in lesions, 
exudates or tissues from clinically appropriate sites by PCR. 
Re-infections, as defined by the laboratory’s own criteria, 
were also notifiable. This case definition was introduced in 
January 2014, and remained current for all of 2015. 
During 2015, 437 cases of syphilis were notified which met 
the criteria for laboratory diagnosis of early syphilis. Of 
these, 268 (61%), where enhanced information was provided 
by clinicians, were reported as early infectious syphilis. 
Stage of infection was reported as unknown or enhanced 
surveillance forms were not received for the remaining 169 
cases. No congenital syphilis cases were notified in 2015.
This analysis focuses on cases fitting the laboratory criteria 
and clinical criteria (n=268) and so the number of early cases 
in this report is likely to be an under-estimate of the true 
number of early infectious syphilis cases.
The crude incidence rate for early infectious syphilis in 2014 
was of 5.8 per 100,000 population, an increase of 22% 
compared to 2014 (4.5 per 100,000). Figure 1 shows the 
trend in crude incidence rate (CIR) for early syphilis cases 
from 2000 to 2015.
Of the 268 early infectious syphilis cases notified in 2015:
•  135 (50%) were classified as primary syphilis, 60 (23%) as 
secondary syphilis and 73 (27%) as early latent
•  Rates varied throughout the country, with the age-
standardised incidence rate (10.6 per 100,000) in HSE 
East (Dublin, Kildare and Wicklow) 1.8 times the national 
rate (5.8 per 100,000). There was also a significant 
increase in HSE South (from 1.1/100,000 to 4.6/100,000) 
due to an outbreak in Cork among MSM (figure 2).
•  The majority of cases occurred in males (n=258; 96%), 
with a male to female ratio of 26:1. 
5.6 Syphilis, 2015
Summary
Number of early infectious syphilis cases: 268
Crude incidence rate of early infectious syphilis: 
5.8/100,000 population
Number of congenital syphilis cases: 0
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Figure 1: Crude incidence rate of early infectious syphilis (per 100,000 population), 2000-2015
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•  The crude incidence rates in men and women were 11.4 
and 0.4 per 100,000 population respectively (figure 1).
•  The majority of cases (85%) were reported in people over 
25 years of age.
•  Almost three quarters of cases (73%) were identified in 
STI clinics, with 21% being diagnosed in general practice. 
•  An increasing proportion of cases (82%) occurred in men 
who have sex with men (MSM). In MSM, a significant 
proportion (30%) was co-infected with HIV at the time of 
syphilis diagnosis.
•  Twelve percent of cases were among heterosexuals. 
Eighteen percent of heterosexuals were co-infected with 
HIV. 
•  One of the 10 female cases one was pregnant at time of 
diagnosis. 
•  Almost a quarter of early cases (23%) were also 
diagnosed with an STI other than HIV during 2015. Since 
full patient identifiers were not provided for all cases, the 
true figure for STI co-infections is likely to be much higher.
Discussion
2015 was the second year for which only cases of early 
infectious syphilis were notifiable. The aim of reporting 
early infectious syphilis was to improve completeness of 
information and data quality. The proportion of cases for 
which enhanced surveillance forms were received decreased 
compared to 2014 (61% vs 73% in 2014 and 60% in 2013). 
The true number of early infectious syphilis cases may 
be higher than reported here, as only cases with both 
laboratory and clinical data indicating early infectious 
syphilis, were included in the analysis. 
In 2015, the crude incidence rate of early syphilis increased 
to 5.8 per 100,000, the highest rate since the syphilis 
outbreak among MSM in Dublin in 2001  (6.1/100,000). The 
increase in early syphilis in 2015 was concentrated among 
men (96% of cases). The rate among men increased to 11.8 
per 100,000 compared to 7.7/100,000 and 8.4/100,000 
in 2013 and 2014, respectively. The rate among women 
decreased slightly in 2015, with a rate of 0.4 per 100,000 
compared to 0.6/100,000 and 0.4/100,000 in 2013 and 
2014, respectively. 
The increase in 2015 was exclusively among MSM. Cases 
among MSM increased by 57% compared to 2014 (220 
versus 140) and by 133% compared to 2012. Cases among 
heterosexuals decreased in 2015 by 8% (33 versus 36 
in 2014) and cases with unknown mode of transmission 
decreased from 28 in 2014 to 15 cases in 2015. The ASIR in 
HSE East (10.6/100,000 population) remains significantly 
higher than the national rate (5.8/100,000 population) with 
more than 80% of cases in HSE East occurring among MSM, 
confirming that this area remains a centre of transmission 
within Ireland.
The proportion of early infectious syphilis cases co-infected 
with HIV in 2015 increased to 29%, the same proportion as 
2013 but an increase on 2014 when 25% were co-infected 
with HIV. The proportion of HIV co-infection continues to 
be higher among MSM (30%) compared to heterosexuals 
(18%). Of those co-infected with HIV, the number diagnosed 
with HIV in the same year as their syphilis diagnosis rose to 
39% in 2015 (compared to 26% in 2014 and 31% in 2013). 
The proportion of cases co-infected with HIV remains a 
concern as co-infection increases the risk of acquiring and 
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Figure 2: Age-standardised incidence rate of early infectious syphilis by HSE area, 2012-2015
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transmitting HIV1. 
Preliminary analysis of 2015 data pointed to a significant 
increase in early infectious syphilis and other sexually 
transmitted infections among MSM2. This analysis also 
pointed to a change in the demographics of cases, with an 
increasing proportion of cases among Latin American MSM 
living in Ireland (up from 6% in 2012 to 25% in 2015). A 
growing number of MSM acquired their infection in Ireland 
in 2015 (74%) compared to previous years (59% in 2014). 
Similar increased trends in HIV and other STIs were also 
a cause for concern. Therefore, in response, a national 
multidisciplinary multi-sectoral group was established. 
The response involves three main strands of work covering 
interventions, communications and epidemiology, including 
ongoing analysis of trends in 20162. 
A more detailed analysis of syphilis in Ireland in 2015 is 
available in the report Syphilis in Ireland, 2015, which is 
available on the HPSC website. 
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Table 1: Summary of early infectious syphilis cases, 2012, 2013, 2014 and 2015
  2012 2013 2014 2015
  n % n % n % n %
Total number of early cases 115 184 204 268
Male 101 87.8 175 95.1 191 93.6 258 96.3
Men who have sex with men (MSM) 81 70.4 120 65.2 140 68.6 220 82.1
Heterosexuals 24 20.9 22 12.0 36 17.6 33 12.3
Unknown mode of transmission 10 8.7 43 23.4 28 13.7 15 5.6
Median age (years) 33 33 32 33
Age range (years) 19-68   19-73   19-70   20-65  
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Encephalitis due to viruses not otherwise specified (NOS) 
are notifiable under the disease category ‘viral encephalitis’. 
Details of viral encephalitis cases caused by other notifiable 
diseases, if any, are presented in other chapters in this 
report. 
In 2015, 47 cases of viral encephalitis (NOS) (VE) were 
notified in Ireland (1.02/100,000 population) compared 
to 68 (1.48/100,000) in the previous year (Figure 1). One 
contributing factor to the decline in numbers can be 
attributable to the late notification of 15 cases from 2013 
(based on their specimen dates) reported during weeks 4 
to 7 in 2014. Another reason for the decline in the reported 
number of VE cases is the fall in varicella/herpes zoster virus 
(VZV) cases in 2015 (n=22) compared to 33 in the previous 
year.
The number of VE cases among males (n=21) and females 
(n=25) was similar, with one case remaining not attributed 
to either sex. The median age of cases was 52 years (range 
three weeks to 94 years); 15 (31.9%) cases occurred in 
those aged 65 or more years. There were four cases of VE 
in children under five years of age in 2015 and 10 of the 15 
VE cases in those aged >65 years were associated with VZV 
(Figure 1, Table 1).
Of the 47 VE cases, all but one were laboratory tested 
positive and case classified as confirmed. All but two had a 
causative pathogen identified: VZV (n=22; 46.8%), herpes 
simplex virus (HSV) (n=20; 42.6%), human herpes virus type 
6 (HHV 6) (n=2; 4.3%), enterovirus (2.1%) and not specified 
(n=2; 4.3%) (Figure 2). 
Caution is advised regarding the detection of HHV 6 DNA 
in cerebral spinal fluid (CSF) specimens, especially in those 
cases aged less than three months as HHV 6 DNA can 
be chromosomally integrated as it may not be clinically 
relevant. Both cases of HHV 6-related encephalitis in 2015 
however, occurred in patients greater than three months of 
age.
There were no reported deaths or imported cases associated 
with VE in 2015. 
6.1 Viral Encephalitis
Summary
Number of cases, 2015: 47 
Number of cases, 2014: 68
Number of cases, 2013: 6
Crude incidence rate, 2015: 1.02/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by age group, Ireland, 2015
  Causative pathogen      
Age Group
herpes 
simplex 
virus
varicella 
/ herpes 
zoster 
virus
human 
herpes 
virus type 
6
enterovirus parechovirus not specified Total ASIR % Proportion
<1 1 0 0 0 0 1 2 2.76 4.3
1-4 1 1 0 0 0 0 2 0.70 4.3
5-14 0 0 1 0 0 0 1 0.16 2.1
15-24 0 3 0 0 0 0 3 0.52 6.4
25-44 7 2 0 1 0 0 10 0.83 21.3
45-64 7 6 1 0 0 0 14 1.34 29.8
65+ 4 10 0 0 0 1 15 2.80 31.9
All ages 20 22 2 1 0 2 47 1.02 100
% total cases 42.6 46.8 4.3 2.1 0.0 4.3 100    
ASIR, age specific incidence rate per 100,000 population of total cases
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 8th August, 2016. These figures 
may differ from those published previously due to on-going 
updating of notification data in CIDR.
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Figure 1. Number of viral encephalitis (NOS) cases by age group and year, Ireland, 1992-2015*
* includes the late notification of 15 cases in 2013 reported in early 2014
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Figure 2. Number of viral encephalitis (NOS) cases by causative pathogen and year, Ireland, 1992-2015*
* includes the late notification of 15 cases in 2013 reported in early 2014
Meningitis due to viruses not otherwise specified (NOS) 
are notifiable under the disease category ‘viral meningitis’. 
Details of viral meningitis caused by other specified 
notifiable diseases (such as mumps and influenza viruses, if 
any) are presented in other chapters in this report. 
The steady increase in annual notifications, which started 
back in 2007 and continued up until 2014, fell sharply in 
2015 when 261 were reported (Figure 1). It should be noted 
that the very high number of cases reported in 2014 include 
the late notification of seven cases from 2013 (based on their 
specimen dates) reported during weeks 5 and 6 of 2014.
Since 1997, eight deaths have been reported with cases of 
viral meningitis (NOS), one of which was attributable to the 
infection itself. None were reported in 2015.
Of the 261 cases notified in 2015, 251 (96.2%) were classified 
as confirmed, seven (2.7%) as probable (1.6%) and three 
(1.1%) as possible. There were slightly more cases among 
males (n=139) than in females (n=117), giving a male to 
female ratio of 1.18:1.0. Five cases were reported with 
unknown gender details in 2015.
The national crude incidence rate in 2015 was 5.7 (95% 
CI 5.0–8.4) cases per 100,000 population, a 40% 
decrease compared with the previous year when 435 cases 
were notified (9.5/100,000). The highest age specific 
incidence rate (ASIR) in 2015 was in infants <1 year of age 
(175.4/100,000; n=127), followed by the 25-34 year age 
group (5.2/100,000; n=39). The lowest ASIR was in the 65+ 
year age group (ASIR 0.7/100,000 (n=4)) (Table 1). 
In 2015 the highest frequency of cases was in children aged 
1 to 2 months (n=88) and in those aged between 15 to 39 
years (n=83) with an overall median age of one year (range 
one week to 81 years) (Figure 2). Seventy percent of cases 
(n=183) occurred in those under 25 years of age (Figure 
3, Table 1). One case had no date of birth recorded and 
therefore had an unknown age.
By HSE region, the highest rate was in HSE E at 7.3/100,000 
(95%CI 5.8–8.6) and lowest in HSE S at 3.3/100,000 
(95%CI 1.9-4.7), with the latter rate significantly below the 
national rate (Figure 4).
In 2015, enteroviruses were the most common pathogen 
associated with viral meningitis, accounting for 78.5% 
(n=205/261) of all notifications (Figure 3, Table 1). As a cause 
of viral meningitis, enteroviruses have accounted for 60% or 
6.2 Viral Meningitis
Summary
Number of cases, 2015: 261 
Number of cases, 2014: 435
Number of cases, 2013: 281
Crude incidence rate, 2015:  5.7/100,0000
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Figure 1. Number of viral meningitis (NOS) cases by organism type and year, Ireland, 1988-2015*
* includes the late notification of seven cases in 2013 reported in early 2014
enterovirus human herpes virus type 6
varicella virus & varicella zoster virus herpes simplex virus***
other viruses not specified
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more of all cases each year since 2006. Enteroviruses are not 
routinely specified on CIDR, so it is not possible to attribute 
which type of enterovirus, of which there are many, account 
for the majority of reported viral meningitis cases in recent 
years. The enterovirus typing service, currently in place in the 
NVRL, will routinely ascertain which type is circulating in the 
population in future.
Enterovirus was also the most common pathogen in infants 
under one year of age with viral meningitis (NOS) in 2015; 
106 out of a total of 127 cases in that age group (83.5%) 
were reported to have this virus. Between 2007 and 2015 
enteroviruses accounted for 73.4% (n=1,389/1,884) of 
all viral meningitis (NOS) cases, with typical summer 
peaks observed each year (Figure 5). The large number 
of enterovirus-related viral meningitis cases observed in 
recent years is likely due in part to improved notification and 
investigation with laboratory confirmation.
In 2015, varicella/herpes zoster virus (VZV) was the causative 
pathogen for 7.3% (n=19) notifications, human herpes virus 
(type 6) (HHV 6) for 6.9% (n=18), parechovirus and herpes 
simplex virus (HSV) each for 1.9% (n=5), and echovirus type 
6 accounting for 1.5% (n=4) of all cases (Figure 3, Table 
1). There were 1.5% (n=4) cases with no viral pathogen 
specified. Caution is recommended regarding the detection 
of HHV 6 DNA in cerebral spinal fluid (CSF) specimens, 
especially in those cases aged less than 3 months (n=7/18; 
38.9%) as HHV 6 DNA can be chromosomally integrated. 
When this occurs the HHV 6 DNA can be inherited through 
the germ line and therefore when it is detected, it may not be 
clinically relevant.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 8th August, 2016. These figures 
may differ from those published previously due to on-going 
updating of notification data in CIDR.
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Figure 2. Number of viral meningitis (NOS) cases by age group and sex, Ireland, 2015
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications by age group and causative pathogen, 
Ireland, 2015
Causative pathogen
Age 
Group
entero-
virus
varicella / 
herpes  zoster 
virus
human 
herpes 
virus
herpes 
simplex 
virus type 6
parecho-virus echo-virus 
type 6
not specified Total ASIR
<1 106 3 13 0 4 0 1 127 175.4
1-4 6 1 3 0 1 0 1 12 4.2
5-9 7 0 0 0 0 1 0 8 2.5
10-14 7 0 1 0 0 0 0 8 2.6
15-19 10 2 0 0 0 1 1 14 4.9
20-24 11 1 0 0 0 1 1 14 4.7
25-34 34 3 0 0 0 1 1 39 5.2
35-44 19 0 0 2 0 0 0 21 3.0
45-54 2 3 1 1 0 0 0 7 1.2
55-64 2 3 0 1 0 0 0 6 1.3
65+ 0 3 0 1 0 0 0 4 0.7
All Ages 205 19 18 5 5 4 5 261 5.7
% Total 78.5 7.3 6.9 1.9 1.9 1.5 1.9 100.0  
ASIR, age specific incidence rate per 100,000 population of total cases
Total enterovirus
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Figure 5. Monthly number of viral meningitis, NOS and enterovirus-related meningitis notifications, 2007-2015*
* includes the late notification of seven cases in 2013 reported in early 2014
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Figure 4. Crude incidence rates per 100,000 population with 95% confidence 
intervals for viral meningitis (NOS) cases by HSE area, Ireland, 2015
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Figure 3. Number of viral meningitis (NOS) cases by age group (<25, >25 years of age) and 
year, Ireland, 2001-2015*
* includes the late notification of seven cases in 2013 reported in early 2014
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Five cases of Creutzfeldt-Jakob disease (CJD) were notified 
in 2015 compared to 2014 when two cases were notified. 
All cases in 2015 were sporadic CJD cases. One of the cases 
was in the age group 45-54 years, two were in the age group 
55-64 years and two were in the age group ≥65 years. Three 
cases were female and two were male.
In total, 75 cases of CJD were notified since CJD was first 
specified as a notifiable disease in December 1996 (figure 1). 
Figure 2 shows the 75 CJD notifications by age group. The 
majority (80%, n=60) of the cases were aged greater than 
54 years. Of the 75 cases, 38 were female and 37 were male. 
Seventy-one cases were sporadic CJD, two were familial CJD 
and two were iatrogenic.
Variant CJD (vCJD) is specified as a separate notifiable 
disease. No cases have been notified since 2006. In total, 
four cases of vCJD were notified since vCJD became 
notifiable in December 1996. A summary of these four cases 
was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on notifications 
from HSE Areas and from the Irish National Creutzfeldt-
Jakob Disease Surveillance Unit. Annual figures published 
here are based on the year the notification was entered 
on the Computerised Infectious Disease Reporting (CIDR) 
system and consequently may differ from annual figures 
published by the Irish National Creutzfeldt-Jakob Disease 
Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2015: 5
Number of cases, 2014: 2
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Figure 1. Number of CJD notifications by year from December 
1996 to 2015
Figure 2. Number of CJD notifications (n=75) from December 1996 to 
2015 by age group
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Outbreaks
During 2015, 508 outbreaks of infectious diseases were 
reported with 5,578 associated cases of illness, including 
242 (4.3%) cases hospitalised and 44 deaths.* Regional 
variation in outbreaks was observed between HSE areas 
with the highest rates= observed in HSE-NW (20.9/100,000 
population) while the lowest rate was observed in HSE-E at 
(8.3) and – MW (8.2). Table 1 details the regional distribution 
of all outbreaks by HSE area and disease.
The number of outbreaks peaked between January and 
March. The January peak observed was mainly due to high 
numbers of norovirus and acute infectious gastroenteritis 
(AIG) outbreaks, February was mainly due to influenza and 
norovirus, while the March peak was mostly due to influenza 
and norovirus outbreaks. Figure 1 illustrates the number of 
IID and non-IID outbreaks by month of notification during 
2015.
Similar to previous years, airborne/person-to-person spread 
was reported as the mode of transmission for the majority of 
outbreaks (76.4%, n=388). Table 2 details all outbreaks by 
infectious disease and probable mode of transmission. 
The most frequently reported outbreak locations were 
private houses (n=131, 25.8%), nursing homes (n=112, 22.0%) 
and community hospital/long-stay units (n=80, 15.7%). The 
highest numbers ill were reported from outbreaks in nursing 
homes (n=1,773), community hospital/long-stay units 
(n=1,165) and hospitals (n=735). 
General outbreaks accounted for 72.2% (n= 367) of all 
outbreaks notified during 2015. The remaining outbreaks 
(27.8%, n= 141) were reported as family/household 
outbreaks. 
7. Outbreaks
Summary
Number of outbreaks: 508
Number of IID outbreaks: 315
Number of non-IID outbreaks: 193
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Figure 1: Number of IID and non-IID outbreaks by month of notification, 2015
* Outbreak data extracted from CIDR on 16/08/2016.
=  All rates are calculated per 100,000 population
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Table 1 Number of IID and non-IID outbreaks by disease and HSE area, 2015
IID/ Non-IID Disease HSEE
HSE-
M
HSE-
MW HPSC
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W Total
IID
Noroviral infection 29 6 3 8 8 14 18 11 97
Verotoxigenic E. coli infection 6 16 11 1 14 4 12 15 12 91
Acute infectious gastroenteritis 21 4 2 2 7 10 12 6 64
Cryptosporidiosis 1 3 1 1 4 3 5 18
C. difficile infection 5 1 2 4 12
Salmonellosis 2 1 1 2 1 2 9
Rotavirus infection 2 3 1 6
Campylobacter infection 1 1 1 1 2 6
Giardiasis 1 2 1 4
Hepatitis A (acute) 3 1 4
Shigellosis 1 1 1 3
Typhoid 1 1
Non-IID
Influenza 25 5 7 6 15 10 19 6 93
Mumps 15 2 4 3 6 1 5 4 40
Acute respiratory infection 6 6 5 9 2 28
Respiratory syncytial virus 
infection 3 1 2 1 7
Pertussis 4 1 1 6
Tuberculosis 1 3 1 5
S. pyogenes/ suspected S. 
pyogenes
2 1 3
MRSA 2 2
Aspergillosis 1 1
Hand foot & mouth disease 1 1
Outbreak 1 1
Measles 1 1
Hepatitis B 1 1
Impetigo 1 1
Chickenpox 1 1
Acinetobacter MDR 1 1
Invasive E. coli 1 1
Total number of outbreaks 134 41 31 1 42 54 59 86 60 508
Crude outbreak incidence rate 8.3 14.5 8.2 n/a 9.5 20.9 11.9 12.9 13.5 11.1
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Table 2: Number of IID and non-IID outbreaks by disease and probable route of transmission, 2015
IID /Non-IID Disease PP/ Air-borne
Animal 
contact
Food-
borne
Water-
borne Unknown Other Total
IID
Noroviral infection 90 7 97
Verotoxigenic E. coli infection 32 10 2 18 28 1 91
Acute infectious gastroenteritis 50 2 12 64
Cryptosporidiosis 7 5 1 3 2 18
C. difficile infection 9 3 12
Salmonellosis 4 1 4 9
Rotavirus infection 6 6
Campylobacter infection 2 2 1 1 6
Giardiasis 1 3 4
Hepatitis A (acute) 3 1 4
Shigellosis 2 1 3
Typhoid 1 1
Non-IID
Influenza 90 3 93
Mumps 38 2 40
Acute respiratory infection 26 1 1 28
Respiratory syncytial virus infection 6 1 7
Pertussis 6 6
Tuberculosis 5 5
S. pyogenes/ suspected S. pyogenes 3 3
MRSA 2 2
Aspergillosis 1 1
Hand Foot and Mouth Disease 1 1
Outbreak 1 1
Measles 1 1
Hepatitis B 1 1
Impetigo 1 1
Chickenpox - hospitalised cases 1 1
Acinetobacter MDR 1 1
Invasive E. coli 1 1
Total 388 18 6 24 69 3 508
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Infectious intestinal disease (IID) outbreaks:
During 2015, 315 IID outbreaks were reported, accounting 
for 62.0% of all outbreaks. This was an increase of 7% 
compared to the number reported during 2014 (n=294). 
After norovirus, the next most commonly reported IID 
outbreaks were verotoxigenic E. coli infection (VTEC) and 
AIG. Table 3 details the total number ill by disease and the 
median number ill per outbreak.
Non-infectious intestinal disease (Non-IID) outbreaks:
During 2015, 193 non-IID outbreaks were reported, 
accounting for 38.0% of all outbreaks. This represents a 
decrease of 4.7% compared to the number reported during 
2014 (n=141). After influenza, the next most commonly 
reported non-IID outbreaks were mumps and acute 
respiratory infection. 
Table 3: Outbreak disease by total number ill and median‡ number ill, 2015
IID/Non-IID Disease Total number ill Median number ill per outbreak
IID
Noroviral infection 1887 16
Acute infectious gastroenteritis 779 8
Verotoxigenic E. coli infection 227 2
Cryptosporidiosis 53 2
C. difficile infection 42 3
Shigellosis 36 2
Rotavirus infection 25 2
Salmonellosis 22 2
Campylobacter infection 15 2
Non-IID
Influenza 1569 10
Mumps 372 4
Acute respiratory infection 369 10
Respiratory syncytial virus infection 72 10
Tuberculosis 18 3
Pertussis 14 2
‡ Median values shown for diseases with more than five outbreaks. 
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Introduction
In 2015, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for each of the 
Local Health Offices (LHOs) in their Area. HPSC collated 
these data and quarterly reports were produced which are 
available on the HPSC website. The annual immunisation 
uptake rates presented here represent the collation 
of the 2015 quarterly data. The proportion of children 
who completed the recommended primary childhood 
immunisation schedule by 12 months (born between 
01/01/2014 and 31/12/2014) and 24 months (born between 
01/01/2013 and 31/12/2013) of age in 2015 are reported.
Children who were 12 and 24 months of age in 2015 were 
recommended one dose of vaccine against tuberculosis 
(BCG vaccine) at birth or by one month of age; three doses 
of vaccines against diphtheria (D3), tetanus (T3), pertussis 
(P3), Haemophilus influenzae type b (Hib3), polio (Polio3) and 
Hepatitis B (HepB3) with one dose of each recommended 
at two, four and six months of age; three doses of 
pneumococcal conjugate vaccine (PCV3) recommended 
at two, six and 12 months of age and three doses of 
meningococcal group C (MenC3) vaccine recommended at 
four, six and 13 months of age (table 1). Also at 12 months 
of age a dose of MMR (MMR1) was recommended and at 
13 months a dose of Hib (Hibb) was recommended (table 
1). A new primary childhood immunisation schedule was 
introduced in 2015 for babies born on or after July 1st 2015. 
Further vaccinations are recommended for older children 
and adults. Please see the HSE-National Immunisation 
Office website at http://www.immunisation.ie for current 
and detailed information on the Irish primary childhood 
immunisation schedule and also recommended vaccinations 
for older children and adults.
In children at 12 months of age in 2015 (born between 
01/01/2014 and 31/12/2014) uptake of BCG, D3, T3, P3, 
Hib3, Polio3, HepB3 and two doses of PCV (PCV2) and MenC 
(MenC2) were measured. In children at 24 months of age in 
8.1  Immunisation uptake at 12 and 24 
months of age
Summary
Among children at 12 months of age in 2015 uptake of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 91%
Among children at 24 months of age in 2015 uptake of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached the target of 
95%
MMR1 was 93%
PCV3 was 92%
Hibb was 91%
MenC3 was 88%
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Table 1. Primary childhood immunisation schedule for children born between 01/07/2008 and 30/06/2015
Age Vaccines
Birth BCG
2 months DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC
12 months MMR + PCV
13 months MenC + Hib
Please note the primary immunisation schedule changed in 2015 for children born on or after 01/07/2015. Please see the HSE-National Immunisation Office 
website at http://www.immunisation.ie for current and detailed information on the Irish primary childhood immunisation schedule and also recommended 
vaccinations for older children and adults
BCG  Bacille Calmette Guerin vaccine 
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
HepB  Hepatitis B vaccine
Hib  Haemophilus influenzae type b vaccine
IPV  Inactivated Polio Virus vaccine
MenC   Meningococcal group C vaccine
MMR  Measles, Mumps and Rubella vaccine
PCV  Pneumococcal Conjugate Vaccine
2015 (born between 01/01/2013 and 31/12/2013) uptake of 
D3, T3, P3, Hib3, Polio3, HepB3, MenC3, PCV3, MMR1, Hibb, one 
dose of vaccine against meningococcal group C (MenCb) 
on or after twelve months of age and one dose of vaccine 
against pneumococcal conjugate vaccine (PCVb) on or after 
twelve months of age were measured.
The immunisation uptake rates are reported here by HSE 
Area and LHO. The uptake rates presented here were 
rounded to zero decimal place. While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee and 
South Lee are reported as a combined figure.
Caveats to data
BCG uptake data at 12 months of age has been incomplete 
since BCG reporting to HPSC began in Quarter 3 2003. 
This has occurred due to differences in implementation of a 
neonatal BCG programme across the HSE Areas as well as 
difficulties in providing these data to the HPSC where the 
programme was implemented. Prior to the establishment 
of the HSE each former health board determined their own 
BCG vaccination policy and some health boards (Western 
and parts of the Southern Health Board) stopped routine 
neonatal BCG vaccination but provided BCG vaccination for 
adolescents or high risk groups. The neonatal programme 
has now been routinely implemented for all neonates in 
most, but not all, HSE Areas. Additionally more complete 
data on neonatal BCG vaccination is now available. 
However, in the HSE NE, where a neonatal programme is 
implemented, data is not currently available for reporting. 
In the HSE W the neonatal programme is not routinely or 
comprehensively implemented in all LHOs. Therefore, data 
provided for the HSE W reflects BCG vaccination data for just 
a small proportion of all babies born in this Area. Galway and 
Roscommon BCG LHO data became available for reporting 
for the first time in Quarter 4 2014. Mayo LHO BCG data 
was not available for reporting purposes prior to 2015. The 
numbers vaccinated with BCG in Mayo were not included in 
the HSE W BCG figures prior to 2015. National data for 2015 
are presented in this report and compared to 2014 data. The 
available national BCG cohort data may be around 90% of 
the national birth cohort in 2015 and 89% in 2014 (these 
figures are estimates only).
As uptake of MenC3 was low since Q3 2010 and as those over 
12 months and less than 12 years of age need only one dose 
of MenC and those aged 12-23 months need only one dose 
of PCV, data on MenCb (one dose of MenC on or after first 
birthday and before second birthday) and PCVb (one dose 
of PCV on or after first birthday and before second birthday) 
were requested in 2012 for the first time. The MenCb and 
PCVb data were available for only six of the eight HSE Areas 
from Quarter 1 2012 to Quarter 4 2014 and for seven HSE 
Areas since Quarter 1 2015. The available national cohort 
data may be around 91% of the national birth cohort in 2015 
and 81% in 2014 (these figures are estimates only).
Immunisation uptake rates at 12 months
Ninety-one per cent of children, at 12 months of age in 2015, 
received D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 (table 
2). Compared with 2014, the uptake rates for these vaccines 
decreased by one per cent in 2015.
The available 2015 BCG cohort data may be around 90% 
(estimate only) of the national birth cohort; based on these 
data BCG uptake was 86% (table 2). In 2014, BCG cohort 
data may be around 89% (estimate only) of the national birth 
cohort; based on these data BCG uptake in 2014 was 87%.
Among the HSE Areas, uptake rates for D3, T3, P3, Hib3, Polio3 
and HepB3 ranged from 90% to 95% and MenC2 and PCV2 
ranged from 87% to 95% (table 2). The target uptake of 
≥95% was reached in the HSE M and HSE W for D3, T3, P3, 
Hib3, Polio3, HepB3, MenC2 and PCV2 (table 2). The target 
uptake of ≥95% was reached in the HSE M and HSE SE for 
BCG (table 2).
Among the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 86% to 97% and MenC2 and PCV2 ranged 
from 83% to 97% (table 2). The target uptake of ≥95% 
was reached in Longford/Westmeath, Galway, Mayo and 
Roscommon for D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and 
PCV2 and in Sligo/Leitrim for D3, T3, P3, Hib3, Polio3, HepB3 
and PCV2 with the highest uptake (97%) of these vaccines 
in Roscommon (table 2). The target uptake of ≥95% was 
reached for BCG in six LHOs reporting data (table 2).
Immunisation uptake rates at 24 months
National annual immunisation uptake rates, in children at 
24 months of age in 2015, were 95% for D3, T3, P3, Hib3, Polio3 
and HepB3, 93% for MMR1, 92% for PCV3, 91% for Hibb and 
88% for MenC3 (table 3). This is the fifth year national annual 
uptake rates reached the target of ≥95% for D3, T3, P3, Hib3, 
Polio3 and HepB3. Compared with 2014, the uptake rates 
for D3, T3, P3, Hib3, Polio3 and Hibb decreased by one percent 
while HepB3, MenC3, PCV3 and MMR1 were unchanged  
(figure 1).
Seven of the eight HSE Areas were able to provide uptake 
data on MenCb (one dose of MenC on or after first birthday 
and before second birthday) and PCVb (one dose of PCV on 
or after first birthday and before second birthday) in 2015. 
The available data may be around 91% (estimate only) of the 
national birth cohort. Where data were available, national 
uptake was 90% for MenCb and 93% for PCVb at 24 months 
of age (table 3).
Among the HSE Areas uptake rates for D3, T3, P3, Hib3, Polio3 
and HepB3 ranged from 94% to 98%, MMR1 ranged from 91% 
to 96%, PCV3 ranged from 90% to 97%, Hibb ranged from 
88% to 97% and MenC3 ranged from 86% to 94% (table 3). 
Among the seven Areas in a position to provide data PCVb 
uptake ranged from 92% to 96% and MenCb uptake ranged 
from 88% to 93% (table 3). 
The target uptake of ≥95% was reached in six HSE Areas 
during 2015 for D3, T3, P3, Hib3, Polio3 and HepB3, in two HSE 
Areas for Hibb and MMR1, in one for PCV3 and PCVb and in 
none for MenC3 and MenCb (table 3).
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Table 2. Immunisation uptake (%) at 12 months of age in 2015 (cohort born 01/01/2014-31/12/2014) by LHO and HSE Area
HSE Area
Local Health Office/
HSE Area
Number in 
cohort for 
BCG 
Number in cohort 
for D3, T3 & P3 *
Immunisation Uptake (%)
BCG D3 Hib3 HepB3 MenC2 PCV2
HSE E
Dublin South 1684 1684 86 91 91 91 90 92
Dublin South East 1748 1748 86 93 93 93 92 93
Dublin South City 1732 1732 93 92 92 92 91 92
Dublin South West 2504 2504 97 92 92 92 91 92
Dublin West 2678 2678 86 90 90 90 90 90
Dublin North West 3649 3649 92 89 89 89 89 89
Dublin North Central 1916 1916 91 86 86 86 86 86
Dublin North 4084 4084 92 88 88 88 88 88
Kildare/West Wicklow 3821 3821 94 91 91 91 91 91
Wicklow 1753 1753 92 91 91 91 90 91
HSE E Total 25569 25569 91 90 90 90 90 90
HSE M
Laois/Offaly 2550 2550 95 94 94 94 94 94
Longford/Westmeath 1959 1959 94 95 95 95 95 95
HSE M Total 4509 4509 95 95 95 95 95 95
HSE MW
Clare 1475 1472 93 93 93 93 92 93
Limerick 1689 1892 96 88 88 88 88 88
Tipperary NR/East Limerick 1807 1762 93 92 92 92 92 92
HSE MW Total 4971 5126 94 91 91 91 91 91
HSE NE
Cavan/Monaghan na 1876 na 93 93 93 94 94
Louth na 1810 na 91 91 91 91 92
Meath na 3169 na 91 91 91 91 91
HSE NE Total na 6855 na 91 91 91 92 92
HSE NW
Donegal 1964 1964 94 92 92 91 91 92
Sligo/Leitrim 1272 1272 95 96 95 95 94 96
HSE NW Total 3236 3236 94 94 94 93 92 94
HSE SE
Carlow/Kilkenny 1991 1991 95 90 90 90 89 89
South Tipperary 1228 1228 97 94 94 94 93 94
Waterford 1807 1807 94 92 92 92 91 91
Wexford 2098 2098 94 93 93 93 92 93
HSE SE Total 7124 7124 95 92 92 92 91 91
HSE S
North Cork 1349 1327 92 89 89 89 87 87
North South Lee 5720 5647 92 90 90 90 87 87
West Cork 681 674 91 87 87 87 83 83
Kerry 1788 1772 90 91 91 91 87 87
HSE S Total 9538 9420 92 90 90 90 87 87
HSE W
Galway 3588 3588 10 95 95 95 95 95
Mayo 1642 1642 68 95 95 95 95 95
Roscommon 855 855 53 97 97 97 97 97
HSE W Total 6085 6085 32 95 95 95 95 95
Ireland 61032 67924 86 91 91 91 91 91
na=not available
* As the denominator/number in cohort varied slightly according to vaccine the D3, T3 and P3 cohorts are shown here
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented 
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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 Table 3. Immunisation uptake (%) at 24 months of age in 2015 (cohort born 01/01/2013-31/12/2013) by LHO and HSE Area
HSE Area Local Health Office/HSE Area
Number in 
cohort for D3, 
T3 & P3 *
Immunisation Uptake (%)
D3 P3 Hib3 Hibb HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE E
Dublin South 1731 95 95 95 92 95 90 92 93 94 94
Dublin South 
East 1635 95 95 95 90 95 88 90 91 93 92
Dublin South City 1726 95 95 95 90 95 89 90 91 92 92
Dublin South 
West 2438 97 97 97 93 97 89 92 93 95 95
Dublin West 2725 95 95 95 87 95 83 86 89 91 91
Dublin North 
West 3717 93 93 93 86 93 83 86 88 90 90
Dublin North 
Central 1892 92 92 92 84 92 81 83 87 89 89
Dublin North 4202 93 93 93 89 93 86 89 90 91 91
Kildare/West 
Wicklow 3860 94 94 94 90 94 88 90 92 93 93
Wicklow 1790 94 94 94 84 94 80 84 89 91 90
HSE E Total 25716 94 94 94 88 94 86 88 90 92 92
 HSE M
Laois/Offaly 2452 97 97 97 97 97 91 93 94 96 96
Longford/
Westmeath 1937 97 97 97 97 97 92 94 95 96 96
HSE M Total 4389 97 97 97 97 97 91 93 94 96 96
HSE MW
Clare 1561 94 94 93 92 93 90 93 91 92 92
Limerick 1842 93 93 93 88 93 85 87 89 90 90
Tipperary NR/
East Limerick 1850 95 95 95 89 95 86 90 90 93 92
HSE MW Total 5253 94 94 94 90 94 87 90 90 92 91
HSE NE
Cavan/
Monaghan 2028 97 97 97 93 97 92 93 95 96 95
Louth 1966 94 94 94 90 94 89 90 92 93 92
Meath 3348 96 96 96 91 96 91 91 94 94 93
HSE NE Total 7342 96 96 96 91 96 90 91 93 94 93
HSE NW
Donegal 2093 96 96 96 89 94 84 89 89 93 91
Sligo/Leitrim 1381 97 97 97 96 97 89 97 91 96 96
HSE NW Total 3474 96 97 96 92 95 86 92 90 94 93
HSE SE
Carlow/Kilkenny 1978 95 95 95 94 95 88 92 92 94 94
South Tipperary 1339 97 97 97 96 97 89 93 94 96 95
Waterford 1890 94 94 94 91 94 87 89 92 93 92
Wexford 2088 97 97 97 96 96 91 93 94 95 95
HSE SE Total 7295 96 96 96 94 96 89 92 93 94 94
HSE S
North Cork 1464 96 96 96 92 97 88 90 92 93 94
North South Lee 5765 95 95 95 91 95 88 89 92 93 93
West Cork 746 93 93 93 87 93 83 85 89 90 91
Kerry 1794 96 96 96 91 96 87 89 91 93 93
HSE S Total 9769 95 95 95 91 96 87 89 91 93 93
HSE W
Galway 3648 98 98 98 95 98 95 na 97 na 96
Mayo 1665 98 98 98 91 98 92 na 98 na 94
Roscommon 905 98 98 98 96 98 96 na 98 na 97
HSE W Total 6218 98 98 98 95 98 94 na 97 na 95
Ireland 69456 95 95 95 91 95 88 90 92 93 93
* As the denominator/number in cohort varied slightly according to vaccine the D3, T3 and P3 cohorts are shown here
Since T3 uptake identical to D3 uptake only D3 uptake figures are presented
Since Polio3 uptake identical to Hib3 uptake only Hib3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here
D3, Hibb, MenC3 and MMR1 uptake rates are mapped by LHO 
in figure 2. Among the LHOs the uptake rates ranged from 
92% to 98% for D3, T3, P3, Hib3, Polio3 and HepB3, 89% to 97% 
for MMR1, 89% to 96% for PCVb, 87% to 98% for PCV3, 84% 
to 97% for Hibb, 83% to 97% for MenCb and 80% to 96% for 
MenC3 (table 3).
The target uptake of ≥95% was reached in 21 LHOs for D3, T3, 
P3, Hib3 and Polio3, 20 for HepB3, in nine LHOs for MMR1, in 
seven for Hibb and PCVb, in five LHOs for PCV3, in two LHOs 
for MenC3 and in one LHO for MenCb (table 3). Galway and 
Roscommon were the only LHOs to reach the target of ≥95% 
for D3, T3, P3, Hib3, Polio3, HepB3, Hibb, MenC3, PCV3 and 
MMR1 for children at 24 months (table 3).
Conclusion
National immunisation uptake rates, in children at 12 
months of age in 2015, were 91% for D3, T3, P3, Hib3, Polio3, 
HepB3, MenC2 and PCV2. Based on available data uptake of 
BCG was 86%. The HSE M and HSE W reached the target 
uptake rate of ≥95% for D3, T3, P3, Hib3, Polio3, HepB3, MenC2 
and PCV2 among children at 12 months of age. Among the 
LHOs, Roscommon had the highest uptake (97%) of D3, T3, 
P3, Hib3, Polio3, HepB3, MenC2 and PCV2 at 12 months of age.
In 2015, national uptake rates at 24 months for MenC3 
(88%), Hibb (91%), PCV3 (92%) and MMR1 (93%) were lower 
than the target uptake of ≥95%. In 2015, national uptake 
rates at 24 months of age for D3, T3, P3, Hib3, Polio3 and 
HepB3 reached the target rate of ≥95%. This is the fifth year 
national annual uptake rates reached the target of ≥95% for 
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Figure 1. National annual immunisation uptake rates (based on available data) at 24 months, 1999-2015 
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE NE during 1999, Quarters 3 and 
4 2000 and Quarter 1 2001 and the HSE NW in 2000 and 2001. The 2002 MenC3 figure is based on uptake rates for Quarter 3 and Quarter 4 2002 only. The 2005 
MMR1 uptake figure is incomplete as the HSE E was unable to provide MMR data for Quarter 4 2005, due to technical problems. The 2006 MMR1 figure includes 
the Quarter-1 2006 HSE E figure, which is an estimate only due to technical problems. The 2007 national Hibb figure is incomplete, as the HSE W data for Quarter 
1 2007 and the HSE NW data for Quarter 3 2007 were not available. The 2007 national Hibb figure also includes the HSE SE data which are an underestimate due 
to data extraction methods.  The 2008 Hibb figure is incomplete as the HSE SE data for Q2 2008 and the HSE MW data for Quarter 3 2008 were not available. 
The 2008 national MenC3 figure is incomplete as the HSE E and HSE MW MenC3 data for Quarter 3 2008 were not available. The 2009 data are incomplete as 
the following were unavailable: the Quarter 1 2009 HSE E D3, T3, P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE E Dublin North 
Hibb uptake data and; the Quarter 4 2009 HSE MW data, HSE E Dublin North Hibb data and HSE SE Hibb data for those given a Hib dose as part of the five in one 
or six in one vaccine after 12 months of age. The 2010 data are incomplete as the following were unavailable: the Quarter 1 2010 HSE M and HSE S data and the 
HSE E Dublin North Hibb data; the Quarter 2 2010 HSE M data and; the Quarter 4 2010 HSE NE data. As a new childhood immunisation schedule was introduced 
in 2008, for those born on or after July 1st 2008, the 2010 HepB3 and PCV3 data at 24 months are for those born between July 1st and December 31st 2008 (i.e. 
Quarters 3 and 4 2010 data) only. The MenCb and PCVb data were available for only six of the eight HSE Areas from Q1 2012 to Q4 2014 and for seven HSE Areas 
since Q1 2015.
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D3 Hibb
MenC3 MMR1 
these vaccines. Based on available data uptake of MenCb 
was 90% and uptake of PCV3 was 93%. The target uptake 
of ≥95% was reached in six HSE Areas during 2015 for D3, 
T3, P3, Hib3, Polio3 and HepB3, in two HSE Areas for Hibb 
and MMR1, in one for PCV3 and PCVb and in none for MenC3 
and MenCb (table 3). Galway and Roscommon were the 
only LHOs to reach the target of ≥95% for D3, T3, P3, Hib3, 
Polio3, HepB3, Hibb, MenC3, PCV3 and MMR1 for children at 24 
months of age.
 
Quarterly Reports
The immunisation reports for Quarters 1 to 4 2015 are 
available on the HPSC website in Topics A-Z under the 
heading vaccination.
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Figure 2. D3, Hibb, MenC3 and MMR1 immunisation uptake rates (%) in those 24 months of age in 2015 by Local Health Office (LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see table 4 to translate LHO abbreviations
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Table 4. Local Health Office (LHO) abbreviations used in this chapter
Local Health Office 
Abbreviations 
Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their 
combined immunisation uptake data are reported   
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Background
Uptake of the DTaP-IPV* and MMR† vaccines in 4-5 year old 
junior Infant schoolchildren was monitored across all Local 
Health Offices (LHOs) during the academic year 2014/2015. 
The uptake data provided by immunisation coordinators 
and other administrative staff1 to HPSC were entered on to a 
MS Excel database and compared to those reported for the 
previous 2013/2014 season, where possible.
HSE-school team versus GP-vaccine administered LHOs
In 29 out the 31 LHOs across the country, the junior infant 
vaccination programme is delivered by HSE school teams 
1   Data for the North West area were provided to HPSC by the local 
Department of Public Health
who administer the vaccine to the children at school. In the 
remaining two LHOs, Donegal and Sligo/Leitrim, these 
vaccines are administered to children exclusively by GPs 
rather than by school teams. During 2014/2015 however, a 
combination of a school team/GP programme also existed 
in seven HSE-administered LHOs with a percentage of 
children been given vaccines by a GP (Table 1). 
Target populations
For the 2014/2015 academic year, the target population in 
HSE-vaccine administered LHOs was all children in Junior 
Infants on the school register on the 30th September 2014. 
For GP-vaccine administered LHOs, the target population 
was all children born between the 1st September 2008 and 
31st August 2009. 
The different ways in which the target populations have 
been defined in the HSE- and GP-vaccinated administered 
LHOs has meant that a national uptake for either vaccine 
could not be calculated.
One of the difficulties in presenting vaccination uptake data 
by community healthcare organisation (CHO) area is the 
fact that Donegal and Sligo/Leitrim, two GP–administered 
LHOs, are part of CHO area 1 which also includes the HSE 
administered LHO Cavan/Monaghan. This means that the 
uptake in CHO area 1 cannot be compared to the other eight 
CHO areas 2 to 9. 
8.2 DTaP/IPV* and MMR† vaccine 
uptake 2014/2015
Key Points
Uptake of the DTap/IPV vaccine among junior 
infant schoolchildren during 2014/2015 in HSE-
adminsistered Local Health Offices (LHOs) was 91.5% 
and in GP-administered LHOs it was 92.3%
Uptake of the MMR vaccine among junior 
infant schoolchildren during 2014/2015 in HSE-
adminsistered LHOs was 91.3% and in GP-
administered LHOs it was 91.8%
Table 1. Proportion of DTaP-IPV vaccine and MMR uptake in HSE-administered LHOs attributable to GPs in 2014/2015
LHO
Separate % DTaP-IPV and MMR Vaccine Uptake 
Administered by GPs
North Cork 46.4%
Kerry 30.9%
North South Lee 12.2%
West Cork 8.9%
Dublin South East 7.4%
Tipperary South 5.2%
Carlow/Kilkenny 3.5%
Wicklow % not specified
Louth % not specified
* DTaP-IPV = Diphtheria, Tetanus, acellular Pertussis and Polio vaccine
†MMR = Measles, Mumps and Rubella vaccine 
‡ Excludes Meath which reported the number of children requiring a catch up MMR dose, but not the number who were vaccinated
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Figure 1. LHO Maps of DTaP-IPV & MMR percentage vaccine uptake at Junior Infants level during the 2014/2015 academic year 
hsE-dtap-ipV Vaccine Administered lhos
gp-dtap-ipV Vaccine Administered lhos 
hsE-mmR Vaccine Administered lho
 gp-mmR Vaccine Administered lhos
Uptake of DTaP-IPV vaccine
Between 2013/2014 and 2014/2015, the overall uptake 
of the DTaP-IPV vaccine in HSE-vaccine administered 
LHOs remained unchanged at 91.5%. In 2014/2015, the 
average uptake among these LHOs was 91.4% with a range 
from 79.2% in Dublin South East to 97.8% in Longford/
Westmeath. Of the 29 HSE administered LHOs, 14 reported 
an average uptake decline of 3.4% whilst 15 others reported 
an average increase of 3.3%. The largest reduction in uptake 
was reported by Galway (-11.9%) and the highest increase 
was reported by Dublin North Central (+12.6%).
During the same period of time, overall DTaP-IPV vaccine 
uptake in exclusively GP-vaccine administered LHOs 
(Donegal; Sligo/Leitrim) rose slightly from 92.2% to 92.3%: 
Donegal reported an uptake reduction of 1.0%, whilst Sligo/
Leitrim reported an increase of 2.1%. 
Uptake of MMR vaccine
The overall uptake of the MMR vaccine between 2013/2014 
and 2014/2015 in HSE-vaccine administered LHOs remain 
unchanged at 91.3% In 2014/2015, the average uptake 
among these LHOs was also 91.3% with a range from 80.3% 
in Dublin South East to 97.6% in Longford/Westmeath. 
Of the 29 HSE administered LHOs, 13 reported an average 
uptake reduction of 3.4% whilst 16 others reported an 
average increase of 3.0%. The largest reduction in uptake 
was reported by Galway (-10.5%) and the highest increase 
was reported by Dublin North Central (+10.6%).
Overall MMR vaccine uptake in exclusively GP-vaccine 
administered LHOs decreased from 92.7% to 91.8% during 
the same time period: Donegal reported an uptake decrease 
of 1.7%, whilst Sligo/Leitrim reported an increase of 1.2%.
MMR catch-up vaccination
Fiftteen‡ HSE-vaccine administered LHOs reported on the 
number of children needing a catch-up MMR dose one 
month later after been given their first dose. The total 
number of children identified was 139 (range zero to 32). Of 
these 139 children, 56 (40.3%) received a catch-up vaccine 
dose (range zero to 19) (data not shown).
Details of the overall uptake of the two vaccines in the HSE- 
and GP-vaccinated LHOs during 2014/2015 are presented in 
Table 2 and in the maps in Figure 1.
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Background
HPV
Background
HPV
Following a recommendation from the National 
Immunisation Advisory Committee (NIAC), that human 
papillomavirus (HPV) vaccine should be given to 12 year 
old girls, a routine Health Service Executive (HSE) school 
HPV vaccination programme began in May 2010 for girls 
in the first year of second level school and age equivalent 
in special schools and home schooled. The aim of the 
programme is to protect girls from their future risk of 
developing cervical cancer. 
An HPV catch-up campaign for girls in sixth year of 
second level schools and their age equivalents in non-
second level schools (ie special schools, home schooled, 
Community Training Centres and Youthreach) was added 
in the academic year 2011/2012 and continued during the 
academic years 2012/2013 and 2013/2014.
Quadrivalent HPV vaccine, which protects against HPV 
types 6, 11, 16 and 18 associated with 70% of cervical cancer, 
is used in the school vaccination programme. A schedule 
of two vaccine doses given at least six months apart was 
recommended in the academic year 2014/2015 for girls 
aged <15 years. Prior to this a schedule of three vaccine 
doses given over a six month period was recommended. 
This change is based on recent data which showed that the 
immune response to two doses of the vaccine in 9-13 year 
old girls is comparable to a three dose course. The HPV 
vaccine does not protect against all cervical cancers, so 
regular cervical screening is still needed.  
Tdap
The NIAC recommends vaccination with Tdap (tetanus and 
low-dose diphtheria and acellular pertussis) vaccine at 11-14 
years of age. The Tdap vaccine was introduced to the HSE 
schools immunisation programme on a phased basis from 
September 2011. The HSE extended the Tdap vaccination 
programme to all areas from September 2012. This vaccine 
is offered to students in first year of second level school and 
their age equivalents in special schools and home schooled. 
It replaces the previous school based Td (Tetanus and low 
dose diphtheria) vaccination programme. The adolescent 
booster was changed because more cases of pertussis have 
been occurring in adolescents and adults due to the waning 
immunity that occurs over time, combined with a reduction 
in natural boosting.
MenC
MenC (meningococcal group C) vaccine is recommended as 
part of the primary childhood immunisation programme. 
In recent years, evidence has emerged that immunity to 
meningococcal disease reduces over time, so a booster 
dose is recommended now to provide additional protection. 
The NIAC recommends vaccination with a booster MenC 
vaccine at 12-13 years of age. The MenC booster vaccine was 
introduced into the HSE schools immunisation programme 
in September 2014. This vaccine is offered to students in 
first year of second level schools and their age equivalents in 
special schools and home schooled. 
The target for uptake of two doses of vaccine for the HPV 
vaccination programme is ≥80% and target uptake of MenC 
booster and Tdap vaccine is ≥95%.
The vaccinations are provided by vaccination teams from 
the Local Health Offices (LHOs) who go into schools in 
their areas to vaccinate or provide vaccination clinics free 
of charge for children in the target cohorts. Vaccinations 
provided through the schools immunisation programme are 
entered into the School Immunisation System (SIS). Please 
see the HSE-National Immunisation Office (NIO) website 
at  http://www.immunisation.ie for detailed and current 
information on the school vaccination programme.
Cohort for vaccination in the academic year 2014/2015
The cohort for the 2014/2015 HPV, Tdap and MenC booster 
vaccination programme was children (girls only for HPV 
vaccine) 
●	 in first year of second level schools 
●	 and their age equivalents ie those who were born 
8.3 HPV, MenC booster and Tdap 
vaccine uptake 2014/2015
Key Points
Among the recommended cohorts in the academic year 
2014/2015:
86.9% of girls had at least stage 2 HPV vaccine 
(considered to have completed a two dose HPV vaccine 
course);
87.9% of children had MenC booster vaccine and;
89.1% of children had Tdap vaccine.
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between 01/09/2002 and 31/08/2003
 ○			attending special schools or
 ○			registered with the National Educational Welfare 
Board to be home schooled.
Terminology used in this report
At least stage 1 - means a girl had a stage 1 HPV vaccine 
recorded on SIS, this girl may or may not have had a stage 
2 HPV vaccine recorded on SIS. At least stage 2 - means a 
girl had a stage 2 HPV vaccine recorded on SIS, she may or 
may not have had stage 1 HPV vaccine recorded on SIS. Girls 
with at least stage 2 HPV are considered to have completed 
a course of vaccination. Prior to the 2014/2015 academic 
year girls with at least stage 3 HPV were considered to have 
completed a course of vaccination.
Home schooled - refers to children registered with the 
National Educational Welfare Board to be educated at 
home. These children were recorded on SIS and reported 
here as home schooled.
Out of school - refers to vaccinated children who were 
neither enrolled in a second level school, special school nor 
registered with the National Educational Welfare Board as 
home schooled.
Local Health Office (LHO) - refers to the LHO the school is 
located in (it does not refer to the LHO the child is resident 
in).
Outside cohort - refers to those who were vaccinated but 
who were not in first year of second level schools or their 
equivalents in non-second level schools ie they were outside 
the cohorts recommended for vaccination.
The denominator for second level schools was defined as the 
number of children (girls only for HPV vaccine) on the school 
roll on 30th September 2014 for first year. The denominator 
for age equivalent to first years in second level schools was 
defined as children (girls only for HPV vaccine) born between 
01/09/2002 and 31/08/2003 on the school roll of special 
schools or registered with the National Educational Welfare 
Board on 30th September 2014. All the denominator data 
was entered onto SIS by the relevant System Administrator.
Uptake of HPV, MenC booster and Tdap vaccines
Here we report on the uptake of HPV, MenC booster and 
Tdap vaccines in the academic year 2014/2015, provided 
through the school immunisation programme and recorded 
on SIS on the 9th August 2016. These figures are subject to 
change due to ongoing updating of data on the database.
The data presented here are the result of collaboration 
between NIO, School Immunisation Teams, Immunisation 
Coordinators, Immunisation System Administrators, 
Immunisation administrative staff and HPSC.
Uptake of HPV vaccine 
In Ireland, 86.9% of girls in second level schools and 
their equivalents in special schools and home schooled 
were recorded as having received at least HPV stage 
2 (considered to have completed a two dose course) 
(Table 1). Data are not directly comparable with previous 
academic years. In previous years a three dose schedule was 
recommended. In the academic year 2013/2014 88.2% of 
girls in first year in second level schools were recorded as 
having received at least HPV stage 2 while 84.9% of girls in 
first year in second level schools were recorded as having 
received at least HPV stage 3.1 
Among the nine Community Healthcare Organisations 
(CHOs), in the academic year 2014/2015, uptake of at least 
HPV stage 2 among girls ranged from 77.4% to 90.8%; with 
eight reaching the target of >=80% uptake.  
In 2014/2015 academic year, an additional 271 girls were 
recorded as being outside the cohort recommended for 
vaccination and having received at least HPV stage 2 (Table 
1). 
Uptake of MenC booster vaccine 
Uptake of the MenC booster vaccine in children in first year 
in second level schools and their equivalents in special 
schools and home schooled was 87.9% (Table 2).There 
was some regional variation with uptake among the CHOs 
ranging from 76.4% to 93.3%.
An additional 283 children were recorded as being outside 
the cohort recommended for vaccination and having 
received MenC booster vaccine (Table 2). 
Uptake of Tdap vaccine 
In the academic year 2014/2015, uptake of the Tdap vaccine 
in children in first year in second level schools and their 
equivalents in special schools and home schooled was 
89.1% (Table 3). Uptake was 82.7% in the academic year 
2013/2014 among the 31 LHOs, out of a total of 32 LHOs, 
reporting data.2
In the academic year 2014/2015, there was some regional 
variation with uptake among the CHOs ranging from 79.2% 
to 93.7%.
In 2014/2015, an additional 329 children were recorded as 
being outside the cohort recommended for vaccination and 
having received Tdap vaccine (Table 3). 
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Table 1. HPV vaccine uptake data, provided through the school immunisation programme, among girls in the academic year 2014/2015 (data 
extracted from SIS 09/08/2016)
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/Community 
Healthcare Organisation (CHO)
2014/2015
Girls in first year in second level schools and age equivalent in special 
schools, home schooled and out of school*
Outside cohort
Numbers vaccinated with: % Vaccinated with:  Numbers vaccinated with:
Denominator
at least 
stage 1
at least 
stage 2
at least 
stage 1
at least 
stage 2
Denominator
at least 
stage 1
at least 
stage 2
CHO1
Cavan/Monaghan 884 752 739 85.1% 83.6% N/A 1 1
Donegal 1148 1055 1042 91.9% 90.8% N/A 3 3
Sligo/Leitrim 639 573 557 89.7% 87.2% N/A 0 0
CHO1 Total 2671 2380 2338 89.1% 87.5% N/A 4 4
CHO2
Galway 1454 1468 1409 101.0% 96.9% N/A 3 3
Mayo 890 749 732 84.2% 82.2% N/A 47 45
Roscommon 316 280 274 88.6% 86.7% N/A 2 2
CHO2 Total 2660 2497 2415 93.9% 90.8% N/A 52 50
CHO3
Clare 784 701 690 89.4% 88.0% N/A 3 3
Limerick 917 834 795 90.9% 86.7% N/A 1 1
Tipperary NR/East Limerick 1007 924 893 91.8% 88.7% N/A 2 2
CHO3 Total 2708 2459 2378 90.8% 87.8% N/A 6 6
CHO4
North Cork 607 545 530 89.8% 87.3% N/A 4 4
North Lee - Cork 1193 1091 1060 91.5% 88.9% N/A 3 2
South Lee - Cork 1304 1139 1119 87.3% 85.8% N/A 1 1
West Cork 363 303 297 83.5% 81.8% N/A 1 1
Kerry 944 815 765 86.3% 81.0% N/A 1 1
CHO4 Total 4411 3893 3771 88.3% 85.5% N/A 10 9
CHO5
Carlow/Kilkenny 1049 968 948 92.3% 90.4% N/A 7 7
South Tipperary 566 525 515 92.8% 91.0% N/A 13 9
Waterford 853 803 793 94.1% 93.0% N/A 0 0
Wexford 1076 972 948 90.3% 88.1% N/A 1 1
CHO5 Total 3544 3268 3204 92.2% 90.4% N/A 21 17
CHO6
Dublin South 928 844 834 90.9% 89.9% N/A 12 7
Dublin South East 701 594 584 84.7% 83.3% N/A 4 4
Wicklow 743 667 640 89.8% 86.1% N/A 2 1
CHO6 Total 2372 2105 2058 88.7% 86.8% N/A 18 12
CHO7
Dublin South City 821 754 707 91.8% 86.1% N/A 0 0
Dublin South West 824 711 694 86.3% 84.2% N/A 0 0
Dublin West 1075 960 885 89.3% 82.3% N/A 2 1
Kildare/West Wicklow 1645 1604 1577 97.5% 95.9% N/A 4 3
CHO7 Total 4365 4029 3863 92.3% 88.5% N/A 6 4
CHO8
Laois/Offaly 1051 978 952 93.1% 90.6% N/A 0 0
Longford/Westmeath 1128 1011 985 89.6% 87.3% N/A 5 5
Louth 1002 882 860 88.0% 85.8% N/A 2 2
Meath 1266 1197 1161 94.5% 91.7% N/A 5 4
CHO8 Total 4447 4068 3958 91.5% 89.0% N/A 12 11
CHO9
Dublin North West 1350 1096 1014 81.2% 75.1% N/A 3 3
Dublin North Central 749 631 626 84.2% 83.6% N/A 1 1
Dublin North 1526 1233 1167 80.8% 76.5% N/A 155 154
CHO9 Total 3625 2960 2807 81.7% 77.4% N/A 159 158
Home schooled 35 9 7 25.7% 20.0% N/A 0 0
Total of LHOs and home schooled 30838 27668 26799 89.7% 86.9% N/A 288 271
Out of School N\A 1 1 N\A N\A N\A 0 0
Total of LHOs and home schooled and out of 
school N\A 27669 26800 N\A N\A N\A 288 271
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 9th August 2016. These figures are subject 
to change due to ongoing updating of data on SIS.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of home schooled and out of school children do not appear.
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination.
N/A-Not applicable
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on SIS, this girl may or may not have had a stage 2 vaccine recorded on SIS. Similarly, ‘at 
least stage 2’ means a girl had a stage 2 HPV vaccine recorded on SIS, she may or may not have had a stage 1 HPV vaccine recorded on SIS. 
*Please see the background section of this report for details of the cohorts recommended HPV vaccine during the academic year 2014/2015.
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Table 2. MenC booster vaccine uptake data, provided through the school immunisation programme, among children in the academic year 
2014/2015 (data extracted from SIS 09/08/2016)
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/Community 
Healthcare Organisation (CHO)
2014/2015
Children in first year in second level schools and age 
equivalent in special schools, home schooled and out of 
school*
Outside cohort
Denominator
Numbers 
vaccinated with 
MenC booster
% Vaccinated with 
MenC booster Denominator
Numbers 
vaccinated with 
MenC booster
CHO1
Cavan/Monaghan 1788 1511 84.5% N/A 6
Donegal 2355 2211 93.9% N/A 2
Sligo/Leitrim 1299 1214 93.5% N/A 0
CHO1 Total 5442 4936 90.7% N/A 8
CHO2
Galway 2986 2870 96.1% N/A 0
Mayo 1744 1554 89.1% N/A 1
Roscommon 641 586 91.4% N/A 0
CHO2 Total 5371 5010 93.3% N/A 1
CHO3
Clare 1544 1367 88.5% N/A 0
Limerick 1963 1625 82.8% N/A 3
Tipperary NR/East Limerick 1958 1721 87.9% N/A 2
CHO3 Total 5465 4713 86.2% N/A 5
CHO4
North Cork 1196 1021 85.4% N/A 1
North Lee - Cork 2548 2287 89.8% N/A 0
South Lee - Cork 2567 2300 89.6% N/A 0
West Cork 706 604 85.6% N/A 0
Kerry 1904 1608 84.5% N/A 0
CHO4 Total 8921 7820 87.7% N/A 1
CHO5
Carlow/Kilkenny 2059 1906 92.6% N/A 1
South Tipperary 1225 1150 93.9% N/A 38
Waterford 1783 1704 95.6% N/A 1
Wexford 2180 1997 91.6% N/A 1
CHO5 Total 7247 6757 93.2% N/A 41
CHO6
Dublin South 2015 1819 90.3% N/A 1
Dublin South East 1278 1070 83.7% N/A 16
Wicklow 1512 1340 88.6% N/A 2
CHO6 Total 4805 4229 88.0% N/A 19
CHO7
Dublin South City 1491 1253 84.0% N/A 1
Dublin South West 1830 1475 80.6% N/A 1
Dublin West 2050 1821 88.8% N/A 1
Kildare/West Wicklow 3461 3318 95.9% N/A 7
CHO7 Total 8832 7867 89.1% N/A 10
CHO8
Laois/Offaly 2201 2014 91.5% N/A 1
Longford/Westmeath 2267 2038 89.9% N/A 8
Louth 2156 1833 85.0% N/A 2
Meath 2780 2489 89.5% N/A 5
CHO8 Total 9404 8374 89.0% N/A 16
CHO9
Dublin North West 2729 2064 75.6% N/A 0
Dublin North Central 1618 1255 77.6% N/A 0
Dublin North 3011 2303 76.5% N/A 182
CHO9 Total 7358 5622 76.4% N/A 182
Home schooled 94 12 12.8% N/A 0
Total of LHOs and home schooled 62939 55340 87.9% N/A 283
Out of School N\A 2 N\A N\A 0
Total of LHOs and home schooled and out of school N\A 55342 N\A N\A 283
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 9th August 2016. These figures are subject 
to change due to ongoing updating of data on SIS.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of home schooled and out of school children do not appear.
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination.
N/A-Not applicable
 *Please see the background section of this report for details of the cohort recommended MenC booster vaccine during the academic year 2014/2015.
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Table 3. Tdap vaccine uptake data, provided through the school immunisation programme, among children in the academic year 2014/2015 
(data extracted from SIS 09/08/2016)
Community 
Healthcare 
Organisation 
(CHO)
Local Health Office/
Community Healthcare 
Organisation (CHO)
2014/2015
Children in first year in second level schools and age 
equivalent in special school, home schooled and out of 
school*
Outside cohort
Denominator
Numbers 
vaccinated 
with Tdap
% Vaccinated with 
Tdap Denominator
Numbers 
vaccinated with 
Tdap
CHO1
Cavan/Monaghan 1788 1521 85.1% N/A 4
Donegal 2355 2212 93.9% N/A 1
Sligo/Leitrim 1299 1211 93.2% N/A 1
CHO1 Total 5442 4944 90.8% N/A 6
CHO2
Galway 2986 2868 96.0% N/A 3
Mayo 1744 1566 89.8% N/A 0
Roscommon 641 600 93.6% N/A 0
CHO2 Total 5371 5034 93.7% N/A 3
CHO3
Clare 1544 1374 89.0% N/A 7
Limerick 1963 1640 83.5% N/A 7
Tipperary NR/East Limerick 1958 1759 89.8% N/A 5
CHO3 Total 5465 4773 87.3% N/A 19
CHO4
North Cork 1196 1031 86.2% N/A 1
North Lee - Cork 2548 2310 90.7% N/A 0
South Lee - Cork 2567 2305 89.8% N/A 2
West Cork 706 610 86.4% N/A 0
Kerry 1904 1610 84.6% N/A 2
CHO4 Total 8921 7866 88.2% N/A 5
CHO5
Carlow/Kilkenny 2059 1905 92.5% N/A 18
South Tipperary 1225 1143 93.3% N/A 39
Waterford 1783 1685 94.5% N/A 0
Wexford 2182 2002 91.8% N/A 0
CHO5 Total 7249 6735 92.9% N/A 57
CHO6
Dublin South 2015 1823 90.5% N/A 17
Dublin South East 1278 1092 85.4% N/A 4
Wicklow 1512 1363 90.1% N/A 6
CHO6 Total 4805 4278 89.0% N/A 27
CHO7
Dublin South City 1491 1310 87.9% N/A 0
Dublin South West 1830 1460 79.8% N/A 1
Dublin West 2050 1845 90.0% N/A 7
Kildare/West Wicklow 3361 3385 100.7% N/A 9
CHO7 Total 8732 8000 91.6% N/A 17
CHO8
Laois/Offaly 2204 2051 93.1% N/A 1
Longford/Westmeath 2267 2074 91.5% N/A 9
Louth 2153 1842 85.6% N/A 4
Meath 2780 2535 91.2% N/A 6
CHO8 Total 9404 8502 90.4% N/A 20
CHO9
Dublin North West 2729 2148 78.7% N/A 7
Dublin North Central 1618 1285 79.4% N/A 0
Dublin North 3011 2398 79.6% N/A 168
CHO9 Total 7358 5831 79.2% N/A 175
Home schooled 94 12 12.8% N/A 0
Total of LHOs and home schooled 62841 55975 89.1% N/A 329
Out of School N\A 0 N\A N\A 0
Total of LHOs and home schooled and out of 
school N\A 55975 N\A N\A 329
The figures presented in this table are based on data recorded on the School Immunisation System (SIS) on the 9th August 2016. These figures are subject 
to change due to ongoing updating of data on SIS.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of home schooled and out of school children do not appear.
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination.
N/A-Not applicable
 *Please see the background section of this report for details of the cohort recommended MenC booster vaccine during the academic year 2014/2015
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8.4  Seasonal influenza vaccine uptake 
in hospitals & Long Term Care 
Facilities (LTCFs) in 2015-2016 
influenza season
Summary
Influenza vaccine uptake in hospitals, 2015-2016 (n=50 
hospitals)
●				89.7% (52/58) of known hospitals (including three 
private ones) participated 
●				Based on 50 complete returns:
 ○			Average uptake among all categories of hospital 
HCWs was 22.5% 
 ○			Average uptake varied by HSE staff category (16.7-
38.2%), the highest value was reported among 
‘medical and dental’ professionals and lowest 
among ‘nursing’ staff
 ○			7 (14.0%) hospitals exceeded the 40% national 
uptake target
 ○			Average uptake varied by Hospital Group (range 
14.7-37.6%) 
 ○			Highest average uptake was reported in Acute 
Paediatric Services Hospital group
 ○			Average uptake generally increased as the category 
size of eligible staff within hospitals also increased
Influenza vaccine uptake in LTCFs, 2015-2016 (n=98 
LTCFs)
●				44.1% (101/229) of known LTCFs participated 
●				Based on 98 complete returns:
 ○			Average uptake among all categories of LTCF 
HCWs was 26.6% 
 ○			At national level, the average uptake varied 
by HSE staff category (25.7-43.4%), the 
highest value was reported among ‘medical 
and dental’ professionals and lowest among 
‘nursing’ staff
 ○			18 (18.4%) LTCFs exceeded the 40% national 
uptake target
 ○			Average uptake varied by Community Health 
Organisation (CHO) (range 15.2-48.1%)
 ○			Highest average uptake was reported in 
CHO 9 (Dublin North, Dublin North Central, 
Dublin North West)
 ○			No association was observed between 
average uptake and the category size of 
eligible staff within LTCFs
●				Uptake among long stay residents since the 
beginning of the season was 87.5% among 101 
LTCFs
●				Uptake among respite residents vaccinated 
within 101 LTCFs was 11.2%
●				Uptake among respite residents vaccinated 
before admission to 101 LTCFs was 26.8%
The National Immunisation Advisory Committee (NIAC) 
of the RCPI and the HSE recommends annual seasonal 
influenza vaccination to individuals at risk of severe 
influenza disease (those who are aged 65 and older, 
pregnant, morbidly obese and those with specified chronic 
medical conditions requiring regular follow up), to certain 
occupational groups (those working with poultry, wild fowl 
and pigs), health care workers (HCWs) and to those likely 
to transmit influenza to those at high risk of influenza 
complications. HSE provides the seasonal influenza 
vaccine free of charge to all health care facilities or to 
the occupational health departments of these facilities. 
Implementation of the vaccination programme is, for the 
most part, organised by the health care facility management 
or the relevant occupational health provider. 
Influenza can cause severe disease in both patients and 
staff and infection can spread rapidly in health care settings. 
Achieving a high uptake of influenza vaccination among 
HCWs is therefore recognised as an important infection 
control intervention and occupational health issue. The HSE 
Leadership team has recommended a national influenza 
vaccination target of 40% among HCWs since October 2013.
HPSC has collected data on seasonal influenza vaccination 
coverage among hospitals and long term care facilities 
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(LTCFs) since the 2011-2012 influenza season. A protocol has 
also been provided to all facilities outlining the rationale and 
methodology for data collection each year since then. For 
the 2015-2016 season, a similar protocol as used for previous 
years was distributed to all facilities and posted on the HPSC 
website. Separate online survey forms for hospitals and 
LTCFs were designed to capture aggregate data on eligible 
and vaccinated staff and were based on six categories of 
HSE staff: management & administration; medical & dental; 
nursing; health & social care professionals; other patient & 
client care; and general support staff. 
For hospitals, occupational health departments were asked 
to provide data on the number and category of HCWs 
vaccinated by the service (numerator). The human resource 
(HR) departments were requested to provide data on the 
numbers of staff employed (denominator). For LTCFs, 
uptake details were sought from nominated coordinators 
(or other named contacts) on the number of staff, residents 
and respite care patients present and vaccinated during the 
influenza season. 
For the 2015-2016 season, a link to an online form was 
emailed to each nominated coordinator (or contact person) 
in 58 known public hospitals (including seven private ones) 
and separately to 229 HSE funded LTCFs 1 on 9th December 
2015. Each coordinator was asked to complete the online 
form using aggregate uptake data since the beginning of 
October 2015. A second and final survey seeking aggregate 
data for the entire season was sent on 25th April 2016. 
Reminders were sent to non-responders in January (for mid-
season data) and May (for end of year data). 
This report presents a summary of key data relating to the 
influenza vaccination uptake programme for 2015-2016, 
which is now available on the HPSC website. For this report, 
average uptake results (rather than overall figures as in 
previous annual reports) were calculated and this was done 
for two reasons: 1) the average is a measure that takes 
account of the different number of reporting institutions 
each season and 2) the numbers of participating hospitals 
1   These also include privately funded facilities, some of which are approved 
by the HSE, are registered with HIQA or avail of the Nursing Home Sup-
port Scheme
Figure 1. Hospital staff uptake by HSE region by season
Table 2. Details of seasonal influenza vaccine uptake among LTCF-based HCWs by influenza season*
Season Total No. Eli-gible HCWs**
Total No. 
Vaccinated 
HCWs
Average % 
Uptake
Average % 
Uptake 95% 
CIs
Median % 
Uptake
Range % 
Uptake
No. Partici-
pating LTCFs
2011-2012 4705 849 16.0 11.45-20.58 10.0 0-90.38 70
2012-2013 14458.01 2082 16.6 13.92-19.25 11.8 0-76 137
2013-2014 14053.8 3268 26.0 22.13-29.9 20.6 0-100 117
2014-2015 10658 2739 28.1 24.2-32.09 25.0 0-96.42 91
2015-2016 9354.64 2420 26.6 22.65-30.47 22.8 0-100 98
*based on complete returns only; **some figures include decimal places because some LTCFs reported whole time equivalent staff numbers rather than 
their actual numbers of staff
Table 1. Details of seasonal influenza vaccine uptake among hospital-based HCWs by influenza season*
Season Total No. Eli-
gible HCWs**
Total No. Vac-
cinated HCWs
Average % 
Uptake
Average % Up-
take 95% CIs
Median % 
Uptake
Range % Up-
take
No. 
Participating 
Hospitals
2011-2012 46329.02 8275 17.7 14.68-20.75 15.7 4.00-39.98 42
2012-2013 41995.16 7325 14.6 11.59-17.52 11.0 3.48-38.79 35
2013-2014 50202.39 12234 21.5 18.48-24.49 19.4 2.56-45.87 46
2014-2015 51324.22 12006 21.3 17.57-25.01 20.1 1.12-47.53 45
2015-2016 59204.52 14833 22.5 19.38-25.62 19.8 6.89-47.04 50
*based on complete returns only; **figures include decimal places because some hospitals reported whole time equivalent staff numbers rather than their 
actual numbers of staff
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and LTCFs that have provided complete data in each of the 
five seasons since 2011-2012 are relatively low.
Figures 1 to 4 below give details of vaccine uptake among 
HCWs based in hospitals and LTCFs that reported over the 
past five seasons by category of staff and HSE Hospital 
Group or Community Health Organisation. 
Hospitals
Fifty-two hospitals participated in the 2015-2016 survey 
and 50 of them provided complete returns, of which seven 
(14.0%) exceeded the 40% national uptake target, compared 
to four (8.9%) of the 45 hospitals in the previous season. 
Average uptake varied by Hospital Group from 14.7% to 
37.6% among the 50 responding hospitals during 2015-
2016 that provided complete returns, with average uptakes 
highest in the Acute Paediatric Services group and lowest in 
the South/South West (UCC) group (Figure 1).
At national level, the average uptake varied by HSE staff 
category (16.7-38.2%), with the highest value reported 
among ‘medical and dental’ professionals and lowest among 
‘nursing’ staff. Between 2014-2015 and 2015-2016 average 
uptake increased among medical and dental professionals 
(+6.3%), health and social care professionals (+3.7%), 
general support staff (+2.8%), nursing staff (+0.1%), but 
declined among other patient and client care staff (-1.1%) 
and management and administration (-2.1%) (Figure 2).
When hospital staff sizes were categorised, average uptake 
increased as staff size increased: average uptake was lowest 
where staff size was <250 HCWs at 11.8% and highest when 
staff size was >=2000 HCWs at 26.5%. 
Long term care facilities
One hundred and one LTCFs participated in the 2015-
2016 survey and 98 of them provided complete returns, of 
which 18 (18.4%) exceeded the 40% national uptake target, 
compared to 24 (26.3%) of the 91 LTCFs in the previous 
season.
Average uptake varied by CHO from 15.2% to 48.1% among 
the 98 responding LTCFs during 2015-2016 that provided 
complete returns, with average uptakes lowest in CHO 5 and 
highest in CHO 9 (Figure 3).
Between 2014-2015 and 2015-2016 average uptake 
decreased across all staff grades with the exception of 
general support staff (+0.6%): medical and dental staff 
(-11.7%), health and social care professionals (-11.0%), other 
patient and client care professionals (-3.8%), nursing (-1.5%) 
and management and administration staff (-1.2%) (Figure 4).
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Figure 2. Hospital staff uptake by HSE grade category by season
Figure 3. LTCF staff uptake by HSE region by season
When LTCF staff sizes were categorised, average uptake 
did not increase as staff size increased: average uptake was 
highest when staff size was <50 HCWs at 28.9% in 2015-
2016.
Uptake among long stay residents since the beginning of 
the season decreased from 96.9% among 100 LTCFs in 
2014-2015 to 87.5% among a different combination of 100 
LTCFs2 in 2015-2016. The percentage of respite residents 
vaccinated prior to admission in 2015-2016 was 26.8%. In 
contrast, over the same period, the percentage of respite 
residents vaccinated in-house among the same LTCFs was 
11.2%. The percentage of LTCFs that reported having a policy 
recommending that respite residents are vaccinated before 
being admitted was 26.0%, an improvement on the previous 
season (20.8%), and it maintains a trend that began in 
2011-2012. The number of LTCFs that reported having a 
staff vaccination policy during 2015-2016 was 18.0%, an 
improvement on the 8.9% reported during 2014-2015.
Target uptake
Overall, the average uptake of the seasonal influenza 
vaccine among HCWs in both hospitals and LTCFs in 2015-
2016 fell substantially short of the 40% target. Participation 
2    One of the 101 LTCFs that participated in the 2015-2016 survey did not 
provide complete information on resident uptake details
by hospitals was very high, but the low participation of 
LTCFs is also of concern as these units care for extremely 
vulnerable populations and outbreaks among these settings 
spread rapidly and have been related to high influenza 
morbidity and mortality in some years. Whether non-
participation of many LTCFs reflects a lack of information 
systems to collect and report on vaccine uptake or other 
non-specified reasons is not known to HPSC, but further 
work is needed to identify reasons for non-participation and 
efforts made to support LTCFs in collating and reporting this 
data. 
The lack of substantial difference in the average uptake 
among hospital–based HCWs (22.5%) compared to those 
in LTCFs (26.6%) occurs against different organisational 
structures for vaccination in these services. Unlike many 
LTCFs, most hospitals have formal occupational health 
services available to hospital staff; however this has not 
translated into overall better coverage in hospital staff. With 
some notable exceptions the lack of progress in this area 
may reflect either a lack of awareness, lack of resources or 
lack of acceptance of vaccination.1 
According to the World Health Organization annual 
vaccination is especially important for people at higher 
risk of serious influenza complications, and for people who 
live with or care for high risk individuals.2 In order to reach 
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a national HSE target of 40% vaccination uptake among 
HCWs, more action is required if unnecessary disease and 
mortality is to be prevented. 
Other countries have already achieved uptake rates well 
above our target. For example, in England vaccination 
uptake among those HCWs with direct patient contact 
is monitored (compared to Ireland where uptake among 
all HCWs is monitored). During the 2015-2016 season, 
influenza vaccine uptake among frontline HCWs was 50.6%, 
a decline of 4.3% from 54.9 % for the previous season.3 
In the United States, the Centre for Disease Control and 
Prevention analysed data from an internet panel survey 
of HCWs conducted from October 29–November 13, 2015. 
Early season 2015-2016 influenza vaccination coverage 
among HCWs was 66.7%, similar to the 64.3% coverage 
reported by early season 2014-2015. Vaccination coverage 
among HCWs was found to be highest in hospitals (83.9%) 
and lowest in LTCFs (52.4%). In the same study, influenza 
vaccination coverage was found to be higher among HCWs 
whose employers required (87.2%) or recommended (61.9%) 
vaccination compared to 39.4% of HCWs who did not4. 
Reports on uptake levels in the US4 and from the UK3 among 
hospital HCWs clearly indicate that they are substantially 
higher generally than in Ireland. Furthermore, a policy of 
vaccination as a mandatory employment requirement in 
some health care institutions in the US4 would appear to 
account for a marked difference with uptake levels reported 
in the UK where vaccination is currently only recommended 
for front-line HCWs5 and also for HCWs generally in Ireland 
where the uptake levels are lower still. 
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Notifiable C. difficile infection 
In May 2008, new cases of CDI in persons two years or older 
became notifiable in Ireland under the disease category 
“acute infectious gastroenteritis” (AIG). Since January 2012, 
CDI has become a notifiable infection in its own category, 
with both new and recurrent CDI cases now notifiable. 
In 2015, 1,943 cases of CDI were notified to Public Health 
Departments via the Computerised Infectious Diseases 
Reporting (CIDR) system. Of those, 1,647 (85%) were 
classified as new, 192 (10%) as recurrent, with 104 (5%) of 
unknown case type. All cases were laboratory-confirmed.
Taking both new and recurrent cases into account, the 
overall CIR for 2015 was 42.3 per 100,000 population, which 
is higher than the reported rate in 2014 (38.5). At 35.9 per 
100,000 population, the national CIR of new CDI cases in 
2015 was a slight increase of 0.8% from 35.1 per 100,000 
population in 2014.
Since surveillance began in 2008, there has been a decrease 
in the incidence of CDI in Ireland (Figure 1). Since 2012, the 
CDI incidence rate has remained stable. There was a slight 
increase in the number of recurrent cases notified in 2015 
(n=192) compared to 2014 (n=155). Identification of seasonal 
patterns from CIDR notification data is hindered by delayed 
and batched laboratory notifications.
9.1 Clostridium difficile Infection
Key Points
●			In 2015, 1,943 cases of Clostridium difficile 
infection (CDI) were notified. Of those, 1,647 
(85%) were classified as new cases, 192 (10%) as 
recurrent, with 104 (5%) of unknown case type. 
This represents a national crude incidence rate 
(CIR) for new and recurrent CDI combined of 
42.3 cases per 100,000 population, an increase 
of 3.8% compared to the rate reported in 2014 
(38.5)
●			Of the 1,943 CDI cases, 1,323 (68%) were 
reported from patients aged 65 years or older
●			For the first time since it was established in 
2009, there were slightly more CDI cases 
reported to the voluntary enhanced CDI 
surveillance scheme than were notified to 
Public Health Departments. Enhanced data was 
received on 1,955 CDI cases from 54 hospitals. Of 
those, 1,221 (62%) were healthcare-associated, 
representing a national CDI incidence rate for 
new and recurrent healthcare-associated CDI 
combined of 2.5 cases per 10,000 bed days used 
for 2015, an increase from 2.3 in 2014 
●			Data collected on patient location at symptom 
onset highlights that CDI is not confined to acute 
healthcare facilities. It is commonly encountered 
in long term care facilities (9% of all CDI) and in 
the community (34% of all CDI) 
●			Of 219 C. difficile isolates with available 
ribotyping data (11% of all cases) reported 
from 20 hospitals, the most frequent ribotypes 
reported in 2015 were: 078 (n=33, 15%), 005 and 
014 (both n=18, 8%), and 002 (n=14, 6%)
Figure 1. Numbers of CDI notifications by month and case type  
(2008 – 2015)
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Figure 2 displays the gender and age breakdown of patients 
with CDI. The majority were female (62%). The mean age 
was 67 years (range: 2 – 102), with 1,323 cases (68%) 
reported in patients aged 65 years and older.
  
Regarding patient location at the time of CDI diagnosis, 
most were classified as ‘hospitalised’ (69%), with 14% from 
general practice, 6% from the emergency department, 4% 
from outpatients or day patients and 7% from either ‘other’, 
or ‘unknown’ patient location. This is similar to that reported 
in 2014. However, notifiable CDI data does not provide 
information on the origin or onset of CDI, as that information 
is collected as part of the enhanced CDI surveillance 
scheme. 
In 2015, 35 deaths were reported in patients with CDI, which 
is higher than that reported in 2014 (n=22). Of those, 28 
deaths were deemed not attributed to CDI, for six cases the 
contribution of CDI to death was unknown and one death 
was attributed to CDI. 
Notifiable C. difficile infection: Outbreaks
In 2015, 12 CDI outbreaks, 11 of which were healthcare-
associated and involving 42 patients, were notified to Public 
Health Departments, as displayed in Table 1. Nine were 
linked to hospitals, two to nursing homes, and one specified 
as “other”.
Enhanced surveillance of C. difficile infection
Although notifiable CDI data provides important preliminary 
information on the burden of CDI in Ireland, it does not 
capture information on the origin, onset or severity of CDI. 
National C. difficile enhanced surveillance commenced 
on a voluntary basis on 1st August 2009. Information on 
case type, origin, onset and infection severity is collected 
using the European Society for Clinical Microbiology and 
Infectious Diseases Study Group on C. difficile (ESCMID-
ESGCD) interim case definitions. To the end of 2015, 54 
acute hospitals participated in enhanced CDI surveillance, 
comprising 45 public hospitals [94% of all public hospitals: 
27 general (100%), nine tertiary (100%) and nine specialist 
(75%)] and nine private hospitals (75%).
In 2015, 1,955 CDI cases were reported to the enhanced 
surveillance scheme. Of those, 1,667 (85%) were classified 
as new, 208 (11%) as recurrent and 80 (4%) of unknown CDI 
case type. 
Of the reported cases, 62% (n=1,221) originated within the 
reporting healthcare facility. The CDI rate is based on the 
number of new and recurrent CDI cases that originated 
in the participating healthcare facility (both public and 
private hospitals). The rate is calculated using acute public 
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* Rates calculated using 2011 census data 
Figure 2. Age and gender distribution of CDI in Ireland, 2015 
(Source: CIDR)
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Table 1. CDI outbreaks reported in Ireland in 2015 by public health 
region (Source: CIDR)
Public Health Region Outbreak location Total number ill
East Hospital 2
East Hospital 2
East Hospital -
East Nursing home 6
East Other 3
MWHB Hospital 4
NEHB Comm. Hosp/Long-stay unit 3
NEHB Hospital 5
WHB Hospital 3
WHB Hospital 3
WHB Hospital 3
WHB Hospital 8
Table 2. Origin and onset of CDI, 2013 – 2015
Year
2013 2014 2015
% % %
ORIGIN: Location of where 
infection was acquired
Healthcare-associated 64 64 62
Hospital 49 48 47
NH/LTCF 11 11 9
Other 4 5 6
Community-associated 18 18 22
Indeterminate 5 5 6
Unknown 13 13 10
ONSET: Location of where pa-
tient symptoms occurred
Healthcare-onset 61 59 59
Hospital 45 44 45
NH/LTCF 11 11 9
Other 4 4 5
Community-onset 29 34 34
Unknown 11 7 7
hospital activity data from the HSE Business Intelligence 
Unit, with private hospital activity data provided directly by 
participating hospitals. The overall national CDI incidence 
rate of new and recurrent healthcare-associated CDI cases 
combined was 2.5 cases per 10,000 bed days used (BDU), an 
increase from 2.3 in 2014. The incidence rate of new CDI was 
2.3 cases per 10,000 BDU, an increase from 2.1 in 2014. The 
incidence of recurrent cases also increased to 0.3 cases per 
10,000 BDU from 0.2 in 2014. 
Since enhanced surveillance began, the national annual 
combined new and recurrent CDI rate declined from 3.1 cases 
per 10,000 BDU (2009) to the lowest recorded rate of 2.3 
(2014), followed by an increase to 2.5 in 2015 (Figure 3). 
Caution should be taken when interpreting national CDI 
trends, particularly prior to 2012 due to: 
(i)  Changes in the numbers of participating hospitals, as 
displayed in Figure 3. Throughout 2012, the total number 
of hospitals participating in enhanced CDI surveillance 
stabilised. Since 2012, there has been a complete 
participation in CDI enhanced surveillance by all tertiary 
and general hospitals
(ii)  Changes in C. difficile laboratory testing protocols: From 
2013 to 2015, there were fewer changes in laboratory 
testing protocols. Please also refer to the section on 
laboratory testing of C. difficile in Ireland
There was a wide range in the incidence of CDI among 
participating hospitals in 2015 (range, 0 – 4.9 cases per 
10,000 BDU; median = 1.8). In 2015, tertiary hospitals (n 
= 9) had a median CDI rate of 3.2 cases per 10,000 BDUs 
(range: 1.9 – 4.1), which was higher when compared to that of 
general hospitals (n = 27), with a median rate of 1.0 (range: 
0 – 4.5). Since 2011, the median CDI rate in general hospitals 
declined from 2.4 to 1.0. However, for tertiary hospitals, 2015 
marked the first increase in median CDI rate since 2010.
The differences in CDI median incidence rates may reflect 
inter-hospital variation with regard to patient case mix, C. 
difficile ribotypes, laboratory testing protocols, antimicrobial 
prescribing policies, antimicrobial stewardship interventions, 
infrastructure and access to en suite isolation rooms and 
surveillance resources. No obvious seasonal trend for CDI is 
distinguishable from enhanced surveillance data in 2015.
The percentage coverage of acute hospital activity was 
calculated using bed days used data from participating 
hospitals as a percentage of total acute hospital bed days 
used activity in Ireland
Severe CDI
A severe case of CDI is defined as (i) a patient requiring 
admission to an intensive care unit (ICU) for treatment of 
CDI or its complications, (ii) a patient requiring colectomy 
or (iii) death within 30 days after diagnosis, if CDI is either 
the primary or contributory cause of death. The enhanced 
CDI surveillance scheme does not collect information on 
patient outcome. Therefore, surgery and ICU admission for 
CDI are the two markers of severity captured via enhanced 
surveillance. In 2015, 30 (1.5%) severe CDI cases were 
reported, similar to 2014 (1.4%). One patient required both 
surgery and ICU admission, five required surgery only and 24 
required ICU admission without surgery. 
Onset & Origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
Fifty-nine percent (n=1,159) of patients had CDI symptom 
onset in a healthcare facility (healthcare-onset), 34% 
(n=669) had symptom onset in the community and for 7% 
(n=127), location at CDI onset was unknown (Table 2). 
Of the 1,159 patients with healthcare onset CDI, 76% (n=876) 
had onset in the reporting hospital, 4% (n=52) in another 
hospital, 16% (n=183) in a long term care facility (LTCF) and 
for the remaining 4% (n=48) onset location was unknown. 
Between 2013 and 2015, there was a decrease in the 
proportion of patients with CDI symptom onset in a 
healthcare facility (61 to 59%). Community onset increased 
from 29% to 34% between 2013 and 2014, where it remained 
unchanged in 2015 (Table 2). 
Origin: Location where the patient acquired the CDI
For the majority of CDI cases, the infection was acquired 
in a healthcare setting (healthcare-associated) (n=1,221; 
62%). Community-associated cases accounted for 22% 
(n=420) and in 6% (n=123) the origin was indeterminate and 
could not be assigned as either healthcare or community-
associated, as the patient had been discharged from a 
healthcare facility between four and 12 weeks prior to the 
CDI onset date. For the remaining 10% (n=191) of cases, the 
origin was unknown (Table 2).
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Table 3. National reporting of C. difficile ribotyping data: 2011 - 2015 
Year
Total number 
of CDI cases 
reported
Number (%) 
of cases with 
ribotype data
Number of hospitals 
providing ribotype 
data
2011 1511 211 (14%) 10
2012 1735 263 (15%) 14
2013 1801 258 (14%) 19
2014 1780 290 (16%) 20
2015 1955 219(11%) 22
Of the 1,221 healthcare-associated CDI cases, 76% (n=928) 
originated in the reporting hospital, 7% (n=83) originated 
in a hospital other than the reporting hospital, 14% (n=173) 
originated in a LTCF and 3% (n=37) originated in another 
unspecified healthcare facility or were of unknown origin.
Between 2013 and 2015, there was a small decrease in the 
proportion of cases associated with a healthcare facility (64 
to 62%), which was demonstrated in the reporting hospital, 
as well as LTCF. The proportion of cases associated with the 
community increased from 18% to 22%, and there was slight 
increase in cases classified as indeterminate (from 5% to 6%). 
Cases classified as ‘unknown’ decreased from 13% to 10% 
between 2014 and 2015 (Table 2). 
    
Of the 1,221 cases of healthcare-associated CDI:
●			87.5% (n=1,068) experienced onset of CDI symptoms at 
least 48 hours following admission to a healthcare facility 
(healthcare-onset, healthcare-associated)
●			12% (n=147) experienced symptom onset in the 
community, within four weeks of discharge from a 
healthcare facility (community-onset, healthcare-
associated)
●			0.5% (n=6) had no information recorded on symptom 
onset
Of the 420 cases of community-associated CDI: 
●			93% (n=389) experienced CDI symptom onset while 
outside a healthcare facility and without a history of 
discharge from a healthcare facility within the previous 12 
weeks (community- onset, community-associated)
●			admission to or residence in a healthcare facility within 
the previous 12 weeks (healthcare-onset, community-
associated)
Information was also captured on the location where the 
patient’s faeces specimen was taken. The reporting hospital 
accounted for the majority (76%) of specimens (n=1,490), 
with 12% (n=225) taken in the GP surgery, 8% (n=156) in LTCF 
and 3% (n=65) in a hospital other than the reporting hospital. 
For the remaining 1% (n=19), no information was provided.
Discussion
The collation of national data on C. difficile through CIDR 
notifications and the enhanced CDI surveillance system has 
provided a valuable insight into the burden of CDI in Ireland. 
Both surveillance systems present a similar decreasing trend 
since 2009. The notifiable surveillance system, which reflects 
total burden of disease, shows that the CDI rate stabilised 
between 2012 and 2015, while the enhanced surveillance 
system shows a decrease in the CDI rate between 2012 and 
2014, but a slight increase in 2015. For the first time in 2015, 
cases reported to enhanced CDI surveillance exceeded those 
notified to public health departments.
In 2015, recurrent CDI accounted for 11% of notifications 
through the enhanced surveillance scheme, which is an 
increase from 8% in 2014. Recurrent CDI may result in 
severe infection, which places a further burden on limited 
hospital isolation resources and results in significant patient 
morbidity. 
CDI is not confined to acute healthcare settings and is 
increasingly common in LTCF and the community. In 2015, 
9% of cases had onset in LTCF, with 34% having onset in 
the community. Of the 420 community-associated cases 
reported in 2015, 93% experienced CDI symptom onset in the 
community, without a history of discharge from a healthcare 
facility within the previous 12 weeks. It is important to 
consider CDI in the differential diagnosis of all patients 
presenting with diarrhoea of potentially infectious origin, 
regardless of patient location and to send a faeces specimen 
in a timely fashion for laboratory diagnosis, which should 
routinely include testing for C. difficile in patients aged over 
two years, in keeping with national CDI guidelines. 
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Figure 3. Quarterly national rate of healthcare-associated CDI (new 
and recurrent): 2009 – 2015
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Figure 4. Most frequently reported C. difficile ribotypes in Ireland: 2010 
– 2015
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C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are requested to provide C. 
difficile PCR ribotyping information, where available. Ireland 
does not yet have a national C. difficile reference laboratory 
or ribotyping service. Therefore, laboratories submit 
specimens abroad for ribotyping. In 2015, ribotyping data 
was provided for 219 C. difficile isolates (11% of all samples) 
from 20 hospitals (Table 3). The most frequent ribotypes 
reported in 2015 were: 078 (n=33, 15%), 005 and 014 (both 
n=18, 8%), and 002 (n=14, 6%) (Figure 4). 
Laboratory Testing of C. difficile in Ireland
Since 2010, information on C. difficile testing has been 
collected quarterly as part of the enhanced surveillance 
system. In Q1 2010, the majority of hospitals participating 
in the enhanced surveillance project were using a one-
step Toxin EIA (60%). By Q4 2015, this had reduced to 0%. 
All hospitals participating in the enhanced surveillance 
system are now using a method which complies with 
recommendations in the 2014 update of the 2008 Irish 
C. difficile guidelines. This includes either a PCR test for 
detection of toxin genes (43%, n=23) or a two-step testing 
method (57%, n=30) (Figure 5). Owing to variations in 
current Irish laboratory C. difficile testing methodologies, 
inter-hospital comparison of CDI rates is not recommended 
where testing methods differ, as the data in the national 
quarterly enhanced surveillance reports are not adjusted 
for differences in the sensitivities of the different diagnostic 
methodologies.
Conclusion
The continued excellent participation in the voluntary CDI 
enhanced surveillance scheme ensures that a significant 
amount of information is collected regarding the burden 
of CDI in Ireland. The National Clinical Guidelines on the 
Surveillance, Diagnosis and Management of CDI in Ireland 
were updated in 2013 and endorsed by the National Clinical 
Effectiveness Committee in 2014. The updated guidelines 
may be accessed on the HPSC website at: http://www.hpsc.
ie/A-Z/Gastroenteric/Clostridiumdifficile/Guidelines/.
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Figure 5. Changes in C. difficile laboratory testing protocols: 2011 - 2015
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Summary
Key Points
•  In 2015, the median rate of alcohol-based hand rub 
consumption in acute hospitals in Ireland increased by 
14% to 31.6 litres per 1,000 bed-days used versus 27.7 
in 2014
Hand hygiene is one of the most important actions to prevent 
HCAI. Alcohol-based hand rubs (ABHR) are an effective 
and rapid method of hand hygiene and recommended 
as the primary means of hand hygiene in national and 
international guidelines. Measurement of hospital-level 
ABHR consumption, inclusive of gel and foam formulations, 
is expressed as volume in litres (L) per 1,000 bed days used 
(BDU). ABHR consumption is a recommended process 
measure of hand hygiene activity by both the World Health 
Organization (WHO) and the US Centers for Disease Control & 
Prevention (CDC). 
HPSC has collated data on ABHR consumption in acute 
public hospitals in Ireland since 2006. The data are collected 
quarterly. For hospitals that provide the data via their phar-
macy department, it represents the total volume of ABHR 
dispensed to wards, clinics and other hospital areas. For hos-
pitals that provide the data via their supplies department, it 
represents the total volume of ABHR purchased by the facility. 
Quantities used for pre-operative surgical hand hygiene were 
excluded. The rate of usage per hospital is calculated as the 
total volume of ABHR consumed in litres (L) per 1,000 BDU 
(Table 1). 
In 2015, the median rate of ABHR consumption increased 
by 14% from 27.7L/1,000 BDU in 2014 to 31.6. The wide 
variation in levels of ABHR consumption between hospitals 
(10.1 – 96.8), although not as wide as in past years, may be 
explained by differences in local methodologies for collect-
ing and reporting the data, along with difference in types and 
range of hand hygiene agents used. One limitation of this 
surveillance system is that the data refer to the use of ABHR 
only, and do not take account of the other hand hygiene 
agents (e.g. medicated liquid soap) that may also be in use 
in hospitals. In addition, the data do not give an indication 
of the frequency with which hand decontamination is carried 
out at a given hospital, whether or not hand hygiene is carried 
out at the correct time or using the correct technique, nor 
distinguish between who has used the ABHR (visitor, patient 
or healthcare worker). Nevertheless, given that ABHR should 
be used for the vast majority of hand hygiene opportunities 
in hospital settings, ABHR consumption remains a useful 
process measure for hand hygiene activity.
In 2015, the total number of hospitals participating in ABHR 
surveillance decreased to 39 versus 43 in 2014. The main rea-
son was reorganisation of data provided by a particular region 
from individual hospital sites to a format that aggregates into 
a small numbers of groups by directorates. In addition, data 
from one hospital could not be provided due to staffing issues. 
The data are prone to reporting artefacts, particularly for 
hospitals that report supplies (rather than pharmacy dispens-
ing) data. For example, the hospital with the highest reported 
rate in past years had undergone a change in suppliers and 
the products had been restocked in all areas of the hospital 
over a relatively short period of time. It is expected that there 
will be occasional outliers of this nature. Using the median 
consumption figure provides a stable indicator of the na-
tional ABHR rate over time. However, the volume of ABHR 
consumed remains a crude measure of hand hygiene activity 
at individual hospital level and must be viewed in conjunc-
tion with other indicators, such as direct observation of hand 
hygiene compliance.
Further information may be found at:
http://www.hpsc.ie/A-Z/Gastroenteric/Handwashing
Table 1. Annual national data on ABHR consumption in acute public 
hospitals in Ireland: 2006 – 2015.
 
Number of 
participating 
hospitals
National 
consumption 
rate*
Range for 
participating 
hospitals 
2006 52 10 0.5 - 29.0
2007 50 15 5.2 - 47.1
2008 50 18.1 5.9 - 67.0
2009 49 20.3 4.1 - 47.7
2010 45 18.8 4.2 - 36.4
2011 43 21.3 10.9 - 130.0
2012 44 23.8 9.6 - 160.0
2013 44 26.3 16.4 - 132.5
2014 43 27.7 4.3 - 72.1
2015 39 31.6 10.1 - 96.8
* The consumption rate is the total volume of ABHR consumed in the defined 
time period in litres per 1,000 bed-days used. The national rate represents the 
median of the national sample for each time period.
9.2 Alcohol Hand Rub Surveillance 
-142-HPSC Annual Epidemiological Report 2015 Healthcare Associated Infections
Summary
•  On a background of on-going hand hygiene compliance 
audits in acute hospitals, national data were collated 
and reported for two audit periods during 2015
•  For Period 9 (May/June), 51 hospitals participated 
[HSE; 44 and private; 7]. In total, 10,667 opportunities 
for hand hygiene were observed; achieving an average 
compliance of 88.4% (range = 75.2 - 96.7)
•  For Period 10 (October/November), 52 hospitals 
participated [HSE; 44 and private; 8]. In total, 10,890 
opportunities for hand hygiene were observed; 
achieving an average compliance of 89.5% (range = 
78.6 - 96.7)
•  While the overall compliance of 88.6% for the 
combined periods for HSE hospitals fell short of the 
HSE target of 90% for 2015 the underlying trend in 
compliance has increased. Compliance for participating 
private hospitals for the combined periods was 91.4%
Hand hygiene is one the most important actions to prevent 
HCAI. Measuring hand hygiene compliance by direct 
observation is described by the World Health Organization 
(WHO) as the gold standard. In Ireland, public reporting 
of biannual hand hygiene compliance audit data from 
acute hospitals commenced in 2011. Healthcare workers 
(HCWs) are observed for their compliance against the ‘5 
moments of hand hygiene’ by trained auditors using the 
WHO methodology for hand hygiene audits. Each hospital 
is required to measure HCW compliance against 30 hand 
hygiene opportunities for each of the seven randomly 
selected wards in the facility, resulting in a maximum of 210 
opportunities per hospital per period. In 2013, the analysis 
and management of data were moved to the HPSC online 
service, MicroB.
Biannual audits were undertaken in May/June (Period 9) 
and October/November 2015 (Period 10). In total, 10,667 
opportunities for hand hygiene were observed for Period 9; 
achieving an average compliance of 88.1% (range = 75.2 - 
96.7). For Period 10, 10,890 opportunities for hand hygiene 
were observed; achieving an average compliance of 89.5% 
(range = 78.6% - 96.7).
9.3 Hand Hygiene Compliance 
Table 1: Summary of hand hygiene compliance in acute hospitals in Ireland combined for the two national audit periods in 2015. 
Note that data from private hospitals were excluded for the Staff Categories and WHO 5 Moments sections.
  Hand Hygiene 
Opportunities
Hand Hygiene 
Actions
Percent 
Compliance
Lower 95% 
Confidence Interval
Upper 95% Confidence 
Interval
Overall 21,557 19,183 89.0% 88.5% 89.4%
HSE Hospitals 18,413 16,308 88.6% 88.1% 89.1%
Private Hospitals 3,144 2,875 91.4% 90.4% 92.5%
HSE - South 6,297 5,620 89.2% 88.4% 90.1%
HSE - Dublin North-East 3,770 3,232 85.7% 84.5% 86.9%
HSE - Dublin Mid-Leinster 4,193 3,791 90.4% 89.5% 91.3%
HSE - West 4,153 3,665 88.2% 87.2% 89.3%
Nurse/Midwife 10,538 9,647 91.5% 91.0% 92.1%
Auxiliary 2,995 2,626 87.7% 86.4% 88.9%
Medical 3,444 2,721 79.0% 77.5% 80.5%
Allied health/Other 1,436 1,314 91.5% 90.0% 93.0%
Moment 1 4,809 4,327 90.0% 89.1% 90.9%
Moment 2 867 742 85.6% 83.1% 88.1%
Moment 3 1,451 1,322 91.1% 89.6% 92.6%
Moment 4 6,424 5,851 91.1% 90.3% 91.8%
Moment 5 5,629 4,777 84.9% 83.8% 85.9%
Staff category: ‘Auxiliary’ includes healthcare assistants, porters, catering and household services; ‘Allied health/Other’ includes physiotherapists, 
radiologists, dieticians, social workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic procedure; Moment 3: After body fluid exposure risk; Moment 4: After touching a 
patient; Moment 5: After touching patient surroundings
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Results for the two periods are combined in a summary 
in Table 1 and Figure 1. In 2015, the overall compliance for 
HSE and private hospitals combined was 89.0%. At 88.6%, 
compliance for HSE hospitals fell short of the target of 90%. 
The underlying trend for compliance among HSE hospitals 
has increased (Figure 2). Participating private hospitals 
reported an overall compliance of 91.4% in 2015.  
In 2015, of the four major HCW categories, medical staff had 
the lowest compliance at 79%, ‘Auxiliary’ which includes 
healthcare assistants had a compliance of 87.7% and both 
nurse/midwife and ‘Allied health/Other’ staff category which 
includes physiotherapists, radiologists, dieticians, social 
workers and pharmacists had the highest at 91.5%. 
Based on the WHO ‘5 moments for hand hygiene’, 
compliance for moment 5 (after touching patient 
surroundings) was the lowest at 84.9% and the highest 
for moment 3 (after body fluid exposure risk) at 91.1%. The 
proportion of hand hygiene actions that were undertaken 
using soap and water was 26.4%, versus alcohol-based hand 
rub which accounted for 73.6% of hand hygiene actions. 
Data from private hospitals were excluded from analysis 
by staff categories and by WHO 5 Moments in Table 1 and 
Figure 1.
Limitations of current methodology
•  While standardised hand hygiene auditor training and 
validation (with inter-rater reliability testing) should ensure 
that measurement of hand hygiene is comparable, these 
results have not been validated by external auditors
•  All auditors measured hand hygiene compliance in the 
facility in which they work. Therefore, there may be an 
element of bias in the results 
•  It is possible that hand hygiene auditing may not have 
been performed in a comparable fashion in all hospitals 
and these results may not reflect HCW compliance at all 
times 
Compliance with hand hygiene is measured by auditors 
observing HCW undertaking patient care and who may 
change their behaviour if aware that they are being 
observed. However, it is also known that this effect (known 
as the Hawthorne effect) diminishes over time and HCWs 
under observation may not be aware of the presence 
of the auditor due to the many competing demands on 
their attention. Auditors are requested to give immediate 
feedback to ward staff following an audit, thereby increasing 
awareness and knowledge of hand hygiene. This risk of bias 
should be balanced by the benefits of increasing local staff’s 
knowledge and awareness of hand hygiene. 
Figure 2: Summary of hand hygiene compliance in HSE acute 
hospitals in Ireland for the last eight national audit periods, 
2011 to 2015. The HSE target for each year is shown as red 
lines.
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Staff category: “Auxiliary” includes healthcare assistants, porter, 
catering and household services; “Allied health/Other” includes 
physiotherapists, radiologists, dieticians, social workers and 
pharmacists
Moment 1: Before touching a patient; 
Moment 2: Before clean/aseptic procedure; 
Moment 3: After body fluid exposure risk; 
Moment 4: After touching a patient; 
Moment 5: After touching patient surroundings
Figure 1: Summary of hand hygiene compliance in acute 
hospitals in Ireland combined for the two national audit periods 
in 2015. The 95% confidence intervals are shown in bars and 
the HSE target for 2015 (90%) is shown as a red line. 
Note that data from private hospitals were excluded for the Staff Categories and 
WHO 5 Moments.
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Ireland participates in ECDC’s European Surveillance of 
Antimicrobial Consumption Network (ESAC-Net), which 
aims to collect systemic antimicrobial usage data from the 
outpatient (ambulatory, community or primary care) setting 
and from the hospital (inpatient) setting. Antimicrobial 
consumption is measured in defined daily dose (DDD), 
which is the assumed average maintenance dose per day 
for a drug used for its main indication in adults. Rates are 
calculated in DDD per 1000 inhabitants per day (DID) for 
outpatients and DDD per 100 bed-days used (DBD) for 
inpatients. Please refer to “Antimicrobial consumption” and 
“Denominator data” parts of the explanatory notes section 
for further details. 
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for Ireland 
in 2015 was 25.6 DID, an increase of 7% on the 2014 rate 
of 23.9 DID. In the latest ESAC-Net report (2015 data), 
the reported range of outpatient J01 (antibacterial agents 
for systemic use) antimicrobial usage among European 
countries was 10.7 to 36.1 DID; the median for 30 European 
countries with reliable data was 20.7 DID, with Ireland 
ranking as the ninth highest. 
The underlying trend for outpatient antimicrobial 
consumption for Ireland (Figure 1) has been increasing 
steadily since 2000. After a decrease in 2008 and 2009, the 
rate increased again to the highest level so far in quarter 4 
2015. There is a marked seasonal fluctuation in usage, with 
the highest consumption contemporaneous with periods of 
increased influenza activity.
In 2015, outpatient consumption of penicillins accounted 
for the largest class used (61% of total at 15.5 DID), followed 
by macrolides (17%, 4.2 DID), tetracyclines (10%, 2.6 DID), 
cephalosporins (5%, 1.2 DID), sulphonamides/trimethoprim 
(4%, 1.1 DID) and fluoroquinolones (4%, 0.9 DID). Penicillin 
in combination with a beta-lactamase inhibitor (such as 
co-amoxiclav) accounted for the largest proportion of all 
penicillins at 44% (6.8 DID). Broad-spectrum penicillin 
(such as amoxicillin) usage was also high at 35% of all 
penicillins (5.4 DID). See Table 1 for a detailed breakdown by 
pharmacological drug groups.
There was considerable variability in the overall outpatient 
antimicrobial usage at county level (19.2 to 35.4 DID), as 
shown in Figure 2.
       
 
Hospital Antimicrobial Consumption
Forty-two acute public hospitals provided valid 
antimicrobial usage data for 2015. The median rate of 
antimicrobial consumption was 82.6 DBD (range 29.3 – 
108.7 DBD). This was a 0.7% increase from 2014’s median 
rate on 82.0 DBD. The overall rate for 2015 was 84.0 DBD. 
These levels are mid-to-high in Europe.
The largest group of antimicrobials, penicillins at 41.2 
DBD accounted for 48% of all inpatient antimicrobial 
usage. The use of fluoroquinolones such as ciprofloxacin 
(representing 6% of all inpatient antimicrobial usage) was 
5.3 DBD. Consumption of cephalosporins, monobactams 
and carbapenems (representing 10% of all inpatient 
antimicrobial usage) was 8.7 DBD. Consumption of 
glycopeptides such as intravenous vancomycin, imidazoles 
such as intravenous metronidazole and nitrofurans 
(representing 10% of all inpatient antimicrobial usage) was 
8.2 DBD. Consumption of erythromycin and related agents 
(macrolides, representing 3% of all inpatient antimicrobial 
usage) was 2.6 DBD. Less frequently used agents in 
hospitals are tetracyclines, sulfonamides/trimethoprim, 
9.4 Antimicrobial Consumption 
Key Points
•  The overall outpatient antimicrobial consumption in 
Ireland for 2015 was 23.6 defined daily doses (DDD) 
per 1000 inhabitants per day (DID), a 7% increase on 
the 2014 rate of 23.9 DID. This rate is mid-to-high in 
comparison with other European countries
•  The median rate of hospital antimicrobial consumption 
in Ireland for 2015 was 82.6 DDD per 100 bed days 
used (DBD) (range = 29.3 – 108.7), a 0.7% increase on 
2014. This rate is mid-range in comparison with other 
European countries. In 2015, 42 acute public hospitals 
contributed data
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aminoglycosides and other systemic antimicrobials; 
collectively these drugs represent just less than 10% of all 
inpatient antimicrobial usage. 
The data do not indicate whether or not the level of 
antimicrobial use is appropriate for a given patient 
population. For example, higher levels of antimicrobial 
consumption among tertiary hospitals may be appropriate 
if such hospitals have specific patient populations that 
are more likely to require antimicrobial therapy (e.g. 
organ transplant, cystic fibrosis etc). Furthermore, DDD 
calculations are based on adult dosing and may therefore 
underestimate antimicrobial consumption in paediatric 
settings.
While antimicrobial consumption data in Ireland are 
comprehensive, gaps remain. Most notably, data from 
private hospitals is missing. All hospitals dispense to 
outpatients, day cases and external long term facilities, 
and the data representing this volume is excluded from our 
analyses. Outpatient data represents 95% of wholesale-to-
retail pharmacy transactions. Therefore, there is a further 
gap in the data. Collectively, these gaps would represent 
about 10% of the total antimicrobial consumption for 
Ireland. While HPSC provides antifungal consumption 
data to ESAC-Net, this report is primarily focussed on 
antibacterial consumption only. ESAC-Net also collects 
data on antiviral and antiprotozoal agents, which are not 
currently analysed in Ireland. 
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Figure 2. Outpatient antibiotic consumption in Ireland by county, in DDD per 1000 inhabitants per day for 2015. 
Table 1. Breakdown by pharmacological drug groups for outpatient antibiotic use in Ireland for 2014 and 2015.
2014 Percent of 2014 2015 Percent of 2015 Percent Change  2014 to 2015
Penicillins 13.5 56.4% 15.5 60.6% 14.9%
Narrow spectrum penicillins 1.1 4.4% 1.1 4.1% 0.6%
Beta-lactamase resistant penicillins 1.9 8.0% 2.3 8.9% 19.1%
Broad spectrum penicillins 4.4 18.4% 5.4 21.1% 22.0%
Penicillin with beta-lactamase inhibitor 6.1 25.6% 6.8 26.5% 10.9%
Macrolides and related drugs 4.5 18.8% 4.2 16.5% -5.6%
Tetracylines 2.8 11.5% 2.6 10.1% -6.0%
Cephalosporins and other beta-lactam drugs 1.1 4.7% 1.2 4.6% 3.7%
First-generation cephalosporins 0.3 1.1% 0.3 1.1% 10.0%
Second-generation cephalosporins 0.8 3.4% 0.8 3.3% 5.2%
Third-generation cephalosporins 0.1 0.3% 0.0 0.2% -39.0%
Quinolones 0.9 3.8% 0.9 3.6% 3.0%
Sulfonamides and Trimethoprim 1.0 4.4% 1.1 4.1% 0.8%
Other antibiotics 0.1 0.4% 0.1 0.4% -1.2%
TOTAL 23.9 100.0% 25.6 100.0% 7.0%
More detailed analyses of antimicrobial usage data can be 
found on the www.hpsc.ie website, through “Topics A-Z”, 
under “Antibiotic Consumption Surveillance”. Details of the 
WHO ATC/DDD system of classifying and measuring drug 
consumption can be found at www.whocc.no/atc_ddd_index/. 
The figures presented in this report may vary from previously 
published levels owing to methodological changes.
Figure 2. Outpatient antibiotic consumption in Ireland by 
county, in DDD per 1000 inhabitants per day for 2015. 
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Figure 3. Overall hospital antimicrobial consumption rate in DDD per 100 BDU by pharmacological subgroup (ATC level 3) by 
year. 
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9.5 Antimicrobial Resistance
Key Points
•    In 2015, there was a slight reduction in coverage of the 
Irish population by EARS-Net versus 2014, from 100% 
to 97% 
•   There were 2,697 reports of invasive Escherichia coli 
infection:  
 o   The proportion resistant to third-generation 
cephalosporins (3GC) at 12.5% and extended-
spectrum beta lactamase (ESBL) producers at 10.6% 
reached the highest levels to date
 o   There were two cases of carbapenemase-producing 
E. coli invasive infection, also known as carbapenem-
resistant Enterobacteriaceae (CRE)
•   T here were 401 reports of Klebsiella pneumoniae 
bloodstream infection (BSI), an increase from 358 in 
2014:
 o   The proportion resistant to 3GCs at 17.5% and ESBL 
producers at 13.3% increased from 2014 levels; 
12.8% and 11.0%, respectively
 o   In Ireland, K. pneumoniae that are both ESBL-
producers and non-susceptible to ciprofloxacin 
and gentamicin are called multi-drug resistant 
K. pneumoniae (MDRKP). Some also produce 
carbapenemases. The proportion of invasive K. 
pneumoniae that were MDRKP increased from 8.2% 
in 2014 to 9.8% in 2015 
 o   There were seven cases of confirmed 
carbapenemase-producing K. pneumoniae invasive 
CRE infection
•    There were 201 reports of invasive 
Pseudomonas aeruginosa infection, an increase from 
2014. Resistance to most indicator antimicrobials, 
except carbapenems, decreased
•    There were 421 reports of Enterococcus faecium BSI, 
an increase from 2014:
 o   The proportion resistant to vancomycin (VREfm) at 
45.6%, reflected one of the highest levels to date
•    There were 1,082 reports of Staphylococcus aureus 
BSI:
 o   The proportion that were meticillin-resistant S. 
aureus (MRSA) at 18.4% is the lowest annual 
proportion reported to date
 o   The overall MRSA BSI rate for acute hospitals was 
0.050 cases per 1,000 bed days used (BDU), a 
slight decrease from 0.055 in 2014. The meticillin-
susceptible S. aureus (MSSA) BSI rate also decreased 
from 0.227 (2014) to 0.223 (2015)
•    There were 304 reports of invasive 
Streptococcus pneumoniae infection:
 o   The proportion deemed penicillin non-susceptible 
(PNSP) at 17.5% represented a slight increase from 
17.1% in 2014
 o   While the national rate of invasive pneumococcal 
infection at 6.8 per 100,000 population, represented 
a decrease compared to 7.2 in 2014
 o   Serotype data was available for the majority of 
invasive S. pneumoniae isolates (n=276; 90.8%). 
Results indicate good coverage (67.1%) for the 
23-valent pneumococcal polysaccharide vaccine 
(PPV23) in its target population (adults ≥65 years) 
•    Enhanced surveillance data were provided on 2,432 
records (cases or isolates under the EARS-Net 
definition) from 22 laboratories, representing 45% of 
all reported cases in 2015
See http://www.hpsc.ie for further details of EARS-Net, 
antimicrobial resistance and enhanced BSI surveillance in 
Ireland  
European data are available at: 
http://ecdc.europa.eu/en/healthtopics/antimicrobial_
resistance/database/Pages/database.aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European Antimicrobial 
Resistance Surveillance System (EARSS), collects routinely-
generated antimicrobial susceptibility testing data on 
seven important bacterial pathogens using the EARS-
Net case definition. Participating laboratories in Ireland 
submit data on the “primary” or first isolate from blood or 
cerebrospinal fluid (CSF) per patient per quarter. EARS-
Net does not distinguish clinically significant isolates from 
contaminants, nor does it distinguish between hospital-
acquired, healthcare-associated and community-acquired 
infections. EARS-Net primarily serves as a surveillance 
system to measure national levels of antimicrobial resistance 
(AMR). In 2015, three of the 39 microbiology laboratories 
suspended their participation in EARS-Net for two quarters 
each, resulting in an estimated 97% coverage of the Irish 
population.
Escherichia coli
There were 2,697 reports of invasive E. coli infection (blood 
= 2,689 and CSF = 8) from 2,645 patients, compared with 
2,771 reports in 2014. The observed decrease was due to 
lower population coverage in 2015 (see introduction). Table 
1 displays annual trends since 2008 in the proportion of 
E. coli isolates resistant to the five “indicator” antimicrobials/
antimicrobial classes: ampicillin, third-generation 
cephalosporins (3GC; cefotaxime, ceftriaxone, ceftazidime or 
cefpodoxime), fluoroquinolones (ciprofloxacin or ofloxacin), 
aminoglycosides (gentamicin, amikacin or tobramycin) and 
carbapenems (meropenem or ertapenem):  
•    Of 2,686 isolates, 337 (12.5%) were 3GC resistant. Of 
those, 273 were ESBL producers and 64 were ESBL 
negative 
•    Of 2,688 isolates, 655 (24.4%) were resistant to 
ciprofloxacin 
•    Of 2,693 isolates, 295 (11%) were resistant to gentamicin 
[360 (13.4%) of 2,694 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)]
•    Six (0.2%) of 2,678 isolates were resistant to 
carbapenems. Of those, two were confirmed 
carbapenemase-producers: NDM (1) and OXA-48 (1)
Resistance to 3GC has been increasing since 2004, reaching 
its highest level to date in 2015 (Figure 1). Resistance 
to ciprofloxacin and aminoglycosides decreased in 2015 
compared with 2014. ESBLs were detected in 284 (10.6%) of 
2,684 isolates tested. In 2015, ESBL production by invasive E. 
coli isolates was at its highest level since surveillance began. 
ESBL production has been increasing since 2004. 
In 2015, Ireland had moderately high levels (10 to 
<25%) of resistance to 3GC (Figure 2), ciprofloxacin and 
aminoglycosides (ranking 16th, 17th and 13th, respectively, of 30 
countries reporting to EARS-Net). The median proportions 
for resistance among EARS-Net countries were 12.5% for 
3GC, 24.7% for ciprofloxacin and 12.5% for aminoglycosides.
Of 2,676 isolates tested against all five “indicator” 
antimicrobials, 389 (14.6%) reported from 46 hospitals/
institutions were identified as multi-drug resistant (MDR) 
E. coli, defined as resistance to three or more of the 
indicator antimicrobials OR any isolate with resistance 
to carbapenems, a slight decrease from 15.0% in 2014. A 
significant increase in MDR-E. coli was observed from 2009 
to 2014 (P<0.001). In 2015, MDR E. coli decreased slightly.
The frequency of invasive E. coli infection increased with 
female gender x 1.2 fold (P<0.001) and age, with the majority 
(n=2,040; 76%) occurring in those over 60 years (median = 
72 years; 95%CI, 71-73).
Klebsiella pneumoniae
There were 401 reports of invasive K. pneumoniae BSI from 
387 patients, an increase of 12% from 2013 (n=358). The 
observed decrease was due to lower population coverage in 
2015 (see introduction). Table 1 displays annual trends since 
2008 in the proportion of K. pneumoniae isolates resistant to 
the five “indicator” antimicrobials (as described in section on 
E. coli above): 
•    Of 399 isolates, 70 (17.5%) were resistant to 3GC, of which 
51 were ESBL producers and 19 were ESBL negative 
•    Of 399 isolates, 86 (21.6%) were resistant to ciprofloxacin
•    Of 401 isolates, 68 (17.0%) were resistant to gentamicin 
[72 (18%) of 401 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)]
•    Of 401 isolates, nine (2.2%) were carbapenem resistant. 
Of those, seven were carbapenemase-producers reported 
from four hospitals; OXA-48 (6) and KPC (1), an increase 
from two in 2014; OXA-48 (1) and KPC (1). The remaining 
two isolates were not carbapenemase-producers  
Resistance to 3GC, ciprofloxacin and gentamicin/
aminoglycosides all increased in 2015, compared with 2014. 
Resistance to ciprofloxacin and gentamicin/aminoglycosides 
reached the highest levels since surveillance began and 3GC-
resistance the second highest level after 2013 (Figure 3).
Three invasive K. pneumoniae isolates were reported as 
susceptible to ampicillin, suggestive of misidentification of 
species or misclassification, as K. pneumoniae are inherently 
resistant to ampicillin.
ESBLs were detected in 53 (13.3%) of 398 isolates tested. In 
2015, ESBL production by invasive K. pneumoniae isolates 
was at its second highest level (after 2013; 18.4%) since 
surveillance began. 
Of 398 isolates, 79 (19.8%) reported by 24 hospitals that 
were tested against all five “indicator” antimicrobials were 
identified as MDRKP, an increase from 13.7% in 2014. In 2015, 
MDRKP reached its highest level since surveillance began.
In 2015, Ireland ranked 21st for both 3GC and fluoroquinolone 
resistance and 18th for aminoglycoside resistance among 
30 countries reporting to EARS-Net. The median 
proportions among EARS-Net countries were 3GC (26.6%), 
fluoroquinolone (31.9%) and aminoglycosides (21.6%), 
respectively. With three cases of invasive carbapenem-
resistant K. pneumoniae (0.8%) meeting the EARS-Net case 
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Pathogen
Year
2008 2009 2010 2011 2012 2013 2014 2015
Number laboratories by year-end 42 43 40† 41† 41 41 39† 38††
E. coli
Number of isolates 1926 2064 2170 2210 2450 2530 2771 2697
%Ampicillin-R* 70.4 68.7 68.4 71.9 69.6 70.9 69.9 66.7
%3GC-R* 6.7 7.1 8.0 9.1 10.3 12.3 12.0 12.5
%ESBL-producers* 5.0 5.8 6.1 7.5 8.8 10.5 10.2 10.6
%Ciprofloxacin-R* 23.3 22.3 23.6 23.8 25.2 25.3 26.2 24.4
%Gentamicin-R* 10.2 7.7 9.4 8.7 9.7 9.8 11.2 11.0
%Gentamicin/Amikacin/Tobramycin-R* 11.0 9.3 11.9 12.4 12.8 12.9 14.5 13.4
%Carbapenem1-R* 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2
%MDR* 11.6 10.3 11.8 13.2 13.6 14.6 15.0 14.5
Number laboratories by year-end 43 43 40† 41† 41 41 39† 38††
S. aureus
Number of isolates 1303 1309 1251 1095 1060 1094 1117 1082
Number Meticillin-R (or MRSA) 439 355 305 263 242 222 217 199
%Meticillin-R (or MRSA) 33.7 27.1 24.4 24.0 22.8 20.3 19.4 18.4
Number laboratories by year-end 42 43 40† 41† 41 41 39† 38††
E. faecium
Number of isolates 406 397 392 364 392 409 405 421
%Ampicillin-R* 95.1 92.9 95.6 95.9 92.9 93.2 95.3 94.3
%Vancomycin-R (VREfm) 35.7 38.3 39.3 37.4 45.4 43.1 45.9 45.6
%HLG-R* 28.1 39.1 39.6 36.8 39.3 41.4 44.3 49.5
%Linezolid-R* 3.4 5.2 2.2 1.1 1.5 1.2 2.0 0.7
%MDR* 16.2 26.7 25.0 21.1 20.3 19.6 22.1 21.3
Number laboratories by year-end 41 42 40† 41† 41 41 39† 38††
K. pneumoniae
Number of isolates 310 323 326 312 345 326 358 401
%Ampicillin-R* 99.7 99.7 99.1 100.0 98.5 99.1 100.0 99.3
%3GC-R* 11.4 11.2 10.2 8.0 11.9 21.2 13.1 17.5
%ESBL-producers* 7.7 8.2 5.1 5.6 8.8 18.4 11.0 13.3
%Ciprofloxacin-R* 12.8 13.0 10.5 13.2 11.9 20.9 17.3 21.6
%Gentamicin-R* 10.7 11.1 6.8 7.4 9.6 16.9 12.6 17.0
%Gentamicin/Amikacin/Tobramycin-R* 10.7 11.1 7.1 8.3 9.9 17.8 13.2 18.0
%Carbapenem1-R* 0.0 0.0 0.0 1.9 0.3 1.2 1.1 2.2
%MDRKP2* 3.9 4.3 2.2 4.6 5.3 12.3 8.2 9.8
%MDR* 10.3 11.9 8.0 9.0 10.2 19.7 13.7 19.8
Number laboratories by year-end 42 43 40† 41† 41 41 39† 38††
S. pneumoniae
Number of isolates 447 356 314 327 321 311 331 304
%Penicillin-NS* 23.1 20.2 18.2 19.6 19.6 20.7 17.1 17.5
of which:   %HLR 6.0 5.6 4.8 6.1 4.7 2.6 2.4 0.3
 %Int 16.8 13.8 12.7 13.5 15.0 18.0 14.5 17.2
%Erythromycin-R* 16.7 17.3 15.7 18.9 16.9 17.9 13.8 15.2
%Penicillin-NS/Erythromycin-R 10.4 11.9 12.6 13.8 12.5 13.0 11.0 10.8
Number laboratories by year-end 42 43 40† 41† 41 41 39† 38††
E. faecalis
Number of isolates 301 289 298 265 298 336 315 294
%Ampicillin-R* 0.7 2.1 0.7 0.8 4.0 2.7 1.6 0.7
%Vancomycin-R (VREfa) 3.7 0.7 0.3 4.9 3.0 2.1 2.9 1.4
%HLG-R* 30.5 36.7 29.7 29.1 32.9 33.6 32.8 28.0
%Linezolid-R* 2.3 3.4 2.5 1.2 0.0 0.6 1.0 0.4
Number laboratories by year-end 41 42 40† 41† 41 41 39† 38††
P. aeruginosa
Number of isolates 199 248 222 184 219 207 182 201
%Piperacillin/tazobactam-R* 9.7 8.9 10.0 2.8 17.4 15.7 16.5 14.0
%Imipenem/meropenem-R* 9.3 10.0 8.3 12.0 19.4 13.1 11.6 16.4
%Ciprofloxacin-R* 21.8 12.1 13.2 12.6 20.6 15.0 13.7 13.5
%Gentamicin-R* 9.0 7.7 8.7 6.5 11.9 11.6 4.9 3.5
%Gentamicin/Amikacin/Tobramycin-R* 9.0 8.1 8.6 6.5 11.9 11.6 5.5 7.0
%MDR* 11.1 6.4 6.5 4.0 13.0 9.4 6.7 7.5
Number laboratories by year-end 41 39† 38††
Acinetobacter spp.
Number of isolates
No data No data No data No data No data
91 93 87
%Ciprofloxacin-R* 3 8 7
%Gentamicin-R* 0 3 4
%Gentamicin/Amikacin/Tobramycin-R* 1 3 5
%Imipenem/meropenem-R* 4 4 6
%MDR* 0 2 3
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VREfm, Vancomycin-Resistant E. faecium; VREfa, Vancomycin-Resistant E. faecalis
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime)
ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
† The number of laboratories processing blood cultures has changed on a number of occasions up to 2014; however, coverage of acute hospitals has remained at 100%
†† Three laboratories each suspended their participation in EARS-Net for a period of two quarters; by the year-end two laboratories had re-commenced EARS-Net and coverage of acute hospitals in 2015 was 
estimated to be 97%
1 Carbapenems include imipenem, meropenem and ertapenem
2 MDRKP, MDR K. pneumoniae phenotype (ESBL-producer plus non-susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase-producer (e.g. KPC, OXA-48)
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definition for carbapenem resistance, which is less sensitive 
than that used in Ireland, Ireland ranked joint 16th of 30 
countries in 2015, with the median proportion among EARS-
Net countries being 0.9% (Figure 5).
The frequency of invasive K. pneumoniae infection increased 
with male gender x 1.7 fold (P=0.001) and age, with the 
majority of infections (n=293; 73%) occurring in those over 
60 years (median = 69 years; 95%CI, 68-71).
Pseudomonas aeruginosa
There were 201 reports of invasive P. aeruginosa infection 
(blood = 200 and CSF = 1) from 195 patients, an increase of 
10.4% from 2014 (n=182). The observed increase occurred 
despite lower population coverage in 2015 (see introduction). 
Table 1 displays annual trends since 2008 in the proportion 
of P. aeruginosa isolates resistant to the five “indicator” 
antimicrobials/antimicrobial classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin or ofloxacin) and 
aminoglycosides (gentamicin, amikacin or tobramycin)]: 
•    Of 200 isolates, 28 (14.0%) were resistant to piperacillin-
tazobactam 
•    Of 201 isolates, 17 (8.5%) were resistant to ceftazidime
•    Of 201 isolates, 33 (16.4%) were resistant to imipenem or 
meropenem
•    Of 200 isolates, 27 (13.5%) were resistant to ciprofloxacin
•    Of 201 isolates, seven (3.5%) were resistant to gentamicin 
[14 (7.0%) of 201 were aminoglycoside-resistant (i.e. 
resistant to gentamicin, tobramycin or amikacin)] 
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3rd generation 
cephalosporins (3GCs), ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and gentamicin/
amikacin/tobramycin (GEN/AMK/TOB) with 95% confidence intervals 
Number of participating laboratories by year-end indicated above the bars
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Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from laboratories participating in enhanced 
surveillance for 2015). The proportion of isolates detected <48 hours and >5 days post-admission is also shown
  Total for 2015 Percent female Mean age in 
years
Detected <48 hours 
after admission
Detected >5 days 
after admission
Staphylococcus 
aureus
Meticillin Resistant (MRSA) 97 34% 69.5 47% 43%
Meticillin Susceptible 462 40% 57.7 68% 22%
Streptococcus 
pneumoniae
Penicillin non-Susceptible 25 40% 61.3 96% 4%
  Penicillin Susceptible 97 51% 63.5 95% 5%
Enterococci Vancomycin Resistant 78 35% 61.7 14% 77%
  Vancomycin Sensitive 191 41% 66.0 43% 48%
Escherichia coli
Fluoroquinolone Resistant 285 46% 73.5 74% 20%
Fluoroquinolone Susceptible 929 59% 67.0 77% 17%
Klebsiella pneumoniae 172 39% 67.3 59% 32%
Pseudomonas aeruginosa 96 40% 69.5 59% 35%
In 2015, resistance to all but one of the indicator 
antimicrobials (imipemen/meropenem) decreased 
compared with 2014.
Fifteen (7.5%) of 200 isolates reported from 12 hospitals 
that were tested against all five “indicator” antimicrobials 
were identified as MDR Pseudomonas aeruginosa, defined as 
resistant to three or more of the indicator antimicrobials:
•    Two resistant to all five antimicrobial classes
•    Seven resistant to four of five antimicrobial classes
•    Six resistant to three of five antimicrobial classes
Antimicrobial resistance in invasive P. aeruginosa isolates 
in Ireland are at moderately low levels in comparison with 
other European countries, with Ireland ranking between 18th 
and 23rd of 30 countries for all five indicator antimicrobials.
The frequency of invasive P. aeruginosa infection increased 
with male gender x 1.5 fold (P=0.002) and age, with the 
majority of infections (n=144; 71.6%) occurring in those over 
60 years (median = 68 years; 95%CI, 66-71).
Acinetobacter spp.
There were 87 reports of invasive infection caused by 
Acinetobacter spp. (blood = 85 and CSF = 2) from 86 
patients, compared with 93 reports in 2014. The observed 
decrease was due to lower population coverage in 2015 (see 
introduction). Table 1 displays annual trends since 2013 in 
the proportion of Acinetobacter spp. isolates resistant to 
the three “indicator” antimicrobials/antimicrobial classes 
[carbapenems (meropenem or imipenem), fluoroquinolones 
(ciprofloxacin or ofloxacin) and gentamicin]:  
•    Of 84 isolates, five were resistant to imipenem or 
meropenem
•    Of 83 isolates, six were resistant to ciprofloxacin
•    Of 81 isolates, three were resistant to gentamicin [four 
of 81 were aminoglycoside-resistant (i.e. resistant to 
gentamicin, tobramycin or amikacin)]
Two of 76 isolates reported from two hospitals were 
identified as MDR Acinetobacter spp., i.e., resistant to all 
three “indicator” antimicrobials.
Enterococcus faecium
There were 421 reports of E. faecium BSI from 406 patients, 
an increase of 4% from 2014 (n=405). The observed increase 
occurred despite lower population coverage in 2015 (see 
introduction). Table 1 displays the annual trends since 2008 
in the proportion of E. faecium isolates resistant to the three 
“indicator” antimicrobials (ampicillin, vancomycin and high-
level gentamicin):  
•    Of 419 isolates, 191 (45.6%) were resistant to vancomycin, 
which is similar to the proportion of vancomycin-resistant 
E. faecium (VREfm) in 2014 (45.9%) (Figure 6) 
•    Of 396 isolates, 196 (49.5%) were resistant to high-level 
gentamicin (Figure 6) 
•    Of 395 isolates tested against the three “indicator” 
antimicrobials, 84 (21.3%) were resistant to all three and 
termed MDR E. faecium. These were reported from 18 
hospitals, with the majority from nine tertiary hospitals 
(n=67; 80%). This represents a slight decrease from the 
proportion of MDR E. faecium at 22.1% in 2014 
Figure 2. Distribution of 3rd-generation cephalosporin resistant E. coli in EARS-Net countries in 2015
Map downloaded from ECDC’s TESSy database on 04/08/2016:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
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The proportion of VREfm first exceeded 40% in 2012 and has 
stayed between 43 and 45% since then. Since 2008, Ireland 
has had the highest proportion of VREfm in Europe. In 2015, 
countries with the next highest proportions of VREfm were: 
Cyprus (28.6%), Croatia (25.8%) and Romania (25.0%) 
(Figure 7). The median proportion of VREfm in EARS-Net 
countries was 9.9%, an increase from 4.5% in 2014.
The frequency of invasive E. faecium infection increased with 
male gender x 1.5 fold (P<0.001) and age, with the majority 
of infections (n=300; 71.3%) occurring in those over 60 years 
(median = 69 years; 95%CI, 67-72).
Enterococcus faecalis
There were 294 reports of E. faecalis BSI from 292 patients, 
a decrease from 315 reports in 2014. The observed decrease 
was due to lower population coverage in 2015 (see 
introduction). Table 1 displays annual trends since 2008 
in the proportions of E. faecalis isolates resistant to the 
three “indicator” antimicrobials (as described in section on 
E. faecium):  
•    Of 294 isolates, four (1.4%) were resistant to vancomycin 
(VREfa), with Ireland ranking 8th of European countries 
for resistance. The proportion of VREfa in Ireland has 
decreased from the highest reported proportion of 4.9% 
in 2011. In 2015, the median proportion in Europe was 
0.3%
•    Of 264 isolates, 74 (28.0%) were resistant to high-level 
gentamicin 
Two isolates were reported resistant to ampicillin, suggestive 
of misidentification of species or misclassification, as 
ampicillin resistance is rare in E. faecalis.
The frequency of invasive E. faecalis infection increased with 
male gender x 1.4 fold (P=0.007) and age, with the majority 
of infections (n=198; 67.3%) occurring in those over 60 years 
(median = 70 years; 95%CI, 66-73).
Staphylococcus aureus
There were 1,082 reports of S. aureus BSI from 1,048 
patients, compared with 1,117 reports in 2014. The observed 
decrease was due to lower population coverage in 2015 
(see introduction). Of those, 199 (18.4%) were MRSA, which 
represents the lowest annual proportion since surveillance 
began in 1999 (Table 1 shows data from 2008). In 2010, the 
proportion was 24.4%, the first year that MRSA accounted 
for <25% of S. aureus BSI in Ireland, thus changing from red 
to orange on the EARS-Net map and 2014 was the eighth 
successive year in which a decrease was observed (significant 
downward trend, P<0.001) (Figure 8). Overall, there was an 
8.3% reduction in MRSA BSI compared with 2014 (199 versus 
217) and 1.9% reduction in MSSA BSI compared with 2014 
(883 versus 900). 
Despite the decrease in numbers and proportion of MRSA 
BSI in 2014, Ireland still had one of the higher proportions 
of MRSA in Europe (Figure 9). Ireland ranked 11th of 30 
countries reporting to EARS-Net (compared to 12th of 30 
countries in 2014), with the median proportion of MRSA BSI 
at 12.6%. All countries with MRSA proportions higher than 
Ireland are located in Southern and Central/Eastern Europe.
The overall rate of MRSA BSI in acute hospitals in 2015 was 
0.050 cases per 1,000 BDU, a decrease from 0.055 in 2014, 
while the rate of MSSA BSI decreased from 0.227 to 0.223 
[rates are calculated from denominator data (bed days used) 
obtained from the HSE’s Business Information Unit (BIU) for 
all acute public hospitals and directly from private hospitals 
where available, where both numerator (S. aureus numbers) 
and denominator data have been provided]. 
Figure 3. Trends for K. pneumoniae – total numbers of K. pneumoniae and percentage resistance 
to 3rd generation cephalosporins (3GCs), ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and 
gentamicin/amikacin/tobramycin (GEN/AMK/TOB) with 95% confidence intervals
Number of participating laboratories by year-end indicated above the bars
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The frequency of invasive S. aureus infection increased with 
male gender x 1.7 fold (P<0.001) and age, with the majority 
of infections (n=657; 60.7%) occurring in those over 60 years. 
The median age for MRSA BSI = 73 years (95%CI, 70-76) was 
older than for MSSA BSI = 64 years (95%CI, 62-66). This was 
considered to be a significant difference, as the confidence 
intervals did not overlap.
 
Streptococcus pneumoniae
There were 304 reports of invasive S. pneumoniae infection 
(blood = 297 and CSF = 7) from 303 patients, compared with 
331 reports in 2014. The lower population coverage attained 
in 2015 may have also contributed to this decrease (see 
introduction). Table 1 displays annual trends since 2008 in 
the proportions of S. pneumoniae isolates non-susceptible/
resistant to penicillin and erythromycin.  
Penicillin non-susceptible S. pneumoniae (PNSP) accounted 
for 17.5% (n=53) of all isolates tested against penicillin 
(n=302). Of the PNSP isolates, 52 were intermediately-
resistant (Int; MIC=0.1-1 mg/L for laboratories following the 
Clinical Laboratory Standards Institute (CLSI) guidelines 
Figure 5. Distribution of carbapenem-resistant K. pneumoniae in EARS-Net countries in 2015
Map downloaded from ECDC’s TESSy database on 04/08/2016:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
Figure 4. Trends for K. pneumoniae isolates with the MDRKP phenotype (simultaneously 
ESBL-producers and non-susceptible to both ciprofloxacin and gentamicin and/or a 
carbapenemase-producer) –– numbers and percentage with MDRKP phenotype with 95% 
confidence intervals
Number of participating laboratories by year-end indicated above the bars
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(for non-meningitis syndrome via oral administration) and 
MIC=0.1-2mg/L for those following European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) non-
meningitis guidelines) and one was high-level resistant 
(HLR; MIC >1.0mg/L for CLSI and >2mg/L for EUCAST) to 
penicillin. Penicillin susceptibility was not determined for 
two isolates. Erythromycin resistance was seen in 45 of 297 
isolates (15%).  
There was a slight increase in the proportion of PNSP 
isolates from 17.1% in 2014 to 17.5% in 2015, as displayed 
in Figure 10. The proportion that displayed penicillin HLR 
decreased from 2.4% to 0.3%. In 2015, Ireland remained 
among European countries with higher proportions of PNSP, 
ranking 11th of 29 countries overall; and 5th of 22 countries 
reporting ≥50 isolates. In 2015, the median proportion of 
EARS-Net countries was 11.2%. However, it is important to 
consider that comparison with other EARS-Net countries can 
be problematic due to the possibility of different interpretive 
criteria being applied to the data from different countries 
(and indeed from different laboratories within a country): 
•    CLSI provides three sets of breakpoints for interpreting 
penicillin susceptibility of S. pneumoniae isolates: 
meningitis, non-meningitis and oral
•    EUCAST provides two sets of breakpoints: meningitis and 
infections other than meningitis 
Most Irish microbiology laboratories have already switched, 
or are currently in the process of switching, from CLSI to 
EUCAST guidelines: 33 laboratories had switched by the 
end of 2015 (unchanged from 2014). In Ireland, EARS-
Net data are reported using the EUCAST breakpoints for 
infections other than meningitis or the CLSI breakpoints 
for “oral administration” (which correspond to the 
original CLSI breakpoints), as these are broadly similar 
for epidemiological purposes and thus facilitate a more 
meaningful analysis of the data. This also permits a 
relatively consistent approach for comparing historical data. 
Moderately high levels of erythromycin resistance were seen, 
with Ireland ranking 14th of 29 countries overall and 9th of 22 
countries reporting 50 or more isolates. This is similar to the 
situation observed in much of Southern and Central/Eastern 
Europe. In 2015, the median proportion amongst EARS-Net 
countries was 14.4%.
Of 295 isolates tested against both penicillin and 
erythromycin in 2015, 32 (10.8%) were simultaneously PNSP 
(31 Int, one HLR) and erythromycin-resistant, which is a 
slight increase from 2014 (10.4%).
In 2007, a national pilot project was established as a 
collaborative initiative between RCSI, Beaumont Hospital, 
Children’s University Hospital, Temple St and HPSC, to 
obtain serotyping data on invasive S. pneumoniae isolates. 
This project pre-dates the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008. PCV13 replaced 
PCV7 from September 2010. 
In 2015, serotype data were available for 276 pneumococcal 
isolates reported by 29 of the 30 laboratories reporting 
pneumococcal isolates to EARS-Net, representing 90.8% of 
all pneumococcal isolates reported: 
•    Of 158 isolates from patients aged ≥65 years, 106 (67.1%) 
belonged to serotypes included in the PPV23 vaccine
•    Only 12 isolates were referred for typing from patients 
aged <2 years (the target population for the PCV13 
vaccine) and three of these were serotypes included in the 
vaccine
Figure 6. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
vancomycin (VREfm) and high-level gentamicin (HLG) with 95% confidence intervals
Number of participating laboratories by year-end indicated above the bars
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Figure 7. Distribution of vancomycin-resistant E. faecium (VREfm) in EARS-Net countries in 2015
Map downloaded from ECDC’s TESSy database on 04/08/2016:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
•    The most common serotypes identified were: 8 (n=28), 
19A (n=27), 12F (n=24), 7F (n=22), 3 (n=21), 22F (n=18), 
9N (n=13), 24F (n=12) and 35B (n=11) representing 68.8% 
of all isolates typed. 
Of the 53 PNSP isolates, 47 (88.7%) were serotyped: 
•    Of 30 isolates from patients age ≥65 years, 13 (43.3%) 
belonged to serotypes included in the PPV23 vaccine
•    Of three isolates from children <2 years, two belonged to 
serotypes included in the PCV13 vaccine
•    The most common serotypes identified were: 19A (n=17), 
35B (n=11) and 15B (n=6) representing 72.3% of all PNSP 
isolates typed. 
Ongoing surveillance of the predominant serotypes is 
required, as strains with non-vaccine serotypes have been 
reported to increase in prevalence following the introduction 
of conjugate vaccines in other countries. Hence the need for 
a fully-resourced Irish pneumococcal reference laboratory. 
Refer to the chapter on invasive pneumococcal disease 
(IPD) in Ireland in 2015 for additional information on 
pneumococcal serotyping.
In 2015, the rate of IPD in Ireland was estimated at 6.8 cases 
per 100,000 population, a decrease compared with 7.2 in 
2014 [note that both rates were calculated using 2011 census 
data; the rate for 2015 is adjusted to account for the reduced 
population coverage (to 97%) by EARS-Net]. The highest 
rates of IPD were observed in the older age groups [adults 
aged 65-74 (22.0 per 100,000), 75-79 (33.3 per 100,000) 
and ≥80 (53.7 per 100,000)], with a smaller peak in young 
children [aged <1 year (6.9 per 100,000) and 1 year (9.6 per 
100,000)] as displayed in Figure 11. The IPD rates in all age 
groups were broadly similar to 2014.  
Males were approximately 1.2-times more likely to have 
an invasive S. pneumoniae infection than females, but this 
was not statistically significant (P=0.17). The frequency of 
invasive S. pneumoniae infection increased with age, the 
majority (n=196; 64%) occurring in those over 60 years 
(median = 68 years; 95%CI, 65-70).
EARS-Net Enhanced Surveillance
Since 2004, EARS-Net participants are invited to also 
provide enhanced demographic and clinical data on a 
voluntary basis regarding invasive pathogens causing BSI. 
In 2015, enhanced surveillance data on 2,432 individual 
records (cases or isolates under the EARS-Net definition) 
were submitted from 22 participating laboratories, 
representing 45% of all reports to EARS-Net. Table 2 
displays demographic and other basic data for the major 
resistance profiles of pathogens reported to EARS-Net 
enhanced surveillance. 
•    S. aureus BSI
 o   71% of MRSA and 51% of MSSA BSI were reported as 
healthcare-associated
 o   25% of MRSA BSIs were reported as device-
associated:
 11% CVC/PICC-associated and 4% PVC-associated 
 o   16% of MSSA BSIs were reported as device-associated:
  6% CVC/PICC-associated and 5% PVC-associated 
 o   A recent antimicrobial exposure history was reported 
for 32% of patients with MRSA and 22% with MSSA 
BSI
•    Enterococcal BSI 
 o   95% of vancomycin-resistant enterococcal (VRE) and 
66% of vancomycin-susceptible enterococcal (VSE) 
BSI were reported as healthcare-associated
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 o   22% of VRE BSIs were reported as device-associated:
   15% CVC/PICC-associated
 o   10% of VSE BSI were reported as device-associated:
   8% CVC/PICC-associated BSI
 o   A recent antimicrobial exposure history was reported 
for 21% of patients with VRE and 14% with VSE BSI
•    S. pneumoniae BSI 
 o   The majority of both PNSP and PSSP BSIs were 
community-acquired
 o   Respiratory tract infection remained the most common 
source of pneumococcal BSI
•    E. coli BSI 
 o   49% of fluoroquinolone-resistant E. coli (FQREC) BSI 
were reported as healthcare-associated versus 33% for 
fluoroquinolone-susceptible E. coli (FQSEC)
 o   The most common source of E. coli BSI was urinary 
tract. Of FQREC and FQSEC BSI, 49% and 41% 
respectively occurred in setting of an indwelling urinary 
catheter
 o   A recent antimicrobial exposure history was reported 
for 8% of patients with E. coli BSI
  
Conclusion
Antimicrobial resistance in key Gram-negative pathogens 
or Enterobacteriaceae causing invasive infection in Ireland, 
namely E. coli and K. pneumoniae increased further in 
2015. As EARS-Net is limited to invasive isolates (blood 
and CSF), the true burden of infection caused by MDR-
Enterobacteriaceae is likely to be far greater. These bacteria 
are among the most frequent causes of common infections, 
such as urinary tract infection and wound infection. They 
also form an important component of normal bowel flora 
(colonisation or carriage) in humans and animals. Therefore, 
carriers of MDR-Enterobacteriaceae tend to remain colonised 
indefinitely and may be an onward source of transmission to 
others. This poses a significant risk in healthcare settings, 
where infection caused by these pathogens is more difficult 
and more costly to treat and associated with increased 
patient morbidity and mortality.
Following the establishment of a national multi-drug 
resistant K. pneumoniae (MDRKP) outbreak control team 
(OCT) in 2013, reports were produced and correspondence 
issued to the acute hospitals between December 2013 
and November 2014. Surveillance data indicated that 
MDRKP was now widely disseminated throughout acute 
and non-acute healthcare settings in Ireland, including 
primary and residential care. The OCT recommended 
that a national taskforce be set up, with recommended 
actions to be taken by the taskforce to address the threat 
of increasing antimicrobial resistance in Ireland. HSE 
established a national healthcare-associated infection 
(HCAI) & AMR taskforce, which convened in September 
2015. The continued increase in antimicrobial resistance 
observed in Enterobacteriaceae requires close attention 
from both HSE and the Department of Health, given 
healthcare in Ireland is delivered by both the public and 
private sector. The increasing incidence of carbapenem 
resistant Enterobacteriaceae (CRE) in Ireland dates back 
to 2011 and a national strategy to curb dissemination 
of these highly antimicrobial resistant pathogens is 
urgently required. Data from other jurisdictions where 
invasive CRE infections have become commonplace 
report mortality rates in excess of 50%. It is vital that 
the recommendations contained in the “Guidelines 
for the prevention and control of multi-drug resistant 
organisms, other than MRSA”, published in 2013 are 
adequately resourced and implemented and that infection 
prevention and control and antimicrobial stewardship 
Figure 8. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA with 95% 
confidence intervals
Number of participating laboratories by year-end indicated above the bars
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resources are strengthened in acute hospitals and in the 
community, including primary and residential care (http://
www.hpsc.ie/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Guidelines/).
For the ninth consecutive year, Ireland remained the 
European country with the highest proportion of VREfm BSI 
(45.6%), with Croatia, Cyprus and Romania also reporting 
proportions over 25% and therefore appearing red on the 
map. 
For the ninth consecutive year, the proportion of S. aureus BSI 
attributable to MRSA further declined to 18.4%, the lowest 
reported level since Ireland joined EARS-Net in 1999. 
EARS-Net enhanced surveillance data are particularly useful 
in informing infection prevention and control programmes, 
both nationally and in those hospitals that participate in the 
surveillance scheme. 
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-Net 
project.
The data presented in this report were taken from the EARS-
Net database on 1st September 2016.
Figure 9. Distribution of MRSA in EARS-Net countries in 2015
Map obtained from ECDC on 04/08/2016:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx
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Figure 10. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and percentage PNSP 
with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
Number of participating laboratories by year-end indicated above the bars
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Enhanced surveillance of Carbapenem Resistant 
Enterobacteriaceae (CRE) 
Summary:
•   In 2015, enhanced surveillance data was received 
on 98 cases of CRE, an increase from 2014 (n=61) 
and 2013 (n=26). In contrast, the national Car-
bapenemase Producing Enterobacteriaceae Refer-
ence Laboratory Service (CPEaRLS) at Galway 
University Hospital confirmed 140 CRE isolates as 
carbapenemase producers in 2015.  
•   Just four patients (4%) had a history of hospitali-
sation abroad: Bosnia and India: NDM; Romania: 
OXA-48 and Spain: KPC
•   Clinical significance was reported for 91 patients, 
with the majority colonised with CRE at the time of 
reporting (n=66; 67%). However, CRE infection was 
reported for 25 patients
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are multi-
drug resistant (MDR) Gram-negative bacteria. The term 
CRE includes Enterobacteriaceae that produce enzymes 
known as carbapenemases and Enterobacteriaceae 
resistant to carbapenems (e.g., meropenem) as a result 
of a combination of resistance mechanisms (e.g., ESBL or 
AmpC β-lactamase production with bacterial cell porin 
loss). Carbapenemases are encoded by genes transmitted 
between Enterobacteriaceae via mobile genetic elements, 
known as plasmids, resulting in colonisation or infection 
for which antimicrobial treatment options are very limited. 
Carbapenemase production has spread worldwide in the 
past 15 years and is now a prominent resistance mechanism 
reported in many countries.
 
Detection of confirmed carbapenemase-producing CRE, 
hereafter known as CRE, became notifiable in Ireland 
in March 2011 under the category of ”unusual cluster 
or changing pattern of illness”. Upon amendment to 
the Infectious Diseases Regulations in September 2011, 
invasive CRE infection (blood, CSF or normally sterile 
site) became notifiable in its own category. The CRE 
enhanced surveillance scheme was established in June 
2011 and reporting of CRE isolates from any site, whether 
colonisation or infection is encouraged.
 
Enhanced surveillance data
CRE cases reported to enhanced surveillance
In 2015, enhanced surveillance data was received from 13 
microbiology laboratories on 98 patients with confirmed 
CRE. Of those, 59 were male (60%) with a median age of 71 
years (range: 1 month – 93 years). No CRE outbreaks were 
reported in 2015. Figure 1 displays annual trends in CRE 
cases and types reported to enhanced surveillance since 
2011. 
Patient location 
At the time of CRE detection, 93 patients (95%) were 
hospitalised, four (3%) were in long-term care facilities 
and one was in the community. Of 93 inpatients, 47 (51%) 
had been admitted from home, 15 (16%) were transfers 
from another acute hospital, five had been admitted from 
long-term care/nursing homes (5%). Admission source was 
not provided for 26 patients (28%). Of 15 patients who had 
been transferred from another acute hospital, two were 
repatriated from hospitals abroad (in Bosnia and Spain). 
The median interval from hospitalisation to first positive 
CRE isolate for 86 of 93 inpatients was six days   
(range: 0 – 91).
Presence of other multi-drug resistant organisms (MDROs)
Known colonisation or infection with MDROs other than 
CRE was reported for 34 patients (35%), 33 of whom were 
inpatients: MRSA (n=19), VRE (n=17), ESBL-producing 
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Figure 11. Numbers and age-specific incidence rates of patients with invasive S. pneumoniae infection 
in 2015 compared with 2014
ASIR, age-specific incidence rate
Enterobacteriaceae (n=12) and MDR E. coli (n=2). Twelve 
patients were colonised with ≥2 other MDROs. 
Travel history
The travel history in the 12 months prior to CRE detection 
was unknown for the majority of patients (n=55; 56%). For 
30 patients, there was no history of foreign travel (31%) and 
13 (13%) reported foreign travel: Africa (country unspecified), 
Bosnia, Egypt, India, Lebanon, Pakistan, Romania, Spain and 
UK].
 
Risk factors
Risk factor data was provided on 86 patients, of whom 52 
(60%) had more than one risk factor for CRE: hospitalisation 
in past 12 months (71; 83%); surgery in past six months (23; 
27%); admission to intensive care in past 12 months (18; 
21%). Reported co-morbidities included: immunocompromise 
(n=14); urological abnormality (n=14); diabetes mellitus 
(n=11); renal disease (n=11); chronic lung (n=7) and liver 
disease (n=1). Seven patients had no identifiable risk factors 
(8%) and risk factor data was unknown or not provided for 
the remaining 12 patients.
Prior antimicrobial exposure
Antimicrobial exposure history prior to isolation of CRE 
was provided for 59 patients (60%), 57 of whom were 
hospitalised and 13 of whom received more than one 
antimicrobial class: 
•   β-lactam/β-lactamase inhibitor combination agents - 
46 (78%) 
•  Carbapenems - 10 (17%) 
•  Fluoroquinolones - 8 (14%) 
•  Aminoglycosides - 6 (10%)
•  Cephalosporins - 6 (10%)
•  Co-trimoxazole - 1 (2%) 
Clinical significance and source of infection
The clinical significance of the CRE isolate was reported 
for 91 patients, representing colonisation in the majority 
(n=66; 73%). Infection was reported for 25 patients (27%), 
with urinary tract infection accounting for the majority (n=7), 
followed by respiratory tract (n=4) and intra-abdominal 
infection (n=4). It is important to note that patients who 
were colonised with CRE may have subsequently developed 
CRE infection after the case was reported to enhanced 
surveillance. 
 
Specimen type
The majority of CRE isolates came from active surveillance 
or screening specimens; rectal or stoma swabs and faeces 
(n=76; 78%). Of CRE isolates from clinical specimens; eight 
came from blood (8%), eight from urine (8%), two from 
sputum and one each from a central vascular catheter tip, 
lung and wound swabs. 
Outcome
Of 93 inpatients with CRE, outcome was reported for 68 
(73%). Of those, 49 (59%) were discharged, 11 remained 
inpatients and eight subsequently died (12%). The 
contribution of CRE to patient death is not collected by 
enhanced surveillance. Five deaths occurred in patients 
with CRE infection. CRE was isolated in a post mortem 
microbiology specimen taken from one patient. Date of 
first CRE specimen and date of death was provided for five 
patients, with a median interval to death of 36 days (range = 
6 - 68). Outcome was also reported for four of the five non-
hospitalised patients, all of whom survived.
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Figure 1. Annual trends in CRE cases and types reported to HPSC since enhanced 
surveillance of CRE commenced in 2011 
Please note that the reduction in reported cases between 2012 and 2013 reflects 
under-reporting rather than a true decline in CRE. Almost twice as many isolates 
were confirmed by the CPEaRLS, Galway University Hospital in 2013 (n=48) and 
approximately one-third as many isolates in 2014 (n=82) and 2015 (n=139) than were 
reported to the voluntary CRE enhanced surveillance scheme
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Carbapenemase types
The rank order of carbapenemase types reported to 
enhanced surveillance in 2015 correlates with CPE 
confirmed by the reference laboratory, although 30% of CPE 
confirmed by the reference laboratory did not have enhanced 
surveillance data submitted: KPC (n=64; 65%), OXA-48 
(n=21; 21%), NDM (n=8; 8%), VIM (n=3) and IMP (n=2). 
Antimicrobial susceptibility 
Antimicrobial susceptibility data was provided on 94 of 98 
isolates (96%):
•   Carbapenems 
 o  Meropenem: reported on 94 isolates, with 72 resistant 
(77%); minimum inhibitory concentrations ranged from 
0.25 to >32 mg/L 
 o  Ertapenem: reported on 91 isolates, with 89 resistant 
(98%); minimum inhibitory concentrations ranged from 
0.25 to >32 mg/L 
•  Aminoglycosides: reported on 92 isolates, with 41 (45%) 
resistant to one or more of the aminoglycosides listed 
below 
 o  Gentamicin: reported on 91 isolates, with 33 resistant 
(36%)
 o  Tobramycin: reported on 61 isolates, with 25 resistant 
(41%)
 o  Amikacin: reported on 88 isolates, with 11 resistant 
(13%)
•  Fluoroquinolones: reported on 88 isolates, with 35 
resistant (40%) 
•  Tigecycline: reported on 82 isolates, with 15 resistant 
(18%) 
•  Colistin: reported on 83 isolates, with two resistant (2%)
Conclusion
In 2015, 98 cases of CRE colonisation/ infection were 
reported to the enhanced CRE surveillance system 
representing an increase of 61% from 61 cases in 2014. 
However, data from the CPEaRLS indicate that there were 
more confirmed CRE than were reported to enhanced 
surveillance. 
Acknowledgements: 
Sincere thanks to colleagues working in microbiology laboratories and 
infection prevention and control teams across Ireland for submitting 
enhanced surveillance data on patients with CRE.
Sincere thanks also to colleagues in the CPEaRLS, Galway University 
Hospital for data on confirmed carbapenemase-producing 
Enterobacteriaceae in 2015 (Source: CPEaRLS annual report 2015). 
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CIDR OPERATIONS
INFORMATION SECURITY ACCREDITATION
The HPSC Information Security Management System (ISMS) 
which includes CIDR was updated in 2015 to ISO 27001:2013 
standard. The system was audited in June followed by a 
full two day on-site maintenance audit in September 2015. 
HPSC and CIDR successfully made the transition to the new 
standard.  
The HPSC Information Governance Framework, which 
includes CIDR, provides re-assurance to users and partners 
of the CIDR system, the Data Protection Commissioner 
and the data subjects relating to sensitive data stored and 
managed by the system. Maintenance of this accreditation 
standard is vital to information security.
CIDR USER TRAINING
Forty-one new CIDR users were trained during 2015. There 
were 30 public health users, (almost a 50% increase on 
2014) and 11 laboratory users trained.
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of statutory infectious disease notifications and corresponding number of diseases in CIDR 
per year, since 2005 when national implementation commenced (as of 28th September, 2016)
Summary
●			The highest ever annual number of notifications was 
recorded on CIDR in 2015 (n=31,936)
●			CIDR was available for 99% of core working hours 
during 2015 
●			Hepatitis E infection became notifiable in December 
2015 and was added to the diseases notified via CIDR, 
bringing the total to 76 diseases
●			CIDR Disaster Recovery / Business Continuity 
infrastructure was commissioned, deployed and 
tested
●			IS27001 Information Security accreditation was 
upgraded to ISO 27001:2013 standard and retained
●			The average number of active CIDR users in 2015 was 
258
●			41 new users were trained during 2015
●			CIDR Server Operating System upgrades were 
completed
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CIDR APPLICATION SOFTWARE UPDATES
There were no functional releases of the CIDR Web 
Application software during 2015. With the emphasis 
on upgrading the hardware operating systems and on 
deployment of an upgraded Disaster Recovery infrastructure, 
risk of system unavailability and unscheduled down-time 
was minimised by strict change management processes that 
included no changes to the application. 
CIDR availability was 99% of core working hours during 
2015. 70% of down-time was scheduled; with users aware 
in advance of service interruption. Un-scheduled down-time 
amounted to less than one working day over the year.
GOVERNANCE AND COMMUNICATIONS
The National CIDR Steering Group continued to provide 
guidance and oversight of CIDR through 2015 and met 
by teleconference on three occasions during the year. The 
National CIDR User Group convened on four occasions 
throughout the year, also by teleconference, to discuss the 
ongoing use of CIDR and associated developments. 
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Figure 2. The number of users of the CIDR system in Departments of 
Public Health, in diagnostic and reference laboratories and in HPSC 
in 2015 (total=258)
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Notes:
Figures for the year 2015 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on the 12th September, 2016. Please note that some figures may differ from figures 
published previously or other chapters in this report, due to ongoing updating of notification data on CIDR. 
Figures for the EARS-Net pathogens (Escherichia coli, Enterococci, Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Staphylococcus aureus) and certain sexually transmitted infections (specifically, ano-genital warts 
and non-specific urethritis) are not provided here, as these diseases were not notified via the CIDR system during 
the above period.
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2015) under Infectious Diseases 
(Amendment) Regulations 2015 (S.I. No. 566 of 2015) (December 2015)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Ano-genital warts Human papilloma virus
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)  
Botulism Clostridium botulinum
Brucellosis Brucella spp.
Campylobacter infection Campylobacter spp.
Carbapenem-resistant Enterobacteriaceae infection (invasive) Carbapenem-resistant Enterobacteriaceae (blood, CSF or other normally sterile site)
Chancroid Haemophilus ducreyi
Chickenpox – hospitalised cases Varicella-zoster virus
Chikungunya disease Chikungunya virus
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium difficile infection Clostridium difficile
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease  
variant Creutzfeldt Jakob disease  
Cryptosporidiosis Cryptosporidium parvum, hominis
Cytomegalovirus infection (congenital) Cytomegalovirus
Dengue fever Dengue virus
Diphtheria Corynebacterium diphtheriae or ulcerans (toxin producing)
Echinococcosis Echinococcus spp.
Enterococcal bacteraemia Enterococcus spp. (blood)
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale Klebsiella granulomatis
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) infection Hepatitis A virus
Hepatitis B (acute and chronic) infection Hepatitis B virus
Hepatitis C infection Hepatitis C virus
Hepatitis E infection Hepatitis E virus
Herpes simplex (genital) Herpes simplex virus
Human immunodeficiency virus infection Human immunodeficiency virus
Influenza Influenza A and B virus
Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF)
Legionellosis Legionella spp.
Leprosy Mycobacterium leprae
Leptospirosis Leptospira spp.
Listeriosis Listeria monocytogenes
Lyme disease (neuroborreliosis) Borrelia burgdorferi
Lymphogranuloma venereum Chlamydia trachomatis
Malaria Plasmodium falciparum, vivax, knowlesi, ovale, malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis  
Noroviral infection Norovirus
Paratyphoid Salmonella Paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Pseudomonas aeruginosa infection (invasive) Pseudomonas aeruginosa (blood or CSF)
Q Fever Coxiella burnetii
Rabies Rabies virus
Respiratory syncytial virus infection Respiratory syncytial virus
Rotavirus infection Rotavirus
Rubella Rubella virus
Salmonellosis Salmonella spp. other than S. Typhi and S. Paratyphi
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
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Infectious Disease Causative Pathogen(s)
Shigellosis Shigella spp.
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus group B infection (invasive) Streptococcus agalactiae (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella spp.
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella Typhi
Typhus Rickettsia prowazekii
Verotoxigenic Escherichia coli infection Verotoxin producing Escherichia coli
Viral encephalitis  
Viral haemorrhagic fevers  
Viral meningitis  
West Nile fever West Nile virus
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
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Table A1.1. (Continued) List of notifiable infectious diseases and their respective causative pathogens (relevant to 2015) under Infectious 
Diseases (Amendment) Regulations 2015 (S.I. No. 566 of 2015) (December 2015) 
Table A1.2 Number of notifiable infectious diseases, 2013-2015 and crude incidence rates of diseases, 2015
Infectious Disease 2013 2014 2015 CIR 2015
Acute anterior poliomyelitis 0 0 0 0.00
Anthrax 0 0 0 0.00
Bacillus cereus food-borne infection or intoxication 0 0 1 0.02
Bacterial meningitis (not otherwise specified) 21 23 32 0.70
Botulism 1 1 0 0.00
Brucellosis 1 3 0 0.00
Campylobacter infection 2275 2612 2452 53.44
Carbapenem-resistant Enterobacteriaceae infection (invasive) 0 5 8 0.17
Chancroid 0 0 0 0.00
Chickenpox - hospitalised cases 53 61 69 1.50
Chikungunya disease 0 1 1 0.02
Chlamydia trachomatis infection^ 6248 6693 6797 148.14
Cholera 0 0 0 0.00
Clostridium difficile infection* 1813 1802 1943 42.35
Clostridium perfringens (type A) food-borne disease 1 0 1 0.02
Creutzfeldt Jakob disease 5 2 5 0.11
Creutzfeldt Jakob disease (variant) 0 0 0 0.00
Cryptosporidiosis 514 394 439 9.57
Cytomegalovirus infection (congenital) 7 12 15 0.33
Dengue fever 15 21 8 0.17
Diphtheria 0 0 1 0.02
Echinococcosis 1 0 0 0.00
Giardiasis 44 71 145 3.16
Gonorrhoea 1283 1314 1302 28.38
Granuloma inguinale 0 0 0 0.00
Haemophilus influenzae disease (invasive) 41 61 52 1.13
Hepatitis A (acute) 50 21 36 0.78
Hepatitis B (acute and chronic) 423 442 549 11.97
Hepatitis C 755 698 675 14.71
Hepatitis E# NA NA 3 -
Herpes simplex (genital) 1127 1234 1274 27.77
Human immunodeficiency virus infection§ 341 377 485 10.57
Influenza (seasonal & pandemic) 1602 1757 2681 58.43
Legionellosis†† 14 8 12 0.26
Leprosy 2 0 0 0.00
Leptospirosis 14 23 16 0.35
Listeriosis 8 15 19 0.41
Lyme disease 13 18 12 0.26
Lymphogranuloma venereum 5 35 20 0.44
Malaria 71 80 81 1.77
Measles‡ 51 33 2 0.04
Meningococcal disease 81 82 75 1.63
Mumps 223 742 2014 43.89
Noroviral infection^ 1486 807 1262 27.51
Paratyphoid 2 5 1 0.02
Pertussis 173 73 117 2.55
Plague 0 0 0 0.00
Q fever 0 0 4 0.09
Rabies 0 0 0 0.00
Respiratory syncytial virus infection^ 1282 2479 2202 47.99
Rotavirus infection^ 2511 2061 4158 90.62
Rubella 0 3 2 0.04
Salmonellosis 324 260 269 5.86
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.00
Shigellosis 49 57 90 1.96
Smallpox 0 0 0 0.00
Staphylococcal food poisoning 0 0 0 0.00
Streptococcus group A infection (invasive) 168 164 107 2.33
Streptococcus group B infection (invasive)|| 66 68 69 1.50
Streptococcus pneumoniae infection (invasive)** 637 680 549 11.97
Syphilis*^ 550 276 438 9.55
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Infectious Disease 2013 2014 2015 CIR 2015
Tetanus 1 1 1 0.02
Toxoplasmosis 32 20 26 0.57
Trichinosis 0 0 0 0.00
Trichomoniasis 74 92 58 1.26
Tuberculosis 370 313 303 6.60
Tularemia 0 0 0 0.00
Typhoid 10 7 9 0.20
Typhus 0 0 0 0.00
Verotoxigenic Escherichia coli infection 701 707 730 15.91
Viral encephalitis 6 67 47 1.02
Viral haemorrhagic fevers 0 0 0 0.00
Viral meningitis 281 435 261 5.69
West Nile fever 1 0 0 0.00
Yellow fever 0 0 0 0.00
Yersiniosis 4 5 13 0.28
Total 25831 27221 31941  
Notes    
1. NA: Indicates that data not available in CIDR for the diseases and years indicated above  
2. CIR, Crude incidence rate per 100,000 total population    
*Since 01/01/2012, both new and recurrent cases of Clostridium difficile infection are notifiable
#Hepatitis E became notifiable on the 15/12/2015.    
§Since 01/01/2015, all new diagnoses of HIV in HSE East were notified on the basis of confirmatory testing of one sample by the National Virus Reference Laboratory. Previously, 
notifications were made following testing of a second sample. This change will result in higher numbers of notifications of HIV in 2015 compared to previous years and makes 
comparison of data with previous years more difficult.
‡Table A1.2 excludes two measles notifications in 2013 that are on CIDR, but were laboratory negative for measles and were not epidemiologically linked to a confirmed measles 
case.
**Streptococcus pneumoniae infection (invasive) figures relate to confirmed cases only since 01/07/2015. 
*^The Irish case definition for syphilis changed on 01/01/2014 and from this date, syphilis notifications include early (infectious) syphilis only. Direct comparison of 2014 syphilis 
notification data with notification data for previous years (which includes non-infectious cases) is not valid.
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications from HSE E rather 
than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence
††Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
For more information on notifiable infectious diseases please see HPSC’s Case Definitions document available at http://www.hpsc.ie
Table A1.2 (Continued) Number of notifiable infectious diseases, 2012-2014 and crude incidence rates of diseases, 2014
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Table A1.3 Number of notifiable infectious diseases by HSE area, 2015
Infectious Disease HSE E HSE M HSE MW HSE NE HSE NW HSE SE HSE S HSE W Total
Bacillus cereus food-borne infection/intoxication * * * * * * * * 1
Bacterial meningitis (not otherwise specified) 14 2 0 3 1 2 5 5 32
Campylobacter infection 757 205 216 160 77 361 386 290 2452
Carbapenem-resistant Enterobacteriaceae infection (invasive) 3 0 1 0 0 4 0 0 8
Chickenpox - hospitalised cases 32 7 2 7 3 8 6 4 69
Chikungunya disease * * * * * * * * 1
Chlamydia trachomatis infection^ 3466 192 454 326 249 712 837 561 6797
Clostridium difficile infection‡ 803 70 127 126 77 243 251 246 1943
Clostridium perfringens (type A) food-borne disease * * * * * * * * 1
Creutzfeldt Jakob disease 2 0 0 0 1 0 1 1 5
Cryptosporidiosis 49 49 44 31 27 89 69 81 439
Cytomegalovirus infection (congenital) 8 0 2 0 1 2 2 0 15
Dengue fever 6 0 1 1 0 0 0 0 8
Diphtheria * * * * * * * * 1
Giardiasis 47 8 7 8 1 15 36 23 145
Gonorrhoea 925 17 55 35 39 62 82 87 1302
Haemophilus influenzae disease (invasive) 26 1 4 4 2 6 5 4 52
Hepatitis A (acute) 20 6 0 0 2 1 5 2 36
Hepatitis B (acute and chronic) 346 15 15 68 12 23 39 31 549
Hepatitis C 462 40 27 37 6 28 42 33 675
Hepatitis E# * * * * * * * * 3
Herpes simplex (genital) 742 25 66 56 35 128 120 102 1274
Human immunodeficiency virus infection 359 13 20 22 7 14 34 16 485
Influenza 1072 146 244 193 120 326 311 269 2681
Legionellosis§ 8 0 1 0 1 0 2 0 12
Leptospirosis 6 1 3 2 0 2 0 2 16
Listeriosis 7 0 1 6 0 1 2 2 19
Lyme disease 2 1 3 0 0 0 3 3 12
Lymphogranuloma venereum 16 1 1 1 0 1 0 0 20
Malaria 51 1 4 7 0 4 10 4 81
Measles * * * * * * * * 2
Meningococcal disease 18 6 9 8 6 9 12 7 75
Mumps 379 57 165 85 267 230 438 393 2014
Noroviral infection^ 735 31 56 161 31 51 78 119 1262
Paratyphoid * * * * * * * * 1
Pertussis 48 7 1 14 4 14 14 15 117
Q fever * * * * * * * * 4
Respiratory syncytial virus infection^ 1046 104 136 104 161 218 282 151 2202
Rotavirus infection^ 1264 339 247 352 197 561 688 510 4158
Rubella * * * * * * * * 2
Salmonellosis 100 16 23 21 10 30 38 31 269
Shigellosis 57 4 5 7 1 3 4 9 90
Streptococcus group A infection (invasive) 40 7 6 10 7 9 11 17 107
Streptococcus group B infection (invasive)|| 33 5 3 5 5 6 7 5 69
Streptococcus pneumoniae infection (invasive) 191 24 75 35 24 100 74 26 549
Syphilis 319 7 20 13 2 13 35 29 438
Tetanus * * * * * * * * 1
Toxoplasmosis 6 0 0 0 0 2 9 9 26
Trichomoniasis 28 0 4 8 9 7 1 1 58
Tuberculosis 132 14 15 16 17 15 69 25 303
Typhoid 5 0 0 1 1 1 1 0 9
Verotoxigenic Escherichia coli infection 84 85 109 67 25 112 112 136 730
Viral encephalitis 21 2 3 3 0 9 5 4 47
Viral meningitis 118 16 19 26 12 20 22 28 261
Yersiniosis 5 0 0 0 0 0 1 7 13
Notes:          
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2015   
*Data not reported to HSE area level when total number in Ireland <5 cases     
#Hepatitis E became notifiable on the 15/12/2015.       
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications from HSE E rather 
than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence 
‡C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2015 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases    
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
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 Table A1.4 Number of notifiable infectious diseases by age group (years), 2015
Infectious Disease
0-
4
5-
9
10-
14
15-
19
20-
24
25-
34
35-
44
45-
54
55-
64
65+ Unknown Total
Bacillus cereus food-borne infection/intoxication 1 0 0 0 0 0 0 0 0 0 0 1
Bacterial meningitis (not otherwise specified) 17 3 0 1 0 2 2 3 1 3 0 32
Campylobacter infection 542 156 90 111 173 325 238 227 219 366 5 2452
Carbapenem-resistant Enterobacteriaceae 
infection (invasive)
0 0 0 0 0 0 0 1 1 6 0 8
Chickenpox - hospitalised cases 37 16 0 2 0 4 4 1 1 4 0 69
Chikungunya disease 0 0 0 0 0 0 0 1 0 0 0 1
Chlamydia trachomatis infection^ * * * 632 2726 2598 608 160 39 6 11 6797
Clostridium difficile infection† 37 15 15 23 30 82 96 106 210 1323 6 1943
Clostridium perfringens (type A) food-borne disease 0 0 0 0 0 0 0 0 0 1 0 1
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 1 2 2 0 5
Cryptosporidiosis 215 103 38 19 18 31 7 3 3 2 0 439
Cytomegalovirus infection (congenital) 15 0 0 0 0 0 0 0 0 0 0 15
Dengue fever 0 0 0 0 1 3 2 2 0 0 0 8
Diphtheria 0 0 0 0 0 0 0 1 0 0 0 1
Giardiasis 25 12 7 4 6 36 20 12 7 16 0 145
Gonorrhoea * * * 149 363 511 194 63 18 3 0 1302
Haemophilus influenzae disease (invasive) 20 2 0 1 3 4 2 2 0 18 0 52
Hepatitis A (acute) 4 6 4 2 6 5 5 2 0 2 0 36
Hepatitis B (acute and chronic) 4 1 1 6 49 231 144 66 25 22 0 549
Hepatitis C 1 0 0 2 30 200 221 125 65 31 0 675
Hepatitis E# 0 0 0 0 0 1 0 0 2 0 0 3
Herpes simplex (genital) * * * 133 353 431 209 75 47 23 0 1274
Human immunodeficiency virus infection * * * 6 33 207 153 63 17 5 0 485
Influenza 216 127 71 86 70 258 301 224 316 997 15 2681
Legionellosis‡ 0 0 0 0 0 0 1 3 2 6 0 12
Leptospirosis 0 0 0 0 0 3 2 4 6 1 0 16
Listeriosis 3 0 0 0 0 1 4 1 1 9 0 19
Lyme disease 0 1 1 0 0 1 3 1 2 3 0 12
Lymphogranuloma venereum * * * 0 1 12 3 3 1 0 0 20
Malaria 2 2 2 4 8 13 28 19 1 2 0 81
Measles 0 0 1 1 0 0 0 0 0 0 0 2
Meningococcal disease 28 8 4 14 2 1 7 1 3 7 0 75
Mumps 42 86 178 630 564 270 120 62 40 22 0 2014
Noroviral infection^ 374 31 15 17 5 35 47 37 74 625 2 1262
Paratyphoid 0 0 0 0 1 0 0 0 0 0 0 1
Pertussis 65 8 10 6 5 6 7 8 1 1 0 117
Q fever 0 0 0 0 0 0 2 0 0 2 0 4
Respiratory syncytial virus infection^ 1984 19 7 5 5 10 22 25 25 96 4 2202
Rotavirus infection^ 3855 128 29 10 6 19 12 10 18 69 2 4158
Rubella 1 0 0 0 1 0 0 0 0 0 0 2
Salmonellosis 54 17 7 13 24 58 27 17 22 30 0 269
Shigellosis 10 5 1 1 7 25 16 15 7 2 1 90
Streptococcus group A infection (invasive) 15 8 2 2 8 8 14 7 9 34 0 107
Streptococcus group B infection (invasive)|| 69 0 0 0 0 0 0 0 0 0 0 69
Streptococcus pneumoniae infection (invasive) 43 15 4 2 3 21 38 34 82 307 0 549
Syphilis * * * 0 50 184 110 70 22 2 0 438
Tetanus 0 0 0 0 0 0 1 0 0 0 0 1
Toxoplasmosis 1 0 1 1 1 9 8 1 2 2 0 26
Trichomoniasis * * * 0 10 18 15 12 3 0 0 58
Tuberculosis 2 6 6 11 15 77 52 32 39 63 0 303
Typhoid 1 0 2 0 0 3 2 1 0 0 0 9
Verotoxigenic Escherichia coli infection 290 66 36 24 32 50 55 35 55 83 4 730
Viral encephalitis 4 1 0 1 2 7 3 7 7 15 0 47
Viral meningitis 139 8 8 14 14 39 21 7 6 4 1 261
Yersiniosis 2 3 1 0 0 2 0 1 1 3 0 13
Notes:             
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2015 
*Data for the age groups 0-4 years, 5-9 years and 10-14 years are not presented here, but data for the age group 0-14 years are available in the STI annual slide-set at  
http://www.hpsc.ie
#Hepatitis E became notifiable on the 15/12/2015.        
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications from HSE E rather 
than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2015 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases     
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
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Table A1.5 Number of notifiable infectious diseases by gender, 2015
Infectious Disease Male Female Unknown Total
Bacillus cereus food-borne infection/intoxication 0 1 0 1
Bacterial meningitis (not otherwise specified) 18 14 0 32
Campylobacter infection 1303 1145 4 2452
Carbapenem-resistant Enterobacteriaceae infection (invasive) 5 3 0 8
Chickenpox - hospitalised cases 38 29 2 69
Chikungunya disease 0 1 0 1
Chlamydia trachomatis infection^ 3214 3556 27 6797
Clostridium difficile infection† 743 1199 1 1943
Clostridium perfringens (type A) food-borne disease 0 1 0 1
Creutzfeldt Jakob disease 2 3 0 5
Cryptosporidiosis 233 205 1 439
Cytomegalovirus infection (congenital) 10 5 0 15
Dengue fever 2 6 0 8
Diphtheria 0 1 0 1
Giardiasis 87 58 0 145
Gonorrhoea 1081 220 1 1302
Haemophilus influenzae disease (invasive) 26 26 0 52
Hepatitis A (acute) 20 16 0 36
Hepatitis B (acute and chronic) 332 215 2 549
Hepatitis C 457 215 3 675
Hepatitis E# 1 2 0 3
Herpes simplex (genital) 341 927 6 1274
Human immunodeficiency virus infection 369 116 0 485
Influenza 1187 1485 9 2681
Legionellosis‡ 6 6 0 12
Leptospirosis 12 4 0 16
Listeriosis 8 11 0 19
Lyme disease 6 6 0 12
Lymphogranuloma venereum 20 0 0 20
Malaria 56 25 0 81
Measles 2 0 0 2
Meningococcal disease 42 33 0 75
Mumps 1173 838 3 2014
Noroviral infection^ 599 659 4 1262
Paratyphoid 1 0 0 1
Pertussis 50 67 0 117
Q fever 4 0 0 4
Respiratory syncytial virus infection^ 1171 1029 2 2202
Rotavirus infection^ 2192 1962 4 4158
Rubella 1 1 0 2
Salmonellosis 135 134 0 269
Shigellosis 61 29 0 90
Streptococcus group A infection (invasive) 60 47 0 107
Streptococcus group B infection (invasive)|| 37 25 7 69
Streptococcus pneumoniae infection (invasive) 265 284 0 549
Syphilis 412 26 0 438
Tetanus 1 0 0 1
Toxoplasmosis 11 15 0 26
Trichomoniasis 0 58 0 58
Tuberculosis 182 121 0 303
Typhoid 5 4 0 9
Verotoxigenic Escherichia coli infection 345 385 0 730
Viral encephalitis 21 25 1 47
Viral meningitis 139 117 5 261
Yersiniosis 10 3 0 13
Total 16496 15363 82 31941
Notes:     
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2015   
#Hepatitis E became notifiable on the 15/12/2015.    
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications from HSE E rather 
than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2015 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases    
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
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Table A1.6 Number of notifiable infectious diseases by case classification, 2015
 Infectious Disease Confirmed Probable Possible Total
Bacillus cereus food-borne infection or intoxication 1 0 0 1
Bacterial meningitis (not otherwise specified) 16 9 7 32
Campylobacter infection 2451 1 0 2452
Carbapenem-resistant Enterobacteriaceae infection (invasive) 8 0 0 8
Chickenpox - hospitalised cases 44 0 25 69
Chikungunya disease 0 1 0 1
Chlamydia trachomatis infection (genital)^ 6797 0 0 6797
Clostridium difficile infection† 1943 0 0 1943
Clostridium perfringens (type A) food-borne disease 1 0 0 1
Creutzfeldt Jakob disease 5 0 0 5
Cryptosporidiosis 434 5 0 439
Cytomegalovirus infection (congenital) 15 0 0 15
Dengue fever 8 0 0 8
Diphtheria 1 0 0 1
Giardiasis 145 0 0 145
Gonorrhoea 1302 0 0 1302
Haemophilus influenzae disease (invasive) 51 0 1 52
Hepatitis A (acute) 35 1 0 36
Hepatitis B (acute and chronic) 549 0 0 549
Hepatitis C 675 0 0 675
Hepatitis E# 3 0 0 3
Herpes simplex (genital) 1251 23 0 1274
Human immunodeficiency virus infection 485 0 0 485
Influenza 2634 13 34 2681
Legionellosis‡ 11 1 0 12
Leptospirosis 16 0 0 16
Listeriosis 19 0 0 19
Lyme disease 12 0 0 12
Lymphogranuloma venereum 20 0 0 20
Malaria 81 0 0 81
Measles 2 0 0 2
Meningococcal disease 66 0 9 75
Mumps 998 381 635 2014
Noroviral infection^ 1262 0 0 1262
Paratyphoid 1 0 0 1
Pertussis 75 8 34 117
Q fever 4 0 0 4
Respiratory syncytial virus infection^ 2202 0 0 2202
Rotavirus infection^ 4132 26 0 4158
Rubella 0 0 2 2
Salmonellosis 269 0 0 269
Shigellosis 87 3 0 90
Streptococcus group A infection (invasive) 105 2 0 107
Streptococcus group B infection (invasive)|| 69 0 0 69
Streptococcus pneumoniae infection (invasive) 368 0 181 549
Syphilis 438 0 0 438
Tetanus 1 0 0 1
Toxoplasmosis 26 0 0 26
Trichomoniasis 58 0 0 58
Tuberculosis 200 56 47 303
Typhoid 9 0 0 9
Verotoxigenic Escherichia coli infection 600 126 4 730
Viral encephalitis 46 0 1 47
Viral meningitis 251 8 2 261
Yersiniosis 13 0 0 13
Total 30295 664 982 31941
Notes:     
1. This table does not include details of diseases for which a zero number of cases were notified; see Table A1.1 for details of these diseases in 2015   
2. The case definitions booklet, available at www.hpsc.ie has been updated since 2016; case classifications are assigned to notifications as per the Case Definitions for Notifiable 
Diseases during 2015    
^Since 17/03/2013, figures for Chlamydia trachomatis, noroviral infection, respiratory syncytial virus infection and rotavirus infection may refer to notifications from HSE E rather 
than events. Such notifications from HSE E may also refer to area of laboratory testing rather than patient’s area of residence    
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2015 epidemiological calendar year as shown here
‡Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases    
||Streptococcus group B (Streptococcus agalactiae) infection (invasive) in infants <90 days old or stillborn infants
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Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) system
For the majority of the notifiable infectious diseases (see 
Appendix 1), data were collated using the Computerised 
Infectious Disease Reporting (CIDR) system. During 2015, 
notification data were inputted directly by areas using the 
system. Enhanced surveillance was undertaken for certain 
diseases and these data are collated on CIDR. Outbreak 
data were also collated on CIDR using the same process 
outlined above. Weekly Reports on infectious disease 
notifications (including a separate report for Clostridium 
difficile associated disease, HIV & STIs) and outbreaks were 
produced by HPSC and published on the HPSC website, 
www.hpsc.ie. Throughout the year data were cleaned and 
validated on an ongoing basis and final data checks and 
cleaning were undertaken following year end by HPSC 
and the Departments of Public Health. Data analysis was 
performed using CIDR Business Objects Reporting and MS 
Excel. Figures for the relevant chapters within this report 
were extracted from CIDR between February and November 
2016. These figures may differ from those previously 
published due to ongoing updating of data on CIDR.
HIV
HIV was made a notifiable disease in Ireland in September 
2011. Since 1st January 2012, CIDR has been used to record 
notifications of HIV, thereby allowing the replacement of HIV 
case based reporting. Since 1st January 2012, AIDS diagnoses 
are only reported if they occur at the time of HIV diagnoses. 
In January 2015, there was a change to the surveillance case 
definition for HIV in HSE East (Dublin, Kildare and Wicklow). 
Previously, confirmatory testing by the National Virus 
Reference Laboratory (NVRL) was required on two separate 
samples prior to notification. From January 2015 onwards, 
confirmatory testing by NVRL on one sample was sufficient 
prior to notification. This change has resulted in increased 
notifications and more timely notifications. 
Sexually Transmitted Infections (STIs)
Data on ano-genital warts (AG) and non-specific urethritis 
(NSU) are not collated using the CIDR system. Instead, 
clinicians notified their respective Departments of Public 
Health of cases of ano-genital warts and non-specific 
urethritis. Data for 2015 were collated and analysed by 
Departments of Public Health and aggregated data were 
reported quarterly to HPSC. National data were collated 
on an MS Access database, analysis preformed and reports 
produced by HPSC.
Data on all other STIs are collated using the CIDR system, 
including: chancroid, Chlamydia trachomatis infection, 
gonorrhoea, granuloma inguinale, herpes simplex (genital), 
lymphogranuloma venereum, syphilis and trichomoniasis.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with the 
National Virus Reference Laboratory (NVRL), the Irish 
College of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project. Sixty-one general practices (located in all HSE-Areas 
and representing 5.8% of the population) were recruited 
to report electronically, on a weekly basis, the number of 
patients who consulted with influenza-like illness (ILI). ILI is 
defined using the Irish case definition for ILI which is sudden 
onset of symptoms AND at least one of the following four 
systemic symptoms: fever, malaise, headache, myalgia; AND 
at least one of the following three respiratory symptoms: 
cough, sore throat, shortness of breath. Sentinel GPs were 
requested to send a combined nasal and throat swab on 
one ILI patient per week to the NVRL. The NVRL also tested 
respiratory non-sentinel specimens, referred mainly from 
hospitals. Other surveillance systems set up to monitor 
influenza/ILI activity include a network of sentinel hospitals 
reporting admissions data. The Departments of Public 
Health also notified HPSC weekly of all cases of influenza 
(including hospitalisation status), all acute respiratory 
infection and influenza outbreaks and enhanced surveillance 
data on all hospitalised cases of confirmed influenza in 0-14 
year olds. HPSC was notified of all registered deaths on a 
daily basis from the General Register Office.
Several surveillance projects that were initiated/augmented 
during the 2009 influenza pandemic were continued during 
subsequent influenza seasons:
•   Surveillance of all calls to GP out-of-hours (OOHs) centres 
were monitored for self-reported influenza. These data 
were provided by HSE-NE.  
Explanatory Notes
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•   Intensive Care Society of Ireland (ICSI) and the Critical 
Care Programme (CCP) enhanced surveillance of all 
critical care patients with confirmed influenza in all critical 
care units. 
•   Enhanced surveillance of all confirmed influenza deaths.
Other routine surveillance include the monitoring of the 
uptake of the seasonal influenza vaccine among residents in 
long term care facilities (LTCFs) and that of the health care 
workers in both LTCFs and hospitals since the 2011/2012 
season. Uptake levels by different categories of staff over 
time, along with other details are presented in the influenza 
chapter of this report.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
www.hpsc.ie. Aggregated clinical and virological data and 
anonymised data on confirmed influenza cases admitted to 
hospital were reported weekly to the European Centre for 
Disease Prevention and Control (ECDC).
Immunisation Uptake
•   Immunisation uptake among children at 12 and 24 
months of age
Each HSE Area maintains a childhood immunisation 
database. In 2015, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each of 
the Local Health Offices in their area on a quarterly basis. 
National data were collated and analysed at HPSC using a 
MS Excel database. Quarterly reports were produced and 
are available on the HPSC website. For further details on 
methods used, please see the immunisation uptake chapter 
within this report.
•   HPV, MenC booster and Tdap vaccine uptake 2014/2015
HPV, MenC booster and Tdap vaccinations provided through 
the schools immunisation programme are collated on the 
national School Immunisation System (SIS). Uptake of 
these vaccines, provided through the school immunisation 
programme in the academic year 2014/2015 and recorded 
on the database, are reported in the chapter within this 
report. Further details are provided within the chapter.
•   DTaP/IPV and MMR vaccine uptake 2014/2015 
Since the 2011/2012 academic year, the uptake of the DTaP/
IPV and MMR vaccines in 4-5 year old schoolchildren (at 
Junior Infant level) has been monitored across all Local 
Health Offices (LHOs) each year. Each LHO provides details 
of the cohort size and the number of vaccinated children and 
the returns collated to calculate uptake levels which are also 
presented in maps in the ‘DTaP/IPV and MMR vaccine uptake 
2014/2015’ chapter. 
European Antimicrobial Resistance Surveillance Network 
(EARS-Net)
Data were collected by participating EARS-Net (formerly the 
European Antimicrobial Resistance Surveillance System, 
EARSS) laboratories in 2015 on the first invasive isolate per 
patient per quarter on Staphylococcus aureus, Enterococcus 
faecium and Enterococcus faecalis from blood only and 
on Streptococcus pneumoniae, Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa and Acinetobacter 
spp. from blood and/or cerebrospinal fluid (CSF). Data were 
reported quarterly to HPSC, via WHONET software, and 
collated in an MS Access database. Quarterly and annual 
reports were produced.
Antimicrobial consumption
Community (outpatient) consumption data were obtained 
from IMS Health and represent wholesaler to retail pharmacy 
sales figures for Ireland. Hospital (inpatient) consumption 
data were obtained directly from clinical pharmacies 
and validated with the support of the Irish Antimicrobial 
Pharmacists Association. Quarterly and annual consumption 
trends by named public acute hospitals are published  
on the HPSC website. All data were interpreted using  
the WHO Anatomical Therapeutic Chemicals index   
(www.whocc.no/atcddd/) in line with European Surveillance 
of Antimicrobial Consumption (ESAC-Net) methodology, 
which is now managed by the ECDC. See relevant section for 
notes on the denominator data.
Healthcare associated infections
•   Clostridium difficile: Data on C. difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to HPSC and stored in an MS Access 
database. Quarterly and annual reports were produced. 
•   Data were also collected on the total volume of alcohol-
based hand rub used per hospital per year/quarter, 
excluding that used for pre-operative surgical “scrub”. 
See relevant section for notes on the denominator data. 
The rate of usage per hospital was calculated as the total 
volume of hand rub consumed (in litres) per 1000 bed days 
used, and quarterly and annual reports were produced for 
publication on the HPSC website.
Denominator Data
To calculate disease incidence rates, Census of Population 
data were used as the denominator (available from the 
Central Statistics Office, http://www.cso.ie).  Population 
figures were applied as follows: 
•   Census 2011 for analysis of 2009-2015 data 
•   Census 2006 for analysis of 2004-2008 data
•   Census 2002 for 2000-2003 data 
•   Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2014 using a curve interpolation method for the 
calculation of outpatient antibiotic consumption rate. 
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring Unit 
of the HSE and used to calculate rates of MRSA, hospital 
antibiotic consumption and rates used in other hospital-
based surveillance systems. Similar activity data were 
obtained directly from private acute hospitals.
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HSE Areas
Although organisational changes have taken place in the 
Health Services, the term HSE Areas are used in this report 
when analysing and presenting data by geographical area 
(equating to the eight former health board regions/areas). 
This is because operationally the surveillance, prevention 
and control of infectious diseases are still managed by eight 
Departments of Public Health, one in each HSE Area.
Regional Directors of Operations (RDO’s)
The range of health and personal social services provided by 
the HSE and its funded agencies were managed within four 
regions known as RDOs. Details of the four RDOs and their 
relationship with the eight HSE areas are shown below.
1.  Dublin Mid Leinster (HSE-Midland plus CCA1-5 and 
CCA9-10 of HSE-East)
2.  Dublin North East (HSE-North East plus CCA6-8 of HSE-
East)
3.  South (HSE-South and HSE-South East)
4.  West (HSE-Midwest, HSE-North West and HSE-West)
Community Healthcare Organisations
Community Healthcare Services are the broad range of 
services that are provided outside of the acute hospital 
system and includes Primary Care, Social Care, Mental 
Health and Health & Wellbeing Services. These services 
are delivered through the HSE and its funded agencies to 
people in local communities, as close as possible to people’s 
homes. The document Community Healthcare Organisations 
– Report and Recommendations of the Integrated Service 
Area Review Group, published in October 2014, sets out how 
health services, outside of acute hospitals, will be organised 
and managed. This document is available at 
http://www.hse.ie/eng/services/publications/corporate/
CHOReport.html  
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Glossary of Terms 
AHR Alcohol hand rubs
CDI Clostridium difficile infection
CIDR Computerised Infectious Disease Reporting
CIR Crude incidence rate
DoH Department of Health
EARS-Net European Antimicrobial Resistance Surveillance Network
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
ICGP Irish College of General Practitioners
ILI Influenza-like illness
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HCWs Healthcare Workers
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
LTCFs Long term care facilities
MRSA Meticillin Resistance Staphylococcus aureus
MSM Men who have sex with men
NSSLRL National Salmonella, Shigella and Listeria Reference Laboratory
NIO National Immunisation Office
NVRL National Virus Reference Laboratory
PWID People who inject drugs
SIS School Immunisation System
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organization
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